{"92cce3ef10b776cbe114b73d3e44e9cf0d867ffe": [["IntroductionHuman infection by the mosquito-borne chikungunya virus (CHIKV) induces fever frequently accompanied by severe joint pain, muscle pain, headache, nausea, fatigue, and rash [1] .", [["joint", "ANATOMY", 123, 128], ["muscle", "ANATOMY", 135, 141], ["infection", "DISEASE", 18, 27], ["chikungunya virus", "DISEASE", 50, 67], ["CHIKV", "DISEASE", 69, 74], ["fever", "DISEASE", 84, 89], ["joint pain", "DISEASE", 123, 133], ["muscle pain", "DISEASE", 135, 146], ["headache", "DISEASE", 148, 156], ["nausea", "DISEASE", 158, 164], ["fatigue", "DISEASE", 166, 173], ["rash", "DISEASE", 179, 183], ["mosquito-borne chikungunya virus", "ORGANISM", 35, 67], ["CHIKV", "ORGANISM", 69, 74], ["joint", "ORGANISM_SUBDIVISION", 123, 128], ["muscle", "ORGAN", 135, 141], ["mosquito-borne chikungunya virus", "SPECIES", 35, 67], ["mosquito-borne chikungunya virus", "SPECIES", 35, 67], ["CHIKV", "SPECIES", 69, 74], ["IntroductionHuman infection", "PROBLEM", 0, 27], ["the mosquito-borne chikungunya virus", "PROBLEM", 31, 67], ["fever", "PROBLEM", 84, 89], ["severe joint pain", "PROBLEM", 116, 133], ["muscle pain", "PROBLEM", 135, 146], ["headache", "PROBLEM", 148, 156], ["nausea", "PROBLEM", 158, 164], ["fatigue", "PROBLEM", 166, 173], ["rash", "PROBLEM", 179, 183], ["infection", "OBSERVATION", 18, 27], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["joint", "ANATOMY", 123, 128], ["muscle", "ANATOMY", 135, 141]]], ["Chikungunya fever mainly occurs in Africa, and South and Southeast Asia [1] .", [["Chikungunya fever", "DISEASE", 0, 17], ["Chikungunya", "ORGANISM", 0, 11], ["Chikungunya fever", "PROBLEM", 0, 17]]], ["However, effective therapeutic drugs are not available at present.", [["effective therapeutic drugs", "TREATMENT", 9, 36]]], ["Chikungunya virus is a member of the genus Alphavirus in the family Togaviridae and has an envelope membrane, as do HIV, Ebola virus, and severe acute respiratory syndrome coronavirus (SARS-CoV).", [["envelope membrane", "ANATOMY", 91, 108], ["Chikungunya virus", "DISEASE", 0, 17], ["HIV, Ebola virus", "DISEASE", 116, 132], ["acute respiratory syndrome coronavirus", "DISEASE", 145, 183], ["SARS", "DISEASE", 185, 189], ["Chikungunya virus", "ORGANISM", 0, 17], ["envelope membrane", "CELLULAR_COMPONENT", 91, 108], ["Ebola virus", "ORGANISM", 121, 132], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 138, 183], ["SARS-CoV", "ORGANISM", 185, 193], ["Chikungunya virus", "SPECIES", 0, 17], ["HIV", "SPECIES", 116, 119], ["Ebola virus", "SPECIES", 121, 132], ["Chikungunya virus", "SPECIES", 0, 17], ["HIV", "SPECIES", 116, 119], ["Ebola virus", "SPECIES", 121, 132], ["severe acute respiratory syndrome coronavirus", "SPECIES", 138, 183], ["SARS-CoV", "SPECIES", 185, 193], ["Chikungunya virus", "PROBLEM", 0, 17], ["Togaviridae", "TREATMENT", 68, 79], ["an envelope membrane", "TREATMENT", 88, 108], ["HIV", "PROBLEM", 116, 119], ["Ebola virus", "PROBLEM", 121, 132], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 138, 183], ["virus", "OBSERVATION", 12, 17], ["envelope membrane", "OBSERVATION", 91, 108], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory syndrome coronavirus", "OBSERVATION", 151, 183]]], ["The molecular mechanism of CHIKV entry into human target cells has not been studied to the same extent as HIV, Ebola virus, and SARS-CoV.IntroductionThe binding of CHIKV to a cognate cell surface receptor initiates CHIKV infection.", [["cells", "ANATOMY", 57, 62], ["cell surface", "ANATOMY", 183, 195], ["HIV, Ebola virus", "DISEASE", 106, 122], ["SARS", "DISEASE", 128, 132], ["CHIKV infection", "DISEASE", 215, 230], ["CHIKV", "ORGANISM", 27, 32], ["human", "ORGANISM", 44, 49], ["cells", "CELL", 57, 62], ["HIV", "ORGANISM", 106, 109], ["Ebola virus", "ORGANISM", 111, 122], ["SARS-CoV", "ORGANISM", 128, 136], ["CHIKV", "ORGANISM", 164, 169], ["cell", "CELL", 183, 187], ["CHIKV", "ORGANISM", 215, 220], ["human target cells", "CELL_TYPE", 44, 62], ["cognate cell surface receptor", "PROTEIN", 175, 204], ["human", "SPECIES", 44, 49], ["HIV", "SPECIES", 106, 109], ["Ebola virus", "SPECIES", 111, 122], ["CHIKV", "SPECIES", 27, 32], ["human", "SPECIES", 44, 49], ["HIV", "SPECIES", 106, 109], ["Ebola virus", "SPECIES", 111, 122], ["SARS-CoV", "SPECIES", 128, 136], ["CHIKV", "SPECIES", 164, 169], ["CHIKV", "SPECIES", 215, 220], ["CHIKV entry into human target cells", "PROBLEM", 27, 62], ["HIV, Ebola virus", "PROBLEM", 106, 122], ["SARS", "PROBLEM", 128, 132], ["CHIKV", "PROBLEM", 164, 169], ["a cognate cell surface receptor", "TREATMENT", 173, 204], ["CHIKV infection", "PROBLEM", 215, 230], ["CHIKV", "OBSERVATION", 27, 32], ["CHIKV", "OBSERVATION", 164, 169], ["CHIKV", "OBSERVATION_MODIFIER", 215, 220], ["infection", "OBSERVATION", 221, 230]]], ["Prohibition [2] , TIM-1 [3] , glycosaminoglycans [4] , heparan sulfate [5] , and ATP synthase \u03b2 subunit [6] have been reported to participate in the CHIKV infection process.", [["heparan sulfate", "CHEMICAL", 55, 70], ["ATP", "CHEMICAL", 81, 84], ["CHIKV infection", "DISEASE", 149, 164], ["ATP", "CHEMICAL", 81, 84], ["TIM-1 [3]", "SIMPLE_CHEMICAL", 18, 27], ["glycosaminoglycans [4]", "SIMPLE_CHEMICAL", 30, 52], ["heparan sulfate [5]", "SIMPLE_CHEMICAL", 55, 74], ["ATP synthase \u03b2 subunit [6", "GENE_OR_GENE_PRODUCT", 81, 106], ["CHIKV", "ORGANISM", 149, 154], ["TIM", "PROTEIN", 18, 21], ["ATP synthase", "PROTEIN", 81, 93], ["\u03b2 subunit", "PROTEIN", 94, 103], ["CHIKV", "SPECIES", 149, 154], ["glycosaminoglycans [4] , heparan sulfate", "TREATMENT", 30, 70], ["ATP synthase \u03b2 subunit", "TREATMENT", 81, 103], ["the CHIKV infection process", "PROBLEM", 145, 172], ["infection", "OBSERVATION", 155, 164]]], ["However, CHIKV infection can occur in the absence of these proteins, indicating that they facilitate the initial binding of CHIKV to host cells.", [["cells", "ANATOMY", 138, 143], ["infection", "DISEASE", 15, 24], ["CHIKV", "ORGANISM", 9, 14], ["CHIKV", "ORGANISM", 124, 129], ["host cells", "CELL", 133, 143], ["host cells", "CELL_TYPE", 133, 143], ["CHIKV", "SPECIES", 9, 14], ["CHIKV", "SPECIES", 124, 129], ["CHIKV infection", "PROBLEM", 9, 24], ["these proteins", "PROBLEM", 53, 67], ["CHIKV", "PROBLEM", 124, 129], ["CHIKV", "OBSERVATION_MODIFIER", 9, 14], ["infection", "OBSERVATION", 15, 24]]], ["Mxra8 was recently reported as the cell surface receptor for CHIKV [7] .IntroductionThere are many lines of evidence showing that CHIKV enters into host cells via clathrin-dependent endocytosis pathway [8] [9] [10] [11] .IntroductionThe inhibitors of endosome acidification attenuate CHIKV infection [12] [13] [14] .", [["cell surface", "ANATOMY", 35, 47], ["cells", "ANATOMY", 153, 158], ["endosome", "ANATOMY", 251, 259], ["infection", "DISEASE", 290, 299], ["Mxra8", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 35, 39], ["CHIKV", "ORGANISM", 130, 135], ["cells", "CELL", 153, 158], ["clathrin", "GENE_OR_GENE_PRODUCT", 163, 171], ["[8] [9] [10] [11]", "SIMPLE_CHEMICAL", 202, 219], ["endosome", "CELLULAR_COMPONENT", 251, 259], ["CHIKV", "ORGANISM", 284, 289], ["Mxra8", "PROTEIN", 0, 5], ["cell surface receptor", "PROTEIN", 35, 56], ["host cells", "CELL_TYPE", 148, 158], ["clathrin", "PROTEIN", 163, 171], ["CHIKV", "SPECIES", 61, 66], ["CHIKV", "SPECIES", 130, 135], ["CHIKV", "SPECIES", 284, 289], ["CHIKV", "PROBLEM", 61, 66], ["CHIKV", "PROBLEM", 130, 135], ["clathrin-dependent endocytosis pathway", "TEST", 163, 201], ["The inhibitors", "TREATMENT", 233, 247], ["endosome acidification", "PROBLEM", 251, 273], ["CHIKV infection", "PROBLEM", 284, 299], ["CHIKV", "OBSERVATION", 130, 135]]], ["Therefore, it is thought that CHIKV particles are internalized into host cell endosomes after binding to the cell surface receptor, and then endosome acidification facilitates fusion between viral and endosome membrane by the CHIKV envelope (E) protein.", [["cell endosomes", "ANATOMY", 73, 87], ["cell surface", "ANATOMY", 109, 121], ["endosome", "ANATOMY", 141, 149], ["endosome membrane", "ANATOMY", 201, 218], ["CHIKV", "ORGANISM", 30, 35], ["cell endosomes", "CELLULAR_COMPONENT", 73, 87], ["cell surface", "CELLULAR_COMPONENT", 109, 121], ["endosome", "CELLULAR_COMPONENT", 141, 149], ["endosome membrane", "CELLULAR_COMPONENT", 201, 218], ["CHIKV envelope (E)", "GENE_OR_GENE_PRODUCT", 226, 244], ["cell surface receptor", "PROTEIN", 109, 130], ["CHIKV envelope (E) protein", "PROTEIN", 226, 252], ["CHIKV", "SPECIES", 30, 35], ["CHIKV", "SPECIES", 226, 231], ["CHIKV particles", "PROBLEM", 30, 45], ["the cell surface receptor", "TREATMENT", 105, 130], ["endosome acidification", "PROBLEM", 141, 163], ["fusion between viral and endosome membrane", "PROBLEM", 176, 218], ["the CHIKV envelope (E) protein", "TREATMENT", 222, 252], ["CHIKV", "OBSERVATION", 30, 35], ["host cell endosomes", "OBSERVATION", 68, 87], ["endosome membrane", "OBSERVATION", 201, 218]]], ["In addition, it has been reported that phogocytosis inhibitors are able to reduce CHIKV infection [15] and antibody-bound viral particles can follow an Fc\u03b3-dependent phagocytosis pathway leading to antibody-dependent enhancement of viral infection [16] , suggesting that CHIKV also enters to target cells via phagosomes.IntroductionCHIKV entry into target cells is mediated by the viral E protein.", [["cells", "ANATOMY", 299, 304], ["phagosomes", "ANATOMY", 309, 319], ["cells", "ANATOMY", 356, 361], ["infection", "DISEASE", 88, 97], ["viral infection", "DISEASE", 232, 247], ["CHIKV", "ORGANISM", 82, 87], ["Fc\u03b3", "GENE_OR_GENE_PRODUCT", 152, 155], ["CHIKV", "ORGANISM", 271, 276], ["cells", "CELL", 299, 304], ["phagosomes", "CELLULAR_COMPONENT", 309, 319], ["cells", "CELL", 356, 361], ["Fc\u03b3", "PROTEIN", 152, 155], ["target cells", "CELL_TYPE", 292, 304], ["phagosomes", "CELL_TYPE", 309, 319], ["target cells", "CELL_TYPE", 349, 361], ["viral E protein", "PROTEIN", 381, 396], ["CHIKV", "SPECIES", 82, 87], ["CHIKV", "SPECIES", 271, 276], ["phogocytosis inhibitors", "TREATMENT", 39, 62], ["CHIKV infection", "PROBLEM", 82, 97], ["antibody", "TEST", 107, 115], ["bound viral particles", "PROBLEM", 116, 137], ["an Fc\u03b3", "TEST", 149, 155], ["dependent phagocytosis pathway", "PROBLEM", 156, 186], ["antibody-dependent enhancement", "PROBLEM", 198, 228], ["viral infection", "PROBLEM", 232, 247], ["CHIKV", "PROBLEM", 271, 276], ["dependent enhancement", "OBSERVATION_MODIFIER", 207, 228], ["viral", "OBSERVATION_MODIFIER", 232, 237], ["infection", "OBSERVATION", 238, 247], ["CHIKV", "OBSERVATION", 271, 276]]], ["The viral protein is synthesized as a precursor polyprotein from a subgenomic 26s RNA and processed into capsid, E3, E2, 6K, and E1 mature proteins.", [["E3", "GENE_OR_GENE_PRODUCT", 113, 115], ["E2", "GENE_OR_GENE_PRODUCT", 117, 119], ["6K", "GENE_OR_GENE_PRODUCT", 121, 123], ["E1", "GENE_OR_GENE_PRODUCT", 129, 131], ["viral protein", "PROTEIN", 4, 17], ["precursor polyprotein", "RNA", 38, 59], ["subgenomic 26s RNA", "RNA", 67, 85], ["capsid, E3, E2, 6K, and E1 mature proteins", "PROTEIN", 105, 147], ["The viral protein", "TEST", 0, 17], ["a precursor polyprotein", "PROBLEM", 36, 59], ["capsid", "TEST", 105, 111], ["E2", "TEST", 117, 119], ["viral protein", "OBSERVATION", 4, 17], ["subgenomic 26s RNA", "OBSERVATION", 67, 85]]], ["Spikes on the CHIKV particles consist of trimers of heterodimers containing E1 and E2 proteins.", [["CHIKV", "ORGANISM", 14, 19], ["E1", "GENE_OR_GENE_PRODUCT", 76, 78], ["E2", "GENE_OR_GENE_PRODUCT", 83, 85], ["heterodimers", "PROTEIN", 52, 64], ["E1", "PROTEIN", 76, 78], ["E2 proteins", "PROTEIN", 83, 94], ["CHIKV", "SPECIES", 14, 19], ["Spikes", "PROBLEM", 0, 6], ["the CHIKV particles", "TREATMENT", 10, 29], ["trimers of heterodimers", "TREATMENT", 41, 64], ["E1 and E2 proteins", "TREATMENT", 76, 94]]], ["The E proteins that emerge from the viral envelope play an important role for attachment to the cell receptor and entry step for many cell types, but not for all.", [["cell", "ANATOMY", 96, 100], ["cell", "ANATOMY", 134, 138], ["E proteins", "GENE_OR_GENE_PRODUCT", 4, 14], ["cell", "CELL", 96, 100], ["cell", "CELL", 134, 138], ["E proteins", "PROTEIN", 4, 14], ["the cell receptor", "TREATMENT", 92, 109]]], ["The E proteins may also be involved in the post-entry step.IntroductionInfections by Ebola virus [17, 18] , SARS-CoV [19] , SARS-CoV-2 [20] , and murine leukemia virus (MLV) [18] also require a transit via the endosome compartment, and are endosome acidification-dependent.", [["endosome compartment", "ANATOMY", 210, 230], ["endosome", "ANATOMY", 240, 248], ["Ebola virus", "DISEASE", 85, 96], ["SARS", "DISEASE", 108, 112], ["murine leukemia virus", "DISEASE", 146, 167], ["E proteins", "GENE_OR_GENE_PRODUCT", 4, 14], ["Ebola virus", "ORGANISM", 85, 96], ["SARS-CoV [19]", "ORGANISM", 108, 121], ["SARS-CoV-2 [20", "ORGANISM", 124, 138], ["murine leukemia virus", "ORGANISM", 146, 167], ["MLV", "ORGANISM", 169, 172], ["endosome", "CELLULAR_COMPONENT", 210, 218], ["endosome", "CELLULAR_COMPONENT", 240, 248], ["E proteins", "PROTEIN", 4, 14], ["Ebola virus", "SPECIES", 85, 96], ["SARS-CoV", "SPECIES", 124, 132], ["murine", "SPECIES", 146, 152], ["leukemia virus", "SPECIES", 153, 167], ["Ebola virus", "SPECIES", 85, 96], ["SARS-CoV", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 124, 132], ["murine leukemia virus", "SPECIES", 146, 167], ["MLV", "SPECIES", 169, 172], ["Ebola virus", "TEST", 85, 96], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["SARS", "TEST", 124, 128], ["CoV", "TEST", 129, 132], ["murine leukemia virus", "PROBLEM", 146, 167], ["endosome acidification", "PROBLEM", 240, 262], ["may also be", "UNCERTAINTY", 15, 26], ["leukemia virus", "OBSERVATION", 153, 167], ["endosome acidification", "OBSERVATION", 240, 262], ["dependent", "OBSERVATION_MODIFIER", 263, 272]]], ["Furthermore, these viral infections require endosomal cathepsin B protease [21] [22] [23] [24] , suggesting that the cleavage of their envelope glycoproteins by cathepsin B protease activates their membrane fusion capability.", [["endosomal", "ANATOMY", 44, 53], ["membrane", "ANATOMY", 198, 206], ["viral infections", "DISEASE", 19, 35], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 54, 65], ["cathepsin B protease", "GENE_OR_GENE_PRODUCT", 161, 181], ["membrane", "CELLULAR_COMPONENT", 198, 206], ["endosomal cathepsin B protease", "PROTEIN", 44, 74], ["envelope glycoproteins", "PROTEIN", 135, 157], ["cathepsin B protease", "PROTEIN", 161, 181], ["these viral infections", "PROBLEM", 13, 35], ["endosomal cathepsin B protease", "TREATMENT", 44, 74], ["the cleavage", "PROBLEM", 113, 125], ["their envelope glycoproteins", "TREATMENT", 129, 157], ["cathepsin B protease", "TREATMENT", 161, 181], ["their membrane fusion capability", "PROBLEM", 192, 224]]], ["However, the involvement of cathepsin B protease in CHIKV infection remains to be elucidated.IntroductionIn this study, we examined whether cathepsin B is important for efficient CHIKV infection in 293T, HeLa, and TE671 cells.", [["293T", "ANATOMY", 198, 202], ["HeLa", "ANATOMY", 204, 208], ["TE671 cells", "ANATOMY", 214, 225], ["CHIKV infection", "DISEASE", 52, 67], ["CHIKV infection", "DISEASE", 179, 194], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 28, 39], ["CHIKV", "ORGANISM", 52, 57], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 140, 151], ["CHIKV", "ORGANISM", 179, 184], ["293T", "CELL", 198, 202], ["HeLa", "CELL", 204, 208], ["TE671 cells", "CELL", 214, 225], ["cathepsin B protease", "PROTEIN", 28, 48], ["cathepsin B", "PROTEIN", 140, 151], ["293T", "CELL_LINE", 198, 202], ["HeLa", "CELL_LINE", 204, 208], ["TE671 cells", "CELL_LINE", 214, 225], ["CHIKV", "SPECIES", 52, 57], ["CHIKV", "SPECIES", 179, 184], ["cathepsin B protease", "TREATMENT", 28, 48], ["CHIKV infection", "PROBLEM", 52, 67], ["this study", "TEST", 108, 118], ["cathepsin B", "TREATMENT", 140, 151], ["efficient CHIKV infection", "PROBLEM", 169, 194], ["HeLa", "TEST", 204, 208], ["CHIKV", "OBSERVATION_MODIFIER", 52, 57], ["infection", "OBSERVATION", 58, 67], ["CHIKV", "OBSERVATION", 179, 184]]], ["293T and HeLa cells are widely used as target cells for in vitro CHIKV infection [25] [26] [27] [28] [29] [30] [31] .", [["293T", "ANATOMY", 0, 4], ["HeLa cells", "ANATOMY", 9, 19], ["cells", "ANATOMY", 46, 51], ["infection", "DISEASE", 71, 80], ["293T", "CELL", 0, 4], ["HeLa cells", "CELL", 9, 19], ["cells", "CELL", 46, 51], ["CHIKV", "ORGANISM", 65, 70], ["[25] [26] [27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 81, 115], ["293T", "CELL_LINE", 0, 4], ["HeLa cells", "CELL_LINE", 9, 19], ["target cells", "CELL_TYPE", 39, 51], ["CHIKV", "SPECIES", 65, 70], ["HeLa cells", "TREATMENT", 9, 19], ["vitro CHIKV infection", "PROBLEM", 59, 80]]], ["TE671 rhabdomyosarcoma cell line was also used, as skeletal muscle cells have found to contain CHIKV antigens [32] .", [["TE671 rhabdomyosarcoma cell line", "ANATOMY", 0, 32], ["skeletal muscle cells", "ANATOMY", 51, 72], ["rhabdomyosarcoma", "DISEASE", 6, 22], ["TE671 rhabdomyosarcoma cell line", "CELL", 0, 32], ["skeletal muscle cells", "CELL", 51, 72], ["CHIKV", "ORGANISM", 95, 100], ["TE671 rhabdomyosarcoma cell line", "CELL_LINE", 0, 32], ["skeletal muscle cells", "CELL_TYPE", 51, 72], ["CHIKV antigens", "PROTEIN", 95, 109], ["CHIKV", "SPECIES", 95, 100], ["TE671 rhabdomyosarcoma cell line", "TREATMENT", 0, 32], ["skeletal muscle cells", "PROBLEM", 51, 72], ["CHIKV antigens", "PROBLEM", 95, 109], ["rhabdomyosarcoma cell line", "OBSERVATION", 6, 32], ["skeletal muscle", "ANATOMY", 51, 66]]], ["Cathepsin B protease is required for uncoating of adeno-associated virus core [33] .", [["Cathepsin B", "GENE_OR_GENE_PRODUCT", 0, 11], ["adeno-associated virus", "ORGANISM", 50, 72], ["Cathepsin B protease", "PROTEIN", 0, 20], ["Cathepsin B protease", "TREATMENT", 0, 20], ["adeno-associated virus core", "PROBLEM", 50, 77]]], ["We used CHIKV E protein-containing MLV vector to examine only the interaction between cathepsin B and CHIKV E proteins, and to exclude the involvement of cathepsin B in viral uncoating.", [["MLV", "ORGANISM", 35, 38], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 86, 97], ["CHIKV E proteins", "GENE_OR_GENE_PRODUCT", 102, 118], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 154, 165], ["CHIKV E protein-containing MLV vector", "DNA", 8, 45], ["cathepsin B", "PROTEIN", 86, 97], ["CHIKV E proteins", "PROTEIN", 102, 118], ["cathepsin B", "PROTEIN", 154, 165], ["CHIKV", "SPECIES", 8, 13], ["CHIKV", "SPECIES", 102, 107], ["CHIKV E protein-containing MLV vector", "TREATMENT", 8, 45], ["cathepsin B", "TREATMENT", 86, 97], ["CHIKV E proteins", "TEST", 102, 118], ["cathepsin B", "TREATMENT", 154, 165], ["viral uncoating", "PROBLEM", 169, 184], ["viral uncoating", "OBSERVATION", 169, 184]]], ["Such pseudotyped MLV vector is widely used to understand the mechanism of cell entry mediated by various viral glycoproteins [34] .CellsHuman 293T, TE671, and HeLa cell lines have been maintained in our laboratory for a long period.", [["cell", "ANATOMY", 74, 78], ["293T", "ANATOMY", 142, 146], ["TE671", "ANATOMY", 148, 153], ["HeLa cell lines", "ANATOMY", 159, 174], ["pseudotyped MLV", "ORGANISM", 5, 20], ["cell", "CELL", 74, 78], ["CellsHuman 293T", "CELL", 131, 146], ["TE671", "CELL", 148, 153], ["HeLa cell lines", "CELL", 159, 174], ["viral glycoproteins", "PROTEIN", 105, 124], ["CellsHuman 293T", "CELL_LINE", 131, 146], ["TE671", "CELL_LINE", 148, 153], ["HeLa cell lines", "CELL_LINE", 159, 174], ["MLV", "SPECIES", 17, 20], ["Such pseudotyped MLV vector", "TREATMENT", 0, 27], ["CellsHuman", "TEST", 131, 141], ["TE671", "TEST", 148, 153], ["HeLa cell lines", "TREATMENT", 159, 174], ["HeLa cell lines", "OBSERVATION", 159, 174]]], ["They were cultured in Dulbecco's modified Eagle's medium with 8% fetal bovine serum and 1% penicillin-streptomycin.PlasmidsThe MLV Gag-Pol expression plasmid was purchased from TaKaRa.", [["fetal bovine serum", "ANATOMY", 65, 83], ["penicillin", "CHEMICAL", 91, 101], ["streptomycin", "CHEMICAL", 102, 114], ["penicillin", "CHEMICAL", 91, 101], ["streptomycin", "CHEMICAL", 102, 114], ["bovine", "ORGANISM", 71, 77], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 91, 114], ["MLV", "ORGANISM", 127, 130], ["Pol", "GENE_OR_GENE_PRODUCT", 135, 138], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 177, 183], ["MLV Gag-Pol expression plasmid", "DNA", 127, 157], ["bovine", "SPECIES", 71, 77], ["bovine", "SPECIES", 71, 77], ["8% fetal bovine serum", "TREATMENT", 62, 83], ["penicillin", "TREATMENT", 91, 101], ["streptomycin", "TREATMENT", 102, 114], ["Plasmids", "TREATMENT", 115, 123], ["Pol expression plasmid", "TREATMENT", 135, 157], ["MLV Gag", "ANATOMY", 127, 134]]], ["The construction of a LacZ-encoding MLV vector genome expression plasmid has been previously reported [35] .", [["LacZ", "GENE_OR_GENE_PRODUCT", 22, 26], ["MLV", "ORGANISM", 36, 39], ["LacZ-encoding MLV vector genome expression plasmid", "DNA", 22, 72], ["a LacZ-encoding MLV vector genome expression plasmid", "TREATMENT", 20, 72]]], ["The VSV-G expression plasmid was kindly provided by Dr. L. Chang [36] .", [["VSV-G", "GENE_OR_GENE_PRODUCT", 4, 9], ["VSV-G expression plasmid", "DNA", 4, 28], ["The VSV-G expression plasmid", "TREATMENT", 0, 28]]], ["The CHIKV E protein expression plasmid was constructed from an artificially synthesized human codon-optimized full-length DNA fragment encoding CHIKV E protein [5] (Eurofins Genomics) that was cloned into a pT ARGE T\u2122 plasmid (Promega, Madison, WI, USA).Pseudotyped MLV Vector293T cells were transfected by the MLV Gag-Pol (TaKaRa, Shiga, Japan), LacZ-encoding MLV vector genome, and appropriate viral envelope protein expression plasmids using Fugene \u00ae HD Transfection Reagent (Promega) ( Figure S1 ).", [["Vector293T cells", "ANATOMY", 270, 286], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 4, 19], ["human", "ORGANISM", 88, 93], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 144, 159], ["MLV Vector293T cells", "CELL", 266, 286], ["MLV", "ORGANISM", 311, 314], ["Gag-Pol", "GENE_OR_GENE_PRODUCT", 315, 322], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 324, 330], ["LacZ", "GENE_OR_GENE_PRODUCT", 347, 351], ["MLV", "ORGANISM", 361, 364], ["CHIKV E protein expression plasmid", "DNA", 4, 38], ["human codon-optimized full-length DNA fragment", "DNA", 88, 134], ["CHIKV E protein", "PROTEIN", 144, 159], ["pT ARGE T\u2122 plasmid", "DNA", 207, 225], ["Pseudotyped MLV Vector293T cells", "CELL_LINE", 254, 286], ["MLV Gag-Pol (TaKaRa, Shiga, Japan), LacZ-encoding MLV vector genome", "DNA", 311, 378], ["viral envelope protein expression plasmids", "DNA", 396, 438], ["human", "SPECIES", 88, 93], ["CHIKV", "SPECIES", 4, 9], ["human", "SPECIES", 88, 93], ["CHIKV", "SPECIES", 144, 149], ["MLV", "SPECIES", 266, 269], ["MLV", "SPECIES", 361, 364], ["The CHIKV E protein expression plasmid", "TREATMENT", 0, 38], ["an artificially synthesized human codon", "TREATMENT", 60, 99], ["optimized full-length DNA fragment encoding CHIKV E protein", "TREATMENT", 100, 159], ["Pseudotyped MLV Vector293T cells", "TREATMENT", 254, 286], ["the MLV Gag", "TEST", 307, 318], ["LacZ-encoding MLV vector genome", "TREATMENT", 347, 378], ["appropriate viral envelope protein expression plasmids", "TREATMENT", 384, 438], ["Fugene \u00ae HD Transfection Reagent (Promega)", "TREATMENT", 445, 487], ["human codon", "OBSERVATION", 88, 99], ["Vector293T cells", "OBSERVATION", 270, 286]]], ["The culture medium was refreshed 24 h following transfection, and the cells were cultured for an additional 24 h.", [["cells", "ANATOMY", 70, 75], ["cells", "CELL", 70, 75], ["The culture medium", "TEST", 0, 18], ["the cells", "TEST", 66, 75]]], ["Then, the culture medium was centrifuged to remove cells and cell debris.", [["cells", "ANATOMY", 51, 56], ["cell", "ANATOMY", 61, 65], ["cells", "CELL", 51, 56], ["cell", "CELL", 61, 65], ["the culture medium", "TEST", 6, 24], ["cell debris", "PROBLEM", 61, 72], ["cell debris", "OBSERVATION", 61, 72]]], ["For the CHIKV-pseudotyped MLV vector, the target cells were incubated with the undiluted supernatant.", [["cells", "ANATOMY", 49, 54], ["supernatant", "ANATOMY", 89, 100], ["CHIKV", "ORGANISM", 8, 13], ["pseudotyped", "ORGANISM", 14, 25], ["MLV", "ORGANISM", 26, 29], ["cells", "CELL", 49, 54], ["target cells", "CELL_TYPE", 42, 54], ["CHIKV-pseudotyped MLV", "SPECIES", 8, 29], ["the CHIKV-pseudotyped MLV vector", "TREATMENT", 4, 36], ["the target cells", "PROBLEM", 38, 54]]], ["For the VSV-pseudotyped MLV vector, the supernatant was diluted 1/10 with fresh medium, and target cells were inoculated with the diluted supernatant.", [["supernatant", "ANATOMY", 40, 51], ["cells", "ANATOMY", 99, 104], ["supernatant", "ANATOMY", 138, 149], ["VSV", "ORGANISM", 8, 11], ["pseudotyped", "ORGANISM", 12, 23], ["MLV", "ORGANISM", 24, 27], ["cells", "CELL", 99, 104], ["target cells", "CELL_TYPE", 92, 104], ["VSV-pseudotyped MLV", "SPECIES", 8, 27], ["the VSV-pseudotyped MLV vector", "TREATMENT", 4, 34], ["target cells", "PROBLEM", 92, 104]]], ["The inoculated cells were cultured for 2 days and then stained with X-Gal (Wako Pure Chemical Industries, Osaka, Japan) for 5 h.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["X-Gal", "GENE_OR_GENE_PRODUCT", 68, 73], ["inoculated cells", "CELL_LINE", 4, 20], ["The inoculated cells", "TEST", 0, 20], ["inoculated cells", "OBSERVATION", 4, 20]]], ["The stained blue cells were counted in eight randomly selected microscope fields using a 10 \u00d7 objective glass in an experiment.", [["blue cells", "ANATOMY", 12, 22], ["blue cells", "CELL", 12, 22], ["stained blue cells", "CELL_LINE", 4, 22], ["The stained blue cells", "PROBLEM", 0, 22], ["a 10 \u00d7 objective glass", "TREATMENT", 87, 109], ["stained", "OBSERVATION_MODIFIER", 4, 11], ["blue cells", "OBSERVATION", 12, 22]]], ["Usually, 10-50 blue cells were detected per microscope field.", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25]]], ["The total numbers of blue cells in the eight microscope fields were compared.", [["blue cells", "ANATOMY", 21, 31], ["blue cells", "CELL", 21, 31], ["blue cells", "CELL_TYPE", 21, 31], ["blue cells", "TREATMENT", 21, 31], ["total", "OBSERVATION_MODIFIER", 4, 9], ["numbers", "OBSERVATION_MODIFIER", 10, 17], ["blue cells", "OBSERVATION", 21, 31]]], ["Numbers of infected blue cells were much lower than those of total target cells (MOI < 1%).", [["blue cells", "ANATOMY", 20, 30], ["cells", "ANATOMY", 74, 79], ["blue cells", "CELL", 20, 30], ["cells", "CELL", 74, 79], ["infected blue cells", "CELL_TYPE", 11, 30], ["total target cells", "CELL_TYPE", 61, 79], ["infected blue cells", "PROBLEM", 11, 30], ["MOI", "TEST", 81, 84], ["infected", "OBSERVATION_MODIFIER", 11, 19], ["blue cells", "OBSERVATION", 20, 30]]], ["As transduction efficiency was changed day-by-day, the control and treated cells were incubated with the same culture supernatant from the transfected cells.Cell ViabilityThe target cells were treated with the indicated inhibitors for 5 h, and were subsequently cultured for an additional 24 h in fresh medium.", [["cells", "ANATOMY", 75, 80], ["supernatant", "ANATOMY", 118, 129], ["cells", "ANATOMY", 151, 156], ["Cell", "ANATOMY", 157, 161], ["cells", "ANATOMY", 182, 187], ["cells", "CELL", 75, 80], ["cells", "CELL", 151, 156], ["Cell", "CELL", 157, 161], ["cells", "CELL", 182, 187], ["treated cells", "CELL_LINE", 67, 80], ["transfected cells", "CELL_LINE", 139, 156], ["target cells", "CELL_TYPE", 175, 187], ["the control and treated cells", "TREATMENT", 51, 80], ["the same culture", "TEST", 101, 117], ["Cell Viability", "TEST", 157, 171], ["The target cells", "PROBLEM", 171, 187], ["inhibitors", "TREATMENT", 220, 230], ["transfected cells", "OBSERVATION", 139, 156], ["Viability", "OBSERVATION_MODIFIER", 162, 171], ["target cells", "OBSERVATION", 175, 187]]], ["The control cells were treated with the same volume of dimethyl sulfoxide (DMSO).", [["cells", "ANATOMY", 12, 17], ["dimethyl sulfoxide", "CHEMICAL", 55, 73], ["DMSO", "CHEMICAL", 75, 79], ["dimethyl sulfoxide", "CHEMICAL", 55, 73], ["DMSO", "CHEMICAL", 75, 79], ["cells", "CELL", 12, 17], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 55, 73], ["DMSO", "SIMPLE_CHEMICAL", 75, 79], ["the same volume of dimethyl sulfoxide (DMSO", "TREATMENT", 36, 79], ["control cells", "OBSERVATION", 4, 17]]], ["The treated cells were stained with trypan blue, and the numbers of unstained (viable) cells were counted using a counting chamber.Macropinocytosis AssayThe target cells were treated with the indicated inhibitors, and the control cells were treated with the same volume of DMSO for 5 h.", [["cells", "ANATOMY", 12, 17], ["cells", "ANATOMY", 87, 92], ["cells", "ANATOMY", 164, 169], ["cells", "ANATOMY", 230, 235], ["trypan blue", "CHEMICAL", 36, 47], ["DMSO", "CHEMICAL", 273, 277], ["trypan blue", "CHEMICAL", 36, 47], ["DMSO", "CHEMICAL", 273, 277], ["cells", "CELL", 12, 17], ["trypan blue", "SIMPLE_CHEMICAL", 36, 47], ["cells", "CELL", 87, 92], ["cells", "CELL", 164, 169], ["cells", "CELL", 230, 235], ["DMSO", "SIMPLE_CHEMICAL", 273, 277], ["treated cells", "CELL_LINE", 4, 17], ["unstained (viable) cells", "CELL_TYPE", 68, 92], ["target cells", "CELL_TYPE", 157, 169], ["control cells", "CELL_LINE", 222, 235], ["The treated cells", "TREATMENT", 0, 17], ["trypan blue", "TEST", 36, 47], ["unstained (viable) cells", "PROBLEM", 68, 92], ["Macropinocytosis Assay", "TEST", 131, 153], ["The target cells", "PROBLEM", 153, 169], ["inhibitors", "TREATMENT", 202, 212], ["the control cells", "TREATMENT", 218, 235], ["the same volume of DMSO", "TREATMENT", 254, 277], ["target cells", "OBSERVATION", 157, 169]]], ["The treated cells were then cultured for an additional 5 h in the presence of FITC-conjugated dextran (molecular weight >70,000) (Life Technologies Corporation, Eugene, OR, USA).", [["cells", "ANATOMY", 12, 17], ["dextran", "CHEMICAL", 94, 101], ["FITC", "CHEMICAL", 78, 82], ["cells", "CELL", 12, 17], ["FITC-conjugated dextran", "SIMPLE_CHEMICAL", 78, 101], ["treated cells", "CELL_LINE", 4, 17], ["The treated cells", "TREATMENT", 0, 17], ["FITC", "TEST", 78, 82], ["conjugated dextran", "TREATMENT", 83, 101], ["molecular weight", "TEST", 103, 119]]], ["The cells were washed with phosphate-buffered saline and treated with 1% acetic acid in phosphate-buffered saline to remove FITC-conjugated dextran bound to the cell surfaces.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 161, 165], ["phosphate", "CHEMICAL", 27, 36], ["acetic acid", "CHEMICAL", 73, 84], ["phosphate", "CHEMICAL", 88, 97], ["dextran", "CHEMICAL", 140, 147], ["phosphate", "CHEMICAL", 27, 36], ["acetic acid", "CHEMICAL", 73, 84], ["phosphate", "CHEMICAL", 88, 97], ["FITC", "CHEMICAL", 124, 128], ["cells", "CELL", 4, 9], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 27, 52], ["acetic acid", "SIMPLE_CHEMICAL", 73, 84], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 88, 113], ["FITC-conjugated dextran", "SIMPLE_CHEMICAL", 124, 147], ["cell", "CELL", 161, 165], ["phosphate-buffered saline", "TREATMENT", 27, 52], ["1% acetic acid in phosphate", "TREATMENT", 70, 97], ["buffered saline", "TREATMENT", 98, 113], ["FITC-conjugated dextran", "TREATMENT", 124, 147], ["cell surfaces", "OBSERVATION", 161, 174]]], ["Means of fluorescence intensities (MFIs) of the cells were measured using a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).Mouse Antiserum against CHIKV E2 ProteinAntiserum against CHIKV E2 protein was produced by Sigma-Aldrich.", [["cells", "ANATOMY", 48, 53], ["E2", "CHEMICAL", 163, 165], ["E2", "CHEMICAL", 197, 199], ["cells", "CELL", 48, 53], ["Mouse", "ORGANISM", 133, 138], ["Antiserum", "ORGANISM_SUBSTANCE", 139, 148], ["CHIKV E2 ProteinAntiserum", "ORGANISM", 157, 182], ["CHIKV", "ORGANISM", 191, 196], ["E2", "ORGANISM", 197, 199], ["Sigma-Aldrich", "ORGANISM", 224, 237], ["CHIKV E2 protein", "PROTEIN", 191, 207], ["Mouse", "SPECIES", 133, 138], ["Mouse", "SPECIES", 133, 138], ["CHIKV", "SPECIES", 157, 162], ["CHIKV", "SPECIES", 191, 196], ["fluorescence intensities", "TEST", 9, 33], ["a flow cytometer", "TEST", 74, 90], ["Mouse Antiserum", "TREATMENT", 133, 148], ["CHIKV E2 ProteinAntiserum", "TREATMENT", 157, 182], ["CHIKV E2 protein", "TEST", 191, 207], ["fluorescence intensities", "OBSERVATION", 9, 33]]], ["Briefly, a peptide derived from CHIKV E2 protein ( Figure S2 ), was inoculated into a rabbit several times, and the serum was isolated from the rabbit.", [["serum", "ANATOMY", 116, 121], ["E2", "CHEMICAL", 38, 40], ["CHIKV", "ORGANISM", 32, 37], ["E2", "GENE_OR_GENE_PRODUCT", 38, 40], ["rabbit", "ORGANISM", 86, 92], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["rabbit", "ORGANISM", 144, 150], ["CHIKV E2 protein", "PROTEIN", 32, 48], ["rabbit", "SPECIES", 86, 92], ["rabbit", "SPECIES", 144, 150], ["CHIKV", "SPECIES", 32, 37], ["rabbit", "SPECIES", 86, 92], ["rabbit", "SPECIES", 144, 150], ["CHIKV E2 protein", "PROBLEM", 32, 48], ["the serum", "TEST", 112, 121]]], ["The amino acid sequence of the antigen peptide was PVIGRERFHSRPOHGKELPC.Western ImmunoblottingCell lysates were prepared from 293T cells transfected by the CHIKV-pseudotyped MLV vector construction plasmids.", [["Cell lysates", "ANATOMY", 94, 106], ["293T cells", "ANATOMY", 126, 136], ["plasmids", "ANATOMY", 198, 206], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["Cell lysates", "CELL", 94, 106], ["293T cells", "CELL", 126, 136], ["CHIKV", "ORGANISM", 156, 161], ["pseudotyped", "ORGANISM", 162, 173], ["MLV", "ORGANISM", 174, 177], ["amino acid sequence", "PROTEIN", 4, 23], ["293T cells", "CELL_LINE", 126, 136], ["CHIKV-pseudotyped MLV vector construction plasmids", "DNA", 156, 206], ["CHIKV-pseudotyped MLV", "SPECIES", 156, 177], ["The amino acid sequence", "TEST", 0, 23], ["the antigen peptide", "TEST", 27, 46], ["PVIGRERFHSRPOHGKELPC", "PROBLEM", 51, 71], ["ImmunoblottingCell lysates", "TREATMENT", 80, 106], ["the CHIKV-pseudotyped MLV vector construction plasmids", "TREATMENT", 152, 206]]], ["Culture supernatants were centrifuged at 1000 rpm for 10 min to remove cells and cell debris.", [["supernatants", "ANATOMY", 8, 20], ["cells", "ANATOMY", 71, 76], ["cell", "ANATOMY", 81, 85], ["cells", "CELL", 71, 76], ["cell", "CELL", 81, 85], ["Culture supernatants", "TEST", 0, 20], ["cell debris", "PROBLEM", 81, 92], ["cell debris", "OBSERVATION", 81, 92]]], ["The MLV vector particles were collected by centrifugation of the supernatants at 15,000 rpm through 20% sucrose.", [["supernatants", "ANATOMY", 65, 77], ["sucrose", "CHEMICAL", 104, 111], ["sucrose", "CHEMICAL", 104, 111], ["MLV", "ORGANISM", 4, 7], ["sucrose", "SIMPLE_CHEMICAL", 104, 111], ["MLV", "SPECIES", 4, 7], ["The MLV vector particles", "TREATMENT", 0, 24], ["the supernatants", "TREATMENT", 61, 77], ["20% sucrose", "TREATMENT", 100, 111]]], ["The cell lysates and virion pellets were subjected to SDS-PAGE.", [["cell lysates", "ANATOMY", 4, 16], ["cell lysates", "ORGANISM_SUBSTANCE", 4, 16], ["The cell lysates", "TREATMENT", 0, 16], ["virion pellets", "TREATMENT", 21, 35], ["cell lysates", "OBSERVATION", 4, 16]]], ["The proteins were transferred onto polyvinylidene difluoride membranes.", [["polyvinylidene difluoride", "CHEMICAL", 35, 60], ["membranes", "CELLULAR_COMPONENT", 61, 70], ["polyvinylidene difluoride membranes", "TREATMENT", 35, 70]]], ["The membranes were treated with the rabbit anti-CHIKV E2 antiserum and goat anti-MLV p30 antibody (ViroMed Laboratories, Burlington, North Carolina, USA) and then with HRP-conjugated antirabbit and antigoat IgG antibodies (Bio-Rad, Herules, California, USA), respectively.", [["membranes", "ANATOMY", 4, 13], ["E2", "CHEMICAL", 54, 56], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["rabbit", "ORGANISM", 36, 42], ["goat", "ORGANISM", 71, 75], ["HRP-conjugated antirabbit", "SIMPLE_CHEMICAL", 168, 193], ["goat anti-MLV p30 antibody", "PROTEIN", 71, 97], ["HRP", "PROTEIN", 168, 171], ["antirabbit", "PROTEIN", 183, 193], ["antigoat IgG antibodies", "PROTEIN", 198, 221], ["rabbit", "SPECIES", 36, 42], ["goat", "SPECIES", 71, 75], ["rabbit", "SPECIES", 36, 42], ["goat", "SPECIES", 71, 75], ["the rabbit anti-CHIKV E2 antiserum", "TREATMENT", 32, 66], ["goat anti-MLV p30 antibody", "TEST", 71, 97], ["HRP", "TEST", 168, 171], ["antigoat IgG antibodies", "TEST", 198, 221]]], ["The antibody-bound proteins were visualized using Clarity Western ECL Substrate (Bio-Rad).RT-PCRTotal RNA was isolated using TRIzol\u2122 reagent (Thermo Fisher Scientific, Carlsbad, California, USA).", [["Bio-Rad", "GENE_OR_GENE_PRODUCT", 81, 88], ["antibody-bound proteins", "PROTEIN", 4, 27], ["PCRTotal RNA", "RNA", 93, 105], ["The antibody-bound proteins", "TEST", 0, 27], ["RT-PCRTotal RNA", "TREATMENT", 90, 105], ["TRIzol\u2122 reagent", "TREATMENT", 125, 140], ["PCRTotal RNA", "ANATOMY", 93, 105]]], ["First strand cDNA was synthesized with ProtoScript \u00ae II Reverse Transcriptase (New England BioLabs, Ipswich, Massachusetts, USA) using random hexamers (TaKaRa).", [["TaKaRa", "GENE_OR_GENE_PRODUCT", 152, 158], ["strand cDNA", "DNA", 6, 17], ["First strand cDNA", "TREATMENT", 0, 17], ["random hexamers (TaKaRa)", "TREATMENT", 135, 159]]], ["Glyceraldehyde-3-phosphate dehydrogenase (control) or cathepsin B sequences were amplified by PCR.Statistical AnalysisDifferences between two groups were determined by the Student's t-test.", [["Glyceraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["Glyceraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["Glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 40], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 54, 65], ["Glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 0, 40], ["cathepsin B sequences", "DNA", 54, 75], ["Glyceraldehyde-3-phosphate dehydrogenase (control", "TREATMENT", 0, 49], ["cathepsin B sequences", "TEST", 54, 75], ["the Student's t-test", "TEST", 168, 188]]], ["The difference was considered statistically significant if the p-value was <0.05 for all tests.Characterization of CHIKV-Pseudotyped Retrovirus VectorWe used a CHIKV-pseudotyped MLV vector to measure the CHIKV E protein-mediated entry into target cells.", [["cells", "ANATOMY", 247, 252], ["CHIKV", "ORGANISM", 115, 120], ["CHIKV", "ORGANISM", 160, 165], ["pseudotyped", "ORGANISM", 166, 177], ["MLV", "ORGANISM", 178, 181], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 204, 219], ["cells", "CELL", 247, 252], ["CHIKV E protein", "PROTEIN", 204, 219], ["target cells", "CELL_TYPE", 240, 252], ["CHIKV", "SPECIES", 115, 120], ["CHIKV", "SPECIES", 160, 165], ["MLV", "SPECIES", 178, 181], ["CHIKV", "SPECIES", 204, 209], ["the p-value", "TEST", 59, 70], ["all tests", "TEST", 85, 94], ["Characterization", "TEST", 95, 111], ["CHIKV", "PROBLEM", 115, 120], ["Pseudotyped Retrovirus VectorWe", "TREATMENT", 121, 152], ["a CHIKV-pseudotyped MLV vector", "TREATMENT", 158, 188], ["the CHIKV E protein", "TEST", 200, 219], ["CHIKV", "OBSERVATION", 115, 120], ["target cells", "OBSERVATION", 240, 252]]], ["To construct the CHIKV-pseudotyped MLV vector, a full-length DNA fragment containing the CHIKV E3-E2-6K-E1 sequence optimized to human codon usage was synthesized and inserted into a pT ARGE T\u2122 expression plasmid.", [["E2", "CHEMICAL", 98, 100], ["CHIKV", "ORGANISM", 17, 22], ["pseudotyped", "ORGANISM", 23, 34], ["MLV", "ORGANISM", 35, 38], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["CHIKV", "ORGANISM", 89, 94], ["E3", "GENE_OR_GENE_PRODUCT", 95, 97], ["human", "ORGANISM", 129, 134], ["CHIKV-pseudotyped MLV vector", "DNA", 17, 45], ["full-length DNA fragment", "DNA", 49, 73], ["CHIKV E3-E2-6K-E1 sequence", "DNA", 89, 115], ["pT ARGE T\u2122 expression plasmid", "DNA", 183, 212], ["human", "SPECIES", 129, 134], ["CHIKV-pseudotyped MLV", "SPECIES", 17, 38], ["CHIKV", "SPECIES", 89, 94], ["human", "SPECIES", 129, 134], ["the CHIKV-pseudotyped MLV vector", "TREATMENT", 13, 45], ["a full-length DNA fragment", "TREATMENT", 47, 73], ["the CHIKV E3-E2", "TREATMENT", 85, 100], ["6K-E1 sequence", "TREATMENT", 101, 115], ["human codon usage", "TREATMENT", 129, 146], ["a pT ARGE T\u2122 expression plasmid", "TREATMENT", 181, 212], ["CHIKV", "OBSERVATION", 17, 22]]], ["293T cells were transfected with the CHIKV E protein expression plasmid together with MLV Gag-Pol and LacZ-encoding MLV vector genome expression plasmids ( Figure S1 ).", [["293T cells", "ANATOMY", 0, 10], ["plasmids", "ANATOMY", 145, 153], ["293T cells", "CELL", 0, 10], ["MLV", "ORGANISM", 86, 89], ["Gag-Pol", "GENE_OR_GENE_PRODUCT", 90, 97], ["LacZ", "GENE_OR_GENE_PRODUCT", 102, 106], ["MLV", "ORGANISM", 116, 119], ["293T cells", "CELL_LINE", 0, 10], ["CHIKV E protein expression plasmid", "DNA", 37, 71], ["MLV Gag-Pol and LacZ-encoding MLV vector genome expression plasmids", "DNA", 86, 153], ["Figure S1", "DNA", 156, 165], ["CHIKV", "SPECIES", 37, 42], ["the CHIKV E protein expression plasmid", "TREATMENT", 33, 71], ["MLV Gag", "TREATMENT", 86, 93], ["LacZ-encoding MLV vector genome expression plasmids", "TREATMENT", 102, 153]]], ["Human 293T, HeLa, or TE671 cells were incubated with the culture supernatants of the transfected cells.", [["293T", "ANATOMY", 6, 10], ["HeLa", "ANATOMY", 12, 16], ["TE671 cells", "ANATOMY", 21, 32], ["supernatants", "ANATOMY", 65, 77], ["cells", "ANATOMY", 97, 102], ["Human", "ORGANISM", 0, 5], ["293T", "CELL", 6, 10], ["HeLa", "CELL", 12, 16], ["TE671 cells", "CELL", 21, 32], ["cells", "CELL", 97, 102], ["Human 293T", "CELL_LINE", 0, 10], ["HeLa", "CELL_LINE", 12, 16], ["TE671 cells", "CELL_LINE", 21, 32], ["transfected cells", "CELL_LINE", 85, 102], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["the culture supernatants", "TEST", 53, 77], ["the transfected cells", "PROBLEM", 81, 102], ["transfected cells", "OBSERVATION", 85, 102]]], ["The inoculated cells were stained with X-Gal, and the resultant blue cells were counted to measure the CHIKV-pseudotyped MLV vector infection.", [["cells", "ANATOMY", 15, 20], ["blue cells", "ANATOMY", 64, 74], ["infection", "DISEASE", 132, 141], ["cells", "CELL", 15, 20], ["X-Gal", "GENE_OR_GENE_PRODUCT", 39, 44], ["blue cells", "CELL", 64, 74], ["CHIKV", "ORGANISM", 103, 108], ["pseudotyped", "ORGANISM", 109, 120], ["MLV", "ORGANISM", 121, 124], ["X-Gal", "DNA", 39, 44], ["resultant blue cells", "CELL_LINE", 54, 74], ["CHIKV-pseudotyped MLV", "SPECIES", 103, 124], ["The inoculated cells", "TEST", 0, 20], ["the resultant blue cells", "PROBLEM", 50, 74], ["the CHIKV", "PROBLEM", 99, 108], ["pseudotyped MLV vector infection", "PROBLEM", 109, 141], ["inoculated cells", "OBSERVATION", 4, 20], ["blue cells", "OBSERVATION", 64, 74], ["CHIKV", "OBSERVATION", 103, 108], ["pseudotyped MLV vector infection", "OBSERVATION", 109, 141]]], ["293T and TE671 cells were used in the subsequent experiments, because the numbers of blue 293T and TE671 cells were much higher than those of the blue HeLa cells ( Figure 1A) .", [["293T", "ANATOMY", 0, 4], ["TE671 cells", "ANATOMY", 9, 20], ["blue 293T", "ANATOMY", 85, 94], ["TE671 cells", "ANATOMY", 99, 110], ["HeLa cells", "ANATOMY", 151, 161], ["293T", "CELL", 0, 4], ["TE671 cells", "CELL", 9, 20], ["blue 293T", "CELL", 85, 94], ["TE671 cells", "CELL", 99, 110], ["blue HeLa cells", "CELL", 146, 161], ["293T", "CELL_LINE", 0, 4], ["TE671 cells", "CELL_LINE", 9, 20], ["blue 293T", "CELL_LINE", 85, 94], ["TE671 cells", "CELL_LINE", 99, 110], ["blue HeLa cells", "CELL_LINE", 146, 161], ["TE671 cells", "TEST", 99, 110]]], ["Only a few infected cells were detected in HeLa cells.Characterization of CHIKV-Pseudotyped Retrovirus VectorWe wanted to verify that the infection by the pseudotyped MLV vector is achieved by a recognition step dependent on CHIKV E protein and is neutralized by an antiserum, as replication-competent CHIKV.", [["cells", "ANATOMY", 20, 25], ["HeLa cells", "ANATOMY", 43, 53], ["infection", "DISEASE", 138, 147], ["cells", "CELL", 20, 25], ["HeLa cells", "CELL", 43, 53], ["CHIKV", "ORGANISM", 74, 79], ["pseudotyped", "ORGANISM", 155, 166], ["MLV", "ORGANISM", 167, 170], ["CHIKV", "ORGANISM", 225, 230], ["CHIKV", "ORGANISM", 302, 307], ["HeLa cells", "CELL_LINE", 43, 53], ["CHIKV E protein", "PROTEIN", 225, 240], ["CHIKV", "SPECIES", 74, 79], ["MLV", "SPECIES", 167, 170], ["CHIKV", "SPECIES", 225, 230], ["CHIKV", "SPECIES", 302, 307], ["a few infected cells", "PROBLEM", 5, 25], ["CHIKV", "PROBLEM", 74, 79], ["Pseudotyped Retrovirus VectorWe", "TREATMENT", 80, 111], ["the infection", "PROBLEM", 134, 147], ["the pseudotyped MLV vector", "TREATMENT", 151, 177], ["CHIKV E protein", "TREATMENT", 225, 240], ["an antiserum", "TREATMENT", 263, 275], ["few", "OBSERVATION_MODIFIER", 7, 10], ["infected cells", "OBSERVATION", 11, 25], ["HeLa cells", "OBSERVATION", 43, 53], ["CHIKV", "OBSERVATION", 74, 79], ["infection", "OBSERVATION", 138, 147], ["CHIKV", "OBSERVATION", 302, 307]]], ["The effect of a serum that was isolated from CHIKV-infected patients and has neutralization activity against CHIKV infection [37] [38] [39] was analyzed.", [["serum", "ANATOMY", 16, 21], ["CHIKV-infected", "DISEASE", 45, 59], ["CHIKV infection", "DISEASE", 109, 124], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["CHIKV", "ORGANISM", 45, 50], ["patients", "ORGANISM", 60, 68], ["CHIKV", "ORGANISM", 109, 114], ["patients", "SPECIES", 60, 68], ["CHIKV", "SPECIES", 45, 50], ["CHIKV", "SPECIES", 109, 114], ["a serum", "TEST", 14, 21], ["CHIKV", "PROBLEM", 45, 50], ["neutralization activity", "TREATMENT", 77, 100], ["CHIKV infection", "PROBLEM", 109, 124]]], ["Human embryonic kidney 293T or rhabdomyosarcoma TE671 cells were incubated with the CHIKV E protein-containing MLV vector in the presence of the serum.", [["embryonic kidney 293T", "ANATOMY", 6, 27], ["rhabdomyosarcoma TE671 cells", "ANATOMY", 31, 59], ["serum", "ANATOMY", 145, 150], ["Human", "ORGANISM", 0, 5], ["embryonic kidney 293T", "CELL", 6, 27], ["rhabdomyosarcoma TE671 cells", "CELL", 31, 59], ["MLV", "ORGANISM", 111, 114], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["Human embryonic kidney 293T", "CELL_LINE", 0, 27], ["rhabdomyosarcoma TE671 cells", "CELL_LINE", 31, 59], ["CHIKV E protein", "PROTEIN", 84, 99], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["CHIKV", "SPECIES", 84, 89], ["Human embryonic kidney", "TEST", 0, 22], ["rhabdomyosarcoma TE671 cells", "PROBLEM", 31, 59], ["the CHIKV E protein", "TEST", 80, 99], ["MLV vector", "TREATMENT", 111, 121], ["kidney", "ANATOMY", 16, 22], ["rhabdomyosarcoma", "OBSERVATION", 31, 47]]], ["Fifty percent focus reduction neutralization value of the serum was 1:2560 (personal communication with Dr. Inoue).", [["serum", "ANATOMY", 58, 63], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["the serum", "TEST", 54, 63], ["focus", "OBSERVATION_MODIFIER", 14, 19], ["reduction", "OBSERVATION_MODIFIER", 20, 29], ["neutralization", "OBSERVATION", 30, 44]]], ["Similarly, when the serum was diluted with medium by 1/2000, infected cell numbers were decreased to about 50% ( Figure 1B) .", [["serum", "ANATOMY", 20, 25], ["cell", "ANATOMY", 70, 74], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["cell", "CELL", 70, 74], ["the serum", "TEST", 16, 25], ["infected cell numbers", "TEST", 61, 82], ["infected cell numbers", "OBSERVATION", 61, 82]]], ["However, the serum less efficiently inhibited vesicular stomatitis virus (VSV)-pseudotyped MLV vector infection than CHIKV-pseudotyped vector.", [["serum", "ANATOMY", 13, 18], ["infection", "DISEASE", 102, 111], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["vesicular stomatitis virus", "ORGANISM", 46, 72], ["VSV", "ORGANISM", 74, 77], ["pseudotyped", "ORGANISM", 79, 90], ["MLV", "ORGANISM", 91, 94], ["CHIKV", "ORGANISM", 117, 122], ["pseudotyped", "ORGANISM", 123, 134], ["stomatitis virus", "SPECIES", 56, 72], ["stomatitis virus", "SPECIES", 56, 72], ["VSV", "SPECIES", 74, 77], ["MLV", "SPECIES", 91, 94], ["CHIKV", "SPECIES", 117, 122], ["the serum", "TEST", 9, 18], ["vesicular stomatitis virus", "PROBLEM", 46, 72], ["pseudotyped MLV vector infection", "PROBLEM", 79, 111], ["CHIKV-pseudotyped vector", "TREATMENT", 117, 141], ["vesicular stomatitis virus", "OBSERVATION", 46, 72]]], ["This result confirmed that the infection is induced by the CHIKV E protein.Characterization of CHIKV-Pseudotyped Retrovirus VectorTo examine whether CHIKV-pseudotyped MLV vector infection required endosome acidification, 293T or TE671 cells were pretreated with the endosome acidification inhibitor concanamycin A (CMA) [40] for 5 h.", [["endosome", "ANATOMY", 197, 205], ["293T", "ANATOMY", 221, 225], ["TE671 cells", "ANATOMY", 229, 240], ["endosome", "ANATOMY", 266, 274], ["infection", "DISEASE", 31, 40], ["infection", "DISEASE", 178, 187], ["concanamycin A", "CHEMICAL", 299, 313], ["CMA", "CHEMICAL", 315, 318], ["concanamycin A", "CHEMICAL", 299, 313], ["CMA", "CHEMICAL", 315, 318], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 59, 74], ["CHIKV-Pseudotyped Retrovirus VectorTo", "ORGANISM", 95, 132], ["CHIKV-pseudotyped MLV", "ORGANISM", 149, 170], ["endosome", "CELLULAR_COMPONENT", 197, 205], ["TE671 cells", "CELL", 229, 240], ["endosome", "CELLULAR_COMPONENT", 266, 274], ["concanamycin A", "SIMPLE_CHEMICAL", 299, 313], ["CMA", "SIMPLE_CHEMICAL", 315, 318], ["CHIKV E protein", "PROTEIN", 59, 74], ["293T", "CELL_LINE", 221, 225], ["TE671 cells", "CELL_LINE", 229, 240], ["pseudotyped", "SPECIES", 155, 166], ["CHIKV", "SPECIES", 59, 64], ["CHIKV", "SPECIES", 95, 100], ["CHIKV", "SPECIES", 149, 154], ["MLV", "SPECIES", 167, 170], ["the infection", "PROBLEM", 27, 40], ["the CHIKV E protein", "PROBLEM", 55, 74], ["CHIKV", "PROBLEM", 95, 100], ["Pseudotyped Retrovirus VectorTo", "TREATMENT", 101, 132], ["CHIKV", "PROBLEM", 149, 154], ["pseudotyped MLV vector infection", "PROBLEM", 155, 187], ["endosome acidification", "PROBLEM", 197, 219], ["TE671 cells", "PROBLEM", 229, 240], ["the endosome acidification inhibitor concanamycin A (CMA)", "TREATMENT", 262, 319], ["infection", "OBSERVATION", 31, 40], ["CHIKV", "OBSERVATION", 95, 100]]], ["This CMA treatment did not significantly suppress the cell viability [18] .", [["cell", "ANATOMY", 54, 58], ["CMA", "CHEMICAL", 5, 8], ["CMA", "CHEMICAL", 5, 8], ["CMA", "SIMPLE_CHEMICAL", 5, 8], ["cell", "CELL", 54, 58], ["This CMA treatment", "TREATMENT", 0, 18], ["cell viability", "OBSERVATION", 54, 68]]], ["The treated cells were incubated with the CHIKV-pseudotyped MLV vector.", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["CHIKV", "ORGANISM", 42, 47], ["pseudotyped", "ORGANISM", 48, 59], ["MLV", "ORGANISM", 60, 63], ["treated cells", "CELL_LINE", 4, 17], ["CHIKV-pseudotyped MLV", "SPECIES", 42, 63], ["The treated cells", "TREATMENT", 0, 17], ["the CHIKV-pseudotyped MLV vector", "TREATMENT", 38, 70]]], ["The CMA treatment inhibited the CHIKV-pseudotyped MLV vector infection in a dose-dependent manner ( Figure 1C ), which confirmed that endosome acidification was required for CHIKV-pseudotyped vector infection, as previously reported [12] [13] [14] .Characterization of CHIKV-Pseudotyped Retrovirus Vectorexpression plasmid together with MLV Gag-Pol and LacZ-encoding MLV vector genome expression plasmids ( Figure S1 ).", [["endosome", "ANATOMY", 134, 142], ["CMA", "CHEMICAL", 4, 7], ["infection", "DISEASE", 61, 70], ["CHIKV-pseudotyped vector infection", "DISEASE", 174, 208], ["CMA", "CHEMICAL", 4, 7], ["CMA", "SIMPLE_CHEMICAL", 4, 7], ["CHIKV", "ORGANISM", 32, 37], ["pseudotyped", "ORGANISM", 38, 49], ["MLV", "ORGANISM", 50, 53], ["endosome", "CELLULAR_COMPONENT", 134, 142], ["CHIKV", "ORGANISM", 174, 179], ["pseudotyped", "ORGANISM", 180, 191], ["[12] [13] [14]", "SIMPLE_CHEMICAL", 233, 247], ["CHIKV", "ORGANISM", 269, 274], ["MLV", "ORGANISM", 337, 340], ["Gag-Pol", "GENE_OR_GENE_PRODUCT", 341, 348], ["LacZ", "GENE_OR_GENE_PRODUCT", 353, 357], ["MLV", "ORGANISM", 367, 370], ["CHIKV-Pseudotyped Retrovirus Vectorexpression plasmid", "DNA", 269, 322], ["MLV Gag-Pol and LacZ-encoding MLV vector genome expression plasmids", "DNA", 337, 404], ["Figure S1", "DNA", 407, 416], ["CHIKV-pseudotyped MLV", "SPECIES", 32, 53], ["CHIKV", "SPECIES", 174, 179], ["CHIKV", "SPECIES", 269, 274], ["MLV", "SPECIES", 337, 340], ["The CMA treatment", "TREATMENT", 0, 17], ["the CHIKV-pseudotyped MLV vector infection", "PROBLEM", 28, 70], ["endosome acidification", "PROBLEM", 134, 156], ["CHIKV", "PROBLEM", 174, 179], ["pseudotyped vector infection", "PROBLEM", 180, 208], ["Characterization", "TEST", 249, 265], ["CHIKV", "PROBLEM", 269, 274], ["Pseudotyped Retrovirus Vectorexpression plasmid", "TREATMENT", 275, 322], ["MLV Gag-Pol", "TREATMENT", 337, 348], ["LacZ-encoding MLV vector genome expression plasmids", "TREATMENT", 353, 404], ["CHIKV", "OBSERVATION", 269, 274]]], ["Human 293T, HeLa, or TE671 cells were incubated with the culture supernatants of the transfected cells.", [["293T", "ANATOMY", 6, 10], ["HeLa", "ANATOMY", 12, 16], ["TE671 cells", "ANATOMY", 21, 32], ["supernatants", "ANATOMY", 65, 77], ["cells", "ANATOMY", 97, 102], ["Human", "ORGANISM", 0, 5], ["293T", "CELL", 6, 10], ["HeLa", "CELL", 12, 16], ["TE671 cells", "CELL", 21, 32], ["cells", "CELL", 97, 102], ["Human 293T", "CELL_LINE", 0, 10], ["HeLa", "CELL_LINE", 12, 16], ["TE671 cells", "CELL_LINE", 21, 32], ["transfected cells", "CELL_LINE", 85, 102], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["the culture supernatants", "TEST", 53, 77], ["the transfected cells", "PROBLEM", 81, 102], ["transfected cells", "OBSERVATION", 85, 102]]], ["The inoculated cells were stained with X-Gal, and the resultant blue cells were counted to measure the CHIKV-pseudotyped MLV vector infection.", [["cells", "ANATOMY", 15, 20], ["blue cells", "ANATOMY", 64, 74], ["infection", "DISEASE", 132, 141], ["cells", "CELL", 15, 20], ["X-Gal", "GENE_OR_GENE_PRODUCT", 39, 44], ["blue cells", "CELL", 64, 74], ["CHIKV", "ORGANISM", 103, 108], ["pseudotyped", "ORGANISM", 109, 120], ["MLV", "ORGANISM", 121, 124], ["X-Gal", "DNA", 39, 44], ["resultant blue cells", "CELL_LINE", 54, 74], ["CHIKV-pseudotyped MLV", "SPECIES", 103, 124], ["The inoculated cells", "TEST", 0, 20], ["the resultant blue cells", "PROBLEM", 50, 74], ["the CHIKV", "PROBLEM", 99, 108], ["pseudotyped MLV vector infection", "PROBLEM", 109, 141], ["inoculated cells", "OBSERVATION", 4, 20], ["blue cells", "OBSERVATION", 64, 74], ["CHIKV", "OBSERVATION", 103, 108], ["pseudotyped MLV vector infection", "OBSERVATION", 109, 141]]], ["293T and TE671 cells were used in the subsequent experiments, because the numbers of blue 293T and TE671 cells were much higher than those of the blue HeLa cells ( Figure 1A) .", [["293T", "ANATOMY", 0, 4], ["TE671 cells", "ANATOMY", 9, 20], ["blue 293T", "ANATOMY", 85, 94], ["TE671 cells", "ANATOMY", 99, 110], ["HeLa cells", "ANATOMY", 151, 161], ["293T", "CELL", 0, 4], ["TE671 cells", "CELL", 9, 20], ["blue 293T", "CELL", 85, 94], ["TE671 cells", "CELL", 99, 110], ["blue HeLa cells", "CELL", 146, 161], ["293T", "CELL_LINE", 0, 4], ["TE671 cells", "CELL_LINE", 9, 20], ["blue 293T", "CELL_LINE", 85, 94], ["TE671 cells", "CELL_LINE", 99, 110], ["blue HeLa cells", "CELL_LINE", 146, 161], ["TE671 cells", "TEST", 99, 110]]], ["Only a few infected cells were detected in HeLa cells.Endocytosis Is Required for CHIKV-Pseudotyped MLV Vector Infection in 293T but Not in TE671 CellsThe above result prompted us to speculate that CHIKV-pseudotyped MLV vector infection occurs via endocytosis in 293T and TE671 cells.", [["cells", "ANATOMY", 20, 25], ["HeLa cells", "ANATOMY", 43, 53], ["293T", "ANATOMY", 124, 128], ["Cells", "ANATOMY", 146, 151], ["293T", "ANATOMY", 263, 267], ["TE671 cells", "ANATOMY", 272, 283], ["infection", "DISEASE", 227, 236], ["cells", "CELL", 20, 25], ["HeLa cells", "CELL", 43, 53], ["CHIKV", "ORGANISM", 82, 87], ["293T", "CELL", 124, 128], ["TE671 Cells", "CELL", 140, 151], ["CHIKV-pseudotyped MLV", "ORGANISM", 198, 219], ["293T", "CELL", 263, 267], ["TE671 cells", "CELL", 272, 283], ["HeLa cells", "CELL_LINE", 43, 53], ["TE671 Cells", "CELL_LINE", 140, 151], ["293T", "CELL_LINE", 263, 267], ["TE671 cells", "CELL_LINE", 272, 283], ["CHIKV", "SPECIES", 82, 87], ["CHIKV", "SPECIES", 198, 203], ["MLV", "SPECIES", 216, 219], ["a few infected cells", "PROBLEM", 5, 25], ["CHIKV", "PROBLEM", 82, 87], ["Pseudotyped MLV Vector Infection", "PROBLEM", 88, 120], ["CHIKV", "PROBLEM", 198, 203], ["pseudotyped MLV vector infection", "PROBLEM", 204, 236], ["few", "OBSERVATION_MODIFIER", 7, 10], ["infected cells", "OBSERVATION", 11, 25], ["HeLa cells", "OBSERVATION", 43, 53], ["CHIKV", "OBSERVATION", 198, 203]]], ["To this end, 293T and TE671 cells were pretreated with an endocytosis inhibitor, dynasore (20 or 40 \u00b5M) or Pitstop2 (50 or 100 \u00b5M) for 5 h.", [["293T", "ANATOMY", 13, 17], ["TE671 cells", "ANATOMY", 22, 33], ["dynasore", "CHEMICAL", 81, 89], ["Pitstop2", "CHEMICAL", 107, 115], ["dynasore", "CHEMICAL", 81, 89], ["Pitstop2", "CHEMICAL", 107, 115], ["293T", "CELL", 13, 17], ["TE671 cells", "CELL", 22, 33], ["dynasore", "SIMPLE_CHEMICAL", 81, 89], ["Pitstop2", "SIMPLE_CHEMICAL", 107, 115], ["293T", "CELL_LINE", 13, 17], ["TE671 cells", "CELL_LINE", 22, 33], ["an endocytosis inhibitor", "TREATMENT", 55, 79], ["dynasore", "TREATMENT", 81, 89], ["Pitstop2", "TREATMENT", 107, 115]]], ["Dynasore inhibits vesicle formation [41] .", [["vesicle", "ANATOMY", 18, 25], ["Dynasore", "CHEMICAL", 0, 8], ["Dynasore", "SIMPLE_CHEMICAL", 0, 8], ["vesicle", "CELLULAR_COMPONENT", 18, 25], ["vesicle formation", "OBSERVATION", 18, 35]]], ["Pitstop2 is a specific inhibitor of clathrin that suppresses clathrin-mediated endocytosis [42] .", [["Pitstop2", "CHEMICAL", 0, 8], ["Pitstop2", "GENE_OR_GENE_PRODUCT", 0, 8], ["clathrin", "GENE_OR_GENE_PRODUCT", 36, 44], ["clathrin", "GENE_OR_GENE_PRODUCT", 61, 69], ["Pitstop2", "PROTEIN", 0, 8], ["clathrin", "PROTEIN", 36, 44], ["clathrin", "PROTEIN", 61, 69], ["Pitstop2", "TREATMENT", 0, 8], ["a specific inhibitor of clathrin", "TREATMENT", 12, 44]]], ["We have already reported that the dynasore treatment inhibits ecotropic MLV infection without affecting the cell viability [18] .", [["cell", "ANATOMY", 108, 112], ["dynasore", "CHEMICAL", 34, 42], ["ecotropic MLV infection", "DISEASE", 62, 85], ["dynasore", "SIMPLE_CHEMICAL", 34, 42], ["ecotropic MLV", "ORGANISM", 62, 75], ["cell", "CELL", 108, 112], ["MLV", "SPECIES", 72, 75], ["the dynasore treatment", "TREATMENT", 30, 52], ["ecotropic MLV infection", "PROBLEM", 62, 85], ["ecotropic MLV infection", "OBSERVATION", 62, 85], ["cell viability", "OBSERVATION", 108, 122]]], ["The Pitstop2 treatment at 50 \u00b5M did not affect cell viability, and that at 100 \u00b5M decreased live cell numbers to about 60% (Figure 2A ).", [["cell", "ANATOMY", 47, 51], ["cell", "ANATOMY", 97, 101], ["Pitstop2", "CHEMICAL", 4, 12], ["Pitstop2", "SIMPLE_CHEMICAL", 4, 12], ["cell", "CELL", 47, 51], ["cell", "CELL", 97, 101], ["The Pitstop2 treatment", "TREATMENT", 0, 22], ["cell viability", "OBSERVATION", 47, 61]]], ["The treated cells were incubated with a CHIKV-or VSV-pseudotyped MLV vector.", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["CHIKV", "ORGANISM", 40, 45], ["VSV", "ORGANISM", 49, 52], ["pseudotyped", "ORGANISM", 53, 64], ["MLV", "ORGANISM", 65, 68], ["treated cells", "CELL_LINE", 4, 17], ["CHIKV", "SPECIES", 40, 45], ["The treated cells", "TREATMENT", 0, 17], ["a CHIKV", "PROBLEM", 38, 45], ["VSV-pseudotyped MLV vector", "TREATMENT", 49, 75], ["pseudotyped MLV vector", "OBSERVATION", 53, 75]]], ["Dynasore ( Figure 2B ) and Pitstop2 ( Figure 2C ) both inhibited the CHIKV-pseudotyped MLV vector infection in 293T cells but not in TE671 cells.", [["293T cells", "ANATOMY", 111, 121], ["TE671 cells", "ANATOMY", 133, 144], ["infection", "DISEASE", 98, 107], ["Pitstop2 ( Figure 2C", "GENE_OR_GENE_PRODUCT", 27, 47], ["CHIKV", "ORGANISM", 69, 74], ["pseudotyped", "ORGANISM", 75, 86], ["MLV", "ORGANISM", 87, 90], ["293T cells", "CELL", 111, 121], ["TE671 cells", "CELL", 133, 144], ["Pitstop2", "PROTEIN", 27, 35], ["293T cells", "CELL_LINE", 111, 121], ["TE671 cells", "CELL_LINE", 133, 144], ["CHIKV", "SPECIES", 69, 74], ["MLV", "SPECIES", 87, 90], ["Pitstop2 ( Figure 2C )", "TREATMENT", 27, 49], ["the CHIKV", "PROBLEM", 65, 74], ["pseudotyped MLV vector infection", "PROBLEM", 75, 107]]], ["These inhibitors more efficiently decreased the infected cell numbers than the live cell numbers in 293T cells.", [["cell", "ANATOMY", 57, 61], ["cell", "ANATOMY", 84, 88], ["293T cells", "ANATOMY", 100, 110], ["cell", "CELL", 57, 61], ["cell", "CELL", 84, 88], ["293T cells", "CELL", 100, 110], ["293T cells", "CELL_LINE", 100, 110], ["These inhibitors", "TREATMENT", 0, 16], ["the infected cell numbers", "PROBLEM", 44, 69], ["infected cell numbers", "OBSERVATION", 48, 69], ["293T cells", "OBSERVATION", 100, 110]]], ["However, the VSV-pseudotyped MLV vector infection was attenuated by the inhibitors inMacropinocytosis is Required for CHIKV-Pseudotyped MLV Vector Infection in TE671 Cells but Not in 293T CellsThe endocytosis inhibitors did not suppress the CHIKV-pseudotyped MLV vector infection in TE671 cells.", [["Cells", "ANATOMY", 166, 171], ["293T Cells", "ANATOMY", 183, 193], ["TE671 cells", "ANATOMY", 283, 294], ["infection", "DISEASE", 40, 49], ["infection", "DISEASE", 270, 279], ["VSV-pseudotyped MLV", "ORGANISM", 13, 32], ["CHIKV", "ORGANISM", 118, 123], ["MLV Vector", "ORGANISM", 136, 146], ["TE671 Cells", "CELL", 160, 171], ["293T Cells", "CELL", 183, 193], ["CHIKV", "ORGANISM", 241, 246], ["pseudotyped", "ORGANISM", 247, 258], ["MLV", "ORGANISM", 259, 262], ["TE671 cells", "CELL", 283, 294], ["TE671 Cells", "CELL_LINE", 160, 171], ["TE671 cells", "CELL_LINE", 283, 294], ["MLV", "SPECIES", 29, 32], ["CHIKV", "SPECIES", 118, 123], ["MLV", "SPECIES", 136, 139], ["CHIKV", "SPECIES", 241, 246], ["MLV", "SPECIES", 259, 262], ["the VSV", "PROBLEM", 9, 16], ["pseudotyped MLV vector infection", "PROBLEM", 17, 49], ["the inhibitors inMacropinocytosis", "PROBLEM", 68, 101], ["CHIKV", "PROBLEM", 118, 123], ["Pseudotyped MLV Vector Infection in TE671 Cells", "PROBLEM", 124, 171], ["The endocytosis inhibitors", "PROBLEM", 193, 219], ["the CHIKV-pseudotyped MLV vector infection in TE671 cells", "PROBLEM", 237, 294], ["293T Cells", "OBSERVATION", 183, 193], ["CHIKV", "OBSERVATION", 241, 246]]], ["To assess whether macropinocytosis was the mechanism of infection in TE671 cells, 293T and TE671 cells were pretreated with the macropinocytosis inhibitors 5-(N-ethyl-N-isopropyl)amiloride (EIPA) (10 or 20 \u03bcM) for 5 h.", [["TE671 cells", "ANATOMY", 69, 80], ["293T", "ANATOMY", 82, 86], ["TE671 cells", "ANATOMY", 91, 102], ["infection", "DISEASE", 56, 65], ["5-(N-ethyl-N-isopropyl)amiloride", "CHEMICAL", 156, 188], ["EIPA", "CHEMICAL", 190, 194], ["5-(N-ethyl-N-isopropyl)amiloride", "CHEMICAL", 156, 188], ["EIPA", "CHEMICAL", 190, 194], ["TE671 cells", "CELL", 69, 80], ["293T", "CELL", 82, 86], ["TE671 cells", "CELL", 91, 102], ["5-(N-ethyl-N-isopropyl)amiloride", "SIMPLE_CHEMICAL", 156, 188], ["EIPA", "SIMPLE_CHEMICAL", 190, 194], ["TE671 cells", "CELL_LINE", 69, 80], ["293T", "CELL_LINE", 82, 86], ["TE671 cells", "CELL_LINE", 91, 102], ["macropinocytosis", "PROBLEM", 18, 34], ["infection in TE671 cells", "PROBLEM", 56, 80], ["the macropinocytosis inhibitors", "TREATMENT", 124, 155], ["N-ethyl-N-isopropyl)amiloride (EIPA)", "TREATMENT", 159, 195], ["infection", "OBSERVATION", 56, 65]]], ["TE671 cells were also treated with wortmannin (WOR) at 50 or 100 \u03bcM, and 293T cells were at 10 or 20 \u03bcM, because the WOR treatment at 50 and 100 \u03bcM had severe cytotoxity in 293T cells.", [["TE671 cells", "ANATOMY", 0, 11], ["293T cells", "ANATOMY", 73, 83], ["293T cells", "ANATOMY", 173, 183], ["wortmannin", "CHEMICAL", 35, 45], ["WOR", "CHEMICAL", 117, 120], ["wortmannin", "CHEMICAL", 35, 45], ["TE671 cells", "CELL", 0, 11], ["wortmannin", "SIMPLE_CHEMICAL", 35, 45], ["WOR", "SIMPLE_CHEMICAL", 47, 50], ["293T cells", "CELL", 73, 83], ["WOR", "SIMPLE_CHEMICAL", 117, 120], ["293T cells", "CELL", 173, 183], ["TE671 cells", "CELL_LINE", 0, 11], ["293T cells", "CELL_LINE", 73, 83], ["293T cells", "CELL_LINE", 173, 183], ["wortmannin", "TREATMENT", 35, 45], ["the WOR treatment", "TREATMENT", 113, 130], ["severe cytotoxity in 293T cells", "PROBLEM", 152, 183], ["293T cells", "OBSERVATION", 173, 183]]], ["EIPA inhibits the Na + /H + ion exchange pump in the plasma membrane, thereby affecting the intracellular pH, resulting in the cessation of macropinocytosis [43] .", [["plasma membrane", "ANATOMY", 53, 68], ["intracellular", "ANATOMY", 92, 105], ["EIPA", "CHEMICAL", 0, 4], ["Na", "CHEMICAL", 18, 20], ["H", "CHEMICAL", 24, 25], ["EIPA", "CHEMICAL", 0, 4], ["Na +", "CHEMICAL", 18, 22], ["H +", "CHEMICAL", 24, 27], ["EIPA", "SIMPLE_CHEMICAL", 0, 4], ["Na +", "SIMPLE_CHEMICAL", 18, 22], ["H +", "SIMPLE_CHEMICAL", 24, 27], ["plasma membrane", "CELLULAR_COMPONENT", 53, 68], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 105], ["EIPA", "TEST", 0, 4], ["the Na", "TEST", 14, 20], ["ion exchange pump", "TREATMENT", 28, 45], ["the plasma membrane", "TREATMENT", 49, 68], ["the intracellular pH", "TEST", 88, 108], ["macropinocytosis", "PROBLEM", 140, 156], ["plasma membrane", "ANATOMY", 53, 68]]], ["WOR specifically inhibits PI3-kinase, which is essential for macropinocytosis [44] .", [["WOR", "SIMPLE_CHEMICAL", 0, 3], ["PI3-kinase", "GENE_OR_GENE_PRODUCT", 26, 36], ["WOR", "PROTEIN", 0, 3], ["PI3-kinase", "PROTEIN", 26, 36], ["PI3-kinase", "TEST", 26, 36], ["macropinocytosis", "PROBLEM", 61, 77]]], ["EIAP treatment only slightly suppressed the cell viability, but not WOR treatment ( Figure 3A,B) .Macropinocytosis Is Required for CHIKV-Pseudotyped MLV Vector Infection in TE671 Cells but Not in 293T CellsThe endocytosis inhibitors did not suppress the CHIKV-pseudotyped MLV vector infection in TE671 cells.", [["cell", "ANATOMY", 44, 48], ["Cells", "ANATOMY", 179, 184], ["293T Cells", "ANATOMY", 196, 206], ["TE671 cells", "ANATOMY", 296, 307], ["EIAP", "CHEMICAL", 0, 4], ["infection", "DISEASE", 283, 292], ["EIAP", "CHEMICAL", 0, 4], ["EIAP", "SIMPLE_CHEMICAL", 0, 4], ["cell", "CELL", 44, 48], ["WOR", "SIMPLE_CHEMICAL", 68, 71], ["CHIKV", "ORGANISM", 131, 136], ["TE671 Cells", "CELL", 173, 184], ["293T Cells", "CELL", 196, 206], ["CHIKV", "ORGANISM", 254, 259], ["pseudotyped", "ORGANISM", 260, 271], ["MLV", "ORGANISM", 272, 275], ["TE671 cells", "CELL", 296, 307], ["WOR", "PROTEIN", 68, 71], ["TE671 Cells", "CELL_LINE", 173, 184], ["293T Cells", "CELL_LINE", 196, 206], ["TE671 cells", "CELL_LINE", 296, 307], ["CHIKV", "SPECIES", 131, 136], ["CHIKV", "SPECIES", 254, 259], ["MLV", "SPECIES", 272, 275], ["EIAP treatment", "TREATMENT", 0, 14], ["Macropinocytosis", "PROBLEM", 98, 114], ["CHIKV", "PROBLEM", 131, 136], ["Pseudotyped MLV Vector Infection", "PROBLEM", 137, 169], ["The endocytosis inhibitors", "PROBLEM", 206, 232], ["the CHIKV-pseudotyped MLV vector infection in TE671 cells", "PROBLEM", 250, 307], ["cell viability", "OBSERVATION", 44, 58], ["293T Cells", "OBSERVATION", 196, 206], ["CHIKV", "OBSERVATION", 254, 259]]], ["To assess whether macropinocytosis was the mechanism of infection in TE671 cells, 293T and TE671 cells were pretreated with the macropinocytosis inhibitors 5-(N-ethyl-N-isopropyl)-amiloride (EIPA) (10 or 20 \u00b5M) for 5 h.", [["TE671 cells", "ANATOMY", 69, 80], ["293T", "ANATOMY", 82, 86], ["TE671 cells", "ANATOMY", 91, 102], ["infection", "DISEASE", 56, 65], ["5-(N-ethyl-N-isopropyl)-amiloride", "CHEMICAL", 156, 189], ["EIPA", "CHEMICAL", 191, 195], ["5-(N-ethyl-N-isopropyl)-amiloride", "CHEMICAL", 156, 189], ["EIPA", "CHEMICAL", 191, 195], ["TE671 cells", "CELL", 69, 80], ["293T", "CELL", 82, 86], ["TE671 cells", "CELL", 91, 102], ["5-(N-ethyl-N-isopropyl)-amiloride", "SIMPLE_CHEMICAL", 156, 189], ["EIPA", "SIMPLE_CHEMICAL", 191, 195], ["TE671 cells", "CELL_LINE", 69, 80], ["293T", "CELL_LINE", 82, 86], ["TE671 cells", "CELL_LINE", 91, 102], ["macropinocytosis", "PROBLEM", 18, 34], ["infection in TE671 cells", "PROBLEM", 56, 80], ["the macropinocytosis inhibitors", "TREATMENT", 124, 155], ["N-ethyl-N-isopropyl)", "TREATMENT", 159, 179], ["amiloride (EIPA)", "TREATMENT", 180, 196], ["infection", "OBSERVATION", 56, 65]]], ["TE671 cells were also treated with wortmannin (WOR) at 50 or 100 \u00b5M, and 293T cells were at 10 or 20 \u00b5M, because the WOR treatment at 50 and 100 \u00b5M had severe cytotoxity in 293T cells.", [["TE671 cells", "ANATOMY", 0, 11], ["293T cells", "ANATOMY", 73, 83], ["293T cells", "ANATOMY", 173, 183], ["wortmannin", "CHEMICAL", 35, 45], ["WOR", "CHEMICAL", 117, 120], ["wortmannin", "CHEMICAL", 35, 45], ["TE671 cells", "CELL", 0, 11], ["wortmannin", "SIMPLE_CHEMICAL", 35, 45], ["WOR", "SIMPLE_CHEMICAL", 47, 50], ["293T cells", "CELL", 73, 83], ["WOR", "SIMPLE_CHEMICAL", 117, 120], ["293T cells", "CELL", 173, 183], ["TE671 cells", "CELL_LINE", 0, 11], ["293T cells", "CELL_LINE", 73, 83], ["293T cells", "CELL_LINE", 173, 183], ["wortmannin", "TREATMENT", 35, 45], ["the WOR treatment", "TREATMENT", 113, 130], ["severe cytotoxity in 293T cells", "PROBLEM", 152, 183], ["293T cells", "OBSERVATION", 173, 183]]], ["EIPA inhibits the Na + /H + ion exchange pump in the plasma membrane, thereby affecting the intracellular pH, resulting in the cessation of macropinocytosis [43] .", [["plasma membrane", "ANATOMY", 53, 68], ["intracellular", "ANATOMY", 92, 105], ["EIPA", "CHEMICAL", 0, 4], ["Na", "CHEMICAL", 18, 20], ["H", "CHEMICAL", 24, 25], ["EIPA", "CHEMICAL", 0, 4], ["Na +", "CHEMICAL", 18, 22], ["H +", "CHEMICAL", 24, 27], ["EIPA", "SIMPLE_CHEMICAL", 0, 4], ["Na +", "SIMPLE_CHEMICAL", 18, 22], ["H +", "SIMPLE_CHEMICAL", 24, 27], ["plasma membrane", "CELLULAR_COMPONENT", 53, 68], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 105], ["EIPA", "TEST", 0, 4], ["the Na", "TEST", 14, 20], ["ion exchange pump", "TREATMENT", 28, 45], ["the plasma membrane", "TREATMENT", 49, 68], ["the intracellular pH", "TEST", 88, 108], ["macropinocytosis", "PROBLEM", 140, 156], ["plasma membrane", "ANATOMY", 53, 68]]], ["WOR specifically inhibits PI3-kinase, which is essential for macropinocytosis [44] .", [["WOR", "SIMPLE_CHEMICAL", 0, 3], ["PI3-kinase", "GENE_OR_GENE_PRODUCT", 26, 36], ["WOR", "PROTEIN", 0, 3], ["PI3-kinase", "PROTEIN", 26, 36], ["PI3-kinase", "TEST", 26, 36], ["macropinocytosis", "PROBLEM", 61, 77]]], ["EIAP treatment only slightly suppressed the cell viability, but not WOR treatment ( Figure 3A,B) .", [["cell", "ANATOMY", 44, 48], ["EIAP", "CHEMICAL", 0, 4], ["EIAP", "CHEMICAL", 0, 4], ["EIAP", "SIMPLE_CHEMICAL", 0, 4], ["cell", "CELL", 44, 48], ["WOR", "SIMPLE_CHEMICAL", 68, 71], ["WOR", "PROTEIN", 68, 71], ["EIAP treatment", "TREATMENT", 0, 14], ["cell viability", "OBSERVATION", 44, 58]]], ["To examine whether the EIPA or WOR treatment inhibits macropinocytosis, fluorescein isothiocyanate (FITC)-labeled dextran (molecular weight >70,000) was added to the treated cells.", [["cells", "ANATOMY", 174, 179], ["EIPA", "CHEMICAL", 23, 27], ["WOR", "CHEMICAL", 31, 34], ["fluorescein isothiocyanate", "CHEMICAL", 72, 98], ["dextran", "CHEMICAL", 114, 121], ["EIPA", "CHEMICAL", 23, 27], ["WOR", "CHEMICAL", 31, 34], ["fluorescein isothiocyanate", "CHEMICAL", 72, 98], ["FITC", "CHEMICAL", 100, 104], ["EIPA", "SIMPLE_CHEMICAL", 23, 27], ["WOR", "SIMPLE_CHEMICAL", 31, 34], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 72, 98], ["FITC", "SIMPLE_CHEMICAL", 100, 104], ["dextran", "SIMPLE_CHEMICAL", 114, 121], ["cells", "CELL", 174, 179], ["treated cells", "CELL_LINE", 166, 179], ["the EIPA", "TEST", 19, 27], ["WOR treatment", "TREATMENT", 31, 44], ["macropinocytosis", "TEST", 54, 70], ["fluorescein isothiocyanate", "TEST", 72, 98], ["dextran (molecular weight", "TREATMENT", 114, 139]]], ["The dextran could be internalized by macropinocytosis, but not by endocytosis, because of its large molecular size.", [["dextran", "CHEMICAL", 4, 11], ["dextran", "SIMPLE_CHEMICAL", 4, 11], ["The dextran", "TREATMENT", 0, 11], ["macropinocytosis", "PROBLEM", 37, 53], ["its large molecular size", "PROBLEM", 90, 114], ["macropinocytosis", "OBSERVATION", 37, 53], ["large", "OBSERVATION_MODIFIER", 94, 99], ["molecular", "OBSERVATION_MODIFIER", 100, 109], ["size", "OBSERVATION_MODIFIER", 110, 114]]], ["293T and TE671 cells were treated with EIPA at 20 \u03bcM.", [["293T", "ANATOMY", 0, 4], ["TE671 cells", "ANATOMY", 9, 20], ["EIPA", "CHEMICAL", 39, 43], ["EIPA", "CHEMICAL", 39, 43], ["293T", "CELL", 0, 4], ["TE671 cells", "CELL", 9, 20], ["EIPA", "SIMPLE_CHEMICAL", 39, 43], ["293T", "CELL_LINE", 0, 4], ["TE671 cells", "CELL_LINE", 9, 20], ["EIPA", "TREATMENT", 39, 43]]], ["293T and TE671 cells were treated with WOR at 20 and 100 \u03bcM, respectively.", [["293T", "ANATOMY", 0, 4], ["TE671 cells", "ANATOMY", 9, 20], ["WOR", "CHEMICAL", 39, 42], ["293T", "CELL", 0, 4], ["TE671 cells", "CELL", 9, 20], ["WOR", "SIMPLE_CHEMICAL", 39, 42], ["293T", "CELL_LINE", 0, 4], ["TE671 cells", "CELL_LINE", 9, 20], ["WOR", "TREATMENT", 39, 42]]], ["The fluorescence intensities of the 293T and TE671 cells were decreased by the EIPA or WOR treatment ( Figure 3C ).", [["293T", "ANATOMY", 36, 40], ["TE671 cells", "ANATOMY", 45, 56], ["EIPA", "CHEMICAL", 79, 83], ["WOR", "CHEMICAL", 87, 90], ["EIPA", "CHEMICAL", 79, 83], ["WOR", "CHEMICAL", 87, 90], ["293T", "CELL", 36, 40], ["TE671 cells", "CELL", 45, 56], ["EIPA", "SIMPLE_CHEMICAL", 79, 83], ["WOR", "SIMPLE_CHEMICAL", 87, 90], ["293T", "CELL_LINE", 36, 40], ["TE671 cells", "CELL_LINE", 45, 56], ["The fluorescence intensities", "TEST", 0, 28], ["the EIPA", "TREATMENT", 75, 83], ["WOR treatment", "TREATMENT", 87, 100]]], ["These results demonstrated that macropinocytosis was indeed suppressed by these inhibitors.Macropinocytosis Is Required for CHIKV-Pseudotyped MLV Vector Infection in TE671 Cells but Not in 293T CellsThen, the effect of the macripinocytosis inhibitors on CHIKV-pseudotyped MLV vector infection To examine whether the EIPA or WOR treatment inhibits macropinocytosis, fluorescein isothiocyanate (FITC)-labeled dextran (molecular weight >70,000) was added to the treated cells.", [["Cells", "ANATOMY", 172, 177], ["293T CellsThen", "ANATOMY", 189, 203], ["cells", "ANATOMY", 467, 472], ["infection", "DISEASE", 283, 292], ["EIPA", "CHEMICAL", 316, 320], ["WOR", "CHEMICAL", 324, 327], ["fluorescein isothiocyanate", "CHEMICAL", 365, 391], ["dextran", "CHEMICAL", 407, 414], ["EIPA", "CHEMICAL", 316, 320], ["WOR", "CHEMICAL", 324, 327], ["fluorescein isothiocyanate", "CHEMICAL", 365, 391], ["FITC", "CHEMICAL", 393, 397], ["CHIKV", "ORGANISM", 124, 129], ["MLV Vector", "ORGANISM", 142, 152], ["TE671 Cells", "CELL", 166, 177], ["293T CellsThen", "CELL", 189, 203], ["CHIKV", "ORGANISM", 254, 259], ["pseudotyped", "ORGANISM", 260, 271], ["MLV", "ORGANISM", 272, 275], ["EIPA", "SIMPLE_CHEMICAL", 316, 320], ["WOR", "SIMPLE_CHEMICAL", 324, 327], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 365, 391], ["FITC", "SIMPLE_CHEMICAL", 393, 397], ["dextran", "SIMPLE_CHEMICAL", 407, 414], ["cells", "CELL", 467, 472], ["TE671 Cells", "CELL_LINE", 166, 177], ["treated cells", "CELL_LINE", 459, 472], ["CHIKV", "SPECIES", 124, 129], ["CHIKV", "SPECIES", 254, 259], ["MLV", "SPECIES", 272, 275], ["macropinocytosis", "PROBLEM", 32, 48], ["these inhibitors", "TREATMENT", 74, 90], ["Macropinocytosis", "PROBLEM", 91, 107], ["CHIKV", "PROBLEM", 124, 129], ["Pseudotyped MLV Vector Infection in TE671 Cells", "PROBLEM", 130, 177], ["the macripinocytosis inhibitors", "TREATMENT", 219, 250], ["CHIKV", "PROBLEM", 254, 259], ["pseudotyped MLV vector infection", "PROBLEM", 260, 292], ["the EIPA", "TREATMENT", 312, 320], ["WOR treatment", "TREATMENT", 324, 337], ["macropinocytosis", "PROBLEM", 347, 363], ["fluorescein isothiocyanate", "TEST", 365, 391], ["dextran (molecular weight", "TREATMENT", 407, 432], ["macropinocytosis", "OBSERVATION", 32, 48]]], ["The dextran could be internalized by macropinocytosis, but not by endocytosis, because of its large molecular size.", [["dextran", "CHEMICAL", 4, 11], ["dextran", "SIMPLE_CHEMICAL", 4, 11], ["The dextran", "TREATMENT", 0, 11], ["macropinocytosis", "PROBLEM", 37, 53], ["its large molecular size", "PROBLEM", 90, 114], ["macropinocytosis", "OBSERVATION", 37, 53], ["large", "OBSERVATION_MODIFIER", 94, 99], ["molecular", "OBSERVATION_MODIFIER", 100, 109], ["size", "OBSERVATION_MODIFIER", 110, 114]]], ["293T and TE671 cells were treated with EIPA at 20 \u00b5M.", [["293T", "ANATOMY", 0, 4], ["TE671 cells", "ANATOMY", 9, 20], ["EIPA", "CHEMICAL", 39, 43], ["EIPA", "CHEMICAL", 39, 43], ["293T", "CELL", 0, 4], ["TE671 cells", "CELL", 9, 20], ["EIPA", "SIMPLE_CHEMICAL", 39, 43], ["293T", "CELL_LINE", 0, 4], ["TE671 cells", "CELL_LINE", 9, 20], ["EIPA", "TREATMENT", 39, 43]]], ["293T and TE671 cells were treated with WOR at 20 and 100 \u00b5M, respectively.", [["293T", "ANATOMY", 0, 4], ["TE671 cells", "ANATOMY", 9, 20], ["WOR", "CHEMICAL", 39, 42], ["293T", "CELL", 0, 4], ["TE671 cells", "CELL", 9, 20], ["WOR", "SIMPLE_CHEMICAL", 39, 42], ["293T", "CELL_LINE", 0, 4], ["TE671 cells", "CELL_LINE", 9, 20], ["WOR", "TREATMENT", 39, 42]]], ["The fluorescence intensities of the 293T and TE671 Viruses 2020, 12, 722 8 of 14 cells were decreased by the EIPA or WOR treatment ( Figure 3C ).", [["293T", "ANATOMY", 36, 40], ["cells", "ANATOMY", 81, 86], ["EIPA", "CHEMICAL", 109, 113], ["WOR", "CHEMICAL", 117, 120], ["EIPA", "CHEMICAL", 109, 113], ["WOR", "CHEMICAL", 117, 120], ["293T", "CELL", 36, 40], ["cells", "CELL", 81, 86], ["EIPA", "SIMPLE_CHEMICAL", 109, 113], ["WOR", "SIMPLE_CHEMICAL", 117, 120], ["The fluorescence intensities", "TEST", 0, 28], ["TE671 Viruses", "TEST", 45, 58], ["the EIPA", "TREATMENT", 105, 113], ["WOR treatment", "TREATMENT", 117, 130]]], ["These results demonstrated that macropinocytosis was indeed suppressed by these inhibitors.Macropinocytosis Is Required for CHIKV-Pseudotyped MLV Vector Infection in TE671 Cells but Not in 293T CellsThen, the effect of the macripinocytosis inhibitors on CHIKV-pseudotyped MLV vector infection was analyzed.", [["Cells", "ANATOMY", 172, 177], ["CHIKV-pseudotyped MLV vector infection", "DISEASE", 254, 292], ["CHIKV", "ORGANISM", 124, 129], ["MLV Vector", "ORGANISM", 142, 152], ["TE671 Cells", "CELL", 166, 177], ["293T CellsThen", "CELL", 189, 203], ["macripinocytosis", "GENE_OR_GENE_PRODUCT", 223, 239], ["CHIKV", "ORGANISM", 254, 259], ["pseudotyped", "ORGANISM", 260, 271], ["MLV", "ORGANISM", 272, 275], ["TE671 Cells", "CELL_LINE", 166, 177], ["CHIKV", "SPECIES", 124, 129], ["CHIKV", "SPECIES", 254, 259], ["MLV", "SPECIES", 272, 275], ["macropinocytosis", "PROBLEM", 32, 48], ["these inhibitors", "TREATMENT", 74, 90], ["Macropinocytosis", "PROBLEM", 91, 107], ["CHIKV", "PROBLEM", 124, 129], ["Pseudotyped MLV Vector Infection in TE671 Cells", "PROBLEM", 130, 177], ["the macripinocytosis inhibitors", "TREATMENT", 219, 250], ["CHIKV", "PROBLEM", 254, 259], ["pseudotyped MLV vector infection", "PROBLEM", 260, 292], ["macropinocytosis", "OBSERVATION", 32, 48]]], ["Both macropinocytosis inhibitors attenuated the CHIKV-pseudotyped MLV vector infection in TE671 cells in a dose-dependent manner but not in 293T cells (Figure 4A,B) .", [["TE671 cells", "ANATOMY", 90, 101], ["293T cells", "ANATOMY", 140, 150], ["infection", "DISEASE", 77, 86], ["CHIKV", "ORGANISM", 48, 53], ["pseudotyped", "ORGANISM", 54, 65], ["MLV", "ORGANISM", 66, 69], ["TE671 cells", "CELL", 90, 101], ["293T cells", "CELL", 140, 150], ["B", "CELL", 162, 163], ["TE671 cells", "CELL_LINE", 90, 101], ["293T cells", "CELL_LINE", 140, 150], ["CHIKV", "SPECIES", 48, 53], ["MLV", "SPECIES", 66, 69], ["Both macropinocytosis inhibitors", "PROBLEM", 0, 32], ["the CHIKV", "PROBLEM", 44, 53], ["pseudotyped MLV vector infection in TE671 cells", "PROBLEM", 54, 101], ["macropinocytosis inhibitors", "OBSERVATION", 5, 32], ["CHIKV", "OBSERVATION", 48, 53], ["pseudotyped MLV vector infection", "OBSERVATION", 54, 86]]], ["When TE671 cells were treated with 10 \u00b5M EIPA, the CHIKV-pseudotyped MLV infection was inhibited ( Figure 4A ) but the VSV-pseudotyped infection was not ( Figure 4C ).", [["TE671 cells", "ANATOMY", 5, 16], ["EIPA", "CHEMICAL", 41, 45], ["MLV infection", "DISEASE", 69, 82], ["infection", "DISEASE", 135, 144], ["EIPA", "CHEMICAL", 41, 45], ["TE671 cells", "CELL", 5, 16], ["EIPA", "SIMPLE_CHEMICAL", 41, 45], ["CHIKV-pseudotyped MLV", "ORGANISM", 51, 72], ["VSV", "ORGANISM", 119, 122], ["pseudotyped", "ORGANISM", 123, 134], ["TE671 cells", "CELL_LINE", 5, 16], ["CHIKV-pseudotyped MLV", "SPECIES", 51, 72], ["VSV-pseudotyped", "SPECIES", 119, 134], ["10 \u00b5M EIPA", "TREATMENT", 35, 45], ["the CHIKV-pseudotyped MLV infection", "PROBLEM", 47, 82], ["the VSV", "PROBLEM", 115, 122], ["pseudotyped infection", "PROBLEM", 123, 144], ["infection", "OBSERVATION", 73, 82], ["pseudotyped", "OBSERVATION_MODIFIER", 123, 134], ["infection", "OBSERVATION", 135, 144]]], ["The EIPA treatment at 20 \u00b5M more significantly inhibited the CHIKV-pseudotyped MLV infection than VSV-pseudotyped infection.", [["EIPA", "CHEMICAL", 4, 8], ["MLV infection", "DISEASE", 79, 92], ["infection", "DISEASE", 114, 123], ["EIPA", "CHEMICAL", 4, 8], ["EIPA", "SIMPLE_CHEMICAL", 4, 8], ["CHIKV-pseudotyped MLV", "ORGANISM", 61, 82], ["VSV-pseudotyped", "ORGANISM", 98, 113], ["CHIKV", "SPECIES", 61, 66], ["MLV", "SPECIES", 79, 82], ["VSV", "SPECIES", 98, 101], ["The EIPA treatment", "TREATMENT", 0, 18], ["the CHIKV-pseudotyped MLV infection", "PROBLEM", 57, 92], ["VSV", "PROBLEM", 98, 101], ["pseudotyped infection", "PROBLEM", 102, 123], ["CHIKV", "OBSERVATION", 61, 66], ["pseudotyped MLV infection", "OBSERVATION", 67, 92], ["pseudotyped", "OBSERVATION_MODIFIER", 102, 113], ["infection", "OBSERVATION", 114, 123]]], ["The EIPA treatment inhibited VSV-pseudotyped MLV vector infection in TE671 cells, but not in 293T cells ( Figure 4C ).", [["TE671 cells", "ANATOMY", 69, 80], ["293T cells", "ANATOMY", 93, 103], ["EIPA", "CHEMICAL", 4, 8], ["infection", "DISEASE", 56, 65], ["EIPA", "CHEMICAL", 4, 8], ["EIPA", "SIMPLE_CHEMICAL", 4, 8], ["VSV", "ORGANISM", 29, 32], ["pseudotyped", "ORGANISM", 33, 44], ["MLV", "ORGANISM", 45, 48], ["TE671 cells", "CELL", 69, 80], ["293T cells", "CELL", 93, 103], ["TE671 cells", "CELL_LINE", 69, 80], ["293T cells", "CELL_LINE", 93, 103], ["VSV", "SPECIES", 29, 32], ["MLV", "SPECIES", 45, 48], ["The EIPA treatment", "TREATMENT", 0, 18], ["VSV", "PROBLEM", 29, 32], ["pseudotyped MLV vector infection in TE671 cells", "PROBLEM", 33, 80], ["pseudotyped MLV vector infection", "OBSERVATION", 33, 65]]], ["The WOR treatment did not affect the VSV-pseudotyped vector infection in 293T cells, and rather enhanced the infection in TE671 cells ( Figure 4D ).", [["293T cells", "ANATOMY", 73, 83], ["TE671 cells", "ANATOMY", 122, 133], ["infection", "DISEASE", 60, 69], ["infection", "DISEASE", 109, 118], ["WOR", "SIMPLE_CHEMICAL", 4, 7], ["VSV", "ORGANISM", 37, 40], ["pseudotyped", "ORGANISM", 41, 52], ["293T cells", "CELL", 73, 83], ["TE671 cells", "CELL", 122, 133], ["293T cells", "CELL_LINE", 73, 83], ["TE671 cells", "CELL_LINE", 122, 133], ["The WOR treatment", "TREATMENT", 0, 17], ["the VSV", "PROBLEM", 33, 40], ["pseudotyped vector infection in 293T cells", "PROBLEM", 41, 83], ["the infection in TE671 cells", "PROBLEM", 105, 133], ["293T cells", "OBSERVATION", 73, 83], ["infection", "OBSERVATION", 109, 118]]], ["These results show that CHIKV-pseudotyped vector infection occurs through macropinocytosis in rhabdomyosarcoma TE671 cells, as previously reported in another rhabdomyosarcoma cell line, SJCRH30 [45] .", [["rhabdomyosarcoma TE671 cells", "ANATOMY", 94, 122], ["rhabdomyosarcoma cell line", "ANATOMY", 158, 184], ["infection", "DISEASE", 49, 58], ["rhabdomyosarcoma", "DISEASE", 94, 110], ["rhabdomyosarcoma", "DISEASE", 158, 174], ["CHIKV", "ORGANISM", 24, 29], ["pseudotyped", "ORGANISM", 30, 41], ["rhabdomyosarcoma TE671 cells", "CELL", 94, 122], ["rhabdomyosarcoma cell line", "CELL", 158, 184], ["SJCRH30 [45", "CELL", 186, 197], ["rhabdomyosarcoma TE671 cells", "CELL_LINE", 94, 122], ["rhabdomyosarcoma cell line", "CELL_LINE", 158, 184], ["SJCRH30 [45", "CELL_LINE", 186, 197], ["CHIKV", "SPECIES", 24, 29], ["CHIKV", "PROBLEM", 24, 29], ["pseudotyped vector infection", "PROBLEM", 30, 58], ["macropinocytosis", "PROBLEM", 74, 90], ["rhabdomyosarcoma TE671 cells", "PROBLEM", 94, 122], ["another rhabdomyosarcoma cell line", "PROBLEM", 150, 184], ["CHIKV", "OBSERVATION", 24, 29], ["rhabdomyosarcoma", "OBSERVATION", 94, 110], ["rhabdomyosarcoma cell line", "OBSERVATION", 158, 184]]], ["To confirm whether the macropinocytosis inhibitors suppress virus entry, target 293T and TE671 cells were first inoculated with CHIKV-pseudotyped MLV vector and then were treated with the inhibitors 2 h after the inoculation.", [["293T", "ANATOMY", 80, 84], ["TE671 cells", "ANATOMY", 89, 100], ["293T", "CELL", 80, 84], ["TE671 cells", "CELL", 89, 100], ["CHIKV", "ORGANISM", 128, 133], ["pseudotyped", "ORGANISM", 134, 145], ["MLV", "ORGANISM", 146, 149], ["target 293T", "CELL_LINE", 73, 84], ["TE671 cells", "CELL_LINE", 89, 100], ["CHIKV-pseudotyped MLV", "SPECIES", 128, 149], ["the macropinocytosis inhibitors suppress virus entry", "PROBLEM", 19, 71], ["TE671 cells", "PROBLEM", 89, 100], ["CHIKV-pseudotyped MLV vector", "TREATMENT", 128, 156], ["the inhibitors", "TREATMENT", 184, 198], ["the inoculation", "TREATMENT", 209, 224]]], ["The treatment after inoculation much less efficiently attenuated CHIKV-pseudotyped MLV infection ( Figure 5 ).", [["MLV infection", "DISEASE", 83, 96], ["CHIKV", "ORGANISM", 65, 70], ["pseudotyped MLV", "ORGANISM", 71, 86], ["CHIKV-pseudotyped MLV", "SPECIES", 65, 86], ["The treatment", "TREATMENT", 0, 13], ["inoculation", "TREATMENT", 20, 31], ["CHIKV", "PROBLEM", 65, 70], ["pseudotyped MLV infection", "PROBLEM", 71, 96], ["pseudotyped MLV infection", "OBSERVATION", 71, 96]]], ["This result suggests that the macropinocytosis inhibitors suppress an early step of pseudotyped vector infection, supporting the result that macropinocytosis is required for CHIKV E protein-mediated entry into host cells.", [["cells", "ANATOMY", 215, 220], ["infection", "DISEASE", 103, 112], ["pseudotyped", "ORGANISM", 84, 95], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 174, 189], ["host cells", "CELL", 210, 220], ["CHIKV E protein", "PROTEIN", 174, 189], ["host cells", "CELL_TYPE", 210, 220], ["CHIKV", "SPECIES", 174, 179], ["the macropinocytosis inhibitors", "PROBLEM", 26, 57], ["pseudotyped vector infection", "PROBLEM", 84, 112], ["macropinocytosis", "PROBLEM", 141, 157], ["CHIKV E protein", "TREATMENT", 174, 189], ["pseudotyped vector infection", "OBSERVATION", 84, 112], ["host cells", "OBSERVATION", 210, 220]]], ["To confirm whether the macropinocytosis inhibitors suppress virus entry, target 293T and TE671 cells were first inoculated with CHIKV-pseudotyped MLV vector and then were treated with the inhibitors 2 h after the inoculation.", [["293T", "ANATOMY", 80, 84], ["TE671 cells", "ANATOMY", 89, 100], ["293T", "CELL", 80, 84], ["TE671 cells", "CELL", 89, 100], ["CHIKV", "ORGANISM", 128, 133], ["pseudotyped", "ORGANISM", 134, 145], ["MLV", "ORGANISM", 146, 149], ["target 293T", "CELL_LINE", 73, 84], ["TE671 cells", "CELL_LINE", 89, 100], ["CHIKV-pseudotyped MLV", "SPECIES", 128, 149], ["the macropinocytosis inhibitors suppress virus entry", "PROBLEM", 19, 71], ["TE671 cells", "PROBLEM", 89, 100], ["CHIKV-pseudotyped MLV vector", "TREATMENT", 128, 156], ["the inhibitors", "TREATMENT", 184, 198], ["the inoculation", "TREATMENT", 209, 224]]], ["The treatment after inoculation much less efficiently attenuated CHIKV-pseudotyped MLV infection ( Figure 5 ).", [["MLV infection", "DISEASE", 83, 96], ["CHIKV", "ORGANISM", 65, 70], ["pseudotyped MLV", "ORGANISM", 71, 86], ["CHIKV-pseudotyped MLV", "SPECIES", 65, 86], ["The treatment", "TREATMENT", 0, 13], ["inoculation", "TREATMENT", 20, 31], ["CHIKV", "PROBLEM", 65, 70], ["pseudotyped MLV infection", "PROBLEM", 71, 96], ["pseudotyped MLV infection", "OBSERVATION", 71, 96]]], ["This result suggests that the macropinocytosis inhibitors suppress an early step of pseudotyped vector infection, supporting the result that macropinocytosis is required for CHIKV E protein-mediated entry into host cells.Macropinocytosis Is Required for CHIKV-Pseudotyped MLV Vector Infection in TE671 Cells but Not in 293T CellsTo confirm whether the macropinocytosis inhibitors suppress virus entry, target 293T and TE671 cells were first inoculated with CHIKV-pseudotyped MLV vector and then were treated with the inhibitors 2 h after the inoculation.", [["cells", "ANATOMY", 215, 220], ["Cells", "ANATOMY", 302, 307], ["293T CellsTo", "ANATOMY", 319, 331], ["293T", "ANATOMY", 409, 413], ["TE671 cells", "ANATOMY", 418, 429], ["infection", "DISEASE", 103, 112], ["pseudotyped", "ORGANISM", 84, 95], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 174, 189], ["host cells", "CELL", 210, 220], ["CHIKV", "ORGANISM", 254, 259], ["MLV Vector", "ORGANISM", 272, 282], ["TE671 Cells", "CELL", 296, 307], ["293T CellsTo", "CELL", 319, 331], ["293T", "CELL", 409, 413], ["TE671 cells", "CELL", 418, 429], ["CHIKV", "ORGANISM", 457, 462], ["pseudotyped", "ORGANISM", 463, 474], ["MLV", "ORGANISM", 475, 478], ["CHIKV E protein", "PROTEIN", 174, 189], ["host cells", "CELL_TYPE", 210, 220], ["TE671 Cells", "CELL_LINE", 296, 307], ["target 293T", "CELL_LINE", 402, 413], ["TE671 cells", "CELL_LINE", 418, 429], ["CHIKV", "SPECIES", 174, 179], ["CHIKV", "SPECIES", 254, 259], ["CHIKV-pseudotyped MLV", "SPECIES", 457, 478], ["the macropinocytosis inhibitors", "PROBLEM", 26, 57], ["pseudotyped vector infection", "PROBLEM", 84, 112], ["macropinocytosis", "PROBLEM", 141, 157], ["CHIKV E protein", "TREATMENT", 174, 189], ["Macropinocytosis", "PROBLEM", 221, 237], ["CHIKV", "PROBLEM", 254, 259], ["Pseudotyped MLV Vector Infection in TE671 Cells", "PROBLEM", 260, 307], ["the macropinocytosis inhibitors suppress virus entry", "PROBLEM", 348, 400], ["TE671 cells", "PROBLEM", 418, 429], ["CHIKV-pseudotyped MLV vector", "TREATMENT", 457, 485], ["the inhibitors", "TREATMENT", 513, 527], ["the inoculation", "TREATMENT", 538, 553], ["pseudotyped vector infection", "OBSERVATION", 84, 112], ["host cells", "OBSERVATION", 210, 220]]], ["The treatment after inoculation much less efficiently attenuated CHIKV-pseudotyped MLV infection ( Figure 5 ).", [["MLV infection", "DISEASE", 83, 96], ["CHIKV", "ORGANISM", 65, 70], ["pseudotyped MLV", "ORGANISM", 71, 86], ["CHIKV-pseudotyped MLV", "SPECIES", 65, 86], ["The treatment", "TREATMENT", 0, 13], ["inoculation", "TREATMENT", 20, 31], ["CHIKV", "PROBLEM", 65, 70], ["pseudotyped MLV infection", "PROBLEM", 71, 96], ["pseudotyped MLV infection", "OBSERVATION", 71, 96]]], ["This result suggests that the macropinocytosis inhibitors suppress an early step of pseudotyped vector infection, supporting the result that macropinocytosis is required for CHIKV E protein-mediated entry into host cells.Cathepsin Protease Is Required for CHIKV-Pseudotyped MLV Vector Infection in 293T and TE671 CellsMLV or Ebola virus infection is also mediated via acidic endosomes and requires endosomal cathepsin B protease.", [["cells", "ANATOMY", 215, 220], ["293T", "ANATOMY", 298, 302], ["acidic endosomes", "ANATOMY", 368, 384], ["endosomal", "ANATOMY", 398, 407], ["infection", "DISEASE", 103, 112], ["Ebola virus infection", "DISEASE", 325, 346], ["pseudotyped", "ORGANISM", 84, 95], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 174, 189], ["host cells", "CELL", 210, 220], ["Cathepsin Protease", "GENE_OR_GENE_PRODUCT", 221, 239], ["CHIKV-Pseudotyped MLV Vector", "ORGANISM", 256, 284], ["293T", "CELL", 298, 302], ["TE671 CellsMLV", "ORGANISM", 307, 321], ["Ebola virus", "ORGANISM", 325, 336], ["acidic endosomes", "CELLULAR_COMPONENT", 368, 384], ["endosomal", "CELLULAR_COMPONENT", 398, 407], ["cathepsin B protease", "GENE_OR_GENE_PRODUCT", 408, 428], ["CHIKV E protein", "PROTEIN", 174, 189], ["host cells", "CELL_TYPE", 210, 220], ["acidic endosomes", "PROTEIN", 368, 384], ["endosomal cathepsin B protease", "PROTEIN", 398, 428], ["Ebola virus", "SPECIES", 325, 336], ["CHIKV", "SPECIES", 174, 179], ["CHIKV", "SPECIES", 256, 261], ["Ebola virus", "SPECIES", 325, 336], ["the macropinocytosis inhibitors", "PROBLEM", 26, 57], ["pseudotyped vector infection", "PROBLEM", 84, 112], ["macropinocytosis", "PROBLEM", 141, 157], ["CHIKV E protein", "TREATMENT", 174, 189], ["Cathepsin Protease", "TREATMENT", 221, 239], ["CHIKV", "PROBLEM", 256, 261], ["Pseudotyped MLV Vector Infection", "PROBLEM", 262, 294], ["Ebola virus infection", "PROBLEM", 325, 346], ["endosomal cathepsin B protease", "TREATMENT", 398, 428], ["pseudotyped vector infection", "OBSERVATION", 84, 112], ["host cells", "OBSERVATION", 210, 220], ["Ebola virus", "OBSERVATION", 325, 336]]], ["To assess whether cathepsin B was needed for the CHIKV-pseudotyped MLV infection, 293T and TE671 cells were pretreated with the cathepsin B inhibitor CA-074Me and then inoculated with the CHIKV-pseudotyped-MLV vector.", [["293T", "ANATOMY", 82, 86], ["TE671 cells", "ANATOMY", 91, 102], ["MLV infection", "DISEASE", 67, 80], ["CA-074Me", "CHEMICAL", 150, 158], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 18, 29], ["CHIKV", "ORGANISM", 49, 54], ["pseudotyped MLV", "ORGANISM", 55, 70], ["293T", "CELL", 82, 86], ["TE671 cells", "CELL", 91, 102], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 128, 139], ["CA-074Me", "GENE_OR_GENE_PRODUCT", 150, 158], ["CHIKV", "ORGANISM", 188, 193], ["pseudotyped", "ORGANISM", 194, 205], ["MLV", "ORGANISM", 206, 209], ["cathepsin B", "PROTEIN", 18, 29], ["293T", "CELL_LINE", 82, 86], ["TE671 cells", "CELL_LINE", 91, 102], ["cathepsin B", "PROTEIN", 128, 139], ["CHIKV-pseudotyped MLV", "SPECIES", 49, 70], ["CHIKV", "SPECIES", 188, 193], ["cathepsin B", "TREATMENT", 18, 29], ["the CHIKV-pseudotyped MLV infection", "PROBLEM", 45, 80], ["the cathepsin B inhibitor CA", "TREATMENT", 124, 152]]], ["We have already reported that CA-074Me treatment at the same concentration inhibits Ebola virus glycoprotein-or ecotropic MLV envelope protein-mediated infection without affecting the cell viability [18] .", [["cell", "ANATOMY", 184, 188], ["CA-074Me", "CHEMICAL", 30, 38], ["infection", "DISEASE", 152, 161], ["CA-074Me", "CHEMICAL", 30, 38], ["CA-074Me", "SIMPLE_CHEMICAL", 30, 38], ["Ebola virus glycoprotein", "ORGANISM", 84, 108], ["ecotropic MLV", "ORGANISM", 112, 125], ["cell", "CELL", 184, 188], ["Ebola virus glycoprotein", "PROTEIN", 84, 108], ["ecotropic MLV envelope protein", "PROTEIN", 112, 142], ["Ebola virus", "SPECIES", 84, 95], ["Ebola virus", "SPECIES", 84, 95], ["MLV", "SPECIES", 122, 125], ["CA-074Me treatment", "TREATMENT", 30, 48], ["Ebola virus glycoprotein", "TREATMENT", 84, 108], ["ecotropic MLV envelope protein", "TREATMENT", 112, 142], ["mediated infection", "PROBLEM", 143, 161], ["infection", "OBSERVATION", 152, 161]]], ["The CA-074Me treatment (20 or 40 \u00b5M) of 293T and TE671 cells inhibited the CHIKV-pseudotyped MLV vector infection in a dose-dependent manner ( Figure 6A ) but not the VSV-pseudotyped vector infection ( Figure 6B ).", [["293T", "ANATOMY", 40, 44], ["TE671 cells", "ANATOMY", 49, 60], ["CA-074Me", "CHEMICAL", 4, 12], ["infection", "DISEASE", 104, 113], ["infection", "DISEASE", 190, 199], ["CA-074Me", "CHEMICAL", 4, 12], ["CA-074Me", "SIMPLE_CHEMICAL", 4, 12], ["293T", "CELL", 40, 44], ["TE671 cells", "CELL", 49, 60], ["CHIKV", "ORGANISM", 75, 80], ["pseudotyped", "ORGANISM", 81, 92], ["MLV", "ORGANISM", 93, 96], ["VSV", "ORGANISM", 167, 170], ["pseudotyped", "ORGANISM", 171, 182], ["293T", "CELL_LINE", 40, 44], ["TE671 cells", "CELL_LINE", 49, 60], ["CHIKV-pseudotyped MLV", "SPECIES", 75, 96], ["The CA-074Me treatment", "TREATMENT", 0, 22], ["TE671 cells", "PROBLEM", 49, 60], ["the CHIKV", "PROBLEM", 71, 80], ["pseudotyped MLV vector infection", "PROBLEM", 81, 113], ["the VSV", "PROBLEM", 163, 170], ["pseudotyped vector infection", "PROBLEM", 171, 199]]], ["To confirm this result, 293T and TE671 cells were transduced by a lentiviral vector encoding cathepsin B (CatB) or a short hairpin RNA (shRNA) against CatB (shCatB).", [["293T", "ANATOMY", 24, 28], ["TE671 cells", "ANATOMY", 33, 44], ["293T", "CELL", 24, 28], ["TE671 cells", "CELL", 33, 44], ["lentiviral", "ORGANISM", 66, 76], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 93, 104], ["CatB", "GENE_OR_GENE_PRODUCT", 106, 110], ["CatB", "GENE_OR_GENE_PRODUCT", 151, 155], ["shCatB", "GENE_OR_GENE_PRODUCT", 157, 163], ["293T", "CELL_LINE", 24, 28], ["TE671 cells", "CELL_LINE", 33, 44], ["cathepsin B", "PROTEIN", 93, 104], ["CatB", "PROTEIN", 106, 110], ["short hairpin RNA", "RNA", 117, 134], ["CatB", "PROTEIN", 151, 155], ["shCatB", "PROTEIN", 157, 163], ["TE671 cells", "TREATMENT", 33, 44], ["a lentiviral vector", "TREATMENT", 64, 83], ["cathepsin B (CatB", "TREATMENT", 93, 110], ["a short hairpin RNA", "TREATMENT", 115, 134]]], ["The cathepsin B mRNA level was analyzed by reverse transcriptase-PCR (RT-PCR).", [["cathepsin B", "GENE_OR_GENE_PRODUCT", 4, 15], ["cathepsin B mRNA", "RNA", 4, 20], ["reverse transcriptase", "PROTEIN", 43, 64], ["The cathepsin B mRNA level", "TEST", 0, 26], ["reverse transcriptase", "TEST", 43, 64], ["PCR", "TEST", 65, 68], ["PCR", "TEST", 73, 76]]], ["Cathepsin B mRNA expression was indeed reduced in the shCatB-expressing cells compared with that in the empty vector-transduced cells ( Figure 6C ).", [["cells", "ANATOMY", 72, 77], ["cells", "ANATOMY", 128, 133], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 0, 11], ["shCatB", "GENE_OR_GENE_PRODUCT", 54, 60], ["cells", "CELL", 72, 77], ["cells", "CELL", 128, 133], ["Cathepsin B mRNA", "RNA", 0, 16], ["shCatB-expressing cells", "CELL_LINE", 54, 77], ["transduced cells", "CELL_LINE", 117, 133], ["Cathepsin B mRNA expression", "TEST", 0, 27], ["expressing cells", "PROBLEM", 61, 77], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["expressing cells", "OBSERVATION", 61, 77]]], ["The exogenous expression of cathepsin B enhanced the infection by CHIKV-pseudotyped MLV vector in 293T and TE671 cells ( Figure 6D ), but slightly reduced the VSV-pseudotyped MLV vector infection ( Figure 6E ).", [["293T", "ANATOMY", 98, 102], ["TE671 cells", "ANATOMY", 107, 118], ["infection", "DISEASE", 53, 62], ["infection", "DISEASE", 186, 195], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 28, 39], ["CHIKV", "ORGANISM", 66, 71], ["pseudotyped", "ORGANISM", 72, 83], ["MLV", "ORGANISM", 84, 87], ["293T", "CELL", 98, 102], ["TE671 cells", "CELL", 107, 118], ["VSV", "ORGANISM", 159, 162], ["pseudotyped", "ORGANISM", 163, 174], ["MLV", "ORGANISM", 175, 178], ["cathepsin B", "PROTEIN", 28, 39], ["293T", "CELL_LINE", 98, 102], ["TE671 cells", "CELL_LINE", 107, 118], ["CHIKV-pseudotyped MLV", "SPECIES", 66, 87], ["293T", "SPECIES", 98, 102], ["VSV-pseudotyped MLV", "SPECIES", 159, 178], ["cathepsin B enhanced the infection", "PROBLEM", 28, 62], ["CHIKV", "PROBLEM", 66, 71], ["pseudotyped MLV vector", "TREATMENT", 72, 94], ["slightly reduced the VSV", "PROBLEM", 138, 162], ["pseudotyped MLV vector infection", "PROBLEM", 163, 195], ["infection", "OBSERVATION", 53, 62], ["slightly", "OBSERVATION_MODIFIER", 138, 146], ["reduced", "OBSERVATION_MODIFIER", 147, 154], ["pseudotyped MLV vector infection", "OBSERVATION", 163, 195]]], ["The cathepsin B silencing decreased the relative infected cell numbers of the CHIKV-pseudotyped MLV vector, but the VSV-pseudotyped MLV vector infection was rather enhanced.", [["cell", "ANATOMY", 58, 62], ["infection", "DISEASE", 143, 152], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 4, 15], ["cell", "CELL", 58, 62], ["CHIKV", "ORGANISM", 78, 83], ["pseudotyped", "ORGANISM", 84, 95], ["MLV", "ORGANISM", 96, 99], ["VSV", "ORGANISM", 116, 119], ["pseudotyped", "ORGANISM", 120, 131], ["MLV", "ORGANISM", 132, 135], ["cathepsin B", "PROTEIN", 4, 15], ["CHIKV-pseudotyped MLV", "SPECIES", 78, 99], ["VSV", "SPECIES", 116, 119], ["MLV", "SPECIES", 132, 135], ["The cathepsin B silencing", "TREATMENT", 0, 25], ["the CHIKV-pseudotyped MLV vector", "TREATMENT", 74, 106], ["the VSV-pseudotyped MLV vector infection", "PROBLEM", 112, 152], ["silencing", "OBSERVATION_MODIFIER", 16, 25], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["infected cell numbers", "OBSERVATION", 49, 70], ["CHIKV", "OBSERVATION", 78, 83], ["pseudotyped MLV vector", "OBSERVATION", 84, 106], ["pseudotyped MLV", "OBSERVATION", 120, 135], ["vector infection", "OBSERVATION", 136, 152], ["enhanced", "OBSERVATION_MODIFIER", 164, 172]]], ["This result demonstrated that cathepsin B is required for the CHIKV-pseudotyped vector infection.Cathepsin Protease Is Required for CHIKV-Pseudotyped MLV Vector Infection in 293T and TE671 CellsTo determine whether the CHIKV E protein was digested by cathepsin B protease, we first generated an antiserum against a peptide derived from the CHIKV E2 protein ( Figure S2 ).", [["293T", "ANATOMY", 174, 178], ["Cells", "ANATOMY", 189, 194], ["CHIKV-pseudotyped vector infection", "DISEASE", 62, 96], ["E2", "CHEMICAL", 346, 348], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 30, 41], ["CHIKV", "ORGANISM", 62, 67], ["pseudotyped", "ORGANISM", 68, 79], ["Cathepsin Protease", "GENE_OR_GENE_PRODUCT", 97, 115], ["CHIKV", "ORGANISM", 132, 137], ["293T", "CELL", 174, 178], ["TE671 Cells", "CELL", 183, 194], ["CHIKV", "ORGANISM", 219, 224], ["E", "GENE_OR_GENE_PRODUCT", 225, 226], ["cathepsin B protease", "GENE_OR_GENE_PRODUCT", 251, 271], ["antiserum", "ORGANISM_SUBSTANCE", 295, 304], ["E2", "GENE_OR_GENE_PRODUCT", 346, 348], ["cathepsin B", "PROTEIN", 30, 41], ["293T", "CELL_LINE", 174, 178], ["TE671 Cells", "CELL_LINE", 183, 194], ["CHIKV E protein", "PROTEIN", 219, 234], ["cathepsin B protease", "PROTEIN", 251, 271], ["CHIKV E2 protein", "PROTEIN", 340, 356], ["Figure S2", "PROTEIN", 359, 368], ["CHIKV", "SPECIES", 62, 67], ["CHIKV", "SPECIES", 132, 137], ["CHIKV", "SPECIES", 219, 224], ["CHIKV", "SPECIES", 340, 345], ["cathepsin B", "TREATMENT", 30, 41], ["the CHIKV", "PROBLEM", 58, 67], ["pseudotyped vector infection", "PROBLEM", 68, 96], ["Cathepsin Protease", "TREATMENT", 97, 115], ["CHIKV", "PROBLEM", 132, 137], ["Pseudotyped MLV Vector Infection", "PROBLEM", 138, 170], ["the CHIKV E protein", "PROBLEM", 215, 234], ["cathepsin B protease", "TREATMENT", 251, 271], ["an antiserum", "TREATMENT", 292, 304]]], ["Briefly, 293T cells were transfected with the CHIKV-pseudotyped MLV vector construction plasmids, and the vector particles were collected by centrifugation of the culture supernatants.", [["293T cells", "ANATOMY", 9, 19], ["plasmids", "ANATOMY", 88, 96], ["supernatants", "ANATOMY", 171, 183], ["293T cells", "CELL", 9, 19], ["CHIKV", "ORGANISM", 46, 51], ["pseudotyped", "ORGANISM", 52, 63], ["MLV", "ORGANISM", 64, 67], ["293T cells", "CELL_LINE", 9, 19], ["CHIKV-pseudotyped MLV vector construction plasmids", "DNA", 46, 96], ["CHIKV-pseudotyped MLV", "SPECIES", 46, 67], ["the CHIKV-pseudotyped MLV vector construction plasmids", "TREATMENT", 42, 96], ["the vector particles", "TREATMENT", 102, 122], ["the culture supernatants", "TEST", 159, 183]]], ["Western immunoblotting of the CHIKV-pseudotyped MLV vector particles using the antiserum readily detected the mature E2 protein of the predicted molecular mass ( Figure 6F ).", [["E2", "CHEMICAL", 117, 119], ["CHIKV", "ORGANISM", 30, 35], ["pseudotyped", "ORGANISM", 36, 47], ["MLV", "ORGANISM", 48, 51], ["antiserum", "ORGANISM_SUBSTANCE", 79, 88], ["E2", "GENE_OR_GENE_PRODUCT", 117, 119], ["mature E2 protein", "PROTEIN", 110, 127], ["pseudotyped", "SPECIES", 36, 47], ["CHIKV-pseudotyped MLV", "SPECIES", 30, 51], ["the CHIKV-pseudotyped MLV vector particles", "TREATMENT", 26, 68], ["the antiserum", "TEST", 75, 88], ["the predicted molecular mass", "PROBLEM", 131, 159], ["mass", "OBSERVATION", 155, 159]]], ["When the viral particles were treated with recombinant cathepsin B for 1 h at 37 \u2022 C, the amount of mature E2 protein was decreased and a novel 19 kDa peptide was observed.", [["E2", "CHEMICAL", 107, 109], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 55, 66], ["E2", "GENE_OR_GENE_PRODUCT", 107, 109], ["recombinant cathepsin B", "PROTEIN", 43, 66], ["mature E2 protein", "PROTEIN", 100, 117], ["the viral particles", "PROBLEM", 5, 24], ["recombinant cathepsin B", "TREATMENT", 43, 66], ["mature E2 protein", "TEST", 100, 117], ["a novel 19 kDa peptide", "PROBLEM", 136, 158], ["mature", "OBSERVATION_MODIFIER", 100, 106], ["E2 protein", "OBSERVATION", 107, 117]]], ["This result indicated that the CHIKV E2 protein was digested by cathepsin B protease.Cathepsin Protease Is Required for CHIKV-Pseudotyped MLV Vector Infection in 293T and TE671 CellsshCatB-expressing cells compared with that in the empty vector-transduced cells ( Figure 6C ).", [["293T", "ANATOMY", 162, 166], ["cells", "ANATOMY", 200, 205], ["cells", "ANATOMY", 256, 261], ["E2", "CHEMICAL", 37, 39], ["CHIKV", "ORGANISM", 31, 36], ["E2", "GENE_OR_GENE_PRODUCT", 37, 39], ["cathepsin B protease", "GENE_OR_GENE_PRODUCT", 64, 84], ["Cathepsin Protease", "GENE_OR_GENE_PRODUCT", 85, 103], ["CHIKV", "ORGANISM", 120, 125], ["293T", "CELL", 162, 166], ["TE671 CellsshCatB", "CELL", 171, 188], ["cells", "CELL", 200, 205], ["cells", "CELL", 256, 261], ["CHIKV E2 protein", "PROTEIN", 31, 47], ["cathepsin B protease", "PROTEIN", 64, 84], ["293T", "CELL_LINE", 162, 166], ["TE671 CellsshCatB-expressing cells", "CELL_LINE", 171, 205], ["transduced cells", "CELL_LINE", 245, 261], ["CHIKV", "SPECIES", 31, 36], ["CHIKV", "SPECIES", 120, 125], ["the CHIKV E2 protein", "TEST", 27, 47], ["cathepsin B protease", "TREATMENT", 64, 84], ["Cathepsin Protease", "TREATMENT", 85, 103], ["CHIKV", "PROBLEM", 120, 125], ["Pseudotyped MLV Vector Infection", "PROBLEM", 126, 158], ["TE671 CellsshCatB", "TEST", 171, 188], ["expressing cells", "PROBLEM", 189, 205]]], ["The exogenous expression of cathepsin B enhanced the infection by CHIKV-pseudotyped MLV vector in 293T and TE671 cells ( Figure 6D ), but slightly reduced the VSV-pseudotyped MLV vector infection ( Figure 6E ).", [["293T", "ANATOMY", 98, 102], ["TE671 cells", "ANATOMY", 107, 118], ["infection", "DISEASE", 53, 62], ["infection", "DISEASE", 186, 195], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 28, 39], ["CHIKV", "ORGANISM", 66, 71], ["pseudotyped", "ORGANISM", 72, 83], ["MLV", "ORGANISM", 84, 87], ["293T", "CELL", 98, 102], ["TE671 cells", "CELL", 107, 118], ["VSV", "ORGANISM", 159, 162], ["pseudotyped", "ORGANISM", 163, 174], ["MLV", "ORGANISM", 175, 178], ["cathepsin B", "PROTEIN", 28, 39], ["293T", "CELL_LINE", 98, 102], ["TE671 cells", "CELL_LINE", 107, 118], ["CHIKV-pseudotyped MLV", "SPECIES", 66, 87], ["293T", "SPECIES", 98, 102], ["VSV-pseudotyped MLV", "SPECIES", 159, 178], ["cathepsin B enhanced the infection", "PROBLEM", 28, 62], ["CHIKV", "PROBLEM", 66, 71], ["pseudotyped MLV vector", "TREATMENT", 72, 94], ["slightly reduced the VSV", "PROBLEM", 138, 162], ["pseudotyped MLV vector infection", "PROBLEM", 163, 195], ["infection", "OBSERVATION", 53, 62], ["slightly", "OBSERVATION_MODIFIER", 138, 146], ["reduced", "OBSERVATION_MODIFIER", 147, 154], ["pseudotyped MLV vector infection", "OBSERVATION", 163, 195]]], ["The cathepsin B silencing decreased the relative infected cell numbers of the CHIKVpseudotyped MLV vector, but the VSV-pseudotyped MLV vector infection was rather enhanced.", [["cell", "ANATOMY", 58, 62], ["infection", "DISEASE", 142, 151], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 4, 15], ["cell", "CELL", 58, 62], ["MLV", "ORGANISM", 95, 98], ["VSV", "ORGANISM", 115, 118], ["pseudotyped", "ORGANISM", 119, 130], ["MLV", "ORGANISM", 131, 134], ["cathepsin B", "PROTEIN", 4, 15], ["MLV", "SPECIES", 95, 98], ["VSV", "SPECIES", 115, 118], ["MLV", "SPECIES", 131, 134], ["The cathepsin B silencing", "TREATMENT", 0, 25], ["the CHIKVpseudotyped MLV vector", "TREATMENT", 74, 105], ["the VSV-pseudotyped MLV vector infection", "PROBLEM", 111, 151], ["silencing", "OBSERVATION_MODIFIER", 16, 25], ["decreased", "OBSERVATION_MODIFIER", 26, 35], ["infected cell numbers", "OBSERVATION", 49, 70], ["MLV vector", "OBSERVATION", 95, 105], ["pseudotyped", "OBSERVATION_MODIFIER", 119, 130], ["MLV vector infection", "OBSERVATION", 131, 151], ["enhanced", "OBSERVATION_MODIFIER", 163, 171]]], ["This result demonstrated that cathepsin B is required for the CHIKV-pseudotyped vector infection.DiscussionThe results of this study suggest that endocytosis and macropinocytosis are necessary for the CHIKV-pseudotyped MLV vector infection in 293T and TE671 cells, respectively.", [["293T", "ANATOMY", 243, 247], ["TE671 cells", "ANATOMY", 252, 263], ["CHIKV-pseudotyped vector infection", "DISEASE", 62, 96], ["infection", "DISEASE", 230, 239], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 30, 41], ["CHIKV", "ORGANISM", 62, 67], ["pseudotyped", "ORGANISM", 68, 79], ["CHIKV", "ORGANISM", 201, 206], ["pseudotyped", "ORGANISM", 207, 218], ["MLV", "ORGANISM", 219, 222], ["293T", "CELL", 243, 247], ["TE671 cells", "CELL", 252, 263], ["cathepsin B", "PROTEIN", 30, 41], ["293T", "CELL_LINE", 243, 247], ["TE671 cells", "CELL_LINE", 252, 263], ["CHIKV", "SPECIES", 62, 67], ["CHIKV", "SPECIES", 201, 206], ["MLV", "SPECIES", 219, 222], ["cathepsin B", "TREATMENT", 30, 41], ["the CHIKV", "PROBLEM", 58, 67], ["pseudotyped vector infection", "PROBLEM", 68, 96], ["this study", "TEST", 122, 132], ["endocytosis", "PROBLEM", 146, 157], ["macropinocytosis", "PROBLEM", 162, 178], ["the CHIKV-pseudotyped MLV vector infection", "PROBLEM", 197, 239]]], ["Consistently, there are many lines of evidence showing that CHIKV enters host cells via endocytosis [8] [9] [10] [11] , and it has been recently reported that CHIVK entry is dependent on macropinocytosis in another rhabdomyosarcoma cell line [45] .", [["cells", "ANATOMY", 78, 83], ["rhabdomyosarcoma cell line", "ANATOMY", 215, 241], ["rhabdomyosarcoma", "DISEASE", 215, 231], ["CHIKV", "ORGANISM", 60, 65], ["host cells", "CELL", 73, 83], ["CHIVK", "GENE_OR_GENE_PRODUCT", 159, 164], ["rhabdomyosarcoma cell line [45", "CELL", 215, 245], ["host cells", "CELL_TYPE", 73, 83], ["CHIVK", "PROTEIN", 159, 164], ["rhabdomyosarcoma cell line", "CELL_LINE", 215, 241], ["CHIKV", "SPECIES", 60, 65], ["CHIKV", "PROBLEM", 60, 65], ["endocytosis", "TEST", 88, 99], ["CHIVK entry", "PROBLEM", 159, 170], ["macropinocytosis", "PROBLEM", 187, 203], ["another rhabdomyosarcoma cell line", "PROBLEM", 207, 241], ["CHIKV", "OBSERVATION", 60, 65], ["rhabdomyosarcoma cell line", "OBSERVATION", 215, 241]]], ["The endocytosis inhibitors inhibited VSV-pseudotyped vector infection both in 293T and TE671 cells, suggesting that VSV-pseudotyped MLV vector infection is medicated by endocytosis.", [["293T", "ANATOMY", 78, 82], ["TE671 cells", "ANATOMY", 87, 98], ["infection", "DISEASE", 60, 69], ["infection", "DISEASE", 143, 152], ["VSV", "ORGANISM", 37, 40], ["pseudotyped", "ORGANISM", 41, 52], ["293T", "CELL", 78, 82], ["TE671 cells", "CELL", 87, 98], ["VSV-pseudotyped MLV", "ORGANISM", 116, 135], ["293T", "CELL_LINE", 78, 82], ["TE671 cells", "CELL_LINE", 87, 98], ["VSV", "SPECIES", 37, 40], ["VSV", "SPECIES", 116, 119], ["MLV", "SPECIES", 132, 135], ["The endocytosis inhibitors", "TREATMENT", 0, 26], ["VSV", "PROBLEM", 37, 40], ["pseudotyped vector infection", "PROBLEM", 41, 69], ["VSV", "PROBLEM", 116, 119], ["pseudotyped MLV vector infection", "PROBLEM", 120, 152], ["pseudotyped vector", "OBSERVATION", 41, 59], ["VSV", "OBSERVATION", 116, 119], ["pseudotyped MLV", "OBSERVATION", 120, 135], ["vector infection", "OBSERVATION", 136, 152]]], ["The viral entry route into the target cells may vary depending on the cell lines used and the environmental conditions, as we have already proposed, because endocytosis and macropinocytosis are complex processes controlled by many cellular factors [46] .", [["cells", "ANATOMY", 38, 43], ["cell lines", "ANATOMY", 70, 80], ["cellular", "ANATOMY", 231, 239], ["cells", "CELL", 38, 43], ["cell lines", "CELL", 70, 80], ["cellular", "CELL", 231, 239], ["target cells", "CELL_TYPE", 31, 43], ["cell lines", "CELL_LINE", 70, 80], ["cellular factors", "PROTEIN", 231, 247], ["the cell lines", "TREATMENT", 66, 80], ["endocytosis", "PROBLEM", 157, 168], ["macropinocytosis", "PROBLEM", 173, 189], ["complex processes", "PROBLEM", 194, 211], ["cell lines", "OBSERVATION", 70, 80]]], ["To understand the mechanism, further study is needed.DiscussionThis study also reveals that cathepsin B protease is important for the CHIKV-pseudotyped vector infection independent of the viral entry pathway.", [["infection", "DISEASE", 159, 168], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 92, 103], ["CHIKV", "ORGANISM", 134, 139], ["pseudotyped", "ORGANISM", 140, 151], ["cathepsin B protease", "PROTEIN", 92, 112], ["CHIKV", "SPECIES", 134, 139], ["further study", "TEST", 29, 42], ["This study", "TEST", 63, 73], ["cathepsin B protease", "TREATMENT", 92, 112], ["the CHIKV", "PROBLEM", 130, 139], ["pseudotyped vector infection", "PROBLEM", 140, 168]]], ["Whether the CHIKV-pseudotyped MLV vector particles are internalized into target cells by endocytosis or by macropinocytosis, cathepsin B protease is undoubtedly important for the infection.", [["cells", "ANATOMY", 80, 85], ["infection", "DISEASE", 179, 188], ["CHIKV-pseudotyped MLV", "ORGANISM", 12, 33], ["cells", "CELL", 80, 85], ["cathepsin B protease", "GENE_OR_GENE_PRODUCT", 125, 145], ["target cells", "CELL_TYPE", 73, 85], ["cathepsin B protease", "PROTEIN", 125, 145], ["CHIKV", "SPECIES", 12, 17], ["MLV", "SPECIES", 30, 33], ["the CHIKV-pseudotyped MLV vector particles", "TREATMENT", 8, 50], ["macropinocytosis", "PROBLEM", 107, 123], ["cathepsin B protease", "TREATMENT", 125, 145], ["the infection", "PROBLEM", 175, 188], ["CHIKV", "OBSERVATION", 12, 17], ["target cells", "OBSERVATION", 73, 85], ["infection", "OBSERVATION", 179, 188]]], ["However, it is thought that only acidification is sufficient for activation of CHIKV E protein to induce membrane fusion [47] .", [["membrane", "ANATOMY", 105, 113], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 79, 94], ["membrane", "CELLULAR_COMPONENT", 105, 113], ["CHIKV E protein", "PROTEIN", 79, 94], ["CHIKV", "SPECIES", 79, 84], ["acidification", "PROBLEM", 33, 46], ["CHIKV E protein", "TREATMENT", 79, 94], ["membrane fusion", "PROBLEM", 105, 120]]], ["CHIKV E2 protein digestion by cathepsin B protease may facilitate ability to promote membrane fusion.", [["membrane", "ANATOMY", 85, 93], ["E2", "CHEMICAL", 6, 8], ["CHIKV", "ORGANISM", 0, 5], ["E2", "GENE_OR_GENE_PRODUCT", 6, 8], ["cathepsin B protease", "GENE_OR_GENE_PRODUCT", 30, 50], ["membrane", "CELLULAR_COMPONENT", 85, 93], ["CHIKV E2 protein", "PROTEIN", 0, 16], ["cathepsin B protease", "PROTEIN", 30, 50], ["CHIKV", "SPECIES", 0, 5], ["CHIKV E2 protein digestion", "TREATMENT", 0, 26], ["cathepsin B protease", "TREATMENT", 30, 50], ["membrane fusion", "TREATMENT", 85, 100], ["membrane fusion", "OBSERVATION", 85, 100]]], ["Cathepsin B overexpression may more efficiently activate the CHIKV E protein fusogenicity and enhance the infection than control cells.", [["cells", "ANATOMY", 129, 134], ["infection", "DISEASE", 106, 115], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 0, 11], ["CHIKV E", "GENE_OR_GENE_PRODUCT", 61, 68], ["cells", "CELL", 129, 134], ["Cathepsin B", "PROTEIN", 0, 11], ["CHIKV E protein", "PROTEIN", 61, 76], ["control cells", "CELL_TYPE", 121, 134], ["CHIKV", "SPECIES", 61, 66], ["Cathepsin B overexpression", "TREATMENT", 0, 26], ["the CHIKV E protein fusogenicity", "PROBLEM", 57, 89], ["the infection than control cells", "PROBLEM", 102, 134], ["CHIKV", "OBSERVATION", 61, 66], ["infection", "OBSERVATION", 106, 115]]], ["Alternatively, cathepsin B may digest host inhibitors against CHIKV-pseudotyped vector infection.", [["CHIKV-pseudotyped vector infection", "DISEASE", 62, 96], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 15, 26], ["CHIKV", "ORGANISM", 62, 67], ["pseudotyped", "ORGANISM", 68, 79], ["cathepsin B", "PROTEIN", 15, 26], ["CHIKV", "SPECIES", 62, 67], ["cathepsin B", "TREATMENT", 15, 26], ["host inhibitors", "TREATMENT", 38, 53], ["CHIKV", "PROBLEM", 62, 67], ["pseudotyped vector infection", "PROBLEM", 68, 96], ["pseudotyped vector", "OBSERVATION", 68, 86]]], ["This study also provides a possibility that cathepsin B inhibitors are potent therapeutic agents against CHIKV-induced diseases.DiscussionCathepsin B silencing enhanced the VSV-pseudotyped MLV vector infection in both 293T and TE671 cells.", [["293T", "ANATOMY", 218, 222], ["TE671 cells", "ANATOMY", 227, 238], ["CHIKV-induced diseases", "DISEASE", 105, 127], ["infection", "DISEASE", 200, 209], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 44, 55], ["CHIKV", "ORGANISM", 105, 110], ["Cathepsin B", "GENE_OR_GENE_PRODUCT", 138, 149], ["VSV", "ORGANISM", 173, 176], ["pseudotyped", "ORGANISM", 177, 188], ["MLV", "ORGANISM", 189, 192], ["293T", "CELL", 218, 222], ["TE671 cells", "CELL", 227, 238], ["Cathepsin B", "PROTEIN", 138, 149], ["293T", "CELL_LINE", 218, 222], ["TE671 cells", "CELL_LINE", 227, 238], ["CHIKV", "SPECIES", 105, 110], ["VSV-pseudotyped MLV", "SPECIES", 173, 192], ["This study", "TEST", 0, 10], ["cathepsin B inhibitors", "TREATMENT", 44, 66], ["potent therapeutic agents", "TREATMENT", 71, 96], ["CHIKV-induced diseases", "PROBLEM", 105, 127], ["Cathepsin B silencing", "TREATMENT", 138, 159], ["the VSV", "TEST", 169, 176], ["pseudotyped MLV vector infection", "PROBLEM", 177, 209], ["VSV", "ANATOMY", 173, 176], ["pseudotyped MLV", "OBSERVATION", 177, 192], ["vector infection", "OBSERVATION", 193, 209]]], ["This suggests that the endogenous cathepsin B protease probably inhibits VSV-pseudotyped vector infection by VSV-G protein digestion.", [["infection", "DISEASE", 96, 105], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 34, 45], ["VSV", "ORGANISM", 73, 76], ["pseudotyped", "ORGANISM", 77, 88], ["VSV-G", "GENE_OR_GENE_PRODUCT", 109, 114], ["endogenous cathepsin B protease", "PROTEIN", 23, 54], ["VSV", "SPECIES", 73, 76], ["VSV", "SPECIES", 109, 112], ["the endogenous cathepsin B protease", "PROBLEM", 19, 54], ["VSV", "PROBLEM", 73, 76], ["pseudotyped vector infection", "PROBLEM", 77, 105], ["pseudotyped vector", "OBSERVATION", 77, 95]]], ["We have previously reported that cathepsin B suppresses infection by CD4-independent strains of HIV [48] .", [["cathepsin B", "CHEMICAL", 33, 44], ["infection", "DISEASE", 56, 65], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 33, 44], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["HIV", "ORGANISM", 96, 99], ["cathepsin B", "PROTEIN", 33, 44], ["CD4", "PROTEIN", 69, 72], ["HIV", "SPECIES", 96, 99], ["HIV", "SPECIES", 96, 99], ["cathepsin B suppresses infection", "PROBLEM", 33, 65], ["HIV", "PROBLEM", 96, 99]]], ["Thus, we proposed that cathepsin proteases originally functioned as a host defense factor against viruses, and cathepsin-utilizing viruses appeared to have escaped the cathepsin protease-mediated host defense response [46] .DiscussionThe suppression of CHIKV-pseudotyped MLV vector infection by these inhibitors is not mediated by affecting autophagy.", [["infection", "DISEASE", 282, 291], ["cathepsin", "GENE_OR_GENE_PRODUCT", 23, 32], ["cathepsin", "GENE_OR_GENE_PRODUCT", 111, 120], ["cathepsin protease", "GENE_OR_GENE_PRODUCT", 168, 186], ["CHIKV-pseudotyped MLV", "ORGANISM", 253, 274], ["cathepsin proteases", "PROTEIN", 23, 42], ["host defense factor", "PROTEIN", 70, 89], ["cathepsin", "PROTEIN", 111, 120], ["cathepsin protease", "PROTEIN", 168, 186], ["CHIKV-pseudotyped MLV", "SPECIES", 253, 274], ["cathepsin proteases", "TREATMENT", 23, 42], ["viruses", "PROBLEM", 98, 105], ["cathepsin", "TREATMENT", 111, 120], ["viruses", "TREATMENT", 131, 138], ["the cathepsin protease", "TREATMENT", 164, 186], ["CHIKV", "PROBLEM", 253, 258], ["pseudotyped MLV vector infection", "PROBLEM", 259, 291], ["these inhibitors", "TREATMENT", 295, 311]]], ["Autophagy participates for CHIKV replication [49, 50] .", [["CHIKV", "ORGANISM", 27, 32], ["CHIKV", "SPECIES", 27, 32]]], ["Since lysosomal cathepsin proteiases are involved in LC3-II proteolysis, a maker for autophagy induction, the inhibitors used in this study should affect autophagy [51] .", [["lysosomal", "ANATOMY", 6, 15], ["cathepsin", "GENE_OR_GENE_PRODUCT", 16, 25], ["LC3-II", "GENE_OR_GENE_PRODUCT", 53, 59], ["lysosomal cathepsin proteiases", "PROTEIN", 6, 36], ["LC3", "PROTEIN", 53, 56], ["lysosomal cathepsin proteiases", "PROBLEM", 6, 36], ["II proteolysis", "PROBLEM", 57, 71], ["autophagy induction", "TREATMENT", 85, 104], ["the inhibitors", "TREATMENT", 106, 120], ["this study", "TEST", 129, 139], ["cathepsin proteiases", "OBSERVATION", 16, 36]]], ["Thus, the inhibitors may suppress the CHIKV-pseudotyped vector infection by modulating autophagy.", [["infection", "DISEASE", 63, 72], ["CHIKV", "ORGANISM", 38, 43], ["pseudotyped", "ORGANISM", 44, 55], ["CHIKV", "SPECIES", 38, 43], ["the inhibitors", "TREATMENT", 6, 20], ["the CHIKV-pseudotyped vector infection", "PROBLEM", 34, 72], ["CHIKV", "OBSERVATION", 38, 43]]], ["If so, the inhibitors should inhibit the infection both in 293T and TE671 cells.", [["293T", "ANATOMY", 59, 63], ["TE671 cells", "ANATOMY", 68, 79], ["infection", "DISEASE", 41, 50], ["293T", "CELL", 59, 63], ["TE671 cells", "CELL", 68, 79], ["293T", "CELL_LINE", 59, 63], ["TE671 cells", "CELL_LINE", 68, 79], ["the inhibitors", "TREATMENT", 7, 21], ["the infection", "PROBLEM", 37, 50], ["infection", "OBSERVATION", 41, 50]]], ["However, the endocytosis inhibitors attenuated the infection in 293T cells but not in TE671 cells, and the macropinocytosis inhibitors suppressed the infection in TE671 cells but not in 293T cells.", [["293T cells", "ANATOMY", 64, 74], ["TE671 cells", "ANATOMY", 86, 97], ["TE671 cells", "ANATOMY", 163, 174], ["293T cells", "ANATOMY", 186, 196], ["infection", "DISEASE", 51, 60], ["infection", "DISEASE", 150, 159], ["293T cells", "CELL", 64, 74], ["TE671 cells", "CELL", 86, 97], ["TE671 cells", "CELL", 163, 174], ["293T cells", "CELL", 186, 196], ["293T cells", "CELL_LINE", 64, 74], ["TE671 cells", "CELL_LINE", 86, 97], ["TE671 cells", "CELL_LINE", 163, 174], ["293T cells", "CELL_LINE", 186, 196], ["the endocytosis inhibitors", "PROBLEM", 9, 35], ["the infection in 293T cells", "PROBLEM", 47, 74], ["TE671 cells", "PROBLEM", 86, 97], ["the macropinocytosis inhibitors", "PROBLEM", 103, 134], ["the infection in TE671 cells", "PROBLEM", 146, 174], ["infection", "OBSERVATION", 51, 60], ["293T cells", "OBSERVATION", 64, 74], ["infection", "OBSERVATION", 150, 159], ["293T cells", "OBSERVATION", 186, 196]]], ["Therefore, the inhibitors suppress CHIKV-pseudotyped vector infection by a mechanism other than affecting autophagy.DiscussionHeLa cells were much less susceptible to CHIKV-pseudotyped MLV vector infection than 293T and TE671 cells.", [["DiscussionHeLa cells", "ANATOMY", 116, 136], ["293T", "ANATOMY", 211, 215], ["TE671 cells", "ANATOMY", 220, 231], ["infection", "DISEASE", 60, 69], ["infection", "DISEASE", 196, 205], ["CHIKV", "ORGANISM", 35, 40], ["pseudotyped", "ORGANISM", 41, 52], ["DiscussionHeLa cells", "CELL", 116, 136], ["CHIKV", "ORGANISM", 167, 172], ["pseudotyped", "ORGANISM", 173, 184], ["MLV", "ORGANISM", 185, 188], ["293T", "CELL", 211, 215], ["TE671 cells", "CELL", 220, 231], ["DiscussionHeLa cells", "CELL_LINE", 116, 136], ["293T", "CELL_LINE", 211, 215], ["TE671 cells", "CELL_LINE", 220, 231], ["CHIKV", "SPECIES", 35, 40], ["CHIKV", "SPECIES", 167, 172], ["MLV", "SPECIES", 185, 188], ["the inhibitors", "TREATMENT", 11, 25], ["CHIKV", "PROBLEM", 35, 40], ["pseudotyped vector infection", "PROBLEM", 41, 69], ["DiscussionHeLa cells", "PROBLEM", 116, 136], ["CHIKV", "PROBLEM", 167, 172], ["pseudotyped MLV vector infection", "PROBLEM", 173, 205]]], ["However, replication-competent CHIKV efficiently proliferates in HeLa cells [52, 53] .", [["HeLa cells", "ANATOMY", 65, 75], ["CHIKV", "ORGANISM", 31, 36], ["HeLa cells", "CELL", 65, 75], ["HeLa cells", "CELL_LINE", 65, 75], ["CHIKV", "SPECIES", 31, 36]]], ["Thus, HeLa cells express the CHIKV receptor.", [["HeLa cells", "ANATOMY", 6, 16], ["HeLa cells", "CELL", 6, 16], ["CHIKV receptor", "GENE_OR_GENE_PRODUCT", 29, 43], ["HeLa cells", "CELL_LINE", 6, 16], ["CHIKV receptor", "PROTEIN", 29, 43], ["CHIKV", "SPECIES", 29, 34], ["HeLa cells", "TREATMENT", 6, 16]]], ["CHIKV-pseudotyped vector infection was inhibited by the neutralizing antiserum, showing that the infection is mediated by the CHIKV E protein.", [["infection", "DISEASE", 25, 34], ["infection", "DISEASE", 97, 106], ["CHIKV", "ORGANISM", 0, 5], ["pseudotyped", "ORGANISM", 6, 17], ["CHIKV E protein", "GENE_OR_GENE_PRODUCT", 126, 141], ["CHIKV E protein", "PROTEIN", 126, 141], ["CHIKV", "SPECIES", 0, 5], ["CHIKV", "SPECIES", 126, 131], ["CHIKV", "PROBLEM", 0, 5], ["pseudotyped vector infection", "PROBLEM", 6, 34], ["the neutralizing antiserum", "TEST", 52, 78], ["the infection", "PROBLEM", 93, 106], ["the CHIKV E protein", "PROBLEM", 122, 141], ["infection", "OBSERVATION", 97, 106]]], ["HeLa cells may express an unknown host restriction factor that is counteracted by a CHIKV protein other than the E protein.DiscussionSurvival of 293T cells was more severely affected by WOR than TE671 cells.", [["HeLa cells", "ANATOMY", 0, 10], ["293T cells", "ANATOMY", 145, 155], ["TE671 cells", "ANATOMY", 195, 206], ["HeLa cells", "CELL", 0, 10], ["E protein", "GENE_OR_GENE_PRODUCT", 113, 122], ["293T cells", "CELL", 145, 155], ["WOR", "SIMPLE_CHEMICAL", 186, 189], ["TE671 cells", "CELL", 195, 206], ["HeLa cells", "CELL_LINE", 0, 10], ["host restriction factor", "PROTEIN", 34, 57], ["CHIKV protein", "PROTEIN", 84, 97], ["E protein", "PROTEIN", 113, 122], ["293T cells", "CELL_LINE", 145, 155], ["WOR", "PROTEIN", 186, 189], ["TE671 cells", "CELL_LINE", 195, 206], ["CHIKV", "SPECIES", 84, 89], ["HeLa cells", "TREATMENT", 0, 10], ["an unknown host restriction factor", "PROBLEM", 23, 57], ["a CHIKV protein", "PROBLEM", 82, 97], ["293T cells", "PROBLEM", 145, 155], ["293T cells", "OBSERVATION", 145, 155]]], ["However, another macropinocytosis inhibitor, EIPA, had a similar effect on cell viability of 293T and TE671 cells.", [["cell", "ANATOMY", 75, 79], ["293T", "ANATOMY", 93, 97], ["TE671 cells", "ANATOMY", 102, 113], ["EIPA", "CHEMICAL", 45, 49], ["EIPA", "CHEMICAL", 45, 49], ["EIPA", "SIMPLE_CHEMICAL", 45, 49], ["cell", "CELL", 75, 79], ["293T", "CELL", 93, 97], ["TE671 cells", "CELL", 102, 113], ["293T", "CELL_LINE", 93, 97], ["TE671 cells", "CELL_LINE", 102, 113], ["another macropinocytosis inhibitor", "PROBLEM", 9, 43], ["EIPA", "TEST", 45, 49], ["cell viability", "TEST", 75, 89], ["macropinocytosis inhibitor", "OBSERVATION", 17, 43], ["cell viability", "OBSERVATION", 75, 89]]], ["Thus, it is unlikely that macropinocytosis plays an important role in 293T cell viability.", [["293T cell", "ANATOMY", 70, 79], ["293T cell", "CELL", 70, 79], ["293T cell", "CELL_LINE", 70, 79], ["macropinocytosis", "PROBLEM", 26, 42], ["unlikely", "UNCERTAINTY", 12, 20], ["macropinocytosis", "OBSERVATION", 26, 42], ["293T cell viability", "OBSERVATION", 70, 89]]], ["WOR is an inhibitor of PI3K, and PI3K activation induces oncogenic cell growth [54] .", [["cell", "ANATOMY", 67, 71], ["WOR", "SIMPLE_CHEMICAL", 0, 3], ["PI3K", "GENE_OR_GENE_PRODUCT", 23, 27], ["PI3K", "GENE_OR_GENE_PRODUCT", 33, 37], ["cell", "CELL", 67, 71], ["WOR", "PROTEIN", 0, 3], ["PI3K", "PROTEIN", 23, 27], ["PI3K", "PROTEIN", 33, 37], ["an inhibitor of PI3K", "TEST", 7, 27], ["oncogenic cell growth", "PROBLEM", 57, 78], ["oncogenic cell", "OBSERVATION", 57, 71]]], ["Proliferation of 293T cells may require PI3K.DiscussionHuman serum from a CHIKV-infected patient inhibited not only CHIKV-pseudotyped MLV vector infection but also VSV-pseudotyped MLV vector infection, although the inhibitory effect on CHIKV infection was higher than that on VSV infection.", [["293T cells", "ANATOMY", 17, 27], ["serum", "ANATOMY", 61, 66], ["CHIKV-infected", "DISEASE", 74, 88], ["infection", "DISEASE", 145, 154], ["infection", "DISEASE", 191, 200], ["CHIKV infection", "DISEASE", 236, 251], ["infection", "DISEASE", 280, 289], ["293T cells", "CELL", 17, 27], ["PI3K", "GENE_OR_GENE_PRODUCT", 40, 44], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["CHIKV", "ORGANISM", 74, 79], ["patient", "ORGANISM", 89, 96], ["CHIKV", "ORGANISM", 116, 121], ["pseudotyped", "ORGANISM", 122, 133], ["MLV", "ORGANISM", 134, 137], ["VSV", "ORGANISM", 164, 167], ["pseudotyped", "ORGANISM", 168, 179], ["MLV", "ORGANISM", 180, 183], ["CHIKV", "ORGANISM", 236, 241], ["VSV", "ORGANISM", 276, 279], ["293T cells", "CELL_LINE", 17, 27], ["PI3K", "PROTEIN", 40, 44], ["patient", "SPECIES", 89, 96], ["CHIKV", "SPECIES", 74, 79], ["CHIKV", "SPECIES", 116, 121], ["MLV", "SPECIES", 134, 137], ["VSV", "SPECIES", 164, 167], ["MLV", "SPECIES", 180, 183], ["CHIKV", "SPECIES", 236, 241], ["VSV", "SPECIES", 276, 279], ["Proliferation of 293T cells", "PROBLEM", 0, 27], ["PI3K", "TREATMENT", 40, 44], ["DiscussionHuman serum", "TEST", 45, 66], ["a CHIKV", "PROBLEM", 72, 79], ["CHIKV", "PROBLEM", 116, 121], ["pseudotyped MLV vector infection", "PROBLEM", 122, 154], ["VSV", "PROBLEM", 164, 167], ["pseudotyped MLV vector infection", "PROBLEM", 168, 200], ["the inhibitory effect", "PROBLEM", 211, 232], ["CHIKV infection", "PROBLEM", 236, 251], ["VSV infection", "PROBLEM", 276, 289], ["293T cells", "OBSERVATION", 17, 27], ["CHIKV", "OBSERVATION", 116, 121], ["pseudotyped MLV vector infection", "OBSERVATION", 168, 200], ["infection", "OBSERVATION", 280, 289]]], ["There are many lines of evidence showing that proteoglycans present in human serum inhibit MLV vector infection [55] [56] [57] .DiscussionIn summary, CHIKV E-containing viral particles are internalized into host cell vesicles by endocytosis or macropinocytosis, dependently on cell lines.", [["serum", "ANATOMY", 77, 82], ["cell vesicles", "ANATOMY", 212, 225], ["cell lines", "ANATOMY", 277, 287], ["infection", "DISEASE", 102, 111], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 46, 59], ["human", "ORGANISM", 71, 76], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["MLV", "ORGANISM", 91, 94], ["CHIKV E", "ORGANISM", 150, 157], ["cell vesicles", "CELLULAR_COMPONENT", 212, 225], ["cell lines", "CELL", 277, 287], ["cell lines", "CELL_LINE", 277, 287], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["MLV", "SPECIES", 91, 94], ["CHIKV", "SPECIES", 150, 155], ["proteoglycans present in human serum inhibit MLV vector infection", "PROBLEM", 46, 111], ["CHIKV E-containing viral particles", "TREATMENT", 150, 184], ["macropinocytosis", "PROBLEM", 244, 260], ["cell lines", "TREATMENT", 277, 287], ["many", "OBSERVATION_MODIFIER", 10, 14], ["lines", "OBSERVATION", 15, 20], ["proteoglycans", "OBSERVATION", 46, 59], ["viral particles", "OBSERVATION", 169, 184], ["host cell vesicles", "OBSERVATION", 207, 225], ["endocytosis", "OBSERVATION_MODIFIER", 229, 240], ["macropinocytosis", "OBSERVATION", 244, 260], ["dependently", "OBSERVATION_MODIFIER", 262, 273], ["cell lines", "OBSERVATION", 277, 287]]], ["By vesicle acidification, conformation of E protein is changed to activate its ability to promote membrane fusion.", [["vesicle", "ANATOMY", 3, 10], ["membrane", "ANATOMY", 98, 106], ["vesicle", "CELLULAR_COMPONENT", 3, 10], ["membrane", "CELLULAR_COMPONENT", 98, 106], ["E protein", "PROTEIN", 42, 51], ["conformation of E protein", "TREATMENT", 26, 51], ["membrane fusion", "TREATMENT", 98, 113], ["acidification", "OBSERVATION", 11, 24], ["membrane fusion", "OBSERVATION", 98, 113]]], ["Although the conformational change of E protein by acidification is sufficient for infection, digestion of the E protein by endosomal cathepsin B protease more efficiently facilitates the membrane fusion activity and enhances infection.Supplementary Materials:The following are available online at http://www.mdpi.com/1999-4915/12/7/722/s1, Figure S1 : Construction of CHIKV-pseudotyped MLV vector.", [["endosomal", "ANATOMY", 124, 133], ["membrane", "ANATOMY", 188, 196], ["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 226, 235], ["E protein", "GENE_OR_GENE_PRODUCT", 38, 47], ["E", "GENE_OR_GENE_PRODUCT", 111, 112], ["endosomal", "CELLULAR_COMPONENT", 124, 133], ["cathepsin B protease", "GENE_OR_GENE_PRODUCT", 134, 154], ["membrane", "CELLULAR_COMPONENT", 188, 196], ["CHIKV", "ORGANISM", 369, 374], ["pseudotyped", "ORGANISM", 375, 386], ["MLV", "ORGANISM", 387, 390], ["E protein", "PROTEIN", 38, 47], ["E protein", "PROTEIN", 111, 120], ["endosomal cathepsin B protease", "PROTEIN", 124, 154], ["the conformational change of E protein", "PROBLEM", 9, 47], ["acidification", "PROBLEM", 51, 64], ["infection", "PROBLEM", 83, 92], ["the E protein", "TREATMENT", 107, 120], ["endosomal cathepsin B protease", "TREATMENT", 124, 154], ["the membrane fusion activity", "PROBLEM", 184, 212], ["enhances infection", "PROBLEM", 217, 235], ["CHIKV", "PROBLEM", 369, 374], ["pseudotyped MLV vector", "TREATMENT", 375, 397], ["infection", "OBSERVATION", 83, 92], ["membrane fusion activity", "OBSERVATION", 188, 212], ["enhances", "OBSERVATION_MODIFIER", 217, 225], ["infection", "OBSERVATION", 226, 235], ["CHIKV", "OBSERVATION", 369, 374]]], ["Figure S2 : Generation of anti-CHIKV E2 antiserum.", [["E2", "CHEMICAL", 37, 39], ["anti-CHIKV E2 antiserum", "GENE_OR_GENE_PRODUCT", 26, 49], ["anti-CHIKV", "SPECIES", 26, 36], ["anti-CHIKV E2 antiserum", "TREATMENT", 26, 49]]]], "39e8760f8f3829119d0048ab9f677d09752b1f8c": [["BackgroundThe coronavirus disease 2019 has resulted in a global pandemic of acute respiratory illness.", [["respiratory", "ANATOMY", 82, 93], ["coronavirus disease", "DISEASE", 14, 33], ["acute respiratory illness", "DISEASE", 76, 101], ["coronavirus", "ORGANISM", 14, 25], ["The coronavirus disease", "PROBLEM", 10, 33], ["acute respiratory illness", "PROBLEM", 76, 101], ["coronavirus disease", "OBSERVATION", 14, 33], ["global", "OBSERVATION_MODIFIER", 57, 63], ["pandemic", "OBSERVATION_MODIFIER", 64, 72], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["respiratory illness", "OBSERVATION", 82, 101]]], ["[1] [2] [3] As of April 27, 2020, there were 2,954,222 COVID-19 confirmed cases and 202,597 deaths reported worldwide.", [["deaths", "DISEASE", 92, 98], ["COVID", "TEST", 55, 60]]], ["3 In the United States (US) alone, COVID-19 has spread to all 55 jurisdictions with 957,875 total confirmed cases, 128,673 hospitalizations, and 56,386 deaths.", [["deaths", "DISEASE", 152, 158], ["COVID", "TEST", 35, 40]]], ["4,5 As COVID-19 continues to spread and case numbers rise, health systems have strained to keep pace with demands for hospital and critical care services, challenging hospitals to provide high-quality patient care while managing potentially scarce resources.", [["patient", "ORGANISM", 201, 208], ["patient", "SPECIES", 201, 208], ["COVID", "TEST", 7, 12], ["high-quality patient care", "TREATMENT", 188, 213]]], ["6 Given these concerns, it is imperative that healthcare systems are able to predict increased utilization and proactively plan effective resource allocation, including when and how much to expand access to hospital beds, intensive care unit (ICU) beds, and ventilators.", [["ventilators", "TREATMENT", 258, 269]]], ["7, 8 Many studies have reported on the basic susceptible-infected-recovered (SIR) model to forecast how potential COVID-19 cases might impact the capacity of healthcare systems.", [["Many studies", "TEST", 5, 17], ["COVID", "TEST", 114, 119], ["infected", "OBSERVATION", 57, 65]]], ["[9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] However, these studies have several limitations: models using national and international infection projections to provide insights for other countries, states, or regions do not: (a) take into consideration variation in transmission and infection rates based on local population characteristics and spatial differences; (b) apply control measures for the type and timing of medical and behavioral interventions including social distancing, border control, and stay at home policies; (c) account for local community resource availability; or (d) adjust for the ability of regional hospital systems to transfer resources between facilities and repurpose spaces for COVID use.", [["[9] [10] [11] [12] [13] [14", "CHEMICAL", 0, 27], ["infection", "DISEASE", 143, 152], ["infection", "DISEASE", 291, 300], ["[9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 0, 53], ["these studies", "TEST", 63, 76], ["international infection projections", "TREATMENT", 129, 164], ["infection rates", "PROBLEM", 291, 306], ["b) apply control measures", "TREATMENT", 375, 400], ["medical and behavioral interventions", "TREATMENT", 428, 464], ["infection", "OBSERVATION", 291, 300]]], ["Additionally, despite their widespread application in the COVID-19 pandemic, basic SIR models were not developed to forecast hospitalizations, resulting in uncertainty about their accuracy.", [["the COVID", "TEST", 54, 63], ["widespread", "OBSERVATION_MODIFIER", 28, 38]]], ["19 In response to the need for actionable data insights, investigators from the Center for Outcomes Research and Evaluation (CORE) at Atrium Health in Charlotte, North Carolina developed a web-based application, or 'app', that embeds COVID-19 forecasting models, developed using local data, to guide the health system's proactive pandemic response.", [["actionable data", "TEST", 31, 46], ["Evaluation", "TEST", 113, 123], ["COVID", "TEST", 234, 239], ["Atrium", "ANATOMY", 134, 140]]], ["The COVID-19 Utilization and Resource Visualization Engine (CURVE) app helps system leaders have access to the forecast predictions and observed utilization, alongside existing and surge capacity.", [["The COVID", "TEST", 0, 9]]], ["Here we present our decision support app as an example for other healthcare systems as COVID-19 pandemic planning efforts are likely to continue for the foreseeable future.Study context and settingAtrium Health is a large, vertically integrated, not-for-profit healthcare system with over 50 hospitals and 900 care locations in North Carolina, South Carolina, and Georgia.", [["Atrium", "ANATOMY", 197, 203], ["large", "OBSERVATION_MODIFIER", 216, 221]]], ["The health system is headquartered in Charlotte, North Carolina, the largest metropolitan region in the Carolinas.", [["largest", "OBSERVATION_MODIFIER", 69, 76], ["Carolinas", "ANATOMY", 104, 113]]], ["In response to the COVID-19 pandemic, Atrium Health activated its Corporate Incident Command structure on March 6, three days after the first case of COVID-19 was reported in North Carolina and five days before Atrium Health diagnosed its first case of COVID-19 on March 11.", [["the COVID", "TEST", 15, 24], ["COVID", "TEST", 150, 155], ["COVID", "TEST", 253, 258], ["Atrium", "ANATOMY", 38, 44], ["Atrium", "ANATOMY", 211, 217]]], ["The primary goal of the Corporate Incident Command is to coordinate resource planning, preparedness, and decision making, while maintaining regular clinical operations and protecting patients and staff.Study context and settingThe development and deployment of the CURVE app was designed for the greater Charlotte region that includes Anson, Cabarrus, Catawba, Cleveland, Gaston, Iredell, Lincoln, Mecklenburg, Rowan, Stanly, and Union counties.", [["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["the CURVE app", "TEST", 261, 274], ["Cabarrus", "TREATMENT", 342, 350], ["Catawba", "TREATMENT", 352, 359], ["Gaston", "TREATMENT", 372, 378]]], ["The app creation was divided into two phases.", [["The app creation", "TREATMENT", 0, 16]]], ["The first phase required the development of COVID-19 infection forecast modeling.", [["infection", "DISEASE", 53, 62], ["COVID", "TEST", 44, 49], ["19 infection forecast modeling", "PROBLEM", 50, 80], ["infection", "OBSERVATION", 53, 62]]], ["20 The second phase involved user interface construction, emphasizing information accessibility to health system leaders, and configuration with the host server.Study context and settingWe collected bed use information from Atrium Health's electronic healthcare record (EHR).", [["Atrium", "ANATOMY", 224, 230]]], ["Unique occupied beds were defined as an occupied bed in a calendar day regardless of the number of patients that used the bed during the day.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107]]], ["No restrictions were placed (e.g., department type, observation encounter) on the calculation of total occupied beds per day.", [["restrictions", "OBSERVATION", 3, 15]]], ["A project management model was initiated to ensure rapid execution and to prioritize user requests for CURVE app development and modifications.", [["A project management model", "TREATMENT", 0, 26], ["CURVE app development", "TREATMENT", 103, 124]]], ["Stakeholders included Atrium Health's executive leadership committee, Information and Analytics Services leaders, and the Strategic Services Group.", [["Atrium", "ANATOMY", 22, 28]]], ["Obtaining stakeholder feedback resulted in a focus on projections for the following domains: hospital utilization, bed capacity, ICU capacity, and ventilator capacity.Susceptible-Infected-Recovered-Social Distancing-Detection Rate (SIR-D2) modelThe COVID-19 infection forecasting model used in the app was an internally developed epidemic SIR model that incorporated social distancing and detection rate (called SIR-D2), where S is the number of individuals that are susceptible to infection in the population, I is the number of individuals that are infected, and R is the number of individuals that are removed from the population via recovery and subsequent immunity or death from infection.", [["infection", "DISEASE", 258, 267], ["infection", "DISEASE", 482, 491], ["death", "DISEASE", 673, 678], ["infection", "DISEASE", 684, 693], ["ICU capacity", "TEST", 129, 141], ["ventilator capacity", "TREATMENT", 147, 166], ["Rate", "TEST", 226, 230], ["The COVID", "TEST", 245, 254], ["infection", "PROBLEM", 482, 491], ["death", "PROBLEM", 673, 678], ["infection", "PROBLEM", 684, 693], ["ventilator capacity", "OBSERVATION", 147, 166], ["Infected", "OBSERVATION_MODIFIER", 179, 187], ["infection", "OBSERVATION", 482, 491], ["infected", "OBSERVATION", 551, 559], ["infection", "OBSERVATION", 684, 693]]], ["The D2 aspect of the model accounts for the stay-athome intervention implemented in North Carolina and imperfect detection of COVID-19 cases to estimate latent prevalence.", [["athome intervention", "TREATMENT", 49, 68], ["COVID", "TEST", 126, 131]]], ["The model is more fully detailed by Turk et al. 20 Determining hospitalization rate In order to forecast hospital resource demand, we needed to first determine rates of hospitalization.", [["more fully", "OBSERVATION_MODIFIER", 13, 23]]], ["The hospital rate p is the rate per person per day at which COVID-19 positive persons transition from an infected state to an implied hospitalized state.", [["persons", "ORGANISM", 78, 85], ["person", "SPECIES", 36, 42], ["persons", "SPECIES", 78, 85], ["infected", "OBSERVATION", 105, 113]]], ["We conjecture the hospitalized state mediates the transition from the infected to the removed state in an SIR-D2 model.", [["infected", "OBSERVATION", 70, 78]]], ["If we assume an average illness duration of 14 days, 21 then by a simple binomial argument, we can solve for the proportion of cases requiring hospitalization.", [["illness", "DISEASE", 24, 31], ["a simple binomial argument", "TREATMENT", 64, 90]]], ["Conversely, for a given proportion of cases requiring hospitalization specified in the app, again assuming an average illness duration of 14 days, we solve for the rate.", [["illness", "DISEASE", 118, 125], ["the rate", "TEST", 160, 168]]], ["This rate is then multiplied by the prevalence of COVID-19 positive people at time t, to give us the incidence of hospitalization at time t.", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["COVID", "TEST", 50, 55]]], ["The equation to calculate the hospital rate p is as follows:Susceptible-Infected-Recovered-Social Distancing-Detection Rate (SIR-D2) modelAll rights reserved.", [["Rate (SIR-D2) model", "TREATMENT", 119, 138], ["Infected", "OBSERVATION", 72, 80]]], ["No reuse allowed without permission.Susceptible-Infected-Recovered-Social Distancing-Detection Rate (SIR-D2) modelwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Susceptible-Infected-Recovered-Social Distancing-Detection Rate (SIR-D2) modelThe copyright holder for this preprint (which this version posted May 6, 2020. where H is the proportion of cases requiring hospitalization, which we estimated from Atrium Health hospital admission data, and n is the average illness duration of 14 days described by the CDC.", [["illness", "DISEASE", 545, 552], ["The copyright holder", "TREATMENT", 320, 340], ["Infected", "OBSERVATION_MODIFIER", 48, 56], ["med", "ANATOMY", 186, 189], ["Infected", "OBSERVATION_MODIFIER", 254, 262], ["Atrium", "ANATOMY", 485, 491]]], ["21Phase II-user interface construction and app development CURVE App DevelopmentWe developed the interactive CURVE app using R Shiny (RStudio Inc., Boston, MA).", [["21Phase II", "CHEMICAL", 0, 10], ["21Phase II", "PROTEIN", 0, 10], ["user interface construction", "TREATMENT", 11, 38]]], ["The main inputs that drive the CURVE app are as follows: 1) the percentage of total projected infections that would require hospitalization; 2) the proportion of total hospital admissions that would require ICU care; 3) the proportion of patients who are admitted to the ICU who will require ventilator support; 4) the average length of stay in the hospital; 5) the average length of stay in the ICU; 6) the average length of ventilator support when required; and 7) the Atrium Health market share within the grater Charlotte area.Phase II-user interface construction and app development CURVE App DevelopmentWe set up three scenarios (best-, moderate-, and worst-case scenario) with different settings to show a range of potential impacts on the hospital system, due to the uncertain nature of the COVID-19 pandemic.", [["infections", "DISEASE", 94, 104], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["total projected infections", "PROBLEM", 78, 104], ["ICU care", "TREATMENT", 207, 215], ["ventilator support", "TREATMENT", 292, 310], ["the average length of ventilator support", "TREATMENT", 404, 444], ["user interface construction", "TREATMENT", 540, 567], ["the COVID", "TEST", 795, 804], ["pandemic", "PROBLEM", 808, 816], ["Atrium", "ANATOMY", 471, 477]]], ["For planning purposes, our health system chose to use the moderate-case scenario.", [["the moderate-case scenario", "TREATMENT", 54, 80]]], ["We adjusted hospitalization, ICU, and on-ventilator percentages for each scenario based on either estimations from the literature or local data trends once we accumulated enough patients.", [["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["-ventilator percentages", "TREATMENT", 40, 63]]], ["18, 19, 23 Dynamically changing input parameters cause results to cascade through the following charts: 1) hospital census by day shows the projected number of infected patients in the hospital adjusted by the average length of hospital stay; 2) hospital census against capacity by day, including additional surge beds, to indicate if forecasted hospitalization requirements will exceed the healthcare system's capacities; 3) the observed ICU proportion of hospitalization and observed mechanical ventilator occupancy status with 95% confidence intervals; 4) new daily admissions; 5) the observed hospital census against the projected hospital census; and 6) the predicted actual prevalence.Model comparisonWe then used the CURVE app to compare predictions from two of our models -one created before and one after the statewide stay-at-home and social distancing orders issued on March 30, 2020 (denoted before-SAH-order and after-SAH-order models hereafter).", [["SAH", "DISEASE", 911, 914], ["SAH", "DISEASE", 931, 934], ["patients", "ORGANISM", 169, 177], ["CURVE app", "DNA", 724, 733], ["patients", "SPECIES", 169, 177], ["additional surge beds", "TREATMENT", 297, 318], ["SAH", "PROBLEM", 911, 914], ["SAH", "PROBLEM", 931, 934], ["infected", "OBSERVATION", 160, 168]]], ["24 Note that the before-SAHorder model was driven by conventional SIR model, which was not adjusted for social distancing and stay-at-home order, i.e., the probability of transmission and exposure rate were not adjusted.", [["exposure rate", "TEST", 188, 201]]], ["We compared the two models' performance in terms of root mean square error (RMSE) between All rights reserved.", [["root", "ANATOMY", 52, 56]]], ["No reuse allowed without permission.Model comparisonwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Model comparisonThe copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087973 doi: medRxiv preprint observed values and predicted results.", [["The copyright holder", "TREATMENT", 196, 216], ["med", "ANATOMY", 124, 127]]], ["Finally, using the after-SAH-order model we present all results for best-, moderate-, and worst-case scenario parameter settings including hospital census in all-bed, ICU-bed, ventilator usage, and RMSE (observed vs. predicted).ResultsThe schematic of the proposed R Shiny app reactivity diagram is shown in Figure 1 .", [["SAH", "PROBLEM", 25, 28], ["ventilator usage", "TREATMENT", 176, 192]]], ["The app contains four major parts-mod_fun.R, global.R, ui.R, and server.R files.", [["mod_fun", "GENE_OR_GENE_PRODUCT", 34, 41], ["mod_fun", "DNA", 34, 41], ["ui.R", "PROTEIN", 55, 59], ["global", "OBSERVATION", 45, 51]]], ["We imported data, such as SIR-D2 forecasting simulation results (e.g. infected latent prevalence), default settings, parameters, current bed and ventilator counts, surge beds and additional ventilators, days for preparing additional resources, etc. stored in a csv file for users to easily modify without hard coding in the app.", [["current bed", "TREATMENT", 129, 140], ["ventilator counts", "TEST", 145, 162], ["surge beds", "TREATMENT", 164, 174], ["additional ventilators", "TREATMENT", 179, 201]]], ["Then global.R feeds the default values and parameters to the input components, followed by calling mod_fun.R to calculate the forecasting numbers, such as initial hospital census, incidence, and new admissions.", [["mod_fun", "GENE_OR_GENE_PRODUCT", 99, 106]]], ["The generated initial dataset is pushed into a main data hub as a reactiveValues object that can notify any reactive functions that depend on it.", [["reactive", "OBSERVATION_MODIFIER", 66, 74]]], ["The reactive functions configure outputs that update the tables, charts, and plots.", [["reactive", "OBSERVATION_MODIFIER", 4, 12]]], ["When users change input values, the observeEvent object is triggered, which pushes the changes to a reactive object for configuration, and then updates the main dataset via mod_fun.R file.", [["mod_fun", "GENE_OR_GENE_PRODUCT", 173, 180], ["mod_fun", "PROTEIN", 173, 180], ["reactive object", "OBSERVATION", 100, 115]]], ["Finally, the main data in the reactiveValues object is altered, followed by a series of updating processes that cascade modifications through all outputs.ResultsThe CURVE app provides health care leaders with: 1) predicted and observed COVID-19 hospital census by day for non-ICU beds, ICU beds, and ventilator utilization; 2) predicted and observed hospital admissions broken down by COVID-19 and non-COVID-19; 3) variance of the modeled prediction from actual occurrences; and 4) projections of the effect of decreasing social distancing measures on different dates.", [["ICU beds", "TREATMENT", 286, 294], ["COVID", "TEST", 385, 390], ["decreasing social distancing measures", "TREATMENT", 511, 548], ["main", "OBSERVATION_MODIFIER", 13, 17], ["altered", "OBSERVATION_MODIFIER", 55, 62]]], ["For planning purposes, users can choose from three preprogramed scenarios that depict a best-, moderate-, and worst-case scenario, or customize these configurations (Figure 2 ).ResultsIn the model comparisons shown in Table 2 , the AH before-SAH-order model projected higher volumes of hospitalized COVID-19 patients and earlier date to reach the peak (April 29 vs. May 20, 2020).", [["SAH", "DISEASE", 242, 245], ["COVID", "DISEASE", 299, 304], ["patients", "ORGANISM", 308, 316], ["patients", "SPECIES", 308, 316], ["SAH", "PROBLEM", 242, 245], ["SAH", "OBSERVATION", 242, 245]]], ["The AH after-SAH-order model estimated a maximum number of COVID-19 patients on May 20, 2020 and the lowest RMSE in total-bed, ICU-bed, and patients on ventilator.", [["SAH", "DISEASE", 13, 16], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 140, 148], ["SAH", "PROBLEM", 13, 16], ["COVID", "TEST", 59, 64], ["ventilator", "TREATMENT", 152, 162], ["SAH", "OBSERVATION", 13, 16]]], ["Note that the observed all-bed and ICU beds experience a flattening phenomenon after April 6, 2020, which likely reflected the social distance and stay-at-home orders issued on March 30, 2020.", [["a flattening phenomenon", "PROBLEM", 55, 78]]], ["The AH after-SAH-order model accordingly also reflects a flatter curve compared with the before-SAH-order model.", [["SAH", "DISEASE", 13, 16], ["SAH", "DISEASE", 96, 99], ["SAH", "PROBLEM", 13, 16], ["a flatter curve", "PROBLEM", 55, 70], ["SAH", "OBSERVATION", 13, 16]]], ["No reuse allowed without permission.Resultswas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ResultsThe copyright holder for this preprint (which this version posted May 6, 2020.DiscussionWe present a novel decision support app that incorporates locally calibrated forecasts with health system specific data and provides healthcare system leadership with timely actionable insights to guide decision making during the COVID-19 pandemic.", [["the COVID", "TEST", 492, 501], ["pandemic", "PROBLEM", 505, 513], ["med", "ANATOMY", 115, 118]]], ["The CURVE app provides information based upon local infectious patterns and allows for frequent updates as new forecast or health system data becomes available.", [["CURVE app", "DNA", 4, 13], ["health system data", "TEST", 123, 141]]], ["By predicting utilization in the context of up-to-date local resources, such as hospital beds, ICU beds, and number of ventilators, it also provides a critical monitoring function (e.g. alignment of model predicting and observed bed statistics).", [["ICU beds", "TREATMENT", 95, 103], ["ventilators", "TREATMENT", 119, 130]]], ["Because this pandemic trajectory is expected to be highly depending on public policy and community behaviors, we present best-, moderate-, and worstcase scenarios, so that leaders can compare side-by-side the range of possible impacts on hospital plans.", [["moderate", "OBSERVATION_MODIFIER", 128, 136]]], ["The reality of this variability can be seen as the observed hospitalizations for COVID-19 positive patients significantly flattened after April 6, 2020, and the trajectory of hospital census shifted from the moderate-to best-case scenario according to Table 3, Table 4 , and Figure 4 .", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["COVID", "TEST", 81, 86], ["moderate", "OBSERVATION_MODIFIER", 208, 216]]], ["One approach to determine a reasonable value is to plot the actual hospital census counts versus the date and modulate the hospital proportion until the predicted hospital census curve is parallel to the trend in the actual counts.", [["the actual counts", "TEST", 213, 230]]], ["Then add an offset to the predictions so that the curve provides a good fit to the actual counts.", [["the actual counts", "TEST", 79, 96]]], ["An offset that minimizes the RMSE is the difference between mean actual counts and the mean predictions.", [["mean actual counts", "TEST", 60, 78], ["offset", "OBSERVATION", 3, 9]]], ["No reuse allowed without permission.Discussionwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint (which this version posted May 6, 2020. . (with an offset of 43.6) gave the optimized fit, i.e., new RMSE=11.5.", [["new RMSE", "TEST", 320, 328], ["med", "ANATOMY", 118, 121]]], ["Importantly, the pandemic behavior has evolved such that deterministic models or models not built to be responsive to local data will have poor fit with observed hospitalizations.", [["the pandemic behavior", "PROBLEM", 13, 34], ["poor fit", "PROBLEM", 139, 147]]], ["Other models and apps provided guidance to predict surge timing and health system demand requirements due to COVID-19; however, these are mostly built on national-and state-level data, are not updated frequently, and do not have actual trends of health system data that most accurately reflect local reality.", [["COVID", "TEST", 109, 114]]], ["6, 8, 19 Our CURVE app addresses these shortcomings by relying upon modeling built on local data that is updated three times a week based upon observed infection and utilization rates.", [["infection", "DISEASE", 152, 161], ["infection", "PROBLEM", 152, 161], ["infection", "OBSERVATION", 152, 161]]], ["It is likely that more advanced models (e.g. Seasonal Autoregressive Integrated Moving Average (SARIMA), or Bayesian generalized additive model) will be required as the pandemic behavior continues to evolve.", [["more advanced models", "PROBLEM", 18, 38], ["Moving Average (SARIMA)", "TREATMENT", 80, 103], ["Bayesian generalized additive model)", "TREATMENT", 108, 144], ["the pandemic behavior", "PROBLEM", 165, 186], ["is likely", "UNCERTAINTY", 3, 12]]], ["The CURVE app allows for these more advanced models to easily be consumed and available to leaders.DiscussionThe CURVE app indicated that the after-SAH-order model with moderate-scenario parameter settings had good fit before April 6, 2020, and in near-real-time allowed our health system to see significant flattening of observed hospitalization for COVID-19 after April 6, 2020.", [["SAH", "DISEASE", 148, 151], ["The CURVE app", "TEST", 0, 13], ["these more advanced models", "TREATMENT", 25, 51], ["The CURVE app", "TEST", 109, 122], ["SAH", "PROBLEM", 148, 151], ["COVID", "TEST", 351, 356]]], ["This local response to social distancing, while immediately apparent in the CURVE app, would not be available to health system leaders relying on models that are neither built on local data nor with frequent recalibration to local trends.", [["local data", "TEST", 179, 189]]], ["Whereas, in the CURVE app, leaders are able to immediately gain these 'on the ground,' local insights -indeed, in this case, that means shifting from a tracking on the moderate-to the best-case scenario.DiscussionAnother benefit of the CURVE app is that it also accounts for non-COVID-19 healthcare utilization, so leaders have a full view of the health system's capacity.", [["moderate", "OBSERVATION_MODIFIER", 168, 176]]], ["While healthcare utilization for non-COVID-19 illness declined early in the pandemic due to canceling of all in-person elective care, 25 this demand is also expected to surge back over time and increasingly become a contributor to overall health system resource consumption.", [["illness", "DISEASE", 46, 53], ["elective care", "TREATMENT", 119, 132]]], ["[26] [27] [28] There are some limitations and scope conditions that should be noted.", [["scope conditions", "TREATMENT", 46, 62]]], ["First, although the CURVE app was developed for healthcare systems to insert local data using either csv files or through direct connection to their enterprise data warehouse, users still require R and R Shiny proficiency to modify or to add more tables, charts, or graphs.", [["CURVE app", "DNA", 20, 29], ["the CURVE app", "TEST", 16, 29], ["local data", "TEST", 77, 87]]], ["Second, in order to provide reliable, locally relevant forecasts, users must have access to local data and modeling expertise with frequent recalibration of the model to local context.", [["local data", "TEST", 92, 102], ["modeling expertise", "TEST", 107, 125]]], ["If such changes are not monitored and accounted for, projections could be taken out of context, leading to erroneous conclusions.ConclusionWe developed an interactive hospital app using R Shiny to provides locally relevant, dynamic, timely information to guide health system decision making and pandemic preparedness.", [["erroneous conclusions", "PROBLEM", 107, 128]]], ["No reuse allowed without permission.Conclusionwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint (which this version posted May 6, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087973 doi: medRxiv preprint Figure 2 .", [["The copyright holder", "TREATMENT", 184, 204], ["The copyright holder", "TREATMENT", 401, 421], ["med", "ANATOMY", 118, 121], ["med", "ANATOMY", 335, 338]]], ["The output of the CURVE app.ConclusionAll rights reserved.", [["CURVE app", "DNA", 18, 27], ["The output", "TEST", 0, 10], ["the CURVE app", "TEST", 14, 27], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["No reuse allowed without permission.Conclusionwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint (which this version posted May 6, 2020.", [["The copyright holder", "TREATMENT", 184, 204], ["med", "ANATOMY", 118, 121]]], ["No reuse allowed without permission.Conclusionwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint (which this version posted May 6, 2020. . https://doi.org/10.1101/2020.05.01.20087973 doi: medRxiv preprint Figure 4 .", [["The copyright holder", "TREATMENT", 184, 204], ["med", "ANATOMY", 118, 121]]], ["Model comparison in (a) all beds, (b) ICU beds, and (c) on ventilators between three models with best-case scenario, moderate-case scenario, and worst-case scenario settings, respectively.", [["ventilators", "TREATMENT", 59, 70]]], ["All graphs on right hand side are zoomed in results between Mar 26 and Apr 15, 2020.ConclusionAll rights reserved.", [["right hand", "ANATOMY", 14, 24], ["right", "ANATOMY_MODIFIER", 14, 19]]], ["No reuse allowed without permission.Conclusionwas not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionThe copyright holder for this preprint (which this version posted May 6, 2020. .", [["The copyright holder", "TREATMENT", 184, 204], ["med", "ANATOMY", 118, 121]]]], "b1be249a7ddd224ba02c77917b1b4ac14d24e439": [["AbstrActThe high rate of thrombotic complications associated with COVID-19 seems likely to reflect viral infection of vascular endothelial cells, which express the ACE2 protein that enables SARS-CoV-2 to invade cells.", [["vascular endothelial cells", "ANATOMY", 118, 144], ["cells", "ANATOMY", 211, 216], ["thrombotic complications", "DISEASE", 25, 49], ["COVID-19", "CHEMICAL", 66, 74], ["infection", "DISEASE", 105, 114], ["COVID-19", "CHEMICAL", 66, 74], ["COVID-19", "GENE_OR_GENE_PRODUCT", 66, 74], ["vascular endothelial cells", "CELL", 118, 144], ["ACE2", "GENE_OR_GENE_PRODUCT", 164, 168], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 190, 200], ["cells", "CELL", 211, 216], ["vascular endothelial cells", "CELL_TYPE", 118, 144], ["ACE2 protein", "PROTEIN", 164, 176], ["thrombotic complications", "PROBLEM", 25, 49], ["COVID", "TEST", 66, 71], ["viral infection of vascular endothelial cells", "PROBLEM", 99, 144], ["the ACE2 protein", "TEST", 160, 176], ["SARS", "PROBLEM", 190, 194], ["CoV", "TEST", 195, 198], ["high", "OBSERVATION_MODIFIER", 12, 16], ["thrombotic", "OBSERVATION_MODIFIER", 25, 35], ["complications", "OBSERVATION", 36, 49], ["likely to reflect", "UNCERTAINTY", 81, 98], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["infection", "OBSERVATION", 105, 114], ["vascular endothelial cells", "OBSERVATION", 118, 144]]], ["Various proinflammatory stimuli can promote thrombosis by inducing luminal endothelial expression of tissue factor (TF), which interacts with circulating coagulation factor VII to trigger extrinsic coagulation.", [["luminal endothelial", "ANATOMY", 67, 86], ["thrombosis", "DISEASE", 44, 54], ["luminal", "CHEMICAL", 67, 74], ["luminal endothelial", "CELL", 67, 86], ["tissue factor", "GENE_OR_GENE_PRODUCT", 101, 114], ["TF", "GENE_OR_GENE_PRODUCT", 116, 118], ["coagulation factor VII", "GENE_OR_GENE_PRODUCT", 154, 176], ["tissue factor", "PROTEIN", 101, 114], ["TF", "PROTEIN", 116, 118], ["circulating coagulation factor VII", "PROTEIN", 142, 176], ["Various proinflammatory stimuli", "TREATMENT", 0, 31], ["thrombosis", "PROBLEM", 44, 54], ["extrinsic coagulation", "PROBLEM", 188, 209], ["proinflammatory stimuli", "OBSERVATION", 8, 31], ["thrombosis", "OBSERVATION", 44, 54], ["luminal", "ANATOMY_MODIFIER", 67, 74], ["endothelial", "ANATOMY", 75, 86], ["coagulation", "OBSERVATION", 198, 209]]], ["The signalling mechanism whereby these stimuli evoke TF expression entails activation of NADPH oxidase, upstream from activation of the NF-kappaB transcription factor that drives the induced transcription of the TF gene.", [["NADPH", "CHEMICAL", 89, 94], ["NADPH", "CHEMICAL", 89, 94], ["TF", "GENE_OR_GENE_PRODUCT", 53, 55], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 89, 102], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 136, 145], ["TF", "GENE_OR_GENE_PRODUCT", 212, 214], ["TF", "PROTEIN", 53, 55], ["NADPH oxidase", "PROTEIN", 89, 102], ["NF-kappaB transcription factor", "PROTEIN", 136, 166], ["TF gene", "DNA", 212, 219], ["The signalling mechanism", "PROBLEM", 0, 24], ["these stimuli", "TREATMENT", 33, 46], ["NADPH oxidase", "TREATMENT", 89, 102], ["the NF-kappaB transcription factor", "TREATMENT", 132, 166], ["NADPH oxidase", "OBSERVATION", 89, 102]]], ["When single-stranded RNA viruses are taken up into cellular endosomes, they stimulate endosomal formation and activation of NADPH oxidase complexes via RNA-responsive toll-like receptor 7.", [["cellular endosomes", "ANATOMY", 51, 69], ["endosomal", "ANATOMY", 86, 95], ["NADPH", "CHEMICAL", 124, 129], ["NADPH", "CHEMICAL", 124, 129], ["cellular endosomes", "CELLULAR_COMPONENT", 51, 69], ["endosomal", "CELLULAR_COMPONENT", 86, 95], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 124, 137], ["toll-like receptor 7", "GENE_OR_GENE_PRODUCT", 167, 187], ["NADPH oxidase complexes", "PROTEIN", 124, 147], ["RNA-responsive toll-like receptor 7", "PROTEIN", 152, 187], ["stranded RNA viruses", "PROBLEM", 12, 32], ["NADPH oxidase complexes", "TREATMENT", 124, 147], ["RNA", "TEST", 152, 155], ["endosomal formation", "OBSERVATION", 86, 105]]], ["It is therefore proposed that SARS-CoV-2 infection of endothelial cells evokes the expression of TF which is contingent on endosomal NADPH oxidase activation.", [["endothelial cells", "ANATOMY", 54, 71], ["endosomal", "ANATOMY", 123, 132], ["SARS", "DISEASE", 30, 34], ["infection", "DISEASE", 41, 50], ["NADPH", "CHEMICAL", 133, 138], ["NADPH", "CHEMICAL", 133, 138], ["SARS-CoV-2", "ORGANISM", 30, 40], ["endothelial cells", "CELL", 54, 71], ["TF", "GENE_OR_GENE_PRODUCT", 97, 99], ["endosomal", "CELLULAR_COMPONENT", 123, 132], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 133, 146], ["endothelial cells", "CELL_TYPE", 54, 71], ["TF", "PROTEIN", 97, 99], ["endosomal NADPH oxidase", "PROTEIN", 123, 146], ["SARS", "PROBLEM", 30, 34], ["CoV", "PROBLEM", 35, 38], ["2 infection of endothelial cells", "PROBLEM", 39, 71], ["TF", "TREATMENT", 97, 99], ["endosomal NADPH oxidase activation", "TREATMENT", 123, 157], ["endothelial cells", "OBSERVATION", 54, 71], ["NADPH oxidase", "OBSERVATION", 133, 146]]], ["If this hypothesis is correct, hydroxychloroquine, spirulina (more specifically, its chromophore phycocyanobilin) and high-dose glycine may have practical potential for mitigating the elevated thrombotic risk associated with COVID-19.AbstrActA key role for endosomAl nAdPH oxidAse in endotHeliAl tissue fACtor exPression COVID-19 is associated with a high incidence of thrombotic complications.", [["endotHeliAl tissue", "ANATOMY", 284, 302], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["spirulina", "CHEMICAL", 51, 60], ["phycocyanobilin", "CHEMICAL", 97, 112], ["glycine", "CHEMICAL", 128, 135], ["thrombotic", "DISEASE", 193, 203], ["COVID-19", "CHEMICAL", 225, 233], ["thrombotic complications", "DISEASE", 369, 393], ["hydroxychloroquine", "CHEMICAL", 31, 49], ["spirulina", "CHEMICAL", 51, 60], ["phycocyanobilin", "CHEMICAL", 97, 112], ["glycine", "CHEMICAL", 128, 135], ["COVID-19", "CHEMICAL", 225, 233], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 31, 49], ["spirulina", "SIMPLE_CHEMICAL", 51, 60], ["phycocyanobilin", "SIMPLE_CHEMICAL", 97, 112], ["glycine", "SIMPLE_CHEMICAL", 128, 135], ["AbstrActA", "GENE_OR_GENE_PRODUCT", 234, 243], ["endosomAl nAdPH oxidAse", "GENE_OR_GENE_PRODUCT", 257, 280], ["endosomAl nAdPH oxidAse", "PROTEIN", 257, 280], ["hydroxychloroquine", "TREATMENT", 31, 49], ["spirulina", "TREATMENT", 51, 60], ["its chromophore phycocyanobilin", "TREATMENT", 81, 112], ["high-dose glycine", "TREATMENT", 118, 135], ["the elevated thrombotic risk", "PROBLEM", 180, 208], ["COVID", "TEST", 225, 230], ["endosomAl nAdPH oxidAse", "TREATMENT", 257, 280], ["thrombotic complications", "PROBLEM", 369, 393], ["elevated", "OBSERVATION_MODIFIER", 184, 192], ["thrombotic", "OBSERVATION", 193, 203], ["nAdPH oxidAse", "OBSERVATION", 267, 280], ["thrombotic", "OBSERVATION_MODIFIER", 369, 379], ["complications", "OBSERVATION", 380, 393]]], ["1 Necropsy studies reveal platelet-fibrin plugs in pulmonary arterioles, likely contributing to the hypoxaemia characteristic of advanced infection.", [["platelet", "ANATOMY", 26, 34], ["pulmonary arterioles", "ANATOMY", 51, 71], ["hypoxaemia", "DISEASE", 100, 110], ["infection", "DISEASE", 138, 147], ["platelet", "CELL", 26, 34], ["fibrin", "GENE_OR_GENE_PRODUCT", 35, 41], ["pulmonary arterioles", "MULTI-TISSUE_STRUCTURE", 51, 71], ["Necropsy studies", "TEST", 2, 18], ["platelet", "TEST", 26, 34], ["fibrin plugs in pulmonary arterioles", "PROBLEM", 35, 71], ["the hypoxaemia", "PROBLEM", 96, 110], ["advanced infection", "PROBLEM", 129, 147], ["platelet", "OBSERVATION", 26, 34], ["fibrin plugs", "OBSERVATION", 35, 47], ["pulmonary arterioles", "ANATOMY", 51, 71], ["likely contributing to", "UNCERTAINTY", 73, 95], ["hypoxaemia", "OBSERVATION", 100, 110], ["advanced", "OBSERVATION_MODIFIER", 129, 137], ["infection", "OBSERVATION", 138, 147]]], ["2 It has been suggested that the thrombotic diathesis associated with COVID-19 reflects an endotheliopathy induced by viral infection of endothelial cells.", [["endothelial cells", "ANATOMY", 137, 154], ["thrombotic diathesis", "DISEASE", 33, 53], ["COVID-19", "CHEMICAL", 70, 78], ["endotheliopathy", "DISEASE", 91, 106], ["viral infection", "DISEASE", 118, 133], ["COVID-19", "CHEMICAL", 70, 78], ["endotheliopathy", "CANCER", 91, 106], ["endothelial cells", "CELL", 137, 154], ["endothelial cells", "CELL_TYPE", 137, 154], ["the thrombotic diathesis", "PROBLEM", 29, 53], ["COVID", "TEST", 70, 75], ["an endotheliopathy", "PROBLEM", 88, 106], ["viral infection of endothelial cells", "PROBLEM", 118, 154], ["thrombotic", "OBSERVATION_MODIFIER", 33, 43], ["diathesis", "OBSERVATION", 44, 53], ["endotheliopathy", "OBSERVATION", 91, 106], ["viral", "OBSERVATION_MODIFIER", 118, 123], ["infection", "OBSERVATION", 124, 133], ["endothelial cells", "OBSERVATION", 137, 154]]], ["[3] [4] [5] These cells prominently express the ACE2 plasma membrane protein to which the spike protein of SARS-CoV-2 virions bind, enabling their endosomal incorporation into cells.", [["cells", "ANATOMY", 18, 23], ["plasma membrane", "ANATOMY", 53, 68], ["endosomal", "ANATOMY", 147, 156], ["cells", "ANATOMY", 176, 181], ["cells", "CELL", 18, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["plasma membrane", "CELLULAR_COMPONENT", 53, 68], ["SARS-CoV-2", "ORGANISM", 107, 117], ["endosomal", "CELLULAR_COMPONENT", 147, 156], ["cells", "CELL", 176, 181], ["ACE2 plasma membrane protein", "PROTEIN", 48, 76], ["spike protein", "PROTEIN", 90, 103], ["These cells", "TEST", 12, 23], ["the ACE2 plasma membrane protein", "TEST", 44, 76], ["the spike protein", "TEST", 86, 103], ["SARS", "TEST", 107, 111], ["CoV", "TEST", 112, 115]]], ["6 7 The thrombotic complications of COVID-19 infection would be readily explained if SARS-CoV-2 infection of endothelial cells induces luminal expression of tissue factor (TF), which could then interact with circulating coagulation factor VII to trigger a proteolytic cascade culminating in the generation of thrombin and fibrin (extrinsic clotting).", [["endothelial cells", "ANATOMY", 109, 126], ["luminal", "ANATOMY", 135, 142], ["thrombotic", "DISEASE", 8, 18], ["COVID-19", "CHEMICAL", 36, 44], ["infection", "DISEASE", 45, 54], ["infection", "DISEASE", 96, 105], ["luminal", "CHEMICAL", 135, 142], ["COVID-19", "CHEMICAL", 36, 44], ["COVID-19", "SIMPLE_CHEMICAL", 36, 44], ["CoV-2", "ORGANISM", 90, 95], ["endothelial cells", "CELL", 109, 126], ["luminal", "MULTI-TISSUE_STRUCTURE", 135, 142], ["tissue factor", "GENE_OR_GENE_PRODUCT", 157, 170], ["TF", "GENE_OR_GENE_PRODUCT", 172, 174], ["coagulation factor VII", "GENE_OR_GENE_PRODUCT", 220, 242], ["thrombin", "GENE_OR_GENE_PRODUCT", 309, 317], ["fibrin", "GENE_OR_GENE_PRODUCT", 322, 328], ["endothelial cells", "CELL_TYPE", 109, 126], ["tissue factor", "PROTEIN", 157, 170], ["TF", "PROTEIN", 172, 174], ["circulating coagulation factor VII", "PROTEIN", 208, 242], ["thrombin", "PROTEIN", 309, 317], ["fibrin", "PROTEIN", 322, 328], ["The thrombotic complications", "PROBLEM", 4, 32], ["COVID-19 infection", "PROBLEM", 36, 54], ["SARS", "PROBLEM", 85, 89], ["CoV", "PROBLEM", 90, 93], ["endothelial cells", "PROBLEM", 109, 126], ["tissue factor", "PROBLEM", 157, 170], ["a proteolytic cascade", "PROBLEM", 254, 275], ["thrombin", "PROBLEM", 309, 317], ["fibrin (extrinsic clotting", "PROBLEM", 322, 348], ["thrombotic", "OBSERVATION_MODIFIER", 8, 18], ["complications", "OBSERVATION", 19, 32], ["infection", "OBSERVATION", 45, 54], ["endothelial cells", "OBSERVATION", 109, 126]]], ["TF expression is negligible in healthy non-inflamed endothelial cells, but it can be upregulated at the transcription level by various proinflammatory stimuli that activate the NF-kappaB transcription factor.", [["endothelial cells", "ANATOMY", 52, 69], ["TF", "GENE_OR_GENE_PRODUCT", 0, 2], ["endothelial cells", "CELL", 52, 69], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 177, 186], ["TF", "PROTEIN", 0, 2], ["healthy non-inflamed endothelial cells", "CELL_TYPE", 31, 69], ["NF-kappaB transcription factor", "PROTEIN", 177, 207], ["various proinflammatory stimuli", "TEST", 127, 158], ["negligible", "OBSERVATION_MODIFIER", 17, 27], ["healthy non-inflamed", "OBSERVATION_MODIFIER", 31, 51], ["endothelial cells", "OBSERVATION", 52, 69], ["proinflammatory stimuli", "OBSERVATION", 135, 158]]], ["More specifically, the heterodimers p65/p50 or p65/c-Rel can bind to a novel 'TF-kappaB' sequence in the promoter of the TF gene, driving its induced expression.", [["p65", "GENE_OR_GENE_PRODUCT", 36, 39], ["p50", "GENE_OR_GENE_PRODUCT", 40, 43], ["p65/c-Rel", "GENE_OR_GENE_PRODUCT", 47, 56], ["TF-kappaB", "GENE_OR_GENE_PRODUCT", 78, 87], ["TF", "GENE_OR_GENE_PRODUCT", 121, 123], ["p65", "PROTEIN", 36, 39], ["p50", "PROTEIN", 40, 43], ["p65/c", "PROTEIN", 47, 52], ["Rel", "PROTEIN", 53, 56], ["TF-kappaB' sequence", "DNA", 78, 97], ["promoter", "DNA", 105, 113], ["TF gene", "DNA", 121, 128], ["the heterodimers p65", "TEST", 19, 39], ["a novel 'TF-kappaB' sequence", "TREATMENT", 69, 97]]], ["[8] [9] [10] Various proinflammatory factors that induce TF in endothelial cells-including tumour necrosis factor-alpha (TNF\u03b1), antiphospholipid antibodies (aPL), ultrafine pollutant particles and homocysteine-have been shown to do so via signalling pathways in which activation of NADPH oxidase complexes plays an obligate role.", [["TF", "ANATOMY", 57, 59], ["endothelial cells", "ANATOMY", 63, 80], ["necrosis", "DISEASE", 98, 106], ["homocysteine", "CHEMICAL", 197, 209], ["NADPH", "CHEMICAL", 282, 287], ["homocysteine", "CHEMICAL", 197, 209], ["NADPH", "CHEMICAL", 282, 287], ["[8] [9] [10", "SIMPLE_CHEMICAL", 0, 11], ["TF", "CELL", 57, 59], ["endothelial cells", "CELL", 63, 80], ["tumour necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 91, 119], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 121, 125], ["antiphospholipid antibodies", "GENE_OR_GENE_PRODUCT", 128, 155], ["aPL", "GENE_OR_GENE_PRODUCT", 157, 160], ["ultrafine pollutant particles", "SIMPLE_CHEMICAL", 163, 192], ["homocysteine", "SIMPLE_CHEMICAL", 197, 209], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 282, 295], ["proinflammatory factors", "PROTEIN", 21, 44], ["TF", "PROTEIN", 57, 59], ["endothelial cells", "CELL_TYPE", 63, 80], ["tumour necrosis factor-alpha", "PROTEIN", 91, 119], ["TNF\u03b1", "PROTEIN", 121, 125], ["antiphospholipid antibodies", "PROTEIN", 128, 155], ["aPL", "PROTEIN", 157, 160], ["NADPH oxidase complexes", "PROTEIN", 282, 305], ["Various proinflammatory factors", "PROBLEM", 13, 44], ["TF in endothelial cells", "PROBLEM", 57, 80], ["tumour necrosis factor", "PROBLEM", 91, 113], ["alpha (TNF\u03b1", "TEST", 114, 125], ["antiphospholipid antibodies (aPL)", "PROBLEM", 128, 161], ["ultrafine pollutant particles", "TREATMENT", 163, 192], ["homocysteine", "TREATMENT", 197, 209], ["NADPH oxidase complexes", "TREATMENT", 282, 305], ["endothelial", "ANATOMY", 63, 74], ["tumour necrosis", "OBSERVATION", 91, 106]]], ["[11] [12] [13] [14] The effects of aPL and of TNF\u03b1 in this regard hinge on the activation of NADPH oxidase in endosomes which has incorporated these agonists.", [["endosomes", "ANATOMY", 110, 119], ["aPL", "DISEASE", 35, 38], ["NADPH", "CHEMICAL", 93, 98], ["NADPH", "CHEMICAL", 93, 98], ["[11] [12] [13] [14]", "SIMPLE_CHEMICAL", 0, 19], ["aPL", "GENE_OR_GENE_PRODUCT", 35, 38], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 46, 50], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 93, 106], ["endosomes", "CELLULAR_COMPONENT", 110, 119], ["aPL", "PROTEIN", 35, 38], ["TNF\u03b1", "PROTEIN", 46, 50], ["NADPH oxidase", "PROTEIN", 93, 106], ["aPL", "PROBLEM", 35, 38], ["TNF", "TREATMENT", 46, 49], ["NADPH oxidase", "TREATMENT", 93, 106], ["these agonists", "TREATMENT", 143, 157], ["aPL", "ANATOMY", 35, 38], ["NADPH oxidase", "OBSERVATION", 93, 106]]], ["12 Prior to the emergence of SARS-CoV-2, it was demonstrated that a number of RNA viruses can activate endosomal NADPH oxidase through a mechanism dependent on toll-like receptor 7 (TLR7), which is activated by binding to single-stranded RNA.", [["endosomal", "ANATOMY", 103, 112], ["SARS", "DISEASE", 29, 33], ["NADPH", "CHEMICAL", 113, 118], ["NADPH", "CHEMICAL", 113, 118], ["SARS-CoV-2", "ORGANISM", 29, 39], ["endosomal", "CELLULAR_COMPONENT", 103, 112], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 113, 126], ["toll-like receptor 7", "GENE_OR_GENE_PRODUCT", 160, 180], ["TLR7", "GENE_OR_GENE_PRODUCT", 182, 186], ["endosomal NADPH oxidase", "PROTEIN", 103, 126], ["toll-like receptor 7", "PROTEIN", 160, 180], ["TLR7", "PROTEIN", 182, 186], ["single-stranded RNA", "RNA", 222, 241], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "TEST", 29, 37], ["RNA viruses", "PROBLEM", 78, 89], ["endosomal NADPH oxidase", "TREATMENT", 103, 126], ["a mechanism dependent", "PROBLEM", 135, 156], ["RNA viruses", "OBSERVATION", 78, 89], ["NADPH oxidase", "OBSERVATION", 113, 126], ["stranded RNA", "OBSERVATION", 229, 241]]], ["15 Presumably, these viruses, after binding to cellular plasma membranes, are incorporated into endosomes, and viral RNA released from the virions can interact with endosomal TLR7, triggering NADPH oxidase activation.", [["cellular plasma membranes", "ANATOMY", 47, 72], ["endosomes", "ANATOMY", 96, 105], ["virions", "ANATOMY", 139, 146], ["endosomal", "ANATOMY", 165, 174], ["NADPH", "CHEMICAL", 192, 197], ["NADPH", "CHEMICAL", 192, 197], ["cellular", "CELL", 47, 55], ["plasma membranes", "CELLULAR_COMPONENT", 56, 72], ["endosomes", "CELLULAR_COMPONENT", 96, 105], ["endosomal", "CELLULAR_COMPONENT", 165, 174], ["TLR7", "GENE_OR_GENE_PRODUCT", 175, 179], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 192, 205], ["viral RNA", "RNA", 111, 120], ["endosomal TLR7", "PROTEIN", 165, 179], ["NADPH oxidase", "PROTEIN", 192, 205], ["these viruses", "PROBLEM", 15, 28], ["cellular plasma membranes", "PROBLEM", 47, 72], ["viral RNA", "PROBLEM", 111, 120], ["endosomal TLR7", "TREATMENT", 165, 179], ["NADPH oxidase activation", "TREATMENT", 192, 216], ["viruses", "OBSERVATION", 21, 28], ["plasma membranes", "OBSERVATION", 56, 72], ["viral RNA", "OBSERVATION", 111, 120], ["endosomal TLR7", "OBSERVATION", 165, 179], ["NADPH oxidase", "OBSERVATION", 192, 205]]], ["Indeed, To and colleagues found that eight different types of single-stranded RNA viruses activated endosomal NADPH oxidase in alveolar macrophages, and the two types that did not activate it do not employ endosomes as their primary entry mechanism.", [["endosomal", "ANATOMY", 100, 109], ["alveolar macrophages", "ANATOMY", 127, 147], ["endosomes", "ANATOMY", 206, 215], ["NADPH", "CHEMICAL", 110, 115], ["NADPH", "CHEMICAL", 110, 115], ["endosomal", "CELLULAR_COMPONENT", 100, 109], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 110, 123], ["alveolar macrophages", "CELL", 127, 147], ["endosomes", "CELLULAR_COMPONENT", 206, 215], ["endosomal NADPH oxidase", "PROTEIN", 100, 123], ["alveolar macrophages", "CELL_TYPE", 127, 147], ["single-stranded RNA viruses activated endosomal NADPH oxidase in alveolar macrophages", "PROBLEM", 62, 147], ["NADPH oxidase", "OBSERVATION", 110, 123], ["alveolar macrophages", "OBSERVATION", 127, 147]]], ["15 Moreover, this effect was DiNicolantonio JJ, McCarty M. Open Heart 2020;7:e001337. doi:10.1136/openhrt-2020-001337 absent in alveolar macrophages in which TLR7 expression was knocked out.AbstrActSARS-CoV-2 is likewise a single-stranded RNA virus, the intracellular uptake of which is mediated by endosomes.", [["alveolar macrophages", "ANATOMY", 128, 148], ["intracellular", "ANATOMY", 254, 267], ["endosomes", "ANATOMY", 299, 308], ["alveolar macrophages", "CELL", 128, 148], ["TLR7", "GENE_OR_GENE_PRODUCT", 158, 162], ["AbstrActSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 190, 208], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 254, 267], ["endosomes", "CELLULAR_COMPONENT", 299, 308], ["alveolar macrophages", "CELL_TYPE", 128, 148], ["TLR7", "PROTEIN", 158, 162], ["AbstrActSARS-CoV-2", "DNA", 190, 208], ["doi:", "TEST", 86, 90], ["absent in alveolar macrophages", "PROBLEM", 118, 148], ["AbstrActSARS", "TEST", 190, 202], ["CoV", "TEST", 203, 206], ["a single-stranded RNA virus", "PROBLEM", 221, 248], ["the intracellular uptake", "TEST", 250, 274], ["Heart", "ANATOMY", 64, 69], ["alveolar macrophages", "OBSERVATION", 128, 148], ["intracellular uptake", "OBSERVATION", 254, 274]]], ["16 We postulated that SARS-CoV-2, after incorporation into endosomes within endothelial cells, can likewise activate endosomal NADPH oxidase via TLR7, and that the resulting local production of superoxide/hydrogen peroxide leads to activation of NF-kappaB-by a mechanism yet to be determined-and subsequently to increased expression of TF.", [["endosomes", "ANATOMY", 59, 68], ["endothelial cells", "ANATOMY", 76, 93], ["endosomal", "ANATOMY", 117, 126], ["NADPH", "CHEMICAL", 127, 132], ["superoxide", "CHEMICAL", 194, 204], ["hydrogen peroxide", "CHEMICAL", 205, 222], ["NADPH", "CHEMICAL", 127, 132], ["superoxide", "CHEMICAL", 194, 204], ["hydrogen peroxide", "CHEMICAL", 205, 222], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["endosomes", "CELLULAR_COMPONENT", 59, 68], ["endothelial cells", "CELL", 76, 93], ["endosomal", "CELLULAR_COMPONENT", 117, 126], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 127, 140], ["TLR7", "GENE_OR_GENE_PRODUCT", 145, 149], ["superoxide", "SIMPLE_CHEMICAL", 194, 204], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 205, 222], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 246, 255], ["TF", "GENE_OR_GENE_PRODUCT", 336, 338], ["endothelial cells", "CELL_TYPE", 76, 93], ["endosomal NADPH oxidase", "PROTEIN", 117, 140], ["TLR7", "PROTEIN", 145, 149], ["NF-kappaB", "PROTEIN", 246, 255], ["TF", "PROTEIN", 336, 338], ["SARS", "PROBLEM", 22, 26], ["CoV", "TEST", 27, 30], ["endosomal NADPH oxidase", "TREATMENT", 117, 140], ["TLR7", "TREATMENT", 145, 149], ["superoxide/hydrogen peroxide", "TREATMENT", 194, 222], ["endothelial cells", "OBSERVATION", 76, 93], ["NADPH oxidase", "OBSERVATION", 127, 140]]], ["At present, while it is difficult to trace clinical studies that have measured serum markers of oxidative stress in COVID-19 patients, the fact that clinical outcomes were poorer in those provinces of China where soil selenium is deficient is compatible with the view that oxidant stress plays a key pathogenic role in this syndrome, and selenium is required for function of multiple antioxidant enzymes, including glutathione peroxidases and thioredoxin reductases.", [["serum", "ANATOMY", 79, 84], ["selenium", "CHEMICAL", 218, 226], ["selenium", "CHEMICAL", 338, 346], ["glutathione", "CHEMICAL", 415, 426], ["selenium", "CHEMICAL", 218, 226], ["selenium", "CHEMICAL", 338, 346], ["glutathione", "CHEMICAL", 415, 426], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["patients", "ORGANISM", 125, 133], ["selenium", "SIMPLE_CHEMICAL", 218, 226], ["selenium", "SIMPLE_CHEMICAL", 338, 346], ["glutathione peroxidases", "GENE_OR_GENE_PRODUCT", 415, 438], ["thioredoxin reductases", "GENE_OR_GENE_PRODUCT", 443, 465], ["antioxidant enzymes", "PROTEIN", 384, 403], ["glutathione peroxidases", "PROTEIN", 415, 438], ["thioredoxin reductases", "PROTEIN", 443, 465], ["patients", "SPECIES", 125, 133], ["trace clinical studies", "TEST", 37, 59], ["serum markers", "TEST", 79, 92], ["oxidative stress", "PROBLEM", 96, 112], ["oxidant stress", "PROBLEM", 273, 287], ["this syndrome", "PROBLEM", 319, 332], ["multiple antioxidant enzymes", "TEST", 375, 403], ["glutathione peroxidases", "TREATMENT", 415, 438], ["thioredoxin reductases", "TREATMENT", 443, 465]]], ["17 18 Moreover, oxidative stress is a key feature of other viral diseases that evoke acute respiratory distress syndrome and cytokine storm.", [["respiratory", "ANATOMY", 91, 102], ["viral diseases", "DISEASE", 59, 73], ["acute respiratory distress syndrome", "DISEASE", 85, 120], ["cytokine", "PROTEIN", 125, 133], ["other viral diseases", "PROBLEM", 53, 73], ["acute respiratory distress syndrome", "PROBLEM", 85, 120], ["cytokine storm", "PROBLEM", 125, 139], ["viral diseases", "OBSERVATION", 59, 73], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["respiratory distress", "OBSERVATION", 91, 111], ["cytokine storm", "OBSERVATION", 125, 139]]], ["19 tHerAPeutiC imPliCAtions of tHe HyPotHesis This hypothesis is of practical significance because practical measures for inhibiting endosomal NADPH activity may be at hand.", [["endosomal", "ANATOMY", 133, 142], ["NADPH", "CHEMICAL", 143, 148], ["NADPH", "CHEMICAL", 143, 148], ["endosomal", "CELLULAR_COMPONENT", 133, 142], ["NADPH", "SIMPLE_CHEMICAL", 143, 148], ["hand", "ORGANISM_SUBDIVISION", 168, 172], ["practical measures", "TREATMENT", 99, 117], ["NADPH activity", "OBSERVATION", 143, 157]]], ["Hydroxychloroquine (HCQ), the antimalarial agent now commonly used to treat systemic lupus erythematosus (SLE) and rheumatoid arthritis, has been shown to decrease the elevated risk for thrombotic complications associated with SLE.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["HCQ", "CHEMICAL", 20, 23], ["systemic lupus erythematosus", "DISEASE", 76, 104], ["SLE", "DISEASE", 106, 109], ["rheumatoid arthritis", "DISEASE", 115, 135], ["thrombotic complications", "DISEASE", 186, 210], ["SLE", "DISEASE", 227, 230], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["HCQ", "CHEMICAL", 20, 23], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["HCQ", "SIMPLE_CHEMICAL", 20, 23], ["Hydroxychloroquine (HCQ)", "TREATMENT", 0, 24], ["the antimalarial agent", "TREATMENT", 26, 48], ["systemic lupus erythematosus", "PROBLEM", 76, 104], ["SLE)", "PROBLEM", 106, 110], ["rheumatoid arthritis", "PROBLEM", 115, 135], ["the elevated risk", "PROBLEM", 164, 181], ["thrombotic complications", "PROBLEM", 186, 210], ["SLE", "PROBLEM", 227, 230], ["systemic", "OBSERVATION_MODIFIER", 76, 84], ["lupus erythematosus", "OBSERVATION", 85, 104], ["rheumatoid arthritis", "OBSERVATION", 115, 135], ["elevated", "OBSERVATION_MODIFIER", 168, 176], ["thrombotic", "OBSERVATION_MODIFIER", 186, 196], ["complications", "OBSERVATION", 197, 210]]], ["20 21 It has recently been demonstrated that HCQ, likely via its alkalinising effect on endosomes, abrogates the ability of aPL to activate endosomal NOX2dependent NADPH oxidase activity, and this reflects a failure of NOX2 to be translocated into endosomes.", [["endosomes", "ANATOMY", 88, 97], ["endosomal", "ANATOMY", 140, 149], ["endosomes", "ANATOMY", 248, 257], ["HCQ", "CHEMICAL", 45, 48], ["NADPH", "CHEMICAL", 164, 169], ["HCQ", "CHEMICAL", 45, 48], ["NADPH", "CHEMICAL", 164, 169], ["HCQ", "SIMPLE_CHEMICAL", 45, 48], ["endosomes", "CELLULAR_COMPONENT", 88, 97], ["aPL", "GENE_OR_GENE_PRODUCT", 124, 127], ["endosomal", "CELLULAR_COMPONENT", 140, 149], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 164, 177], ["NOX2", "GENE_OR_GENE_PRODUCT", 219, 223], ["endosomes", "CELLULAR_COMPONENT", 248, 257], ["aPL", "PROTEIN", 124, 127], ["endosomal NOX2dependent NADPH oxidase", "PROTEIN", 140, 177], ["NOX2", "PROTEIN", 219, 223], ["HCQ", "TEST", 45, 48], ["endosomal NOX2dependent NADPH oxidase activity", "TREATMENT", 140, 186], ["a failure of NOX2", "PROBLEM", 206, 223]]], ["22 The authors further demonstrated that HCQ treatment protects mice from aPL-induced thrombosis.", [["HCQ", "CHEMICAL", 41, 44], ["aPL", "DISEASE", 74, 77], ["thrombosis", "DISEASE", 86, 96], ["HCQ", "CHEMICAL", 41, 44], ["HCQ", "SIMPLE_CHEMICAL", 41, 44], ["mice", "ORGANISM", 64, 68], ["aPL", "GENE_OR_GENE_PRODUCT", 74, 77], ["aPL", "PROTEIN", 74, 77], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["HCQ treatment", "TREATMENT", 41, 54], ["thrombosis", "PROBLEM", 86, 96], ["thrombosis", "OBSERVATION", 86, 96]]], ["We postulated that HCQ can likewise prevent endosomal NADPH oxidase activation in SARS-CoV-2-exposed endothelial cells, thereby reducing risk for the thrombotic complications associated with COVID-19 infection.", [["endosomal", "ANATOMY", 44, 53], ["endothelial cells", "ANATOMY", 101, 118], ["HCQ", "CHEMICAL", 19, 22], ["NADPH", "CHEMICAL", 54, 59], ["thrombotic complications", "DISEASE", 150, 174], ["COVID-19", "CHEMICAL", 191, 199], ["infection", "DISEASE", 200, 209], ["HCQ", "CHEMICAL", 19, 22], ["NADPH", "CHEMICAL", 54, 59], ["HCQ", "SIMPLE_CHEMICAL", 19, 22], ["endosomal", "CELLULAR_COMPONENT", 44, 53], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 54, 67], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 82, 92], ["endothelial cells", "CELL", 101, 118], ["COVID-19", "GENE_OR_GENE_PRODUCT", 191, 199], ["endosomal NADPH oxidase", "PROTEIN", 44, 67], ["SARS-CoV-2-exposed endothelial cells", "CELL_LINE", 82, 118], ["HCQ", "TREATMENT", 19, 22], ["endosomal NADPH oxidase activation", "PROBLEM", 44, 78], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["exposed endothelial cells", "PROBLEM", 93, 118], ["the thrombotic complications", "PROBLEM", 146, 174], ["COVID-19 infection", "PROBLEM", 191, 209], ["NADPH oxidase activation", "OBSERVATION", 54, 78], ["endothelial cells", "ANATOMY", 101, 118], ["thrombotic", "OBSERVATION", 150, 160], ["infection", "OBSERVATION", 200, 209]]], ["This is of particular interest in light of the ability of HCQ to inhibit SARS-CoV-2 in vitro, and of preliminary evidence that administration of HCQ early in the course of COVID-19 may improve therapeutic outcomes, likely by slowing cell-to-cell spread of the virus.", [["cell", "ANATOMY", 233, 237], ["cell", "ANATOMY", 241, 245], ["HCQ", "CHEMICAL", 58, 61], ["HCQ", "CHEMICAL", 145, 148], ["COVID-19", "CHEMICAL", 172, 180], ["HCQ", "CHEMICAL", 58, 61], ["HCQ", "CHEMICAL", 145, 148], ["COVID-19", "CHEMICAL", 172, 180], ["HCQ", "SIMPLE_CHEMICAL", 58, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 73, 83], ["HCQ", "SIMPLE_CHEMICAL", 145, 148], ["cell", "CELL", 233, 237], ["cell", "CELL", 241, 245], ["HCQ", "TREATMENT", 58, 61], ["SARS", "TEST", 73, 77], ["CoV", "TEST", 78, 81], ["HCQ", "TREATMENT", 145, 148], ["COVID", "TEST", 172, 177], ["slowing cell", "PROBLEM", 225, 237], ["the virus", "PROBLEM", 256, 265], ["slowing cell", "OBSERVATION", 225, 237], ["cell spread", "OBSERVATION", 241, 252]]], ["23-25 HCQ-mediated alkalination of endosomes could be expected to suppress the proteolytic activity of cathepsin L, required for endosomally entrapped SARS-CoV-2 virions to escape into the cytoplasm.", [["endosomes", "ANATOMY", 35, 44], ["cytoplasm", "ANATOMY", 189, 198], ["23-25 HCQ", "CHEMICAL", 0, 9], ["HCQ", "CHEMICAL", 6, 9], ["23-25", "SIMPLE_CHEMICAL", 0, 5], ["HCQ", "SIMPLE_CHEMICAL", 6, 9], ["endosomes", "CELLULAR_COMPONENT", 35, 44], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 103, 114], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 151, 161], ["cytoplasm", "ORGANISM_SUBSTANCE", 189, 198], ["cathepsin L", "PROTEIN", 103, 114], ["cathepsin L", "TREATMENT", 103, 114], ["endosomally entrapped SARS", "PROBLEM", 129, 155], ["CoV", "TEST", 156, 159], ["cytoplasm", "ANATOMY_MODIFIER", 189, 198]]], ["16 26 27 In addition, phycocyanobilin (PCB), a biliverdin metabolite prominently expressed as a light-absorbing chromophore in cyanobacteria (such as spirulina) and many blue-green algae, has been found to mimic the ability of its chemical relative unconjugated bilirubin to inhibit NADPH oxidase complexes.", [["phycocyanobilin", "CHEMICAL", 22, 37], ["PCB", "CHEMICAL", 39, 42], ["biliverdin", "CHEMICAL", 47, 57], ["bilirubin", "CHEMICAL", 262, 271], ["NADPH", "CHEMICAL", 283, 288], ["phycocyanobilin", "CHEMICAL", 22, 37], ["PCB", "CHEMICAL", 39, 42], ["biliverdin", "CHEMICAL", 47, 57], ["bilirubin", "CHEMICAL", 262, 271], ["NADPH", "CHEMICAL", 283, 288], ["phycocyanobilin", "SIMPLE_CHEMICAL", 22, 37], ["PCB", "SIMPLE_CHEMICAL", 39, 42], ["biliverdin", "SIMPLE_CHEMICAL", 47, 57], ["blue-green algae", "ORGANISM", 170, 186], ["bilirubin", "SIMPLE_CHEMICAL", 262, 271], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 283, 296], ["NADPH oxidase complexes", "PROTEIN", 283, 306], ["a biliverdin metabolite", "TEST", 45, 68], ["cyanobacteria", "PROBLEM", 127, 140], ["many blue-green algae", "PROBLEM", 165, 186], ["NADPH oxidase complexes", "PROBLEM", 283, 306], ["green algae", "OBSERVATION", 175, 186], ["NADPH oxidase", "OBSERVATION", 283, 296]]], ["28 29 This likely explains the strong antioxidant/anti-inflammatory effects of orally administered spirulina (or of phycocyanin, the spirulina protein to which PCB is covalently attached) in a number of rodent models of heath disorders in which NADPH oxidase activation plays a pathogenic role.", [["spirulina", "CHEMICAL", 99, 108], ["PCB", "CHEMICAL", 160, 163], ["heath disorders", "DISEASE", 220, 235], ["NADPH", "CHEMICAL", 245, 250], ["PCB", "CHEMICAL", 160, 163], ["NADPH", "CHEMICAL", 245, 250], ["spirulina", "SIMPLE_CHEMICAL", 99, 108], ["phycocyanin", "GENE_OR_GENE_PRODUCT", 116, 127], ["PCB", "SIMPLE_CHEMICAL", 160, 163], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 245, 258], ["phycocyanin", "PROTEIN", 116, 127], ["spirulina protein", "PROTEIN", 133, 150], ["NADPH oxidase", "PROTEIN", 245, 258], ["orally administered spirulina", "TREATMENT", 79, 108], ["phycocyanin", "TREATMENT", 116, 127], ["the spirulina protein", "TREATMENT", 129, 150], ["heath disorders", "PROBLEM", 220, 235], ["NADPH oxidase activation", "TREATMENT", 245, 269], ["anti-inflammatory", "OBSERVATION_MODIFIER", 50, 67], ["heath disorders", "OBSERVATION", 220, 235]]], ["28 30 It is therefore proposed that oral administration of PCB (or of spirulina or of phycocyanin) could help prevent thrombotic complications of COVID-19.", [["oral", "ANATOMY", 36, 40], ["PCB", "CHEMICAL", 59, 62], ["thrombotic complications", "DISEASE", 118, 142], ["COVID-19", "CHEMICAL", 146, 154], ["PCB", "CHEMICAL", 59, 62], ["COVID-19", "CHEMICAL", 146, 154], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["PCB", "SIMPLE_CHEMICAL", 59, 62], ["spirulina", "SIMPLE_CHEMICAL", 70, 79], ["phycocyanin", "GENE_OR_GENE_PRODUCT", 86, 97], ["oral administration of PCB", "TREATMENT", 36, 62], ["spirulina", "TREATMENT", 70, 79], ["phycocyanin", "TREATMENT", 86, 97], ["thrombotic complications", "PROBLEM", 118, 142], ["COVID", "TEST", 146, 151]]], ["Independent considerations suggested that this agent might also be useful for boosting the type 1 interferon response to SARS-CoV-2 and other RNA viruses and for blunting the cytokine storm that complicates late-stage COVID-19.", [["SARS", "DISEASE", 121, 125], ["type 1 interferon", "GENE_OR_GENE_PRODUCT", 91, 108], ["SARS-CoV-2", "ORGANISM", 121, 131], ["interferon", "PROTEIN", 98, 108], ["cytokine", "PROTEIN", 175, 183], ["SARS-CoV", "SPECIES", 121, 129], ["this agent", "TREATMENT", 42, 52], ["the type 1 interferon response", "PROBLEM", 87, 117], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["other RNA viruses", "PROBLEM", 136, 153], ["blunting the cytokine storm", "PROBLEM", 162, 189], ["stage COVID", "TEST", 212, 223], ["cytokine storm", "OBSERVATION", 175, 189]]], ["31 Theoretical considerations suggested that elevated plasma levels of the amino acid glycine-which is known to have intriguing anti-inflammatory properties-may suppress endosomal activation of NADPH oxidase in cells that express strychnine-inhibitable glycine receptors.", [["plasma", "ANATOMY", 54, 60], ["endosomal", "ANATOMY", 170, 179], ["cells", "ANATOMY", 211, 216], ["amino acid", "CHEMICAL", 75, 85], ["glycine", "CHEMICAL", 86, 93], ["NADPH", "CHEMICAL", 194, 199], ["strychnine", "CHEMICAL", 230, 240], ["glycine", "CHEMICAL", 253, 260], ["amino acid", "CHEMICAL", 75, 85], ["glycine", "CHEMICAL", 86, 93], ["NADPH", "CHEMICAL", 194, 199], ["strychnine", "CHEMICAL", 230, 240], ["glycine", "CHEMICAL", 253, 260], ["plasma", "ORGANISM_SUBSTANCE", 54, 60], ["amino acid", "AMINO_ACID", 75, 85], ["glycine", "AMINO_ACID", 86, 93], ["endosomal", "CELLULAR_COMPONENT", 170, 179], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 194, 207], ["cells", "CELL", 211, 216], ["strychnine", "SIMPLE_CHEMICAL", 230, 240], ["glycine receptors", "GENE_OR_GENE_PRODUCT", 253, 270], ["NADPH oxidase", "PROTEIN", 194, 207], ["glycine receptors", "PROTEIN", 253, 270], ["elevated plasma levels", "PROBLEM", 45, 67], ["the amino acid glycine", "TEST", 71, 93], ["intriguing anti-inflammatory properties", "TREATMENT", 117, 156], ["NADPH oxidase in cells", "PROBLEM", 194, 216], ["inhibitable glycine receptors", "TREATMENT", 241, 270], ["anti-inflammatory properties", "OBSERVATION", 128, 156], ["NADPH oxidase", "OBSERVATION", 194, 207]]], ["32 Indeed, endothelial cells express such receptors.", [["endothelial cells", "ANATOMY", 11, 28], ["endothelial cells", "CELL", 11, 28], ["endothelial cells", "CELL_TYPE", 11, 28], ["endothelial cells", "OBSERVATION", 11, 28]]], ["33 34 Hence, the impact of supplemental glycine-inexpensive, well-tolerated and pleasantly sweet-on TF expression in endothelial cells exposed to proinflammatory stimuli-including SARS-CoV-2-would be of interest to study.", [["endothelial cells", "ANATOMY", 117, 134], ["glycine", "CHEMICAL", 40, 47], ["glycine", "CHEMICAL", 40, 47], ["glycine", "SIMPLE_CHEMICAL", 40, 47], ["TF", "CELL", 100, 102], ["endothelial cells", "CELL", 117, 134], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 180, 190], ["TF", "PROTEIN", 100, 102], ["endothelial cells", "CELL_TYPE", 117, 134], ["supplemental glycine", "TREATMENT", 27, 47], ["TF expression in endothelial cells", "TREATMENT", 100, 134]]], ["Glycine supplementation might also aid control of thrombotic complications via a direct antiaggregatory effect on platelets mediated by glycine receptors.", [["platelets", "ANATOMY", 114, 123], ["Glycine", "CHEMICAL", 0, 7], ["thrombotic complications", "DISEASE", 50, 74], ["glycine", "CHEMICAL", 136, 143], ["Glycine", "CHEMICAL", 0, 7], ["glycine", "CHEMICAL", 136, 143], ["Glycine", "SIMPLE_CHEMICAL", 0, 7], ["platelets", "CELL", 114, 123], ["glycine receptors", "GENE_OR_GENE_PRODUCT", 136, 153], ["platelets", "CELL_TYPE", 114, 123], ["glycine receptors", "PROTEIN", 136, 153], ["Glycine supplementation", "TREATMENT", 0, 23], ["thrombotic complications", "PROBLEM", 50, 74], ["a direct antiaggregatory effect on platelets", "TREATMENT", 79, 123], ["glycine receptors", "TREATMENT", 136, 153], ["thrombotic", "OBSERVATION", 50, 60]]], ["35 The upregulatory impact of NADPH oxidase activity on NF-kappaB activation and TF expression is likely mediated by reversible oxidation by hydrogen peroxide of sulfhydryl groups in specific proteins that participate in this activation.", [["NADPH", "CHEMICAL", 30, 35], ["hydrogen peroxide", "CHEMICAL", 141, 158], ["sulfhydryl", "CHEMICAL", 162, 172], ["NADPH", "CHEMICAL", 30, 35], ["hydrogen peroxide", "CHEMICAL", 141, 158], ["sulfhydryl", "CHEMICAL", 162, 172], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 30, 43], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 56, 65], ["TF", "GENE_OR_GENE_PRODUCT", 81, 83], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 141, 158], ["sulfhydryl", "SIMPLE_CHEMICAL", 162, 172], ["NADPH oxidase", "PROTEIN", 30, 43], ["NF-kappaB", "PROTEIN", 56, 65], ["TF", "PROTEIN", 81, 83], ["NADPH oxidase activity", "TREATMENT", 30, 52], ["NF-kappaB activation", "TREATMENT", 56, 76], ["TF expression", "TREATMENT", 81, 94], ["reversible oxidation", "PROBLEM", 117, 137], ["hydrogen peroxide of sulfhydryl groups", "TREATMENT", 141, 179], ["NADPH oxidase activity", "OBSERVATION", 30, 52], ["reversible oxidation", "OBSERVATION", 117, 137]]], ["36 37 If so, then boosting synthesis of glutathione and thioredoxin while upregulating the expression of enzymes that work with them to reverse cysteine oxidations (eg, glutathione reductase and thioredoxin reductase) would be expected to counteract the impact of hydrogen peroxide on NF-kappaB activation.", [["glutathione", "CHEMICAL", 40, 51], ["cysteine", "CHEMICAL", 144, 152], ["glutathione", "CHEMICAL", 169, 180], ["hydrogen peroxide", "CHEMICAL", 264, 281], ["glutathione", "CHEMICAL", 40, 51], ["cysteine", "CHEMICAL", 144, 152], ["glutathione", "CHEMICAL", 169, 180], ["hydrogen peroxide", "CHEMICAL", 264, 281], ["glutathione", "SIMPLE_CHEMICAL", 40, 51], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 56, 67], ["cysteine", "SIMPLE_CHEMICAL", 144, 152], ["glutathione reductase", "GENE_OR_GENE_PRODUCT", 169, 190], ["thioredoxin reductase", "GENE_OR_GENE_PRODUCT", 195, 216], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 264, 281], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 285, 294], ["thioredoxin", "PROTEIN", 56, 67], ["enzymes", "PROTEIN", 105, 112], ["glutathione reductase", "PROTEIN", 169, 190], ["thioredoxin reductase", "PROTEIN", 195, 216], ["NF-kappaB", "PROTEIN", 285, 294], ["synthesis of glutathione", "TREATMENT", 27, 51], ["thioredoxin", "TREATMENT", 56, 67], ["enzymes", "TEST", 105, 112], ["cysteine oxidations (eg, glutathione reductase", "TREATMENT", 144, 190], ["thioredoxin reductase", "TREATMENT", 195, 216], ["hydrogen peroxide", "TREATMENT", 264, 281]]], ["38 Moreover, increasing the expression of glutathione peroxidase would also counteract the signalling impacts of hydrogen peroxide.", [["glutathione", "CHEMICAL", 42, 53], ["hydrogen peroxide", "CHEMICAL", 113, 130], ["glutathione", "CHEMICAL", 42, 53], ["hydrogen peroxide", "CHEMICAL", 113, 130], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 42, 64], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 113, 130], ["glutathione peroxidase", "PROTEIN", 42, 64], ["glutathione peroxidase", "TREATMENT", 42, 64], ["hydrogen peroxide", "TREATMENT", 113, 130], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["glutathione peroxidase", "OBSERVATION", 42, 64], ["hydrogen peroxide", "OBSERVATION", 113, 130]]], ["These benefits could be achieved with clinically useful phase 2 inducer nutraceuticals-such as lipoic acid, ferulic acid or sulforaphane-complemented by supplementation with N-acetylcysteine; the latter supplies cysteine, the rate-limiting substrate for glutathione synthesis.", [["lipoic acid", "CHEMICAL", 95, 106], ["ferulic acid", "CHEMICAL", 108, 120], ["sulforaphane", "CHEMICAL", 124, 136], ["N-acetylcysteine", "CHEMICAL", 174, 190], ["cysteine", "CHEMICAL", 212, 220], ["glutathione", "CHEMICAL", 254, 265], ["lipoic acid", "CHEMICAL", 95, 106], ["ferulic acid", "CHEMICAL", 108, 120], ["sulforaphane", "CHEMICAL", 124, 136], ["N-acetylcysteine", "CHEMICAL", 174, 190], ["cysteine", "CHEMICAL", 212, 220], ["glutathione", "CHEMICAL", 254, 265], ["lipoic acid", "SIMPLE_CHEMICAL", 95, 106], ["ferulic acid", "SIMPLE_CHEMICAL", 108, 120], ["sulforaphane", "SIMPLE_CHEMICAL", 124, 136], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 174, 190], ["cysteine", "SIMPLE_CHEMICAL", 212, 220], ["glutathione", "SIMPLE_CHEMICAL", 254, 265], ["inducer nutraceuticals", "TREATMENT", 64, 86], ["lipoic acid", "TREATMENT", 95, 106], ["ferulic acid", "TREATMENT", 108, 120], ["sulforaphane", "TREATMENT", 124, 136], ["N-acetylcysteine", "TREATMENT", 174, 190], ["the rate", "TEST", 222, 230], ["glutathione synthesis", "TREATMENT", 254, 275]]], ["[39] [40] [41] [42] [43] [44] [45] [46] Glycine supplementation can also promote glutathione synthesis.", [["[39] [40] [41] [42] [43] [44] [45] [46] Glycine", "CHEMICAL", 0, 47], ["glutathione", "CHEMICAL", 81, 92], ["[39] [40] [41] [42] [43] [44] [45] [46] Glycine", "CHEMICAL", 0, 47], ["glutathione", "CHEMICAL", 81, 92], ["[39] [40] [41] [42] [43] [44] [45] [46] Glycine", "SIMPLE_CHEMICAL", 0, 47], ["glutathione", "SIMPLE_CHEMICAL", 81, 92], ["Glycine supplementation", "TREATMENT", 40, 63], ["glutathione synthesis", "TREATMENT", 81, 102], ["glutathione synthesis", "OBSERVATION", 81, 102]]], ["47 48 A number of studies have observed that nitric oxide (NO) and endothelial NO synthase (eNOS) activity oppose the endothelial induction of TF by various proinflammatory stimuli.", [["endothelial", "ANATOMY", 118, 129], ["TF", "ANATOMY", 143, 145], ["nitric oxide", "CHEMICAL", 45, 57], ["NO", "CHEMICAL", 59, 61], ["NO", "CHEMICAL", 79, 81], ["nitric oxide", "CHEMICAL", 45, 57], ["NO", "CHEMICAL", 59, 61], ["NO", "CHEMICAL", 79, 81], ["nitric oxide", "SIMPLE_CHEMICAL", 45, 57], ["NO", "SIMPLE_CHEMICAL", 59, 61], ["endothelial NO synthase", "GENE_OR_GENE_PRODUCT", 67, 90], ["eNOS", "GENE_OR_GENE_PRODUCT", 92, 96], ["endothelial", "CELL", 118, 129], ["TF", "GENE_OR_GENE_PRODUCT", 143, 145], ["endothelial NO synthase", "PROTEIN", 67, 90], ["eNOS", "PROTEIN", 92, 96], ["TF", "PROTEIN", 143, 145], ["studies", "TEST", 18, 25], ["nitric oxide", "TREATMENT", 45, 57], ["the endothelial induction of TF", "TREATMENT", 114, 145], ["various proinflammatory stimuli", "TEST", 149, 180], ["endothelial", "ANATOMY", 118, 129], ["proinflammatory stimuli", "OBSERVATION", 157, 180]]], ["The ability of drugs that stimulate or activate soluble guanylate cyclase (sGC) to replicate this effect suggests that cGMP is the downstream mediator of NO's impact in this regard.", [["cGMP", "CHEMICAL", 119, 123], ["NO", "CHEMICAL", 154, 156], ["guanylate", "CHEMICAL", 56, 65], ["cGMP", "CHEMICAL", 119, 123], ["NO", "CHEMICAL", 154, 156], ["guanylate cyclase", "GENE_OR_GENE_PRODUCT", 56, 73], ["sGC", "GENE_OR_GENE_PRODUCT", 75, 78], ["cGMP", "SIMPLE_CHEMICAL", 119, 123], ["NO", "SIMPLE_CHEMICAL", 154, 156], ["guanylate cyclase", "PROTEIN", 56, 73], ["sGC", "PROTEIN", 75, 78], ["drugs", "TREATMENT", 15, 20], ["soluble guanylate cyclase", "TREATMENT", 48, 73]]], ["49 Intriguingly, these drugs do not influence the ability of TNF\u03b1 to suppress protein levels of IkappaB, but nonetheless they do suppress the transcriptional activity of NF-kappaB as assessed with a transfected reporter gene.", [["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 61, 65], ["IkappaB", "GENE_OR_GENE_PRODUCT", 96, 103], ["NF-kappaB", "GENE_OR_GENE_PRODUCT", 170, 179], ["TNF\u03b1", "PROTEIN", 61, 65], ["IkappaB", "PROTEIN", 96, 103], ["NF-kappaB", "PROTEIN", 170, 179], ["transfected reporter gene", "DNA", 199, 224], ["these drugs", "TREATMENT", 17, 28], ["TNF\u03b1", "TREATMENT", 61, 65], ["protein levels", "TEST", 78, 92], ["IkappaB", "TREATMENT", 96, 103]]], ["49 Since the oxidative stress induced by NADPH oxidase activation would seem likely to promote uncoupling of eNOS, agents that correct this uncoupling might be expected to downregulate COVID-19-mediated TF induction.", [["TF", "ANATOMY", 203, 205], ["NADPH", "CHEMICAL", 41, 46], ["NADPH", "CHEMICAL", 41, 46], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 41, 54], ["eNOS", "GENE_OR_GENE_PRODUCT", 109, 113], ["COVID-19", "GENE_OR_GENE_PRODUCT", 185, 193], ["TF", "GENE_OR_GENE_PRODUCT", 203, 205], ["NADPH oxidase", "PROTEIN", 41, 54], ["eNOS", "PROTEIN", 109, 113], ["COVID", "PROTEIN", 185, 190], ["TF", "PROTEIN", 203, 205], ["the oxidative stress", "PROBLEM", 9, 29], ["NADPH oxidase activation", "PROBLEM", 41, 65], ["agents", "TREATMENT", 115, 121], ["COVID", "TEST", 185, 190], ["TF induction", "TREATMENT", 203, 215]]], ["Specifically, supplemental intakes of citrulline and of high-dose folate might be useful in this regard, as these agents counteract the uncoupling induced by asymmetric dimethylarginine and by oxidation of Hydroxychloroquine-200 mg, 2 times per day Spirulina-15 g (rounded tablespoon), one time per day Glycine powder-5 g, 2-3 times per day Lipoic acid-600 mg, 2-3 times per day Ferulic acid-500 mg, 2 times per day Broccoli sprout powder-5 g, 1-2 times per day (providing 20-40 mg of sulforaphane) N-acetylcysteine-600 mg, 2-3 times per day Citrulline powder-2 g, 2 times per day Folic acid-40 mg, one time per day Biotin-10 mg, 2-3 times per day tetrahydrobiopterin, respectively.", [["citrulline", "CHEMICAL", 38, 48], ["folate", "CHEMICAL", 66, 72], ["asymmetric dimethylarginine", "CHEMICAL", 158, 185], ["Hydroxychloroquine", "CHEMICAL", 206, 224], ["Lipoic acid", "CHEMICAL", 341, 352], ["Ferulic acid", "CHEMICAL", 379, 391], ["sulforaphane", "CHEMICAL", 485, 497], ["N-acetylcysteine", "CHEMICAL", 499, 515], ["Citrulline", "CHEMICAL", 542, 552], ["Folic acid", "CHEMICAL", 581, 591], ["Biotin", "CHEMICAL", 616, 622], ["tetrahydrobiopterin", "CHEMICAL", 648, 667], ["citrulline", "CHEMICAL", 38, 48], ["folate", "CHEMICAL", 66, 72], ["dimethylarginine", "CHEMICAL", 169, 185], ["Hydroxychloroquine", "CHEMICAL", 206, 224], ["Lipoic acid", "CHEMICAL", 341, 352], ["Ferulic acid", "CHEMICAL", 379, 391], ["sulforaphane", "CHEMICAL", 485, 497], ["N-acetylcysteine", "CHEMICAL", 499, 515], ["Citrulline", "CHEMICAL", 542, 552], ["Folic acid", "CHEMICAL", 581, 591], ["tetrahydrobiopterin", "CHEMICAL", 648, 667], ["citrulline", "SIMPLE_CHEMICAL", 38, 48], ["folate", "SIMPLE_CHEMICAL", 66, 72], ["dimethylarginine", "SIMPLE_CHEMICAL", 169, 185], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 206, 224], ["Lipoic acid", "SIMPLE_CHEMICAL", 341, 352], ["Ferulic acid", "SIMPLE_CHEMICAL", 379, 391], ["sulforaphane", "SIMPLE_CHEMICAL", 485, 497], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 499, 515], ["Folic acid", "SIMPLE_CHEMICAL", 581, 591], ["Biotin", "SIMPLE_CHEMICAL", 616, 622], ["tetrahydrobiopterin", "SIMPLE_CHEMICAL", 648, 667], ["citrulline", "TREATMENT", 38, 48], ["high-dose folate", "TREATMENT", 56, 72], ["the uncoupling", "PROBLEM", 132, 146], ["asymmetric dimethylarginine", "TREATMENT", 158, 185], ["Hydroxychloroquine", "TREATMENT", 206, 224], ["Spirulina", "TREATMENT", 249, 258], ["Glycine powder", "TREATMENT", 303, 317], ["Lipoic acid", "TREATMENT", 341, 352], ["Ferulic acid", "TREATMENT", 379, 391], ["Broccoli sprout powder", "TREATMENT", 416, 438], ["N-acetylcysteine", "TREATMENT", 499, 515], ["Citrulline powder", "TREATMENT", 542, 559], ["Folic acid", "TREATMENT", 581, 591], ["Biotin", "TREATMENT", 616, 622], ["tetrahydrobiopterin", "TREATMENT", 648, 667]]], ["[50] [51] [52] [53] Alternatively, agents that directly stimulate or activate sGC might also be useful for suppressing TF induction; in addition to pharmaceuticals that have this effect, supraphysiological concentrations of biotin can stimulate sGC activity.", [["TF", "ANATOMY", 119, 121], ["biotin", "CHEMICAL", 224, 230], ["biotin", "CHEMICAL", 224, 230], ["[50] [51] [52] [53]", "SIMPLE_CHEMICAL", 0, 19], ["sGC", "GENE_OR_GENE_PRODUCT", 78, 81], ["TF", "CELL", 119, 121], ["biotin", "SIMPLE_CHEMICAL", 224, 230], ["sGC", "GENE_OR_GENE_PRODUCT", 245, 248], ["sGC", "PROTEIN", 78, 81], ["TF", "PROTEIN", 119, 121], ["sGC", "PROTEIN", 245, 248], ["agents", "TREATMENT", 35, 41], ["suppressing TF induction", "TREATMENT", 107, 131], ["pharmaceuticals", "TREATMENT", 148, 163], ["supraphysiological concentrations of biotin", "TREATMENT", 187, 230]]], ["54 55 Measures that quell endothelial oxidative stress while supporting effective eNOS activity might not only help to control the thrombotic complications of COVID-19, but also be expected to blunt the exuberant influx of neutrophils that promote respiratory distress in this syndrome.", [["endothelial", "ANATOMY", 26, 37], ["neutrophils", "ANATOMY", 223, 234], ["respiratory", "ANATOMY", 248, 259], ["thrombotic", "DISEASE", 131, 141], ["COVID-19", "CHEMICAL", 159, 167], ["respiratory distress", "DISEASE", 248, 268], ["COVID-19", "CHEMICAL", 159, 167], ["endothelial", "CELL", 26, 37], ["eNOS", "GENE_OR_GENE_PRODUCT", 82, 86], ["neutrophils", "CELL", 223, 234], ["eNOS", "PROTEIN", 82, 86], ["neutrophils", "CELL_TYPE", 223, 234], ["endothelial oxidative stress", "TREATMENT", 26, 54], ["the thrombotic complications", "PROBLEM", 127, 155], ["COVID", "TEST", 159, 164], ["blunt the exuberant influx of neutrophils", "PROBLEM", 193, 234], ["respiratory distress", "PROBLEM", 248, 268], ["this syndrome", "PROBLEM", 272, 285], ["thrombotic", "OBSERVATION", 131, 141], ["exuberant", "OBSERVATION_MODIFIER", 203, 212], ["influx of neutrophils", "OBSERVATION", 213, 234], ["respiratory distress", "OBSERVATION", 248, 268]]], ["Nitric oxide, by both cGMP-dependent and cGMP-independent mechanism, inhibits endothelial expression of adhesion factors for neutrophils whereas oxidants upregulate such expression.", [["endothelial", "ANATOMY", 78, 89], ["neutrophils", "ANATOMY", 125, 136], ["Nitric oxide", "CHEMICAL", 0, 12], ["cGMP", "CHEMICAL", 22, 26], ["cGMP", "CHEMICAL", 41, 45], ["Nitric oxide", "CHEMICAL", 0, 12], ["cGMP", "CHEMICAL", 22, 26], ["cGMP", "CHEMICAL", 41, 45], ["Nitric oxide", "SIMPLE_CHEMICAL", 0, 12], ["cGMP", "SIMPLE_CHEMICAL", 22, 26], ["cGMP", "SIMPLE_CHEMICAL", 41, 45], ["endothelial", "CELL", 78, 89], ["neutrophils", "CELL", 125, 136], ["adhesion factors", "PROTEIN", 104, 120], ["neutrophils", "CELL_TYPE", 125, 136], ["Nitric oxide", "TREATMENT", 0, 12], ["adhesion factors", "PROBLEM", 104, 120], ["neutrophils", "PROBLEM", 125, 136]]], ["[56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Box 1 proposes dose schedules for the drugs/nutraceuticals cited earlier that might have practical potential for reducing the thrombotic risk associated with COVID-19.", [["thrombotic", "DISEASE", 186, 196], ["COVID-19", "CHEMICAL", 218, 226], ["[56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Box 1", "CHEMICAL", 0, 65], ["COVID-19", "CHEMICAL", 218, 226], ["[56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Box 1", "SIMPLE_CHEMICAL", 0, 65], ["Box 1 proposes dose schedules", "TREATMENT", 60, 89], ["the drugs/nutraceuticals", "TREATMENT", 94, 118], ["the thrombotic risk", "PROBLEM", 182, 201], ["COVID", "TEST", 218, 223], ["thrombotic", "OBSERVATION", 186, 196]]], ["These suggestions deal with agents that might impact the endothelial activation associated with COVID-19.", [["endothelial", "ANATOMY", 57, 68], ["COVID-19", "CHEMICAL", 96, 104], ["endothelial", "CELL", 57, 68], ["COVID", "PROTEIN", 96, 101], ["agents", "TREATMENT", 28, 34], ["the endothelial activation", "PROBLEM", 53, 79], ["COVID", "TEST", 96, 101], ["endothelial", "ANATOMY", 57, 68]]], ["Evidently, drugs that address overactive coagulation or platelet activation may also have potential for controlling the thrombotic complications of this syndrome; in that regard, many physicians are currently employing heparin injections.", [["platelet", "ANATOMY", 56, 64], ["overactive coagulation", "DISEASE", 30, 52], ["thrombotic complications", "DISEASE", 120, 144], ["heparin", "CHEMICAL", 219, 226], ["platelet", "CELL", 56, 64], ["heparin", "SIMPLE_CHEMICAL", 219, 226], ["drugs", "TREATMENT", 11, 16], ["overactive coagulation", "PROBLEM", 30, 52], ["platelet activation", "PROBLEM", 56, 75], ["the thrombotic complications", "PROBLEM", 116, 144], ["this syndrome", "PROBLEM", 148, 161], ["heparin injections", "TREATMENT", 219, 237], ["thrombotic", "OBSERVATION", 120, 130]]], ["68 69 limitAtions This essay proposes a hypothesis that, in the authors' opinion, is credible and, if true, it should help to explain the common thromboembolic complications of COVID-19, while also suggesting practical measures that could lessen the thrombogenicity of vascular endothelium infected by the virus, or exposed to proinflammatory cytokines released in response to viral infection.", [["vascular endothelium", "ANATOMY", 269, 289], ["thromboembolic", "DISEASE", 145, 159], ["viral infection", "DISEASE", 377, 392], ["COVID-19", "CHEMICAL", 177, 185], ["vascular endothelium", "TISSUE", 269, 289], ["proinflammatory cytokines", "PROTEIN", 327, 352], ["the common thromboembolic complications", "PROBLEM", 134, 173], ["COVID", "TEST", 177, 182], ["practical measures", "TREATMENT", 209, 227], ["vascular endothelium", "PROBLEM", 269, 289], ["the virus", "PROBLEM", 302, 311], ["proinflammatory cytokines", "PROBLEM", 327, 352], ["viral infection", "PROBLEM", 377, 392], ["thrombogenicity", "OBSERVATION", 250, 265], ["vascular endothelium", "ANATOMY", 269, 289], ["proinflammatory cytokines", "OBSERVATION", 327, 352], ["viral", "OBSERVATION_MODIFIER", 377, 382], ["infection", "OBSERVATION", 383, 392]]], ["It is intended to stimulate preclinical study of interactions between SARS-CoV-2 and vascular endothelial cells which could be useful for affirming or disproving the hypothesis.", [["vascular endothelial cells", "ANATOMY", 85, 111], ["SARS-CoV-2", "CELL", 70, 80], ["vascular endothelial cells", "CELL", 85, 111], ["vascular endothelial cells", "CELL_TYPE", 85, 111], ["preclinical study", "TEST", 28, 45], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["vascular endothelial cells", "PROBLEM", 85, 111], ["the hypothesis", "PROBLEM", 162, 176], ["vascular endothelial", "ANATOMY", 85, 105]]], ["This hypothesis should not be considered to be proven, and the suggestions it provides regarding drugs or nutraceuticals which might ameliorate vascular dysfunction during COVID-19 should not be considered as prescriptive.AbstrActContributors All authors contributed to the final manuscript.AbstrActfunding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.AbstrActCompeting interests JJD is Director of Scientific Affairs at AIDP.", [["vascular", "ANATOMY", 144, 152], ["vascular dysfunction", "DISEASE", 144, 164], ["JJD", "DISEASE", 476, 479], ["COVID-19", "CHEMICAL", 172, 180], ["vascular", "MULTI-TISSUE_STRUCTURE", 144, 152], ["drugs", "TREATMENT", 97, 102], ["nutraceuticals", "TREATMENT", 106, 120], ["vascular dysfunction", "PROBLEM", 144, 164], ["COVID", "TEST", 172, 177]]], ["MM is an owner of a nutraceutical company and co-inventor and co-owner of a US patent covering nutraceutical uses of phycocyanobilin oligopeptides derived from cyanobacteria such as spirulina.AbstrActPatient consent for publication Not required.Provenance and peer review Not commissioned; internally peer reviewed.open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.", [["MM", "DISEASE", 0, 2], ["phycocyanobilin oligopeptides", "CHEMICAL", 117, 146], ["phycocyanobilin", "CHEMICAL", 117, 132], ["phycocyanobilin oligopeptides", "SIMPLE_CHEMICAL", 117, 146], ["spirulina", "GENE_OR_GENE_PRODUCT", 182, 191], ["co-inventor", "TREATMENT", 46, 57], ["a US", "TEST", 74, 78], ["phycocyanobilin oligopeptides", "TREATMENT", 117, 146], ["cyanobacteria", "PROBLEM", 160, 173], ["open access", "TREATMENT", 315, 326], ["patent", "OBSERVATION", 79, 85]]], ["See: http:// creativecommons. org/ licenses/ by-nc/ 4.", [["http", "GENE_OR_GENE_PRODUCT", 5, 9], ["org", "GENE_OR_GENE_PRODUCT", 30, 33]]], ["0/. orCid id James J DiNicolantonio http:// orcid. org/ 0000-0002-7888-1528", [["org/ 0000-0002-7888-1528", "SPECIES", 51, 75]]]], "PMC7521193": [["IntroductionEver since the outbreak of COVID-19 occurred in Wuhan, China in December 2019, it has rapidly spread throughout the globe.", [["COVID-19", "CHEMICAL", 39, 47], ["globe", "ORGAN", 128, 133], ["COVID", "TEST", 39, 44], ["rapidly", "OBSERVATION_MODIFIER", 98, 105], ["spread", "OBSERVATION_MODIFIER", 106, 112], ["globe", "ANATOMY", 128, 133]]], ["By now, it has affected approximately 16.5 million people worldwide (as on 28th July, 2020) and the number continues to increase.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["16.5 million", "OBSERVATION_MODIFIER", 38, 50]]], ["Thus, the entire human population is being threatened to get exposed to this highly contagious virus sooner or later [2].", [["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22]]], ["Infection with COVID-19 has been associated with significant mortality, particularly in the high-risk group such as health care providers and elderly people, with or without comorbidities [3, 4].", [["Infection", "DISEASE", 0, 9], ["COVID-19", "CHEMICAL", 15, 23], ["COVID-19", "CHEMICAL", 15, 23], ["people", "ORGANISM", 150, 156], ["people", "SPECIES", 150, 156], ["Infection", "PROBLEM", 0, 9], ["COVID", "TEST", 15, 20], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["mortality", "OBSERVATION", 61, 70]]], ["Very recently, it has been proposed that people with an underlying chronic inflammation of the gut are more predisposed to a heightened cytokine storm when infected with this virus [5].", [["gut", "ANATOMY", 95, 98], ["people", "ORGANISM", 41, 47], ["gut", "ORGANISM_SUBDIVISION", 95, 98], ["cytokine", "PROTEIN", 136, 144], ["people", "SPECIES", 41, 47], ["an underlying chronic inflammation of the gut", "PROBLEM", 53, 98], ["a heightened cytokine storm", "TREATMENT", 123, 150], ["this virus", "PROBLEM", 170, 180], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["inflammation", "OBSERVATION", 75, 87], ["gut", "ANATOMY", 95, 98]]], ["Cytokine storm has been defined as the over-production of early response cytokines leading to an increased risk of vascular hyper-permeability, multi-organ failure and eventually death, as a result of high cytokine concentrations which are not found to reduce over time [6].IntroductionFurther, chronic gut inflammation has been suggested to result from a specific constitution of gut microbiome, with the latter being regulated by diet.", [["vascular", "ANATOMY", 115, 123], ["multi-organ", "ANATOMY", 144, 155], ["gut", "ANATOMY", 303, 306], ["gut microbiome", "ANATOMY", 381, 395], ["multi-organ failure", "DISEASE", 144, 163], ["death", "DISEASE", 179, 184], ["gut inflammation", "DISEASE", 303, 319], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["vascular", "MULTI-TISSUE_STRUCTURE", 115, 123], ["gut", "ORGANISM_SUBDIVISION", 303, 306], ["gut", "ORGANISM_SUBDIVISION", 381, 384], ["Cytokine", "PROTEIN", 0, 8], ["early response cytokines", "PROTEIN", 58, 82], ["cytokine", "PROTEIN", 206, 214], ["Cytokine storm", "PROBLEM", 0, 14], ["early response cytokines", "PROBLEM", 58, 82], ["vascular hyper-permeability", "PROBLEM", 115, 142], ["multi-organ failure", "PROBLEM", 144, 163], ["eventually death", "PROBLEM", 168, 184], ["high cytokine concentrations", "PROBLEM", 201, 229], ["chronic gut inflammation", "PROBLEM", 295, 319], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["vascular", "ANATOMY", 115, 123], ["hyper", "OBSERVATION", 124, 129], ["multi-organ", "ANATOMY", 144, 155], ["failure", "OBSERVATION", 156, 163], ["chronic", "OBSERVATION_MODIFIER", 295, 302], ["gut", "ANATOMY", 303, 306], ["inflammation", "OBSERVATION", 307, 319]]], ["For example, plant-based foods are likely to support a gut microbiome capable of inducing an appropriate level of anti-inflammatory response in the host in contrast to a pro-inflammatory immune response elicited by the gut microbiome of individuals consuming food products such as wheat, red meat and alcohol, thereby resulting in chronic gut inflammation [5].", [["gut microbiome", "ANATOMY", 55, 69], ["gut microbiome", "ANATOMY", 219, 233], ["red meat", "ANATOMY", 288, 296], ["gut", "ANATOMY", 339, 342], ["alcohol", "CHEMICAL", 301, 308], ["inflammation", "DISEASE", 343, 355], ["alcohol", "CHEMICAL", 301, 308], ["gut", "ORGANISM_SUBDIVISION", 55, 58], ["gut", "ORGANISM_SUBDIVISION", 219, 222], ["wheat", "ORGANISM_SUBDIVISION", 281, 286], ["meat", "ORGANISM_SUBDIVISION", 292, 296], ["alcohol", "SIMPLE_CHEMICAL", 301, 308], ["gut", "ORGANISM_SUBDIVISION", 339, 342], ["wheat", "SPECIES", 281, 286], ["wheat", "SPECIES", 281, 286], ["plant-based foods", "TREATMENT", 13, 30], ["food products", "TREATMENT", 259, 272], ["chronic gut inflammation", "PROBLEM", 331, 355], ["anti-inflammatory response", "OBSERVATION", 114, 140], ["chronic", "OBSERVATION_MODIFIER", 331, 338], ["gut", "ANATOMY", 339, 342], ["inflammation", "OBSERVATION", 343, 355]]], ["Simultaneously, since many people had to undergo forced fasting during the COVID-19 pandemic, it might have affected their microbiota.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["forced fasting", "PROBLEM", 49, 63], ["the COVID", "TEST", 71, 80]]], ["The main hypothesis underlying the study is that, can this lead to susceptibility to infections?", [["infections", "DISEASE", 85, 95], ["the study", "TEST", 31, 40], ["susceptibility to infections", "PROBLEM", 67, 95], ["main", "OBSERVATION_MODIFIER", 4, 8], ["infections", "OBSERVATION", 85, 95]]], ["And can vegetarian diet help to boost immunity and help human beings to fight the pathogens?", [["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["the pathogens", "PROBLEM", 78, 91]]], ["Believing the notion: 'We are, what we eat', this manuscript provides an opportunity to the researchers in the field of Microbiology and Medical health to carry out studies on the effect of forced fasting on gut microbiota and means to counter any potential ill effects.", [["gut", "ANATOMY", 208, 211], ["gut", "ORGANISM_SUBDIVISION", 208, 211]]], ["In this context, the present review envisages the possible association of diet and microbiota with the incidence/severity/recovery of COVID-19 cases during the lockdown period (from 25th March to 31st May 2020) in India.Dietary Nutrients ::: Diet and Gut Microbiota in the Population of Developed and Developing CountriesFurther, the amount of dietary nutrients including micronutrients (polyphenols and vitamins), macronutrients (carbohydrates, fats and proteins) as well as minerals and trace metals (magnesium, iron, selenium, zinc) have been reported to exhibit substantial effect on the gut microbiota [22].", [["gut", "ANATOMY", 592, 595], ["polyphenols and vitamins", "CHEMICAL", 388, 412], ["magnesium", "CHEMICAL", 503, 512], ["iron", "CHEMICAL", 514, 518], ["selenium", "CHEMICAL", 520, 528], ["zinc", "CHEMICAL", 530, 534], ["polyphenols", "CHEMICAL", 388, 399], ["vitamins", "CHEMICAL", 404, 412], ["carbohydrates", "CHEMICAL", 431, 444], ["magnesium", "CHEMICAL", 503, 512], ["iron", "CHEMICAL", 514, 518], ["selenium", "CHEMICAL", 520, 528], ["zinc", "CHEMICAL", 530, 534], ["polyphenols", "SIMPLE_CHEMICAL", 388, 399], ["vitamins", "SIMPLE_CHEMICAL", 404, 412], ["macronutrients", "SIMPLE_CHEMICAL", 415, 429], ["carbohydrates", "SIMPLE_CHEMICAL", 431, 444], ["fats", "SIMPLE_CHEMICAL", 446, 450], ["minerals", "SIMPLE_CHEMICAL", 476, 484], ["trace metals", "SIMPLE_CHEMICAL", 489, 501], ["magnesium", "SIMPLE_CHEMICAL", 503, 512], ["iron", "SIMPLE_CHEMICAL", 514, 518], ["selenium", "SIMPLE_CHEMICAL", 520, 528], ["zinc", "SIMPLE_CHEMICAL", 530, 534], ["gut", "ORGANISM_SUBDIVISION", 592, 595], ["COVID", "TEST", 134, 139], ["dietary nutrients", "TREATMENT", 344, 361], ["micronutrients (polyphenols", "TREATMENT", 372, 399], ["vitamins)", "TREATMENT", 404, 413], ["macronutrients (carbohydrates, fats and proteins", "TREATMENT", 415, 463], ["trace metals (magnesium, iron, selenium, zinc", "TREATMENT", 489, 534]]], ["In vitro studies have suggested that polyphenols such as phenols, flavonoids, and lignans present abundantly in raw vegetables and fruits along with cereals and drinks such as coffee, tea and wine could greatly modulate the gut flora favouring the growth of potentially beneficial organisms such as Lactobacillus, Bifidobacteria, Akkermansia and Fecalibacteria, simultaneously inhibiting the growth of potentially pathogenic bacteria such as Helicobacter pylori and Staphylococcus species [23].", [["vegetables", "ANATOMY", 116, 126], ["fruits", "ANATOMY", 131, 137], ["gut flora", "ANATOMY", 224, 233], ["phenols", "CHEMICAL", 57, 64], ["flavonoids", "CHEMICAL", 66, 76], ["lignans", "CHEMICAL", 82, 89], ["coffee, tea and wine", "CHEMICAL", 176, 196], ["Lactobacillus", "CHEMICAL", 299, 312], ["Bifidobacteria", "CHEMICAL", 314, 328], ["Fecalibacteria", "CHEMICAL", 346, 360], ["Helicobacter pylori", "DISEASE", 442, 461], ["polyphenols", "CHEMICAL", 37, 48], ["phenols", "CHEMICAL", 57, 64], ["flavonoids", "CHEMICAL", 66, 76], ["lignans", "CHEMICAL", 82, 89], ["polyphenols", "SIMPLE_CHEMICAL", 37, 48], ["phenols", "SIMPLE_CHEMICAL", 57, 64], ["flavonoids", "SIMPLE_CHEMICAL", 66, 76], ["lignans", "SIMPLE_CHEMICAL", 82, 89], ["vegetables", "ORGANISM_SUBDIVISION", 116, 126], ["fruits", "ORGANISM_SUBDIVISION", 131, 137], ["cereals", "ORGANISM_SUBDIVISION", 149, 156], ["tea", "ORGANISM_SUBDIVISION", 184, 187], ["wine", "SIMPLE_CHEMICAL", 192, 196], ["gut flora", "ORGANISM_SUBDIVISION", 224, 233], ["Lactobacillus", "SIMPLE_CHEMICAL", 299, 312], ["Bifidobacteria", "SIMPLE_CHEMICAL", 314, 328], ["Akkermansia", "SIMPLE_CHEMICAL", 330, 341], ["Fecalibacteria", "SIMPLE_CHEMICAL", 346, 360], ["Helicobacter pylori", "ORGANISM", 442, 461], ["Staphylococcus species", "ORGANISM", 466, 488], ["Helicobacter pylori", "SPECIES", 442, 461], ["Helicobacter pylori", "SPECIES", 442, 461], ["vitro studies", "TEST", 3, 16], ["polyphenols", "TREATMENT", 37, 48], ["phenols", "TREATMENT", 57, 64], ["flavonoids", "TREATMENT", 66, 76], ["lignans", "TREATMENT", 82, 89], ["the gut flora", "PROBLEM", 220, 233], ["beneficial organisms", "PROBLEM", 270, 290], ["Lactobacillus", "PROBLEM", 299, 312], ["Bifidobacteria", "PROBLEM", 314, 328], ["Akkermansia", "PROBLEM", 330, 341], ["Fecalibacteria", "PROBLEM", 346, 360], ["pathogenic bacteria", "PROBLEM", 414, 433], ["Helicobacter pylori", "PROBLEM", 442, 461], ["Staphylococcus species", "PROBLEM", 466, 488], ["Helicobacter pylori", "OBSERVATION", 442, 461]]], ["Preclinical studies and clinical trials have shown that polyphenols affect the ratio of Firmicutes to Bacteroides (F/B) [24].", [["polyphenols", "CHEMICAL", 56, 67], ["polyphenols", "SIMPLE_CHEMICAL", 56, 67], ["Preclinical studies", "TEST", 0, 19], ["clinical trials", "TEST", 24, 39], ["Bacteroides", "PROBLEM", 102, 113]]], ["This could be attributed to the prebiotic like activity of the polyphenols (for example, inulin has been reported as a prebiotic for Lactobacillus plantarum [25] and their biotransformation to produce SCFAs, along with other bacterial metabolites, that contribute to the growth of beneficial bacteria resulting in a significant reduction in inflammation and thereby improving the systemic state of disease [26].", [["inulin", "CHEMICAL", 89, 95], ["Lactobacillus plantarum", "CHEMICAL", 133, 156], ["SCFAs", "CHEMICAL", 201, 206], ["inflammation", "DISEASE", 341, 353], ["polyphenols", "CHEMICAL", 63, 74], ["SCFAs", "CHEMICAL", 201, 206], ["polyphenols", "SIMPLE_CHEMICAL", 63, 74], ["inulin", "SIMPLE_CHEMICAL", 89, 95], ["Lactobacillus plantarum", "ORGANISM", 133, 156], ["SCFAs", "SIMPLE_CHEMICAL", 201, 206], ["Lactobacillus plantarum", "SPECIES", 133, 156], ["Lactobacillus plantarum", "SPECIES", 133, 156], ["inulin", "TREATMENT", 89, 95], ["Lactobacillus plantarum", "TREATMENT", 133, 156], ["SCFAs", "PROBLEM", 201, 206], ["other bacterial metabolites", "PROBLEM", 219, 246], ["beneficial bacteria", "PROBLEM", 281, 300], ["a significant reduction in inflammation", "PROBLEM", 314, 353], ["disease", "PROBLEM", 398, 405], ["significant", "OBSERVATION_MODIFIER", 316, 327], ["reduction", "OBSERVATION_MODIFIER", 328, 337], ["inflammation", "OBSERVATION", 341, 353]]], ["Likewise, vitamins C (lemon, spinach, broccoli), D (eggs, fish) and E (almonds, spinach, broccoli, olive oil) supplementation have been found to modulate health-beneficial microbiota (Bifidobacteria, Lactobacillus, and microbes of the genus Roseburia) and reduce the F/B ratio [27].", [["olive oil", "ANATOMY", 99, 108], ["vitamins C (lemon, spinach, broccoli", "CHEMICAL", 10, 46], ["vitamins C", "CHEMICAL", 10, 20], ["vitamins C", "SIMPLE_CHEMICAL", 10, 20], ["lemon", "ORGANISM_SUBDIVISION", 22, 27], ["spinach", "ORGANISM_SUBDIVISION", 29, 36], ["broccoli", "ORGANISM_SUBDIVISION", 38, 46], ["D", "SIMPLE_CHEMICAL", 49, 50], ["eggs", "ORGANISM_SUBDIVISION", 52, 56], ["fish", "ORGANISM_SUBDIVISION", 58, 62], ["almonds", "ORGANISM_SUBDIVISION", 71, 78], ["spinach", "ORGANISM_SUBDIVISION", 80, 87], ["broccoli", "ORGANISM_SUBDIVISION", 89, 97], ["olive oil", "SIMPLE_CHEMICAL", 99, 108], ["Bifidobacteria", "SIMPLE_CHEMICAL", 184, 198], ["Lactobacillus", "SIMPLE_CHEMICAL", 200, 213], ["spinach", "SPECIES", 80, 87], ["broccoli", "SPECIES", 89, 97], ["broccoli", "SPECIES", 89, 97], ["vitamins C (lemon", "TREATMENT", 10, 27], ["D (eggs, fish) and E (almonds, spinach, broccoli, olive oil", "TREATMENT", 49, 108], ["supplementation", "TREATMENT", 110, 125], ["Bifidobacteria", "TEST", 184, 198], ["Lactobacillus", "TREATMENT", 200, 213], ["the F/B ratio", "TEST", 263, 276]]], ["However, modulation of the gut microbial profile depends on the level of vitamins in the host.", [["gut", "ANATOMY", 27, 30], ["gut", "ORGANISM_SUBDIVISION", 27, 30], ["vitamins", "SIMPLE_CHEMICAL", 73, 81], ["vitamins", "TREATMENT", 73, 81], ["gut", "ANATOMY", 27, 30]]], ["Therefore, clinical trial pertaining to concerns regarding excess vitamin supplementation are required to address these issues.", [["vitamin", "CHEMICAL", 66, 73], ["vitamin", "SIMPLE_CHEMICAL", 66, 73], ["excess vitamin supplementation", "TREATMENT", 59, 89]]], ["Out of the minerals, zinc supplementation (milk products, nuts, read meat) has been reported to reduce the deleterious microbes and increase the beneficial ones in various preclinical studies [28].Dietary Nutrients ::: Diet and Gut Microbiota in the Population of Developed and Developing CountriesCarbohydrates also play a pivotal role in influencing the gut flora.", [["meat", "ANATOMY", 69, 73], ["gut flora", "ANATOMY", 356, 365], ["zinc", "CHEMICAL", 21, 25], ["zinc", "CHEMICAL", 21, 25], ["zinc", "SIMPLE_CHEMICAL", 21, 25], ["milk", "ORGANISM_SUBDIVISION", 43, 47], ["nuts", "ORGANISM_SUBDIVISION", 58, 62], ["meat", "ORGANISM_SUBDIVISION", 69, 73], ["gut flora", "PATHOLOGICAL_FORMATION", 356, 365], ["zinc supplementation (milk products", "TREATMENT", 21, 56], ["the deleterious microbes", "PROBLEM", 103, 127], ["Gut Microbiota", "OBSERVATION_MODIFIER", 228, 242], ["gut", "ANATOMY", 356, 359], ["flora", "OBSERVATION", 360, 365]]], ["Plant derived carbohydrate based high-fiber diet was found to increase the abundance of Bifidobacterium and reduce the F/B ratio [29].", [["Bifidobacterium", "CHEMICAL", 88, 103], ["carbohydrate", "CHEMICAL", 14, 26], ["carbohydrate", "SIMPLE_CHEMICAL", 14, 26], ["Plant derived carbohydrate based high-fiber diet", "TREATMENT", 0, 48], ["Bifidobacterium", "PROBLEM", 88, 103], ["the F/B ratio", "TEST", 115, 128]]], ["Most of the carbohydrates such as galacto-oligosaccharides, arabinoxylan, oligofructose institutes the growth of bacteria such as Bifidobacteria, Lactobacillus, Roseburia, etc., which have been known to confer health benefits and has been found to influence the F/B ratio [27].", [["galacto-oligosaccharides", "CHEMICAL", 34, 58], ["arabinoxylan", "CHEMICAL", 60, 72], ["oligofructose", "CHEMICAL", 74, 87], ["Bifidobacteria", "CHEMICAL", 130, 144], ["carbohydrates", "CHEMICAL", 12, 25], ["arabinoxylan", "CHEMICAL", 60, 72], ["oligofructose", "CHEMICAL", 74, 87], ["galacto-oligosaccharides", "SIMPLE_CHEMICAL", 34, 58], ["arabinoxylan", "SIMPLE_CHEMICAL", 60, 72], ["oligofructose", "SIMPLE_CHEMICAL", 74, 87], ["Bifidobacteria", "SIMPLE_CHEMICAL", 130, 144], ["Lactobacillus", "SIMPLE_CHEMICAL", 146, 159], ["F/B", "GENE_OR_GENE_PRODUCT", 262, 265], ["the carbohydrates", "TREATMENT", 8, 25], ["galacto-oligosaccharides", "TREATMENT", 34, 58], ["arabinoxylan", "TREATMENT", 60, 72], ["oligofructose", "TREATMENT", 74, 87], ["bacteria", "PROBLEM", 113, 121], ["Bifidobacteria", "PROBLEM", 130, 144], ["Lactobacillus", "PROBLEM", 146, 159], ["the F/B ratio", "TEST", 258, 271]]], ["Certain carbohydrates have been reported to possess restorative activity in reversing the state of dysbiosis, thereby indicating their potential as a possible therapeutic intervention for management of various metabolic diseases.Dietary Nutrients ::: Diet and Gut Microbiota in the Population of Developed and Developing CountriesIn case of fats, both the quantity as well as their type plays a major role in modulating the gut microbiota [27].", [["fats", "ANATOMY", 341, 345], ["gut", "ANATOMY", 424, 427], ["dysbiosis", "DISEASE", 99, 108], ["metabolic diseases", "DISEASE", 210, 228], ["carbohydrates", "CHEMICAL", 8, 21], ["fats", "ORGANISM_SUBDIVISION", 341, 345], ["gut", "ORGANISM_SUBDIVISION", 424, 427], ["Certain carbohydrates", "TREATMENT", 0, 21], ["dysbiosis", "PROBLEM", 99, 108], ["therapeutic intervention", "TREATMENT", 159, 183], ["management", "TREATMENT", 188, 198], ["various metabolic diseases", "PROBLEM", 202, 228], ["metabolic diseases", "OBSERVATION", 210, 228]]], ["For example, saturated fat reduces beneficial microbes such as Bifidobacterium and Fecalibacterium, thereby increasing the F/B ratio.", [["fat", "ANATOMY", 23, 26], ["Fecalibacterium", "CHEMICAL", 83, 98], ["fat", "TISSUE", 23, 26], ["Bifidobacterium", "SIMPLE_CHEMICAL", 63, 78], ["Fecalibacterium", "SIMPLE_CHEMICAL", 83, 98], ["F/B", "GENE_OR_GENE_PRODUCT", 123, 126], ["saturated fat reduces beneficial microbes", "PROBLEM", 13, 54], ["Bifidobacterium", "PROBLEM", 63, 78], ["Fecalibacterium", "PROBLEM", 83, 98], ["the F/B ratio", "TEST", 119, 132]]], ["On the contrary, unsaturated fat has been found to reduce detrimental microbes such as Escherichia and Streptococcus species and simultaneously increasing the beneficial bacteria such as Bifidobacteria and Akkermansia, hence lowering the F/B ratio.", [["fat", "TISSUE", 29, 32], ["Escherichia", "ORGANISM", 87, 98], ["Streptococcus species", "ORGANISM", 103, 124], ["Bifidobacteria", "SIMPLE_CHEMICAL", 187, 201], ["F/B", "GENE_OR_GENE_PRODUCT", 238, 241], ["detrimental microbes", "PROBLEM", 58, 78], ["Escherichia", "PROBLEM", 87, 98], ["Streptococcus species", "PROBLEM", 103, 124], ["the beneficial bacteria", "PROBLEM", 155, 178], ["Bifidobacteria", "PROBLEM", 187, 201], ["Akkermansia", "PROBLEM", 206, 217], ["the F/B ratio", "TEST", 234, 247], ["Streptococcus species", "OBSERVATION", 103, 124]]], ["Moreover, studies have also reported that high fat deteriorates the density of beneficial microbes whereas following it with a low-fat diet reverses this effect.", [["fat", "ANATOMY", 47, 50], ["fat", "TISSUE", 47, 50], ["studies", "TEST", 10, 17], ["high fat", "PROBLEM", 42, 50], ["beneficial microbes", "PROBLEM", 79, 98], ["a low-fat diet", "TREATMENT", 125, 139]]], ["Similarly, based on their quality and quantity, proteins have also been reported to affect the heterogeneity and the constitution of gut flora [27].", [["gut flora", "ANATOMY", 133, 142], ["gut", "ORGANISM_SUBDIVISION", 133, 136], ["gut flora", "PROBLEM", 133, 142]]], ["For example, whey protein increases Bifidobacteria at low concentrations but decreases the same at higher concentrations.", [["Bifidobacteria", "CHEMICAL", 36, 50], ["Bifidobacteria", "SIMPLE_CHEMICAL", 36, 50], ["whey protein", "PROTEIN", 13, 25], ["whey protein increases Bifidobacteria at low concentrations", "PROBLEM", 13, 72], ["increases", "OBSERVATION_MODIFIER", 26, 35], ["Bifidobacteria", "OBSERVATION", 36, 50], ["low concentrations", "OBSERVATION_MODIFIER", 54, 72], ["decreases", "OBSERVATION_MODIFIER", 77, 86]]], ["Furthermore, animal-based proteins (eggs, fish, meat) have been reported to increase deleterious gut microbiota, thereby increasing the susceptibility of an individual to intestinal inflammation.", [["eggs", "ANATOMY", 36, 40], ["meat", "ANATOMY", 48, 52], ["gut microbiota", "ANATOMY", 97, 111], ["intestinal", "ANATOMY", 171, 181], ["inflammation", "DISEASE", 182, 194], ["eggs", "ORGANISM_SUBDIVISION", 36, 40], ["fish", "ORGANISM_SUBDIVISION", 42, 46], ["meat", "ORGANISM_SUBDIVISION", 48, 52], ["gut microbiota", "PATHOLOGICAL_FORMATION", 97, 111], ["intestinal", "ORGAN", 171, 181], ["deleterious gut microbiota", "PROBLEM", 85, 111], ["intestinal inflammation", "PROBLEM", 171, 194], ["intestinal", "ANATOMY", 171, 181], ["inflammation", "OBSERVATION", 182, 194]]], ["However, preclinical, and clinical trials are still being carried out to confirm these effects on gut microbiota.", [["gut microbiota", "ANATOMY", 98, 112], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 98, 112]]], ["On the other hand, dysbiosis is linked to various kinds of gut inflammation which eventually culminate in gut-associated co-morbidities [30].Symbiosis, Immune Regulation, and HomeostasisInterdependence between the host and gut microbiota has been found to be indispensable [31].", [["gut", "ANATOMY", 59, 62], ["gut", "ANATOMY", 106, 109], ["gut microbiota", "ANATOMY", 223, 237], ["dysbiosis", "DISEASE", 19, 28], ["inflammation", "DISEASE", 63, 75], ["Symbiosis", "DISEASE", 141, 150], ["gut", "ORGANISM_SUBDIVISION", 59, 62], ["gut", "ORGANISM_SUBDIVISION", 106, 109], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 223, 237], ["dysbiosis", "PROBLEM", 19, 28], ["gut inflammation", "PROBLEM", 59, 75], ["associated co-morbidities", "PROBLEM", 110, 135], ["Symbiosis", "PROBLEM", 141, 150], ["Immune Regulation", "TREATMENT", 152, 169], ["dysbiosis", "OBSERVATION", 19, 28], ["gut", "ANATOMY", 59, 62], ["inflammation", "OBSERVATION", 63, 75]]], ["Various studies have reported that mutualistic association between the two holds immense significance in maintaining an equipoise as the former provides the latter with a nutrient rich milieu and the latter in turn aids in various key functions necessary for host sustenance [32].", [["Various studies", "TEST", 0, 15], ["a nutrient rich milieu", "TREATMENT", 169, 191]]], ["In this regard, the impact of gut microbiota can broadly be classified into structural, metabolic, and protective functions.", [["gut microbiota", "ANATOMY", 30, 44], ["gut", "ORGANISM_SUBDIVISION", 30, 33]]], ["The gut microflora has been known to strengthen the gut barrier by enhancing expression of tight junction proteins and simultaneously inducing IgA production and prominent bacteria that aid in both include Bacteroides spp., F. prausnitzii, Akkermansia muciniphila, Roseburia spp.; probiotic bacteria including Bifidobacterium and Lactobacillus spp.", [["gut microflora", "ANATOMY", 4, 18], ["gut barrier", "ANATOMY", 52, 63], ["tight junction", "ANATOMY", 91, 105], ["gut microflora", "MULTI-TISSUE_STRUCTURE", 4, 18], ["gut barrier", "TISSUE", 52, 63], ["tight junction proteins", "GENE_OR_GENE_PRODUCT", 91, 114], ["IgA", "GENE_OR_GENE_PRODUCT", 143, 146], ["Bacteroides spp.", "ORGANISM", 206, 222], ["F. prausnitzii", "ORGANISM", 224, 238], ["Akkermansia muciniphila", "ORGANISM", 240, 263], ["Roseburia spp.", "ORGANISM", 265, 279], ["Bifidobacterium", "SIMPLE_CHEMICAL", 310, 325], ["Lactobacillus spp", "ORGANISM", 330, 347], ["tight junction proteins", "PROTEIN", 91, 114], ["IgA", "PROTEIN", 143, 146], ["Bacteroides spp.", "SPECIES", 206, 222], ["F. prausnitzii", "SPECIES", 224, 238], ["Akkermansia muciniphila", "SPECIES", 240, 263], ["Roseburia spp.", "SPECIES", 265, 279], ["Lactobacillus spp", "SPECIES", 330, 347], ["Bacteroides spp.", "SPECIES", 206, 222], ["F. prausnitzii", "SPECIES", 224, 238], ["Akkermansia muciniphila", "SPECIES", 240, 263], ["Roseburia spp.", "SPECIES", 265, 279], ["tight junction proteins", "PROBLEM", 91, 114], ["IgA production", "PROBLEM", 143, 157], ["prominent bacteria", "PROBLEM", 162, 180], ["Bacteroides spp.", "PROBLEM", 206, 222], ["Akkermansia muciniphila", "PROBLEM", 240, 263], ["Roseburia spp.", "PROBLEM", 265, 279], ["probiotic bacteria", "PROBLEM", 281, 299], ["Bifidobacterium", "PROBLEM", 310, 325], ["Lactobacillus spp", "PROBLEM", 330, 347], ["gut", "ANATOMY", 4, 7], ["microflora", "OBSERVATION", 8, 18], ["tight junction", "OBSERVATION", 91, 105], ["IgA production", "OBSERVATION", 143, 157], ["prominent", "OBSERVATION_MODIFIER", 162, 171], ["bacteria", "OBSERVATION", 172, 180], ["Lactobacillus spp", "OBSERVATION", 330, 347]]], ["The metabolic functions include their ability to produce essential vitamins and simultaneously metabolize iron, other dietary carcinogens along with fermentation of non-digestible carbohydrates.", [["iron", "CHEMICAL", 106, 110], ["iron", "CHEMICAL", 106, 110], ["carbohydrates", "CHEMICAL", 180, 193], ["vitamins", "SIMPLE_CHEMICAL", 67, 75], ["iron", "SIMPLE_CHEMICAL", 106, 110], ["essential vitamins", "TREATMENT", 57, 75], ["simultaneously metabolize iron", "TREATMENT", 80, 110], ["non-digestible carbohydrates", "TREATMENT", 165, 193], ["carcinogens", "OBSERVATION", 126, 137]]], ["The indigenous microflora also protects the host by preventing establishment of gut pathogens due to enhanced competitive binding by competing for nutrients, space, and host cell receptors along with production of various anti-microbial factors thereby resulting in pathogen displacement [7].", [["gut", "ANATOMY", 80, 83], ["cell", "ANATOMY", 174, 178], ["gut", "ORGANISM_SUBDIVISION", 80, 83], ["host cell", "CELL", 169, 178], ["host cell receptors", "PROTEIN", 169, 188], ["anti-microbial factors", "PROTEIN", 222, 244], ["The indigenous microflora", "TREATMENT", 0, 25], ["gut pathogens", "PROBLEM", 80, 93], ["enhanced competitive binding", "PROBLEM", 101, 129], ["space, and host cell receptors", "TREATMENT", 158, 188], ["various anti-microbial factors", "PROBLEM", 214, 244], ["pathogen displacement", "PROBLEM", 266, 287], ["host cell", "OBSERVATION", 169, 178], ["pathogen displacement", "OBSERVATION", 266, 287]]], ["The fermentation of dietary fiber by gut microbes, resulting in formation of short chain fatty acids, has been further known to regulate immune functioning via various receptors and pathways involving molecules such as G-protein coupled receptors (GPCRs).", [["gut microbes", "ANATOMY", 37, 49], ["fatty acids", "CHEMICAL", 89, 100], ["fatty acids", "CHEMICAL", 89, 100], ["gut", "ORGANISM_SUBDIVISION", 37, 40], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 219, 246], ["G-protein coupled receptors", "PROTEIN", 219, 246], ["GPCRs", "PROTEIN", 248, 253], ["The fermentation of dietary fiber", "TREATMENT", 0, 33], ["short chain fatty acids", "PROBLEM", 77, 100], ["various receptors and pathways involving molecules", "PROBLEM", 160, 210], ["G-protein coupled receptors", "TEST", 219, 246]]], ["GPCRs such as GPCR43 and GPCR120 have been reported to regulate anti-inflammatory pathways such as enhanced reactive oxygen species (ROS) mediated killing coupled with enhanced phagocytosis, induction of apoptosis, recruitment of specific proteins and cytokine production thereby contributing immensely to immune regulation [12].", [["oxygen", "CHEMICAL", 117, 123], ["ROS", "CHEMICAL", 133, 136], ["oxygen", "CHEMICAL", 117, 123], ["GPCR43", "GENE_OR_GENE_PRODUCT", 14, 20], ["GPCR120", "GENE_OR_GENE_PRODUCT", 25, 32], ["reactive oxygen species", "SIMPLE_CHEMICAL", 108, 131], ["ROS", "SIMPLE_CHEMICAL", 133, 136], ["GPCR43", "PROTEIN", 14, 20], ["GPCR120", "PROTEIN", 25, 32], ["specific proteins", "PROTEIN", 230, 247], ["cytokine", "PROTEIN", 252, 260], ["GPCRs", "TEST", 0, 5], ["GPCR43", "TEST", 14, 20], ["GPCR120", "TEST", 25, 32], ["anti-inflammatory pathways", "TEST", 64, 90], ["enhanced reactive oxygen species", "PROBLEM", 99, 131], ["enhanced phagocytosis", "PROBLEM", 168, 189], ["apoptosis", "PROBLEM", 204, 213], ["specific proteins", "PROBLEM", 230, 247], ["cytokine production", "PROBLEM", 252, 271], ["reactive", "OBSERVATION_MODIFIER", 108, 116], ["oxygen species", "OBSERVATION", 117, 131]]], ["All these findings substantiate the role of gut flora, its composition and its role in immune system regulation owing to its ability in producing molecules such as SCFA, peptidoglycans and polysaccharide A from a fibre rich diet, which significantly contributes to the maintenance of homeostasis.", [["gut flora", "ANATOMY", 44, 53], ["immune system", "ANATOMY", 87, 100], ["SCFA", "CHEMICAL", 164, 168], ["polysaccharide A", "CHEMICAL", 189, 205], ["SCFA", "CHEMICAL", 164, 168], ["gut flora", "MULTI-TISSUE_STRUCTURE", 44, 53], ["SCFA", "SIMPLE_CHEMICAL", 164, 168], ["peptidoglycans", "SIMPLE_CHEMICAL", 170, 184], ["polysaccharide A", "SIMPLE_CHEMICAL", 189, 205], ["gut flora", "PROBLEM", 44, 53], ["immune system regulation", "TREATMENT", 87, 111], ["SCFA, peptidoglycans", "TREATMENT", 164, 184], ["a fibre rich diet", "TREATMENT", 211, 228], ["gut", "ANATOMY", 44, 47], ["flora", "OBSERVATION", 48, 53], ["SCFA", "ANATOMY", 164, 168]]], ["In addition to the regular diet intake, fasting is an integral part of many cultures worldwide and is considered auspicious traditionally.", [["many cultures", "TEST", 71, 84]]], ["This concept has been getting scientific validations for its role in maintaining gut and immune homeostasis.", [["gut", "ANATOMY", 81, 84], ["gut", "ORGANISM_SUBDIVISION", 81, 84], ["immune", "ANATOMICAL_SYSTEM", 89, 95], ["gut", "ANATOMY", 81, 84], ["immune homeostasis", "OBSERVATION", 89, 107]]], ["Intermittent fasting (IF) (which includes alternate day fasting or time restricted feeding) has been reported to favorably influence the gut microbiota [34] by increasing the abundance of beneficial Akkermansia muciniphila and Bacteroides fragilis [35].", [["gut", "ANATOMY", 137, 140], ["gut", "ORGANISM_SUBDIVISION", 137, 140], ["Akkermansia muciniphila", "ORGANISM", 199, 222], ["Bacteroides fragilis", "ORGANISM", 227, 247], ["Akkermansia muciniphila", "SPECIES", 199, 222], ["Bacteroides fragilis", "SPECIES", 227, 247], ["Akkermansia muciniphila", "SPECIES", 199, 222], ["Bacteroides fragilis", "SPECIES", 227, 247], ["Intermittent fasting (IF)", "PROBLEM", 0, 25], ["beneficial Akkermansia muciniphila", "PROBLEM", 188, 222], ["Bacteroides fragilis", "PROBLEM", 227, 247]]], ["In fact, various animal trials and some human intervention studies have clearly demonstrated health benefits associated with IF in people with underlying diabetes, obesity, and cardiovascular ailments [36].Diet Induced Dysbiosis, Inflammation and ComorbidityIt has been established that plant food-based diet promotes the microbes that ensue anti-inflammatory response and is thus, known to maintain a more diverse and stable microbiota [37].", [["cardiovascular", "ANATOMY", 177, 191], ["diabetes", "DISEASE", 154, 162], ["obesity", "DISEASE", 164, 171], ["cardiovascular ailments", "DISEASE", 177, 200], ["Inflammation", "DISEASE", 230, 242], ["human", "ORGANISM", 40, 45], ["people", "ORGANISM", 131, 137], ["human", "SPECIES", 40, 45], ["people", "SPECIES", 131, 137], ["human", "SPECIES", 40, 45], ["various animal trials", "TREATMENT", 9, 30], ["some human intervention studies", "TEST", 35, 66], ["underlying diabetes", "PROBLEM", 143, 162], ["obesity", "PROBLEM", 164, 171], ["cardiovascular ailments", "PROBLEM", 177, 200], ["Diet Induced Dysbiosis", "PROBLEM", 206, 228], ["Inflammation", "PROBLEM", 230, 242], ["Comorbidity", "PROBLEM", 247, 258], ["diabetes", "OBSERVATION", 154, 162], ["obesity", "OBSERVATION", 164, 171], ["cardiovascular", "ANATOMY", 177, 191], ["Dysbiosis", "OBSERVATION", 219, 228], ["Inflammation", "OBSERVATION", 230, 242], ["stable", "OBSERVATION_MODIFIER", 419, 425]]], ["In other words, a vegetarian diet seems to be more beneficial for human health due to its ability to maintain a state of symbiosis i.e., balanced microflora within the host.", [["human", "ORGANISM", 66, 71], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71]]], ["In contrast to this, certain food items such as gluten in wheat, red meat and alcohol can promote the growth of dysbiotic microorganisms which trigger a heightened pro-inflammatory response, thereby culminating in chronic inflammation [5].", [["red meat", "ANATOMY", 65, 73], ["alcohol", "CHEMICAL", 78, 85], ["inflammation", "DISEASE", 222, 234], ["alcohol", "CHEMICAL", 78, 85], ["wheat", "ORGANISM_SUBDIVISION", 58, 63], ["meat", "ORGANISM_SUBDIVISION", 69, 73], ["alcohol", "SIMPLE_CHEMICAL", 78, 85], ["wheat", "SPECIES", 58, 63], ["wheat", "SPECIES", 58, 63], ["gluten in wheat", "PROBLEM", 48, 63], ["dysbiotic microorganisms", "PROBLEM", 112, 136], ["a heightened pro-inflammatory response", "PROBLEM", 151, 189], ["chronic inflammation", "PROBLEM", 214, 234], ["chronic", "OBSERVATION_MODIFIER", 214, 221], ["inflammation", "OBSERVATION", 222, 234]]], ["This chronic inflammation has been reported to cause gut leakiness due to degradation of tight junctions by various proteases [38], thus allowing the dissemination of cells, pathogenic bacteria, and viruses into the blood circulation and transforming the existing state of gut inflammation into chronic systemic inflammation [39].", [["gut", "ANATOMY", 53, 56], ["tight junctions", "ANATOMY", 89, 104], ["cells", "ANATOMY", 167, 172], ["blood", "ANATOMY", 216, 221], ["gut", "ANATOMY", 273, 276], ["inflammation", "DISEASE", 13, 25], ["inflammation", "DISEASE", 277, 289], ["inflammation", "DISEASE", 312, 324], ["gut", "ORGANISM_SUBDIVISION", 53, 56], ["tight junctions", "CELLULAR_COMPONENT", 89, 104], ["cells", "CELL", 167, 172], ["blood", "ORGANISM_SUBSTANCE", 216, 221], ["gut", "ORGANISM_SUBDIVISION", 273, 276], ["proteases", "PROTEIN", 116, 125], ["This chronic inflammation", "PROBLEM", 0, 25], ["gut leakiness", "PROBLEM", 53, 66], ["various proteases", "TEST", 108, 125], ["the dissemination of cells", "PROBLEM", 146, 172], ["pathogenic bacteria", "PROBLEM", 174, 193], ["viruses into the blood circulation", "PROBLEM", 199, 233], ["gut inflammation", "PROBLEM", 273, 289], ["chronic systemic inflammation", "PROBLEM", 295, 324], ["chronic", "OBSERVATION_MODIFIER", 5, 12], ["inflammation", "OBSERVATION", 13, 25], ["leakiness", "OBSERVATION", 57, 66], ["tight junctions", "OBSERVATION", 89, 104], ["blood", "ANATOMY", 216, 221], ["gut", "ANATOMY", 273, 276], ["inflammation", "OBSERVATION", 277, 289], ["chronic", "OBSERVATION_MODIFIER", 295, 302], ["systemic", "OBSERVATION_MODIFIER", 303, 311], ["inflammation", "OBSERVATION", 312, 324]]], ["This chronic inflammation may remain undetected for years altogether, serving as a predisposing risk factor which may, at any time soon, aggravate into ailments and other serious manifestations, and therefore can be considered as a comorbidity.", [["inflammation", "DISEASE", 13, 25], ["This chronic inflammation", "PROBLEM", 0, 25], ["other serious manifestations", "PROBLEM", 165, 193], ["chronic", "OBSERVATION_MODIFIER", 5, 12], ["inflammation", "OBSERVATION", 13, 25]]], ["The term 'comorbidity' refers to any added illness in patients already suffering from a disease.", [["illness", "DISEASE", 43, 50], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["The term 'comorbidity'", "PROBLEM", 0, 22], ["a disease", "PROBLEM", 86, 95], ["disease", "OBSERVATION", 88, 95]]], ["In the recent decade, occurrence of psychiatric comorbidity in chronic disease has been widely observed and has been emphasized as an important aspect of disease management [40].Diet Induced Dysbiosis, Inflammation and ComorbidityVarious studies have reported the association of dysbiosis with the pathogenesis of various intestinal or extra-intestinal disorders such as coeliac disease, cardiovascular disease, diabetes, and obesity [9, 41].", [["intestinal", "ANATOMY", 322, 332], ["coeliac", "ANATOMY", 371, 378], ["cardiovascular", "ANATOMY", 388, 402], ["psychiatric comorbidity", "DISEASE", 36, 59], ["chronic disease", "DISEASE", 63, 78], ["Inflammation", "DISEASE", 202, 214], ["dysbiosis", "DISEASE", 279, 288], ["extra-intestinal disorders", "DISEASE", 336, 362], ["coeliac disease", "DISEASE", 371, 386], ["cardiovascular disease", "DISEASE", 388, 410], ["diabetes", "DISEASE", 412, 420], ["obesity", "DISEASE", 426, 433], ["intestinal", "ORGAN", 322, 332], ["cardiovascular", "ANATOMICAL_SYSTEM", 388, 402], ["psychiatric comorbidity", "PROBLEM", 36, 59], ["chronic disease", "PROBLEM", 63, 78], ["disease management", "TREATMENT", 154, 172], ["Diet Induced Dysbiosis", "PROBLEM", 178, 200], ["Inflammation", "PROBLEM", 202, 214], ["ComorbidityVarious studies", "TEST", 219, 245], ["dysbiosis", "PROBLEM", 279, 288], ["various intestinal or extra-intestinal disorders", "PROBLEM", 314, 362], ["coeliac disease", "PROBLEM", 371, 386], ["cardiovascular disease", "PROBLEM", 388, 410], ["diabetes", "PROBLEM", 412, 420], ["obesity", "PROBLEM", 426, 433], ["psychiatric", "OBSERVATION_MODIFIER", 36, 47], ["comorbidity", "OBSERVATION", 48, 59], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["disease", "OBSERVATION", 71, 78], ["Dysbiosis", "OBSERVATION", 191, 200], ["Inflammation", "OBSERVATION", 202, 214], ["dysbiosis", "OBSERVATION", 279, 288], ["intestinal", "ANATOMY", 322, 332], ["extra-intestinal", "ANATOMY", 336, 352], ["coeliac", "ANATOMY", 371, 378], ["cardiovascular disease", "OBSERVATION", 388, 410], ["diabetes", "OBSERVATION", 412, 420]]], ["Similarly, Kedia et al. [7] have reported comparable changes in the gut microbiome of patients suffering from autoimmune (Inflammatory Bowel Disease, IBD) as well as infectious diseases, suggesting the role of inflammation in the altered status of the gut microbiome.", [["gut microbiome", "ANATOMY", 68, 82], ["Bowel", "ANATOMY", 135, 140], ["gut microbiome", "ANATOMY", 252, 266], ["Inflammatory Bowel Disease", "DISEASE", 122, 148], ["IBD", "DISEASE", 150, 153], ["infectious diseases", "DISEASE", 166, 185], ["inflammation", "DISEASE", 210, 222], ["gut", "ORGANISM_SUBDIVISION", 68, 71], ["patients", "ORGANISM", 86, 94], ["gut", "ORGANISM_SUBDIVISION", 252, 255], ["patients", "SPECIES", 86, 94], ["autoimmune (Inflammatory Bowel Disease", "PROBLEM", 110, 148], ["IBD", "PROBLEM", 150, 153], ["infectious diseases", "PROBLEM", 166, 185], ["inflammation", "PROBLEM", 210, 222], ["autoimmune", "OBSERVATION", 110, 120], ["Inflammatory", "OBSERVATION_MODIFIER", 122, 134], ["infectious", "OBSERVATION", 166, 176], ["inflammation", "OBSERVATION", 210, 222], ["gut", "ANATOMY", 252, 255]]], ["Hence, it can also be inferred that comorbidity can arise because of dysbiotic inflammatory condition.Effect of Microbiota on COVID-19 Cases During LockdownThe prevailing COVID-19 pandemic situation arising from the spread of highly contagious virus led to a lockdown in various countries.", [["comorbidity", "PROBLEM", 36, 47], ["dysbiotic inflammatory condition", "PROBLEM", 69, 101], ["COVID", "TEST", 126, 131], ["The prevailing COVID-19 pandemic situation", "TREATMENT", 156, 198], ["highly contagious virus", "PROBLEM", 226, 249], ["dysbiotic", "OBSERVATION_MODIFIER", 69, 78], ["inflammatory", "OBSERVATION", 79, 91]]], ["Based on the interim guidelines of WHO, most of the countries opted for several non-pharmacological measures such as social distancing and masking along with lockdown of varying time intervals.", [["several non-pharmacological measures", "TREATMENT", 72, 108]]], ["Though a huge global economic loss was incurred due to enforcement of restriction on outdoor activities [42], but lockdown was propounded to be the most effective way to mitigate this dreadful situation in the absence of any treatment procedures or therapeutic/prophylactic agents.", [["a huge global economic loss", "PROBLEM", 7, 34], ["any treatment procedures", "TREATMENT", 221, 245], ["therapeutic/prophylactic agents", "TREATMENT", 249, 280], ["huge", "OBSERVATION_MODIFIER", 9, 13], ["global", "OBSERVATION_MODIFIER", 14, 20], ["economic loss", "OBSERVATION", 21, 34]]], ["Lockdown implementation proved to be a reasonably effective strategy even in India (despite being one of the most populous country in the world), as by the end of 4th lockdown (31st May 2020), total number of confirmed infection cases in India were 182,143 (Fig. 1a) with 5164 deceased cases [43].", [["infection", "DISEASE", 219, 228], ["infection cases", "PROBLEM", 219, 234], ["infection", "OBSERVATION", 219, 228]]], ["Thus, on an average, only 12 infected cases per lakh people were seen during the lockdown period (Fig. 1b).", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["infected", "OBSERVATION_MODIFIER", 29, 37]]], ["The fatality rate (2.83) of India was also observed to be the lowest as compared to the worst affected Western countries (Fig. 1b) and basic reproduction unit (Ro) was significantly reduced during the course of lockdown from R = 1.26 to R = 1.06 till the end of 4th lockdown (31st May 2020).", [["The fatality rate", "TEST", 0, 17]]], ["Ro or basic reproduction unit is the ratio of transmission rate to recovery rate calculated by SIR modelling study [44] conducted in our lab (Data not reported here).", [["Ro", "CHEMICAL", 0, 2], ["Ro", "SIMPLE_CHEMICAL", 0, 2]]], ["A positive impact of lockdown up to the second lockdown period is clearly visible in Fig. 1c, after which a rapid upsurge in the cases was observed which can be mainly attributed to considerable relaxations made by the Government of India.Effect of Microbiota on COVID-19 Cases During LockdownIt may be argued that the number of confirmed cases represented may not be correct because of insufficient testing of the Indian population as only symptomatic people with a travel history to affected countries or people in close contact with the COVID-19 positive case were being tested [45].", [["people", "ORGANISM", 453, 459], ["people", "ORGANISM", 507, 513], ["people", "SPECIES", 453, 459], ["people", "SPECIES", 507, 513], ["COVID", "TEST", 263, 268], ["the COVID", "TEST", 536, 545], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["impact", "OBSERVATION_MODIFIER", 11, 17], ["visible", "OBSERVATION_MODIFIER", 74, 81], ["rapid", "OBSERVATION_MODIFIER", 108, 113], ["relaxations", "OBSERVATION", 195, 206]]], ["In this case, it is also worth noting that in India, an enough percentage of infected individuals have been reported to be asymptomatic (approximately 80%) [46].", [["individuals", "ORGANISM", 86, 97], ["infected individuals", "PROBLEM", 77, 97], ["infected", "OBSERVATION", 77, 85]]], ["Therefore, it can be presumed that even if infected cases are there, these are probably asymptomatic due to the healthy dietary habits and symbiosis.", [["infected cases", "PROBLEM", 43, 57], ["asymptomatic", "PROBLEM", 88, 100], ["symbiosis", "PROBLEM", 139, 148]]], ["However, being asymptomatic is always a risk of transmission of infection to others and that is where measures like social distancing, masking and respiratory etiquettes prove to be of immense benefit.Effect of Microbiota on COVID-19 Cases During LockdownHere, it may be inferred that plant based, home cooked, rich fiber diet consumed by the Indian population during lockdown, might have resulted in generation of symbiotic microflora, thereby eliciting anti-inflammatory responses.", [["infection", "DISEASE", 64, 73], ["infection", "PROBLEM", 64, 73], ["COVID", "TEST", 225, 230], ["symbiotic microflora", "PROBLEM", 415, 435], ["infection", "OBSERVATION", 64, 73], ["symbiotic microflora", "OBSERVATION", 415, 435]]], ["Indian diet is also rich in whole grains, which are a rich source of dietary fiber, carbohydrates, resistant starch and oligosaccharides.", [["whole grains", "ANATOMY", 28, 40], ["carbohydrates", "CHEMICAL", 84, 97], ["grains", "ORGANISM_SUBDIVISION", 34, 40], ["carbohydrates", "SIMPLE_CHEMICAL", 84, 97], ["starch", "SIMPLE_CHEMICAL", 109, 115], ["oligosaccharides", "SIMPLE_CHEMICAL", 120, 136], ["dietary fiber", "TREATMENT", 69, 82], ["resistant starch and oligosaccharides", "TREATMENT", 99, 136], ["resistant starch", "OBSERVATION", 99, 115]]], ["These are fermented in the colon after escaping digestion in the small intestine and result in production of SCFAs, which act as an energy source for the colonocytes, lower the colonic pH as well as alter the blood lipids, hence eliciting an immune response beyond the gut [47].", [["colon", "ANATOMY", 27, 32], ["small intestine", "ANATOMY", 65, 80], ["colonocytes", "ANATOMY", 154, 165], ["colonic", "ANATOMY", 177, 184], ["blood", "ANATOMY", 209, 214], ["gut", "ANATOMY", 269, 272], ["SCFAs", "CHEMICAL", 109, 114], ["SCFAs", "CHEMICAL", 109, 114], ["colon", "ORGAN", 27, 32], ["small intestine", "ORGAN", 65, 80], ["SCFAs", "SIMPLE_CHEMICAL", 109, 114], ["colonocytes", "CELL", 154, 165], ["colonic", "ORGAN", 177, 184], ["blood", "ORGANISM_SUBSTANCE", 209, 214], ["lipids", "ORGANISM_SUBSTANCE", 215, 221], ["gut", "ORGANISM_SUBDIVISION", 269, 272], ["colonocytes", "CELL_TYPE", 154, 165], ["escaping digestion in the small intestine", "PROBLEM", 39, 80], ["production of SCFAs", "PROBLEM", 95, 114], ["the colonocytes", "PROBLEM", 150, 165], ["lower the colonic pH", "PROBLEM", 167, 187], ["the blood lipids", "TEST", 205, 221], ["colon", "ANATOMY", 27, 32], ["small intestine", "ANATOMY", 65, 80], ["production", "OBSERVATION_MODIFIER", 95, 105], ["colonic", "ANATOMY", 177, 184]]], ["Whole grains are also rich in antioxidants such as phenolic compounds which have been shown to result in disease prevention [48].", [["grains", "ANATOMY", 6, 12], ["Whole grains", "PROBLEM", 0, 12], ["antioxidants", "TREATMENT", 30, 42], ["phenolic compounds", "PROBLEM", 51, 69], ["phenolic compounds", "OBSERVATION", 51, 69]]], ["Moreover, whole grains also possess certain compounds which may reduce the risk of chronic diseases such as diabetes, obesity, and cancer.", [["whole grains", "ANATOMY", 10, 22], ["cancer", "ANATOMY", 131, 137], ["diabetes", "DISEASE", 108, 116], ["obesity", "DISEASE", 118, 125], ["cancer", "DISEASE", 131, 137], ["cancer", "CANCER", 131, 137], ["certain compounds", "PROBLEM", 36, 53], ["chronic diseases", "PROBLEM", 83, 99], ["diabetes", "PROBLEM", 108, 116], ["obesity", "PROBLEM", 118, 125], ["cancer", "PROBLEM", 131, 137], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["diseases", "OBSERVATION", 91, 99], ["diabetes", "OBSERVATION", 108, 116], ["obesity", "OBSERVATION", 118, 125], ["cancer", "OBSERVATION", 131, 137]]], ["Furthermore, state wise data distribution within India presented that the states where millet is the staple food, less prevalence of the disease was observed along with a higher recovery rate and a lower fatality rate.Effect of Microbiota on COVID-19 Cases During LockdownSimultaneously, a shift from animal-based diet to plant-based, fiber rich diet, has been reported to be associated with a change in microbiota (which changes within days to weeks) [49].", [["millet", "ORGANISM_SUBDIVISION", 87, 93], ["millet", "SPECIES", 87, 93], ["millet", "SPECIES", 87, 93], ["the disease", "PROBLEM", 133, 144], ["a lower fatality rate", "PROBLEM", 196, 217], ["COVID", "TEST", 242, 247], ["plant-based, fiber rich diet", "TREATMENT", 322, 350], ["a change in microbiota", "PROBLEM", 392, 414], ["disease", "OBSERVATION", 137, 144]]], ["This might have downregulated any pre-existing chronic inflammation, thereby reducing the occurrence of cytokine storm.", [["inflammation", "DISEASE", 55, 67], ["cytokine", "PROTEIN", 104, 112], ["any pre-existing chronic inflammation", "PROBLEM", 30, 67], ["cytokine storm", "PROBLEM", 104, 118], ["chronic", "OBSERVATION_MODIFIER", 47, 54], ["inflammation", "OBSERVATION", 55, 67], ["cytokine storm", "OBSERVATION", 104, 118]]], ["Due to an almost total shutdown, it can be presumed that the public had limited access to animal based or ready to eat processed food, which is generally rich in refined carbohydrates and fats.", [["carbohydrates", "CHEMICAL", 170, 183], ["carbohydrates", "SIMPLE_CHEMICAL", 170, 183], ["fats", "SIMPLE_CHEMICAL", 188, 192]]], ["The lockdown very successfully steered the public to consciously consuming homemade healthy diet, which probably resulted in reduced incidence/severity of disease during this period due to an improved microbiota or symbiosis.Effect of Microbiota on COVID-19 Cases During LockdownIt was also observed that besides having many cases, India was spared from the fatality caused by SARS-CoV-2 as compared to other countries, especially Western countries, such as USA (Fig. 1b).", [["fatality", "DISEASE", 358, 366], ["SARS", "DISEASE", 377, 381], ["SARS-CoV", "SPECIES", 377, 385], ["reduced incidence/severity of disease", "PROBLEM", 125, 162], ["symbiosis", "PROBLEM", 215, 224], ["COVID", "TEST", 249, 254], ["SARS", "PROBLEM", 377, 381], ["disease", "OBSERVATION", 155, 162], ["symbiosis", "OBSERVATION", 215, 224]]], ["Both the regions consume meat rich diet and saturated fatty acids.", [["meat", "ANATOMY", 25, 29], ["fatty acids", "CHEMICAL", 54, 65], ["saturated fatty acids", "CHEMICAL", 44, 65], ["meat", "ORGANISM_SUBDIVISION", 25, 29], ["saturated fatty acids", "SIMPLE_CHEMICAL", 44, 65], ["saturated fatty acids", "TREATMENT", 44, 65]]], ["Pro-inflammatory responses triggered due to such a diet may lead to fatal complications in patients infected with COVID-19, where lung epithelial cell inflammation might have detrimental consequences.", [["lung epithelial cell", "ANATOMY", 130, 150], ["inflammation", "DISEASE", 151, 163], ["patients", "ORGANISM", 91, 99], ["lung epithelial cell", "CELL", 130, 150], ["patients", "SPECIES", 91, 99], ["Pro-inflammatory responses", "PROBLEM", 0, 26], ["fatal complications", "PROBLEM", 68, 87], ["COVID", "TEST", 114, 119], ["lung epithelial cell inflammation", "PROBLEM", 130, 163], ["lung", "ANATOMY", 130, 134], ["epithelial cell inflammation", "OBSERVATION", 135, 163]]], ["Moreover, it was also observed that due to lockdown restrictions in the Western countries, access to fresh vegetables or fruits were also restricted to the population, unlike India, where daily grocery items such as fresh fruits, vegetables, and milk were accessible to the public daily.", [["vegetables", "ANATOMY", 107, 117], ["fruits", "ANATOMY", 121, 127], ["fruits", "ANATOMY", 222, 228], ["vegetables", "ANATOMY", 230, 240], ["milk", "ANATOMY", 246, 250], ["fruits", "ORGANISM_SUBDIVISION", 121, 127], ["fruits", "ORGANISM_SUBDIVISION", 222, 228], ["vegetables", "ORGANISM_SUBDIVISION", 230, 240], ["milk", "ORGANISM_SUBSTANCE", 246, 250]]], ["The former situation might have resulted in increased consumption of processed food, leading to dysbiosis and simultaneously resulting in addition of more cytokines to the pro-inflammatory milieu.", [["dysbiosis", "DISEASE", 96, 105], ["cytokines", "PROTEIN", 155, 164], ["dysbiosis", "PROBLEM", 96, 105], ["increased", "OBSERVATION_MODIFIER", 44, 53]]], ["Increased consumption of processed foods which are mostly rich in fats, sugars, and salts, not only increases the risk of lifestyle diseases such as obesity and cardiovascular problems in patients suffering from chronic inflammation, but has also been found to have grave implications in enhancing COVID-19 related complications [47].", [["cardiovascular", "ANATOMY", 161, 175], ["fats, sugars, and salts", "CHEMICAL", 66, 89], ["obesity", "DISEASE", 149, 156], ["cardiovascular problems", "DISEASE", 161, 184], ["inflammation", "DISEASE", 220, 232], ["sugars", "CHEMICAL", 72, 78], ["fats", "SIMPLE_CHEMICAL", 66, 70], ["sugars", "SIMPLE_CHEMICAL", 72, 78], ["salts", "SIMPLE_CHEMICAL", 84, 89], ["cardiovascular", "ANATOMICAL_SYSTEM", 161, 175], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["sugars", "TEST", 72, 78], ["salts", "TREATMENT", 84, 89], ["lifestyle diseases", "PROBLEM", 122, 140], ["obesity", "PROBLEM", 149, 156], ["cardiovascular problems", "PROBLEM", 161, 184], ["chronic inflammation", "PROBLEM", 212, 232], ["mostly", "OBSERVATION_MODIFIER", 51, 57], ["rich", "OBSERVATION_MODIFIER", 58, 62], ["obesity", "OBSERVATION", 149, 156], ["chronic", "OBSERVATION_MODIFIER", 212, 219], ["inflammation", "OBSERVATION", 220, 232], ["grave", "OBSERVATION_MODIFIER", 266, 271], ["enhancing", "OBSERVATION_MODIFIER", 288, 297]]], ["Most of the COVID-19 related deaths reported in India so far, might be attributed to the immunocompromised status of the individual as most of them were found to be suffering from some comorbidity such as hypertension, diabetes or other cardiovascular diseases [3].Effect of Microbiota on COVID-19 Cases During LockdownTherefore, early implementation of lockdown by Indian Government was a great step towards preventing a catastrophe as there are over 8 crore hypertension patients and about 77 million diabetic patients in India [50].", [["cardiovascular", "ANATOMY", 237, 251], ["deaths", "DISEASE", 29, 35], ["hypertension", "DISEASE", 205, 217], ["diabetes", "DISEASE", 219, 227], ["cardiovascular diseases", "DISEASE", 237, 260], ["hypertension", "DISEASE", 460, 472], ["diabetic", "DISEASE", 503, 511], ["patients", "ORGANISM", 473, 481], ["patients", "ORGANISM", 512, 520], ["patients", "SPECIES", 473, 481], ["patients", "SPECIES", 512, 520], ["the immunocompromised status", "PROBLEM", 85, 113], ["some comorbidity", "PROBLEM", 180, 196], ["hypertension", "PROBLEM", 205, 217], ["diabetes", "PROBLEM", 219, 227], ["other cardiovascular diseases", "PROBLEM", 231, 260], ["COVID", "TEST", 289, 294], ["a catastrophe", "PROBLEM", 420, 433], ["hypertension", "OBSERVATION", 205, 217], ["catastrophe", "OBSERVATION", 422, 433]]], ["A tool developed by the Oxford University, Oxford COVID-19 Government Response tracker (OFCGRT), also applauded the Indian Government for having done exceptionally well in curtailing the coronavirus outbreak [51].Effect of Microbiota on COVID-19 Cases During LockdownAn Italian Survey carried out by Di Renzo et al. [49], has also highlighted some of the positive effects of the lockdown, such as, a higher indulgence in physical activity and adoption of healthier lifestyles by quitting smoking.", [["coronavirus", "DISEASE", 187, 198], ["coronavirus", "ORGANISM", 187, 198], ["COVID", "TEST", 237, 242], ["positive", "OBSERVATION", 355, 363]]], ["Moreover, an increased adherence to the Mediterranean diet was seen in the age group of 18\u201330, which might have reduced the risk of oxidative damage and in turn, the susceptibility to COVID-19 infection.", [["COVID-19", "CHEMICAL", 184, 192], ["infection", "DISEASE", 193, 202], ["COVID-19", "GENE_OR_GENE_PRODUCT", 184, 192], ["oxidative damage", "PROBLEM", 132, 148], ["COVID", "TEST", 184, 189], ["infection", "PROBLEM", 193, 202], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["adherence", "OBSERVATION_MODIFIER", 23, 32], ["oxidative damage", "OBSERVATION", 132, 148], ["infection", "OBSERVATION", 193, 202]]], ["This survey also emphasized the protective potential of healthy plant-based diet as compared to the processed food or animal-based diet.Effect of Microbiota on COVID-19 Cases During LockdownFurther during the lockdown period several of the daily wagers including migrant workers faced adversity and underwent phases of forced starvation.", [["COVID", "TEST", 160, 165], ["forced starvation", "TREATMENT", 319, 336]]], ["Similarly, people working in corporates away from their homes and taking their meals outside may also have faced situations where they underwent phases of no or little food during the lockdown.", [["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17]]], ["This situation is comparable to an intermittent fasting condition.", [["an intermittent fasting condition", "PROBLEM", 32, 65]]], ["In this context, it can be speculated that IF might have given the advantage to some by enriching their beneficial gut microbiota and thus the former non-pharmacological interventions can have special implication amidst the COVID-19 crisis, assisting the microbiome-immune axis.", [["gut", "ANATOMY", 115, 118], ["IF", "GENE_OR_GENE_PRODUCT", 43, 45], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 115, 129], ["the former non-pharmacological interventions", "TREATMENT", 139, 183], ["the COVID", "TEST", 220, 229]]], ["It may be noted that perhaps, deaths which occurred amongst migrants were due to road accidents or starvation but not due to SARS-CoV-2 infection!Effect of Microbiota on COVID-19 Cases During LockdownOn the other hand, quarantine has also been reported to induce stress which leads to \u2018stress eating\u2019 wherein individuals tend to increasingly consume food with high fat and sugar content thereby leading to obesity.", [["fat", "ANATOMY", 365, 368], ["deaths", "DISEASE", 30, 36], ["accidents", "DISEASE", 86, 95], ["SARS", "DISEASE", 125, 129], ["infection", "DISEASE", 136, 145], ["obesity", "DISEASE", 406, 413], ["sugar", "CHEMICAL", 373, 378], ["CoV-2", "ORGANISM", 130, 135], ["fat", "TISSUE", 365, 368], ["sugar", "SIMPLE_CHEMICAL", 373, 378], ["SARS", "PROBLEM", 125, 129], ["CoV", "PROBLEM", 130, 133], ["2 infection", "PROBLEM", 134, 145], ["COVID", "TEST", 170, 175], ["obesity", "PROBLEM", 406, 413], ["infection", "OBSERVATION", 136, 145], ["obesity", "OBSERVATION", 406, 413]]], ["An obese individual has been reported to possess a decreased immune function demonstrated by a deficit in CD8+ T cells responses used to combat viral infections.", [["T cells", "ANATOMY", 111, 118], ["viral infections", "DISEASE", 144, 160], ["CD8", "GENE_OR_GENE_PRODUCT", 106, 109], ["T cells", "CELL", 111, 118], ["CD8", "PROTEIN", 106, 109], ["T cells", "CELL_TYPE", 111, 118], ["a decreased immune function", "PROBLEM", 49, 76], ["a deficit in CD8", "PROBLEM", 93, 109], ["viral infections", "PROBLEM", 144, 160], ["obese", "OBSERVATION", 3, 8]]], ["This leads to higher mortality due to increased viral load in lungs and is also coupled with lung pathology [52].", [["lungs", "ANATOMY", 62, 67], ["lung", "ANATOMY", 93, 97], ["lungs", "ORGAN", 62, 67], ["lung", "ORGAN", 93, 97], ["increased viral load in lungs", "PROBLEM", 38, 67], ["lung pathology", "PROBLEM", 93, 107], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["viral load", "OBSERVATION", 48, 58], ["lungs", "ANATOMY", 62, 67], ["lung", "ANATOMY", 93, 97], ["pathology", "OBSERVATION", 98, 107]]], ["Furthermore, in Western countries it was observed that a diet poor in fresh fruits and vegetables was more frequently ingested, thereby reducing the daily required intake of antioxidants and vitamins, which have been reported as potential weapons against the COVID-19.", [["fruits", "ANATOMY", 76, 82], ["vegetables", "ANATOMY", 87, 97], ["vitamins", "CHEMICAL", 191, 199], ["vitamins", "CHEMICAL", 191, 199], ["COVID-19", "CHEMICAL", 259, 267], ["fruits", "ORGANISM_SUBDIVISION", 76, 82], ["vegetables", "ORGANISM_SUBDIVISION", 87, 97], ["vitamins", "SIMPLE_CHEMICAL", 191, 199], ["antioxidants", "TREATMENT", 174, 186], ["vitamins", "TREATMENT", 191, 199], ["the COVID", "TEST", 255, 264]]], ["Therefore, strategies which encourage healthy diet and increased home-based physical activities should be implemented to reduce the risk of above-mentioned conditions.Effect of Microbiota on COVID-19 Cases During LockdownIn addition to a decline in the physical health of individuals due to ingestion of improper food, the effect of quarantine in deteriorating the mental health, especially in children, was also observed [53].", [["children", "ORGANISM", 394, 402], ["children", "SPECIES", 394, 402], ["COVID", "TEST", 191, 196], ["a decline", "PROBLEM", 236, 245], ["improper food", "PROBLEM", 304, 317], ["quarantine", "TREATMENT", 333, 343], ["decline", "OBSERVATION_MODIFIER", 238, 245]]], ["Herein, we would like to point out that such a condition may be avoided if the person is accustomed to healthy diet or diet supplemented with healthy microbes such as probiotics [54, 55].", [["person", "SPECIES", 79, 85]]], ["Disturbances at the gut-brain axis, occurring due to various gastro-intestinal conditions, have been implicated in various mental health abnormalities as well such as anxiety, mood disorders and depression [56].", [["gut", "ANATOMY", 20, 23], ["brain", "ANATOMY", 24, 29], ["gastro-intestinal", "ANATOMY", 61, 78], ["anxiety", "DISEASE", 167, 174], ["mood disorders", "DISEASE", 176, 190], ["depression", "DISEASE", 195, 205], ["gut", "ORGANISM_SUBDIVISION", 20, 23], ["brain", "ORGAN", 24, 29], ["intestinal", "ORGAN", 68, 78], ["Disturbances at the gut-brain axis", "PROBLEM", 0, 34], ["various gastro-intestinal conditions", "PROBLEM", 53, 89], ["various mental health abnormalities", "PROBLEM", 115, 150], ["anxiety", "PROBLEM", 167, 174], ["mood disorders", "PROBLEM", 176, 190], ["depression", "PROBLEM", 195, 205], ["gut", "ANATOMY", 20, 23], ["brain axis", "ANATOMY", 24, 34], ["intestinal", "ANATOMY", 68, 78]]], ["Probiotics have been reported to restore this balance and act as \u2018psychobiotics\u2019, thereby serving as an alternate treatment option.", [["Probiotics", "TREATMENT", 0, 10], ["an alternate treatment option", "TREATMENT", 101, 130]]], ["In this context, we recently studied the effect of a potential probiotic strain, Lactiplantibacillus plantarum (RTA 8), on psychological, histological and physiological status of diseased host and its role in ameliorating host health by modulating various aspects of the gut-brain axis [57].", [["gut", "ANATOMY", 271, 274], ["brain", "ANATOMY", 275, 280], ["Lactiplantibacillus plantarum", "ORGANISM", 81, 110], ["RTA 8", "ORGANISM", 112, 117], ["gut", "ORGANISM_SUBDIVISION", 271, 274], ["brain", "ORGAN", 275, 280], ["Lactiplantibacillus plantarum", "SPECIES", 81, 110], ["Lactiplantibacillus plantarum", "SPECIES", 81, 110], ["a potential probiotic strain", "TREATMENT", 51, 79], ["Lactiplantibacillus plantarum (RTA", "TREATMENT", 81, 115], ["gut", "ANATOMY", 271, 274], ["brain axis", "ANATOMY", 275, 285]]], ["Given the purported association of microbiota with COVID-19 cases, studies on analysis of gut microbiome using faecal samples of these cases are warranted to validate this hypothesis.Effect of Microbiota on COVID-19 Cases During LockdownBriefly, it can be concluded that the high fatality rate in Western countries as compared to India, during the lockdown, can be attributed to (1) their animal based diet which increases dysbiosis, hence increasing the pro-inflammatory cytokines resulting in cytokine storm in contrast to the Sattvic diet of the Indian culture including plant based diet and use of traditional medicine as recommended by the Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy), Government of India [58]; (2) the unhealthy dietary habits during lockdown, especially attributed to limited access to fresh grocery shopping, thus resulting in an increase in underlying conditions; (3) the late implementation of lockdown in contrast to the timely implementation of lockdown by the Government of India; (4) the possibility of a more virulent variant of COVID-19 strain prevalent in Western countries in comparison to that prevalent in India due to high mutation rate in the genome of SARS-CoV-2 virus [59, 60] and; (5) India, being a developing country, is more exposed to infections as compared to the developed nations, thereby resulting in priming of their immune response against a wide variety of microbes leading to a better immune status than that observed in the Western population.Concluding Remarks and Future PerspectivesThere has been a growing appreciation of the role played by commensal microbiota in human health.", [["gut microbiome", "ANATOMY", 90, 104], ["faecal samples", "ANATOMY", 111, 125], ["dysbiosis", "DISEASE", 423, 432], ["COVID-19", "CHEMICAL", 1097, 1105], ["SARS", "DISEASE", 1228, 1232], ["infections", "DISEASE", 1317, 1327], ["gut microbiome", "MULTI-TISSUE_STRUCTURE", 90, 104], ["faecal samples", "MULTI-TISSUE_STRUCTURE", 111, 125], ["COVID-19 strain", "ORGANISM", 1097, 1112], ["SARS-CoV-2 virus", "ORGANISM", 1228, 1244], ["human", "ORGANISM", 1660, 1665], ["pro-inflammatory cytokines", "PROTEIN", 455, 481], ["cytokine", "PROTEIN", 495, 503], ["CoV-2 virus", "SPECIES", 1233, 1244], ["human", "SPECIES", 1660, 1665], ["SARS-CoV-2 virus", "SPECIES", 1228, 1244], ["human", "SPECIES", 1660, 1665], ["COVID", "TEST", 51, 56], ["studies on analysis", "TEST", 67, 86], ["gut microbiome", "TEST", 90, 104], ["faecal samples", "TEST", 111, 125], ["these cases", "TEST", 129, 140], ["this hypothesis", "PROBLEM", 167, 182], ["COVID", "TEST", 207, 212], ["dysbiosis", "PROBLEM", 423, 432], ["the pro-inflammatory cytokines", "TREATMENT", 451, 481], ["cytokine storm", "TREATMENT", 495, 509], ["the Indian culture", "TREATMENT", 545, 563], ["traditional medicine", "TREATMENT", 602, 622], ["an increase in underlying conditions", "PROBLEM", 888, 924], ["lockdown in contrast", "TREATMENT", 957, 977], ["COVID", "TEST", 1097, 1102], ["high mutation rate", "PROBLEM", 1192, 1210], ["SARS", "PROBLEM", 1228, 1232], ["CoV", "TEST", 1233, 1236], ["infections", "PROBLEM", 1317, 1327], ["dysbiosis", "OBSERVATION", 423, 432], ["increase", "OBSERVATION_MODIFIER", 891, 899], ["infections", "OBSERVATION", 1317, 1327], ["growing", "OBSERVATION_MODIFIER", 1593, 1600]]], ["Here, diet has been found to play a crucial role in modulating the gut microbiota, thereby resulting in symbiosis or dysbiosis.", [["gut microbiota", "ANATOMY", 67, 81], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 67, 81], ["symbiosis", "PROBLEM", 104, 113], ["dysbiosis", "PROBLEM", 117, 126], ["symbiosis", "OBSERVATION", 104, 113], ["dysbiosis", "OBSERVATION", 117, 126]]], ["In this context, people should be enlightened about the importance of daily intake of a balanced diet which can be better defined and prescribed through the help of nutritional biologists and food industries.", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23], ["a balanced diet", "TREATMENT", 86, 101]]], ["A balanced diet, like the ones prepared by the dieticians in hospitals and hostels of educational institutions, can also be defined for public.", [["A balanced diet", "TREATMENT", 0, 15]]], ["The same can also be supplied to the migrants and the economically weaker sections of the society to prevent malnutrition.", [["malnutrition", "DISEASE", 109, 121], ["malnutrition", "PROBLEM", 109, 121], ["malnutrition", "OBSERVATION", 109, 121]]], ["Furthermore, the importance of intermittent fasting or following a fasting-mimicking diet can be an important advisory to the population, for not only restoring beneficial gut microbiota but promoting overall health as well.Concluding Remarks and Future PerspectivesRapid advancements in the molecular techniques for assessment of human gut microbiome has helped in defining the diversity and metabolic properties of the gut microbiota.", [["gut microbiota", "ANATOMY", 172, 186], ["gut microbiome", "ANATOMY", 337, 351], ["gut microbiota", "ANATOMY", 421, 435], ["gut microbiota", "PATHOLOGICAL_FORMATION", 172, 186], ["human", "ORGANISM", 331, 336], ["gut", "ORGANISM_SUBDIVISION", 337, 340], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 421, 435], ["human", "SPECIES", 331, 336], ["human", "SPECIES", 331, 336], ["intermittent fasting", "PROBLEM", 31, 51], ["a fasting-mimicking diet", "TREATMENT", 65, 89], ["assessment", "TEST", 317, 327], ["metabolic properties", "OBSERVATION", 393, 413], ["gut microbiota", "ANATOMY", 421, 435]]], ["Intestinal microbiota of the host can be modulated through administration of synbiotics (probiotics and prebiotics), thereby conferring holistic health benefits.", [["Intestinal", "ANATOMY", 0, 10], ["Intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 0, 21], ["synbiotics", "SIMPLE_CHEMICAL", 77, 87], ["synbiotics (probiotics", "TREATMENT", 77, 99], ["prebiotics", "TREATMENT", 104, 114]]], ["Developing such a combination of probiotics and prebiotics may ultimately prove to be more cost effective than developing new drugs.", [["probiotics", "TREATMENT", 33, 43], ["prebiotics", "TREATMENT", 48, 58]]], ["Gut microbiota can be modulated by enriching it with beneficial ones and eliminating the pathogenic microbes using antipathogens as an alternative to antibiotics [61\u201367].", [["Gut microbiota", "ANATOMY", 0, 14], ["Gut microbiota", "TISSUE", 0, 14], ["beneficial ones", "TREATMENT", 53, 68], ["antipathogens", "TREATMENT", 115, 128], ["antibiotics", "TREATMENT", 150, 161]]], ["The acceptance of scientific community/physicians for their application, specific to the control of infection, beyond the accepted source of health promoting effects is important.", [["infection", "DISEASE", 100, 109], ["their application", "TREATMENT", 54, 71], ["infection", "PROBLEM", 100, 109], ["infection", "OBSERVATION", 100, 109]]], ["In addition to the regulatory and scientific constraints, public acceptance may be another hurdle which needs to be surmounted by educating and enhancing awareness to increase intake of probiotics/prebiotics along with plant-based fiber rich diet to the recommended level.Concluding Remarks and Future PerspectivesAs per the experience gathered during the lockdown period, a significant increase in the cleanliness quotient has been observed in the environment which is crucial for decreasing the incidence of infections along with contributing to robust health status of individuals.", [["infections", "DISEASE", 510, 520], ["individuals", "ORGANISM", 572, 583], ["probiotics", "TREATMENT", 186, 196], ["prebiotics", "TREATMENT", 197, 207], ["plant-based fiber rich diet", "TREATMENT", 219, 246], ["a significant increase in the cleanliness quotient", "PROBLEM", 373, 423], ["infections", "PROBLEM", 510, 520], ["significant", "OBSERVATION_MODIFIER", 375, 386], ["increase", "OBSERVATION_MODIFIER", 387, 395], ["infections", "OBSERVATION", 510, 520]]], ["This would also give opportunity, particularly to the next generation, in inculcating good habits of healthy diet to strengthen their immune system.Concluding Remarks and Future PerspectivesIn this regard, the concept \u2018Let food be thy medicine\u2019, proposed by Hippocrates way back in 431 BC, needs to be revisited, particularly during such situation as the present one, when there is no therapeutic or protective agent available and for now, cure lies only in prevention.", [["immune system", "ANATOMY", 134, 147], ["immune system", "ANATOMICAL_SYSTEM", 134, 147], ["protective agent", "TREATMENT", 400, 416]]]], "PMC7149651": [["Developmental Anatomy of the Mammary Gland ::: PHYSIOLOGY OF LACTATIONThe rudimentary mammary tissue undergoes several developmental changes during morphogenesis and lactogenesis: In the 4-mm human embryo, the breast tissue appears as a tiny mammary band on the chest wall2,3; by the 7-mm embryonic stage, the mammary band develops into the mammary line, along which eventually develops the true mammary anlage; by the 12-mm stage, a primitive epithelial nodule develops; by the 30-mm stage, the primitive mammary bud appears.", [["Mammary Gland", "ANATOMY", 29, 42], ["mammary tissue", "ANATOMY", 86, 100], ["embryo", "ANATOMY", 198, 204], ["breast tissue", "ANATOMY", 210, 223], ["mammary band", "ANATOMY", 242, 254], ["chest wall2,3", "ANATOMY", 262, 275], ["embryonic", "ANATOMY", 289, 298], ["mammary band", "ANATOMY", 310, 322], ["mammary line", "ANATOMY", 341, 353], ["mammary anlage", "ANATOMY", 396, 410], ["epithelial nodule", "ANATOMY", 444, 461], ["mammary bud", "ANATOMY", 506, 517], ["Mammary Gland", "CANCER", 29, 42], ["mammary tissue", "TISSUE", 86, 100], ["human", "ORGANISM", 192, 197], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 198, 204], ["breast tissue", "TISSUE", 210, 223], ["mammary", "ORGAN", 242, 249], ["mammary band", "ORGAN", 310, 322], ["mammary line", "CELL", 341, 353], ["mammary anlage", "MULTI-TISSUE_STRUCTURE", 396, 410], ["epithelial nodule", "CANCER", 444, 461], ["mammary bud", "MULTI-TISSUE_STRUCTURE", 506, 517], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 192, 197], ["The rudimentary mammary tissue", "PROBLEM", 70, 100], ["several developmental changes", "PROBLEM", 111, 140], ["a tiny mammary band on the chest wall2,3", "PROBLEM", 235, 275], ["the 7-mm embryonic stage", "PROBLEM", 280, 304], ["a primitive epithelial nodule", "PROBLEM", 432, 461], ["Mammary Gland", "ANATOMY", 29, 42], ["rudimentary", "ANATOMY_MODIFIER", 74, 85], ["mammary", "ANATOMY", 86, 93], ["tissue", "OBSERVATION", 94, 100], ["several", "OBSERVATION_MODIFIER", 111, 118], ["developmental", "OBSERVATION_MODIFIER", 119, 132], ["4-mm", "OBSERVATION_MODIFIER", 187, 191], ["human embryo", "OBSERVATION", 192, 204], ["breast tissue", "ANATOMY", 210, 223], ["tiny", "OBSERVATION_MODIFIER", 237, 241], ["mammary", "ANATOMY", 242, 249], ["band", "OBSERVATION", 250, 254], ["chest", "ANATOMY", 262, 267], ["7-mm", "OBSERVATION_MODIFIER", 284, 288], ["mammary", "ANATOMY", 310, 317], ["mammary", "ANATOMY", 341, 348], ["line", "OBSERVATION", 349, 353], ["mammary", "ANATOMY", 396, 403], ["anlage", "ANATOMY_MODIFIER", 404, 410], ["12-mm", "OBSERVATION_MODIFIER", 419, 424], ["primitive", "OBSERVATION_MODIFIER", 434, 443], ["epithelial", "ANATOMY_MODIFIER", 444, 454], ["nodule", "OBSERVATION", 455, 461], ["30-mm", "OBSERVATION_MODIFIER", 479, 484], ["primitive", "ANATOMY_MODIFIER", 496, 505], ["mammary", "ANATOMY", 506, 513], ["bud", "ANATOMY_MODIFIER", 514, 517]]], ["Further development in the male, however, appears to be limited by androgenic or other male-associated substances.4,5 Castration in male rat embryos early in gestation leads to female breast development, whereas ovariectomy in the female does not alter the course of development of the mammary anlage.", [["embryos", "ANATOMY", 141, 148], ["breast", "ANATOMY", 184, 190], ["mammary anlage", "ANATOMY", 286, 300], ["rat", "ORGANISM", 137, 140], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 141, 148], ["breast", "ORGANISM_SUBDIVISION", 184, 190], ["mammary anlage", "MULTI-TISSUE_STRUCTURE", 286, 300], ["rat", "SPECIES", 137, 140], ["rat", "SPECIES", 137, 140], ["Castration", "TREATMENT", 118, 128], ["substances", "OBSERVATION", 103, 113], ["rat embryos", "OBSERVATION", 137, 148], ["breast", "ANATOMY", 184, 190], ["ovariectomy", "OBSERVATION", 212, 223], ["mammary", "ANATOMY", 286, 293]]], ["Toward the end of pregnancy, initial phases of fetal mammary differentiation seem to occur under the influence of placental and transplacentally acquired maternal hormones, with transient development of the excretory and lactiferous ductular systems.", [["fetal mammary", "ANATOMY", 47, 60], ["placental", "ANATOMY", 114, 123], ["excretory", "ANATOMY", 207, 216], ["lactiferous ductular systems", "ANATOMY", 221, 249], ["fetal mammary", "MULTI-TISSUE_STRUCTURE", 47, 60], ["placental", "ANATOMICAL_SYSTEM", 114, 123], ["ductular systems", "MULTI-TISSUE_STRUCTURE", 233, 249], ["placental and transplacentally acquired maternal hormones", "PROBLEM", 114, 171], ["the excretory and lactiferous ductular systems", "PROBLEM", 203, 249], ["fetal mammary", "ANATOMY", 47, 60], ["lactiferous ductular", "OBSERVATION", 221, 241]]], ["Such growth, differentiation, and secretory activities are transient and regress soon after birth.5,6", [["5,6", "CHEMICAL", 98, 101]]]], "PMC7092852": [], "c2ece2784753e05b88c63fb2fa09edd60d354650": [], "PMC7527287": [["IntroductionThe outbreak of novel coronavirus disease 2019 (COVID-19) started in Wuhan, Hubei Province, China, in late December 2019.", [["coronavirus disease", "DISEASE", 34, 53], ["COVID-19", "CHEMICAL", 60, 68], ["coronavirus", "ORGANISM", 34, 45], ["novel coronavirus disease", "PROBLEM", 28, 53], ["coronavirus disease", "OBSERVATION", 34, 53]]], ["The resulting pandemic has infected almost 7 million people globally with nearly 400,000 deaths, as of May 8, 2020.(2020) According to current evidence, COVID-19 virus is primarily transmitted between people through respiratory droplets and contact routes.(\u201cModes of transmission of virus causing COVID-19,\u201d n.d.; Sahu et al., 2020b).IntroductionAerosol transmission is possible in procedures that lead to the generation of aerosol, which include endotracheal intubation, open suctioning, bronchoscopy, administration of nebulised medications, non-invasive positive pressure ventilation and cardiopulmonary resuscitation (CPR).(Mick and Murphy, 2020) Health care workers (HCW) are particularly at risk of contracting the infection, and they are exposed to these aerosols while performing such procedures.(Sahu et al., 2020) CPR is a standard emergency room procedure leading to high aerosol generation and is associated with the risk of transmission of infection to health care workers.(Couper et al., 2020) The European Resuscitation Council (ERC), the American Heart Association (AHA) and the Australasian College for Emergency Medicine recommend the use of personal protective equipment (PPE) by the HCW involved in resuscitating cardiac arrest patients(Couper et al., 2020; Edelson Dana P. et al.,Malysz et al.,2020).", [["respiratory droplets", "ANATOMY", 216, 236], ["endotracheal", "ANATOMY", 447, 459], ["cardiac", "ANATOMY", 1233, 1240], ["deaths", "DISEASE", 89, 95], ["infection", "DISEASE", 721, 730], ["infection", "DISEASE", 953, 962], ["cardiac arrest", "DISEASE", 1233, 1247], ["people", "ORGANISM", 53, 59], ["COVID-19 virus", "ORGANISM", 153, 167], ["people", "ORGANISM", 201, 207], ["patients", "ORGANISM", 1248, 1256], ["people", "SPECIES", 53, 59], ["people", "SPECIES", 201, 207], ["patients", "SPECIES", 1248, 1256], ["COVID-19 virus", "SPECIES", 153, 167], ["COVID", "TEST", 153, 158], ["virus", "PROBLEM", 283, 288], ["COVID", "TEST", 297, 302], ["IntroductionAerosol transmission", "TREATMENT", 334, 366], ["aerosol", "TREATMENT", 424, 431], ["endotracheal intubation", "TREATMENT", 447, 470], ["open suctioning", "TREATMENT", 472, 487], ["bronchoscopy", "TREATMENT", 489, 501], ["nebulised medications", "TREATMENT", 521, 542], ["non-invasive positive pressure ventilation", "TREATMENT", 544, 586], ["cardiopulmonary resuscitation", "TREATMENT", 591, 620], ["the infection", "PROBLEM", 717, 730], ["such procedures", "TREATMENT", 788, 803], ["a standard emergency room procedure", "TREATMENT", 831, 866], ["high aerosol generation", "TREATMENT", 878, 901], ["infection", "PROBLEM", 953, 962], ["personal protective equipment", "TREATMENT", 1160, 1189], ["pandemic", "OBSERVATION_MODIFIER", 14, 22], ["infected", "OBSERVATION_MODIFIER", 27, 35], ["almost 7 million", "OBSERVATION_MODIFIER", 36, 52], ["respiratory droplets", "OBSERVATION", 216, 236], ["endotracheal intubation", "OBSERVATION", 447, 470], ["pressure ventilation", "OBSERVATION", 566, 586], ["cardiopulmonary", "ANATOMY", 591, 606], ["infection", "OBSERVATION", 721, 730], ["aerosol generation", "OBSERVATION", 883, 901], ["infection", "OBSERVATION", 953, 962], ["Heart", "ANATOMY", 1063, 1068], ["cardiac", "ANATOMY", 1233, 1240], ["arrest", "OBSERVATION", 1241, 1247]]], ["Few studies have demonstrated that the performance level of HCW during life-saving procedures like CPR, intravenous cannulation and endotracheal intubation decreases while wearing PPE.(Chen et al., 2016; Donoghue et al., 2020; Smereka et al., 2020).IntroductionHigh-quality CPR is the backbone of the management of a cardiac arrest and AHA has given the particular emphasis on the rate of chest compressions (CC), depth of CC and minimising the interruptions between CC in defining a high-quality CPR.(Link Mark S. et al., 2015) This systematic review and meta-analysis aimed to investigate the impact of PPE on different chest compression (CC) parameters during CPR.", [["intravenous", "ANATOMY", 104, 115], ["endotracheal", "ANATOMY", 132, 144], ["cardiac", "ANATOMY", 317, 324], ["chest", "ANATOMY", 389, 394], ["chest", "ANATOMY", 622, 627], ["cardiac arrest", "DISEASE", 317, 331], ["AHA", "DISEASE", 336, 339], ["CC", "CHEMICAL", 423, 425], ["CC", "CHEMICAL", 467, 469], ["CC", "CHEMICAL", 641, 643], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 115], ["chest", "ORGANISM_SUBDIVISION", 389, 394], ["chest", "ORGANISM_SUBDIVISION", 622, 627], ["Few studies", "TEST", 0, 11], ["saving procedures", "TREATMENT", 76, 93], ["CPR", "TREATMENT", 99, 102], ["intravenous cannulation", "TREATMENT", 104, 127], ["endotracheal intubation", "TREATMENT", 132, 155], ["High-quality CPR", "TREATMENT", 261, 277], ["the management", "TREATMENT", 297, 311], ["a cardiac arrest", "PROBLEM", 315, 331], ["chest compressions", "TREATMENT", 389, 407], ["depth of CC", "TREATMENT", 414, 425], ["a high-quality CPR", "TREATMENT", 482, 500], ["This systematic review", "TEST", 529, 551], ["meta-analysis", "TEST", 556, 569], ["PPE", "TREATMENT", 605, 608], ["different chest compression (CC) parameters during CPR", "TREATMENT", 612, 666], ["endotracheal intubation", "OBSERVATION", 132, 155], ["cardiac", "ANATOMY", 317, 324], ["arrest", "OBSERVATION", 325, 331], ["chest", "ANATOMY", 389, 394], ["chest", "ANATOMY", 622, 627], ["compression", "OBSERVATION", 628, 639]]], ["The primary objective was to summarise the changes in mean CC rate and CC depth, in study arms (no-PPE arm versus PPE arm).", [["CC", "CHEMICAL", 59, 61], ["CC", "CHEMICAL", 71, 73], ["the changes", "PROBLEM", 39, 50], ["mean CC rate", "TEST", 54, 66], ["study arms", "TEST", 84, 94], ["no-PPE arm versus PPE arm", "TREATMENT", 96, 121]]], ["The secondary objectives were to summarise the proportion of adequate CC rate and depth provided and compare this in both the study arms.", [["CC", "CHEMICAL", 70, 72]]], ["This study was prospectively registered in PROSPERO (CRD42020192031).(Sahu, n.d.)Data sources and searches ::: Materials and methodsThis systematic review was performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA guidelines).(Moher, 2009) Databases including PubMed, EMBASE and Web of Science were searched from inception to June-6, 2020.", [["This study", "TEST", 0, 10], ["Systematic Review", "TEST", 216, 233], ["Meta-analysis", "TEST", 238, 251]]], ["Two independent investigators (AK, RM) searched the databases using search terms like \u2018chest compression\u2019, \u2018cardiopulmonary resuscitation\u2019, \u2018CPR\u2019, \u2018personal protective equipment\u2019, \u2018PPE\u2019 and \u2018N95 mask\u2019 (search query available in Supplementary Table \u2013 S1.", [["chest", "ANATOMY", 87, 92], ["cardiopulmonary", "ANATOMY", 108, 123], ["chest compression\u2019", "TREATMENT", 87, 105], ["cardiopulmonary resuscitation", "TREATMENT", 108, 137], ["\u2018PPE", "TREATMENT", 180, 184], ["\u2018N95 mask", "TREATMENT", 190, 199], ["chest", "ANATOMY", 87, 92], ["cardiopulmonary", "ANATOMY", 108, 123], ["S1", "ANATOMY", 250, 252]]], ["There were no restrictions in terms of country, publication language or publication date.", [["no", "UNCERTAINTY", 11, 13]]], ["Reference lists of all relevant articles and \u2018related citation\u2019 search tool of PubMed was checked for any additional publications.Selection Criteria ::: Materials and methodsStudy selection was performed by two independent investigators (AK, SS).", [["methodsStudy selection", "TEST", 167, 189]]], ["We included studies that reported the data on the comparison of the effectiveness of CC in terms of either CC rate, CC depth, the proportion of adequate CC rate, proportion of adequate CC depth or proportion of adequate recoil; in study arms with (PPE group) or without PPE (no-PPE group).", [["CC", "CHEMICAL", 85, 87], ["CC", "CHEMICAL", 107, 109], ["CC", "CHEMICAL", 116, 118], ["CC", "CHEMICAL", 153, 155], ["CC", "CHEMICAL", 185, 187], ["studies", "TEST", 12, 19], ["the data", "TEST", 34, 42], ["CC rate", "TEST", 107, 114], ["PPE", "PROBLEM", 270, 273], ["adequate recoil", "OBSERVATION", 211, 226]]], ["Discrepancies between reviewers were resolved in the presence of a third reviewer (RM).Data abstraction and quality assessment ::: Materials and methodsData collected included study characteristics such as authors, publication date, study design, information about both study arms (PPE versus no-PPE group) like sample size, type of PPE used and different CC parameters.", [["CC", "CHEMICAL", 356, 358], ["methodsData", "TEST", 145, 156], ["study characteristics", "TEST", 176, 197], ["no-PPE group)", "TREATMENT", 293, 306], ["type of PPE", "TREATMENT", 325, 336], ["different CC parameters", "TEST", 346, 369], ["size", "OBSERVATION_MODIFIER", 319, 323]]], ["The CC parameters collected were mean CC rate (per minute), mean CC depth (in millimetres), the proportion of adequate CC rate provided, the proportion of adequate CC depth provided, proportion of time adequate chest recoil was allowed and duration of CC provided along with the definitions used for appropriate CC rate and depth.", [["chest", "ANATOMY", 211, 216], ["CC", "CHEMICAL", 4, 6], ["CC", "CHEMICAL", 38, 40], ["CC", "CHEMICAL", 65, 67], ["CC", "CHEMICAL", 164, 166], ["CC", "CHEMICAL", 252, 254], ["CC", "CHEMICAL", 312, 314], ["chest", "ORGANISM_SUBDIVISION", 211, 216], ["The CC parameters", "TEST", 0, 17], ["mean CC depth", "TEST", 60, 73], ["CC", "TREATMENT", 252, 254], ["chest", "ANATOMY", 211, 216]]], ["The proportion of the parameters mentioned above was defined as the ratio of the duration of correct CC (rate, depth or recoil) to the total duration for which CC was provided.", [["CC", "CHEMICAL", 101, 103], ["CC", "CHEMICAL", 160, 162]]], ["Qualitative assessment of rescuer's fatigue was also extracted from the included studies.Data abstraction and quality assessment ::: Materials and methodsOne reviewer (AK) extracted the data, and the second reviewer verified the data independently (SS).", [["fatigue", "DISEASE", 36, 43], ["Qualitative assessment", "TEST", 0, 22], ["rescuer's fatigue", "PROBLEM", 26, 43], ["the included studies", "TEST", 68, 88]]], ["The methodological quality of the randomised trials was assessed by Cochrane's ROB-2 (Risk of Bias \u2013 2) tool (\u201cRoB 2,\u201d n.d.), and that of non-randomised studies was determined by Cochrane's ROBINS-I (Risk of Bias in Non-randomised Studies of Interventions) tool (\u201cROBINS-I tool,\u201d n.d.).", [["the randomised trials", "TREATMENT", 30, 51], ["non-randomised studies", "TEST", 138, 160]]], ["Two authors (JN, SS) performed the quality assessment separately, and disagreements were resolved by consensus in the presence of a third reviewer (AK).Quantitative data synthesis ::: Materials and methodsThe change (no-PPE versus PPE group) in the continuous variables like mean CC rate and mean CC depth were summarised in terms of standardised mean difference (SMD) by Cohen's method using generic inverse variance method(Cooper and Hedges, 1993).", [["CC", "CHEMICAL", 280, 282], ["CC", "CHEMICAL", 297, 299], ["the quality assessment", "TEST", 31, 53], ["The change", "PROBLEM", 205, 215], ["no-PPE versus PPE group)", "TREATMENT", 217, 241], ["mean CC rate", "TEST", 275, 287], ["mean CC depth", "PROBLEM", 292, 305]]], ["The proportion of adequate CC rate, CC depth and CC recoil were pooled separately in both the arms (no-PPE versus PPE group) and were compared using Chi-square statistics (p-value < 0.05 was considered statistically significant), as described by Campbell (Campbell, 2007) and Richardson et al. (Richardson, 2011).", [["CC", "CHEMICAL", 27, 29], ["CC", "CHEMICAL", 36, 38], ["CC", "CHEMICAL", 49, 51], ["Chi-square statistics", "TEST", 149, 170], ["p-value", "TEST", 172, 179], ["adequate", "OBSERVATION_MODIFIER", 18, 26], ["arms", "ANATOMY", 94, 98]]], ["Fixed effects pooling was used for meta-analysis.", [["Fixed effects pooling", "PROBLEM", 0, 21], ["meta-analysis", "TEST", 35, 48]]], ["Significant heterogeneity was considered to be present when I2 was greater than 50%(Higgins et al., 2003).", [["Significant heterogeneity", "PROBLEM", 0, 25], ["I2", "TEST", 60, 62], ["heterogeneity", "OBSERVATION", 12, 25], ["considered to be", "UNCERTAINTY", 30, 46]]], ["Publication bias was assessed visually by constructing funnel plots and calculating Egger's regression equation.", [["Publication bias", "TEST", 0, 16], ["funnel plots", "TEST", 55, 67], ["calculating Egger's regression equation", "TREATMENT", 72, 111]]], ["The p-value for Egger's regression coefficient less than 0.10 was considered as significant publication bias(Egger et al., 1997).", [["The p-value", "TEST", 0, 11], ["Egger's regression coefficient", "TEST", 16, 46]]], ["Subgroup analysis, according to the type of manikin used was undertaken.", [["Subgroup analysis", "TEST", 0, 17]]], ["All data were collected in Microsoft Excel Spreadsheet (Office 365).", [["All data", "TEST", 0, 8]]], ["Fixed-effects analysis, generation of forest plot, assessment of heterogeneity and publication bias were performed with the METAN, METAPROP and METAFUNNEL platform for STATA (version-14.2); StataCorp, College Station, TX).", [["Fixed-effects analysis", "PROBLEM", 0, 22], ["forest plot", "TEST", 38, 49], ["assessment", "TEST", 51, 61], ["publication bias", "TEST", 83, 99], ["STATA (version", "TREATMENT", 168, 182], ["TX", "TREATMENT", 218, 220]]], ["Ethical approval was not needed, as this study was a systematic review.Search results and study characteristics ::: ResultsThe literature search flow diagram is summarised in PRISMA format (Fig. 1) and detailed PRISMA checklist is available in Supplementary Table \u2013 S2.", [["this study", "TEST", 36, 46], ["a systematic review", "TEST", 51, 70], ["The literature search flow diagram", "TEST", 123, 157], ["flow diagram", "OBSERVATION", 145, 157]]], ["A total of 22 records were screened after removal of duplicates.", [["removal of duplicates", "TREATMENT", 42, 63]]], ["Finally, five studies were included in this meta-analysis.Characteristics of the included studies ::: ResultsA total of five studies, consisting of 456 observations (228 in each of no-PPE and PPE arms), were selected for this meta-analysis (Table 1and Supplementary Table \u2013 S3).", [["five studies", "TEST", 9, 21], ["this meta-analysis", "TEST", 39, 57], ["five studies", "TEST", 120, 132], ["no-PPE and PPE arms", "TREATMENT", 181, 200], ["this meta-analysis", "TEST", 221, 239]]], ["All the studies were simulation-based, of which four were conducted in adult manikins (Chen et al., 2016; Kim et al., 2016; Shin, Dong-Min et al., 2015; Tian et al., 2020) and one in paediatric manikin (Donoghue et al., 2020).", [["All the studies", "TEST", 0, 15], ["Shin", "ANATOMY", 124, 128]]], ["Two studies were of \u2018before and after PPE\u2019 design (Donoghue et al., 2020; Shin, Dong-Min et al., 2015), two of \u2018crossover randomised\u2019 design (Chen et al., 2016; Kim et al., 2016) and one was of \u2018parallel randomised\u2019 design (Tian et al., 2020).", [["Two studies", "TEST", 0, 11], ["Shin", "ANATOMY", 74, 78]]], ["CC providers were physicians, nurses and emergency medical technicians.", [["CC", "CHEMICAL", 0, 2]]], ["During CPR, providers used Level-C PPE (gloves, gown, respirator with filter, boots according to Occupational Safety and Health Administration guidelines) in three studies (Chen et al., 2016; Kim et al., 2016; Shin, Dong-Min et al., 2015), Level-B/C PPE in one study (Donoghue et al., 2020) and only N95 face mask in one study (Tian et al., 2020).", [["Level-C PPE (gloves", "TREATMENT", 27, 46], ["respirator", "TREATMENT", 54, 64], ["filter", "TREATMENT", 70, 76], ["boots", "TREATMENT", 78, 83], ["Level", "TEST", 240, 245], ["one study", "TEST", 257, 266], ["N95 face mask", "TREATMENT", 300, 313], ["Shin", "ANATOMY", 210, 214]]], ["Practical assessment of different parameters was done for 2 min in two studies (Chen et al., 2016; Tian et al., 2020) and 4 min in two studies (Kim et al., 2016; Shin, Dong-Min et al., 2015).", [["Practical assessment", "TEST", 0, 20], ["Shin", "ANATOMY", 162, 166]]], ["As Donoghue et al. had provided CC data from 0.5 min to 5 min duration, only CC parameters recorded at 2 min were included for this meta-analysis(Donoghue et al., 2020).", [["CC", "CHEMICAL", 32, 34], ["CC", "CHEMICAL", 77, 79], ["CC parameters", "TEST", 77, 90], ["this meta-analysis", "TEST", 127, 145]]], ["All five studies had provided information on the mean rate and depth of CC.", [["CC", "CHEMICAL", 72, 74], ["All five studies", "TEST", 0, 16], ["the mean rate", "TEST", 45, 58]]], ["In contrast, only 3 out of 5 studies (Supplementary Table \u2013 S3) had provided information on the proportion of adequate CC rate and adequate CC depth (Chen et al., 2016; Kim et al., 2016; Tian et al., 2020), and only Tian et al. had provided data on CC recoil(Tian et al., 2020).", [["CC", "CHEMICAL", 119, 121], ["CC", "CHEMICAL", 140, 142], ["CC", "CHEMICAL", 249, 251], ["5 studies", "TEST", 27, 36]]], ["Adequate CC rate was defined as the rate of 100 to 120/min in all studies except in the study by Shin et al., where a minimum rate of 100/min was considered adequate.", [["CC", "CHEMICAL", 9, 11], ["the rate", "TEST", 32, 40], ["all studies", "TEST", 62, 73], ["the study", "TEST", 84, 93], ["a minimum rate", "TEST", 116, 130]]], ["Adequate CC depth was defined as the depth of minimum 50 mm in all the included studies.Characteristics of the included studies ::: ResultsResults of the quality assessment of the included studies are summarised in Table 1, and the detailed risk of bias analysis is available in Supplementary Figure \u2013 S1 (ROB-2 infographics) and Figure \u2013 S2 (ROBINS-I infographics).", [["CC", "CHEMICAL", 9, 11], ["the quality assessment", "TEST", 150, 172], ["the included studies", "TEST", 176, 196], ["bias analysis", "TEST", 249, 262], ["CC depth", "OBSERVATION_MODIFIER", 9, 17]]], ["Among the randomised trials, studies by Chen et al. (Chen et al., 2016) and Tian et al. (Tian et al., 2020) were of low risk of bias, whereas Kim et al. (Kim et al., 2016) were of a high risk of bias due to unavailability of information about randomisation process.", [["randomisation process", "PROBLEM", 243, 264]]], ["ROB could not be assessed for Shin et al. due to unavailability of information in multiple domains of ROBINS-I tool.Quantitative data synthesis results ::: ResultsA Significant decrease in CC rate was observed in the PPE arm as compared to no-PPE arm (SMD: -0.28, 95%CI: \u22120.47 to \u22120.10) (Fig. 2).", [["CC", "CHEMICAL", 189, 191], ["ROB", "GENE_OR_GENE_PRODUCT", 0, 3], ["CC", "PATHOLOGICAL_FORMATION", 189, 191], ["ROB", "PROTEIN", 0, 3], ["Quantitative data synthesis", "TEST", 116, 143], ["Significant decrease in CC rate", "PROBLEM", 165, 196], ["SMD", "TEST", 252, 255], ["CI", "TEST", 267, 269], ["Significant", "OBSERVATION_MODIFIER", 165, 176], ["decrease", "OBSERVATION_MODIFIER", 177, 185], ["CC rate", "OBSERVATION", 189, 196], ["PPE arm", "ANATOMY", 217, 224], ["arm", "ANATOMY", 247, 250]]], ["Similarly, with the use of PPE, there was a significant reduction in CC depth also (SMD: -0.26, 95%CI: \u22120.44 to \u22120.07) (Fig. 3).", [["CC", "CHEMICAL", 69, 71], ["PPE", "TREATMENT", 27, 30], ["a significant reduction in CC depth", "PROBLEM", 42, 77], ["SMD", "TEST", 84, 87], ["CI", "TEST", 99, 101], ["\u2212", "TEST", 103, 104], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["reduction", "OBSERVATION_MODIFIER", 56, 65], ["CC depth", "OBSERVATION", 69, 77]]], ["Significant statistical heterogeneity was observed in the meta-analysis of studies for CC rate (I2: 76.5%) and CC depth (I2: 77.2%).", [["CC", "CHEMICAL", 87, 89], ["CC", "CHEMICAL", 111, 113], ["Significant statistical heterogeneity", "PROBLEM", 0, 37], ["studies", "TEST", 75, 82], ["CC rate", "TEST", 87, 94], ["I2", "TEST", 96, 98], ["CC depth", "TEST", 111, 119], ["I2", "TEST", 121, 123], ["heterogeneity", "OBSERVATION", 24, 37]]], ["To investigate the cause of heterogeneity, subgroup analysis according to the type of manikin used was undertaken.", [["heterogeneity", "PROBLEM", 28, 41], ["subgroup analysis", "TEST", 43, 60]]], ["It was found that during adult CPR, there was a significantly higher reduction in CC rate after use of PPE (SMD: -0.65, 95%CI: \u22120.39 to \u22120.91, I2: 0%), as compared to that during paediatric CPR (SMD: 0.10, 95%CI: \u22120.17 to 0.36, I2: not applicable, as only one study was included).", [["CC", "CHEMICAL", 82, 84], ["adult CPR", "TREATMENT", 25, 34], ["a significantly higher reduction in CC rate", "PROBLEM", 46, 89], ["PPE", "TEST", 103, 106], ["SMD", "TEST", 108, 111], ["CI", "TEST", 123, 125], ["I2", "TEST", 143, 145], ["paediatric CPR", "TEST", 179, 193], ["SMD", "TEST", 195, 198], ["CI", "TEST", 209, 211], ["I2", "TEST", 228, 230], ["one study", "TEST", 256, 265], ["higher", "OBSERVATION_MODIFIER", 62, 68], ["reduction", "OBSERVATION_MODIFIER", 69, 78]]], ["For CC depth, statistical heterogeneity among the included studies, reduced from overall I2 of 77.2% to I2 of 71.8% for the subgroup of adult manikin's studies.Quantitative data synthesis results ::: ResultsTo have a better clinical understanding of the effect of PPE use on CC parameters, the overall proportion of adequate CC rate and depth were calculated and compared in both arms.", [["CC", "CHEMICAL", 4, 6], ["PPE", "CHEMICAL", 264, 267], ["CC", "CHEMICAL", 275, 277], ["CC", "CHEMICAL", 325, 327], ["PPE", "SIMPLE_CHEMICAL", 264, 267], ["overall I2", "TEST", 81, 91], ["I2", "TEST", 104, 106], ["adult manikin's studies", "TEST", 136, 159], ["Quantitative data synthesis", "TEST", 160, 187], ["CC parameters", "TEST", 275, 288], ["heterogeneity", "OBSERVATION", 26, 39], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["both", "ANATOMY_MODIFIER", 375, 379], ["arms", "ANATOMY", 380, 384]]], ["Without PPE, the proportion of adequate CC rate was 0.74 (95%CI: 0.69\u20130.79), which reduced significantly to 0.60 (95%CI: 0.54\u20130.65) after use of PPE (chi-square p-value: 0.035) (Fig. 4).", [["CC", "CHEMICAL", 40, 42], ["PPE", "PROBLEM", 8, 11], ["adequate CC rate", "TEST", 31, 47], ["CI", "TEST", 61, 63], ["CI", "TEST", 117, 119], ["PPE (chi-square p-value", "TREATMENT", 145, 168]]], ["Similarly, the proportion of adequate CC depth was significantly less (chi-square p-value < 0.001) in PPE arm (0.55, 95%CI: 0.50\u20130.61), as compared to that of no-PPE arm (0.78, 95%CI: 0.73\u20130.82) (Fig. 5).", [["CC", "CHEMICAL", 38, 40], ["p-value", "TEST", 82, 89], ["PPE arm", "TEST", 102, 109], ["CI", "TEST", 120, 122], ["CI", "TEST", 180, 182], ["adequate", "OBSERVATION_MODIFIER", 29, 37], ["CC", "OBSERVATION_MODIFIER", 38, 40], ["depth", "OBSERVATION_MODIFIER", 41, 46], ["PPE arm", "ANATOMY", 102, 109], ["arm", "ANATOMY", 166, 169]]], ["Only Tian et al. had provided data on the proportion of adequate recoil, hence meta-analysis could not be done (0.98 in the no-PPE arm versus 0.91 in PPE arm).Quantitative data synthesis results ::: ResultsThere was no publication bias observed among the included studies (Egger's regression coefficients for meta-analysis of CC rate and CC depth were 0.166 and 0.646, respectively depicted in Supplementary Figure \u2013 S1 and S2).DiscussionOur systematic review and meta-analysis showed that the use of PPE affects the quality of CPR as there was a significant reduction in rate and depth of chest compressions while using PPE as compared to the no PPE arm.", [["chest", "ANATOMY", 590, 595], ["CC", "CHEMICAL", 326, 328], ["CC", "CHEMICAL", 338, 340], ["chest", "ORGANISM_SUBDIVISION", 590, 595], ["Quantitative data synthesis", "TEST", 159, 186], ["publication bias", "PROBLEM", 219, 235], ["studies", "TEST", 264, 271], ["Egger", "TEST", 273, 278], ["meta-analysis", "TEST", 309, 322], ["CC rate", "TEST", 326, 333], ["CC depth", "TEST", 338, 346], ["meta-analysis", "TEST", 464, 477], ["PPE", "TREATMENT", 501, 504], ["CPR", "TREATMENT", 528, 531], ["a significant reduction in rate", "PROBLEM", 545, 576], ["chest compressions", "TREATMENT", 590, 608], ["PPE", "TREATMENT", 621, 624], ["S2", "ANATOMY", 424, 426], ["significant", "OBSERVATION_MODIFIER", 547, 558], ["reduction", "OBSERVATION_MODIFIER", 559, 568], ["chest", "ANATOMY", 590, 595], ["arm", "ANATOMY", 651, 654]]], ["It was also found that the decrease in chest compression rate and depth was significantly higher after the use of PPE in adults as compared to the paediatric CPR.DiscussionERC and AHA guidelines on the management of cardiac arrest give equal emphasis on the rate and depth of chest compressions in determining the survival and outcome of cardiac arrest [12].", [["chest", "ANATOMY", 39, 44], ["cardiac", "ANATOMY", 216, 223], ["chest", "ANATOMY", 276, 281], ["cardiac", "ANATOMY", 338, 345], ["cardiac arrest", "DISEASE", 216, 230], ["cardiac arrest", "DISEASE", 338, 352], ["chest", "ORGAN", 39, 44], ["cardiac", "ORGAN", 216, 223], ["chest", "ORGANISM_SUBDIVISION", 276, 281], ["the decrease in chest compression rate", "PROBLEM", 23, 61], ["PPE", "TREATMENT", 114, 117], ["the paediatric CPR", "TREATMENT", 143, 161], ["cardiac arrest", "PROBLEM", 216, 230], ["the rate", "TEST", 254, 262], ["chest compressions", "TREATMENT", 276, 294], ["cardiac arrest", "PROBLEM", 338, 352], ["decrease", "OBSERVATION_MODIFIER", 27, 35], ["chest", "ANATOMY", 39, 44], ["compression", "OBSERVATION", 45, 56], ["higher", "OBSERVATION_MODIFIER", 90, 96], ["cardiac", "ANATOMY", 216, 223], ["arrest", "OBSERVATION", 224, 230], ["chest", "ANATOMY", 276, 281], ["cardiac", "ANATOMY", 338, 345], ["arrest", "OBSERVATION", 346, 352]]], ["Chen et al. in their randomised cross over simulation study done demonstrated a significant reduction in the percentage of effective chest compressions delivered while wearing PPE [10].", [["chest", "ANATOMY", 133, 138], ["chest", "ORGANISM_SUBDIVISION", 133, 138], ["simulation study", "TEST", 43, 59], ["a significant reduction", "PROBLEM", 78, 101], ["effective chest compressions", "TREATMENT", 123, 151], ["significant", "OBSERVATION_MODIFIER", 80, 91], ["reduction", "OBSERVATION_MODIFIER", 92, 101], ["percentage", "OBSERVATION_MODIFIER", 109, 119], ["effective", "OBSERVATION_MODIFIER", 123, 132], ["chest", "ANATOMY", 133, 138]]], ["It was shown that high quality of chest compression is associated with a degree of work comparable to high-intensity aerobic exercise.", [["chest", "ANATOMY", 34, 39], ["chest compression", "DISEASE", 34, 51], ["chest", "ORGAN", 34, 39], ["high quality of chest compression", "PROBLEM", 18, 51], ["high", "OBSERVATION_MODIFIER", 18, 22], ["chest", "ANATOMY", 34, 39], ["compression", "OBSERVATION", 40, 51]]], ["Rescuers develop fatigue during CPR, and fatigue leads to deterioration of quality of chest compression.", [["chest", "ANATOMY", 86, 91], ["fatigue", "DISEASE", 17, 24], ["fatigue", "DISEASE", 41, 48], ["chest compression", "DISEASE", 86, 103], ["chest", "ORGANISM_SUBDIVISION", 86, 91], ["fatigue", "PROBLEM", 17, 24], ["CPR", "TREATMENT", 32, 35], ["fatigue", "PROBLEM", 41, 48], ["chest compression", "PROBLEM", 86, 103], ["fatigue", "OBSERVATION", 17, 24], ["chest", "ANATOMY", 86, 91], ["compression", "OBSERVATION", 92, 103]]], ["Chen et al. had also shown that the increase in heart rate, mean arterial pressure and subjective fatigue score values were significant with the use of PPE (p < 0.001) [10].", [["heart", "ANATOMY", 48, 53], ["arterial", "ANATOMY", 65, 73], ["fatigue", "DISEASE", 98, 105], ["heart", "ORGAN", 48, 53], ["arterial", "MULTI-TISSUE_STRUCTURE", 65, 73], ["heart rate", "TEST", 48, 58], ["mean arterial pressure", "TEST", 60, 82], ["subjective fatigue score values", "PROBLEM", 87, 118], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["heart", "ANATOMY", 48, 53]]], ["The study by Kim et al. had shown an increase in interruption in chest compressions while wearing PPE and has attributed it to the difficulty in changing body postures and securing the airway for proper positive pressure ventilation [23].", [["chest", "ANATOMY", 65, 70], ["body", "ANATOMY", 154, 158], ["airway", "ANATOMY", 185, 191], ["chest", "ORGANISM_SUBDIVISION", 65, 70], ["body", "ORGANISM_SUBDIVISION", 154, 158], ["airway", "MULTI-TISSUE_STRUCTURE", 185, 191], ["The study", "TEST", 0, 9], ["chest compressions", "TREATMENT", 65, 83], ["PPE", "TREATMENT", 98, 101], ["the difficulty in changing body postures", "PROBLEM", 127, 167], ["proper positive pressure ventilation", "TREATMENT", 196, 232], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["interruption", "OBSERVATION_MODIFIER", 49, 61], ["chest", "ANATOMY", 65, 70], ["airway", "ANATOMY", 185, 191]]], ["Another simulation trial by Malysz et al. has also shown that use of PPE causes a significant reduction in chest compression quality and hence has recommended the use of automated chest compression devices or reducing the duration of CPR cycle to 1 min [25].", [["chest", "ANATOMY", 107, 112], ["chest", "ANATOMY", 180, 185], ["PPE", "CHEMICAL", 69, 72], ["chest", "ORGANISM_SUBDIVISION", 107, 112], ["Another simulation trial", "TREATMENT", 0, 24], ["PPE", "TREATMENT", 69, 72], ["a significant reduction in chest compression quality", "PROBLEM", 80, 132], ["automated chest compression devices", "TREATMENT", 170, 205], ["CPR cycle", "TREATMENT", 234, 243], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["reduction", "OBSERVATION_MODIFIER", 94, 103], ["chest", "ANATOMY", 107, 112], ["compression", "OBSERVATION", 113, 124], ["chest", "ANATOMY", 180, 185]]], ["Since most of these studies were carried out in manikins/simulated environment, none of the study could include the psychological factors which may hinder the delivery of high quality chest compressions while wearing PPE like the fear of breach in PPE and the associated risk of acquiring infection while performing resuscitation.DiscussionOut of all studies included only the one conducted by Donoghue et al. was done on the paediatric manikin(Donoghue et al., 2020).", [["chest", "ANATOMY", 184, 189], ["infection", "DISEASE", 289, 298], ["chest", "ORGANISM_SUBDIVISION", 184, 189], ["these studies", "TEST", 14, 27], ["the study", "TEST", 88, 97], ["high quality chest compressions", "TREATMENT", 171, 202], ["breach in PPE", "PROBLEM", 238, 251], ["acquiring infection", "PROBLEM", 279, 298], ["resuscitation", "TREATMENT", 316, 329], ["all studies", "TEST", 347, 358], ["infection", "OBSERVATION", 289, 298]]], ["Donoghue et al. had found no significant difference in chest compression parameters between the PPE and no PPE arm.", [["chest", "ANATOMY", 55, 60], ["chest", "ORGANISM_SUBDIVISION", 55, 60], ["chest compression parameters", "TEST", 55, 83], ["the PPE", "TREATMENT", 92, 99], ["PPE arm", "TREATMENT", 107, 114], ["no", "UNCERTAINTY", 26, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["difference", "OBSERVATION", 41, 51], ["chest", "ANATOMY", 55, 60], ["compression", "OBSERVATION", 61, 72], ["no", "UNCERTAINTY", 104, 106], ["PPE arm", "ANATOMY", 107, 114]]], ["There was also no difference in fatigue of rescuers at 2 min in both arms(Donoghue et al., 2020).", [["fatigue", "DISEASE", 32, 39], ["difference in fatigue of rescuers", "PROBLEM", 18, 51], ["no", "UNCERTAINTY", 15, 17], ["difference", "OBSERVATION_MODIFIER", 18, 28], ["both", "ANATOMY_MODIFIER", 64, 68], ["arms", "ANATOMY", 69, 73]]], ["This may be because of the lesser amount of physical activity required in paediatric chest compression as compared to adult chest compression.DiscussionAs CPR is an aerosol-generating procedure, and there are risks of acquiring COVID 19 infection during resuscitation, HCW involved in such procedures must be wearing PPE(Edelson Dana P. et al., n.d.).", [["chest", "ANATOMY", 85, 90], ["chest", "ANATOMY", 124, 129], ["chest compression", "DISEASE", 85, 102], ["chest compression", "DISEASE", 124, 141], ["infection", "DISEASE", 237, 246], ["chest", "ORGANISM_SUBDIVISION", 85, 90], ["chest", "ORGANISM_SUBDIVISION", 124, 129], ["paediatric chest compression", "TREATMENT", 74, 102], ["adult chest compression", "TEST", 118, 141], ["an aerosol-generating procedure", "TREATMENT", 162, 193], ["acquiring COVID 19 infection", "PROBLEM", 218, 246], ["resuscitation", "TREATMENT", 254, 267], ["lesser", "OBSERVATION_MODIFIER", 27, 33], ["amount", "OBSERVATION_MODIFIER", 34, 40], ["physical activity", "OBSERVATION", 44, 61], ["chest", "ANATOMY", 85, 90], ["compression", "OBSERVATION", 91, 102], ["chest", "ANATOMY", 124, 129], ["compression", "OBSERVATION", 130, 141], ["infection", "OBSERVATION", 237, 246]]], ["This at the same time carries the concern of delivery of inadequate chest compression (in terms of both rate and depth of chest compressions) and easy fatigability of rescuers while wearing PPE, which will affect the outcome of cardiac arrest adversely [10,11,[22], [23], [24], [25]].", [["chest", "ANATOMY", 68, 73], ["chest", "ANATOMY", 122, 127], ["cardiac", "ANATOMY", 228, 235], ["chest compression", "DISEASE", 68, 85], ["cardiac arrest", "DISEASE", 228, 242], ["chest", "ORGANISM_SUBDIVISION", 68, 73], ["chest", "ORGANISM_SUBDIVISION", 122, 127], ["cardiac", "ORGAN", 228, 235], ["inadequate chest compression", "PROBLEM", 57, 85], ["chest compressions", "TREATMENT", 122, 140], ["easy fatigability of rescuers", "PROBLEM", 146, 175], ["PPE", "TREATMENT", 190, 193], ["cardiac arrest", "PROBLEM", 228, 242], ["chest", "ANATOMY", 68, 73], ["compression", "OBSERVATION", 74, 85], ["chest", "ANATOMY", 122, 127], ["cardiac", "ANATOMY", 228, 235], ["arrest", "OBSERVATION", 236, 242]]], ["Though AHA recommends minimum interruption while doing compression, in a scenario where the operator has to wear a level-C PPE, can frequent switching with a shorter-cycles of one minute or 90 s improve quality of CPR has to be studied(Couper et al., 2020; Edelson Dana P. et al., n.d.).", [["compression", "TREATMENT", 55, 66], ["a level-C PPE", "TREATMENT", 113, 126], ["a shorter-cycles", "TREATMENT", 156, 172], ["CPR", "TREATMENT", 214, 217]]], ["Another solution is to increase the number of chest compressors in a CPR team and hence to give enough rest in between compression.", [["chest", "ANATOMY", 46, 51], ["compression", "TREATMENT", 119, 130], ["chest", "ANATOMY", 46, 51], ["compression", "OBSERVATION", 119, 130]]], ["But this, in turn, is possible only at the cost of more HCW being exposed to the aerosol.", [["the aerosol", "TREATMENT", 77, 88]]], ["Giving quality resuscitation in the time of infectious disease pandemic is a unique challenge.", [["infectious disease pandemic", "DISEASE", 44, 71], ["quality resuscitation", "TREATMENT", 7, 28], ["infectious", "OBSERVATION", 44, 54]]], ["With the fear of contracting the infection and reduced work efficiency associated with wearing a level-C PPE, there is a need to improvise and devise ways so that the quality of care is not compromised to our patients.", [["infection", "DISEASE", 33, 42], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["the infection", "PROBLEM", 29, 42], ["reduced work efficiency", "PROBLEM", 47, 70], ["infection", "OBSERVATION", 33, 42]]], ["This may include a more breathable PPE gown, a separate resuscitation team who are on a shorter shift, and a shift to mechanical CPR devices wherever feasible.", [["mechanical CPR devices", "TREATMENT", 118, 140]]], ["Further studies, both simulations based and real-time resuscitation has to be done in this regard.LimitationsThere were several limitations to our study.", [["Further studies", "TEST", 0, 15], ["both simulations", "TEST", 17, 33], ["resuscitation", "TREATMENT", 54, 67], ["our study", "TEST", 143, 152]]], ["Only simulation-based studies were included in this meta-analysis.", [["simulation-based studies", "TEST", 5, 29], ["this meta-analysis", "TEST", 47, 65]]], ["None of these studies were conducted in real-life scenarios and during this COVID-19 pandemic (except Tian et al.)", [["these studies", "TEST", 8, 21], ["this COVID", "TEST", 71, 81]]], ["Out of the five studies included, only three studies had provided information on the proportion of adequate CC rate and depth, and only one study has provided information on CC recoil.", [["CC", "CHEMICAL", 108, 110], ["CC", "CHEMICAL", 174, 176], ["three studies", "TEST", 39, 52], ["one study", "TEST", 136, 145], ["CC recoil", "TREATMENT", 174, 183]]], ["Significant statistical heterogeneity was observed among the included studies for CC depth.", [["CC", "CHEMICAL", 82, 84], ["Significant statistical heterogeneity", "PROBLEM", 0, 37], ["CC depth", "TEST", 82, 90], ["heterogeneity", "OBSERVATION", 24, 37]]], ["Utilization of simulation based studies, the limited number of studies included and the sample size in these studies pose a challenge to our findings to be applied in real clinical scenarios.", [["simulation based studies", "TEST", 15, 39], ["studies", "TEST", 63, 70], ["these studies", "TEST", 103, 116], ["size", "OBSERVATION_MODIFIER", 95, 99]]], ["Finally, it is possible that new studies were published between the completion of the literature review and when this article was completed.", [["new studies", "TEST", 29, 40]]], ["However, we are not aware of any new publication since that time.ConclusionUse of personal protective equipment compromises with the quality of chest compression during CPR.", [["chest", "ANATOMY", 144, 149], ["chest", "ORGANISM_SUBDIVISION", 144, 149], ["chest compression", "TREATMENT", 144, 161], ["CPR", "TREATMENT", 169, 172], ["new", "OBSERVATION_MODIFIER", 33, 36], ["publication", "OBSERVATION", 37, 48], ["chest", "ANATOMY", 144, 149], ["compression", "OBSERVATION", 150, 161]]], ["As COVID-19 pandemic is expected to stay for a long time, further research needs to be done to find ways to improve CPR without compromising on the safety of the healthcare worker.Credit(Authors' contribution)The conceptualisation of the study: PA, AK, RM.Credit(Authors' contribution)Data curation.Credit(Authors' contribution)Article searching and study selection: AK, RM, SSCredit(Authors' contribution)Data extraction: AK, SSCredit(Authors' contribution)Formal analysis and software:Credit(Authors' contribution)Quality assessment of the studies: AK, SS, JNCredit(Authors' contribution)Data analysis: AK, JNCredit(Authors' contribution)Manuscript writing: AK, RM, SS.Credit(Authors' contribution)Overall conduct of the study: AK, PA.FundingThe authors did not receive any financial support from any source.Uncited references", [["PA", "GENE_OR_GENE_PRODUCT", 245, 247], ["CPR", "TREATMENT", 116, 119], ["the study", "TEST", 234, 243], ["the studies", "TEST", 538, 549], ["the study", "TEST", 719, 728], ["any financial support", "TREATMENT", 772, 793]]]], "15dba867591d7e7615fe63ab5971a2a462eed249": [["cleaved into at least 16 predicted nonstructural proteins (nsp), among which nsp3, nsp5, nsp12, and nsp13 encode putative papain-like viral protease (PLVP), 3C-like protease (chymotrypsin-like or 3C-like protease, 3CL pro ), RNA-dependent RNA polymerase (RdRp), and helicase, respectively .", [["nsp", "GENE_OR_GENE_PRODUCT", 59, 62], ["nsp3", "GENE_OR_GENE_PRODUCT", 77, 81], ["nsp5", "GENE_OR_GENE_PRODUCT", 83, 87], ["nsp12", "GENE_OR_GENE_PRODUCT", 89, 94], ["nsp13", "GENE_OR_GENE_PRODUCT", 100, 105], ["papain-like viral protease", "GENE_OR_GENE_PRODUCT", 122, 148], ["PLVP", "GENE_OR_GENE_PRODUCT", 150, 154], ["3C-like protease", "GENE_OR_GENE_PRODUCT", 157, 173], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 175, 187], ["3C-like protease", "GENE_OR_GENE_PRODUCT", 196, 212], ["3CL pro", "GENE_OR_GENE_PRODUCT", 214, 221], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 225, 253], ["RdRp", "GENE_OR_GENE_PRODUCT", 255, 259], ["nonstructural proteins", "PROTEIN", 35, 57], ["nsp", "PROTEIN", 59, 62], ["nsp3", "PROTEIN", 77, 81], ["nsp5", "PROTEIN", 83, 87], ["nsp12", "PROTEIN", 89, 94], ["nsp13", "PROTEIN", 100, 105], ["papain-like viral protease (PLVP), 3C-like protease", "PROTEIN", 122, 173], ["chymotrypsin-like or 3C-like protease", "PROTEIN", 175, 212], ["3CL pro", "PROTEIN", 214, 221], ["RNA-dependent RNA polymerase", "PROTEIN", 225, 253], ["RdRp", "PROTEIN", 255, 259], ["helicase", "PROTEIN", 266, 274], ["nsp12", "TEST", 89, 94], ["putative papain", "TREATMENT", 113, 128], ["viral protease (PLVP", "TREATMENT", 134, 154], ["3C-like protease (chymotrypsin", "TREATMENT", 157, 187], ["3C-like protease", "TREATMENT", 196, 212], ["RNA", "TEST", 225, 228]]], ["Besides, the viral ORF1ab, ORF10, and ORF3a proteins can attack heme on hemoglobin 1-\u03b2 chain synergistically, resulting in decomposing iron to form porphyrin, which will subsequently lead to less and less hemoglobin carrying oxygen and carbon dioxide, produce extremely strong poisoning and inflammation in lung cells, and interfere with the normal heme anabolism pathway .", [["lung cells", "ANATOMY", 307, 317], ["iron", "CHEMICAL", 135, 139], ["porphyrin", "CHEMICAL", 148, 157], ["oxygen", "CHEMICAL", 225, 231], ["carbon dioxide", "CHEMICAL", 236, 250], ["poisoning", "DISEASE", 277, 286], ["inflammation", "DISEASE", 291, 303], ["heme", "CHEMICAL", 64, 68], ["iron", "CHEMICAL", 135, 139], ["porphyrin", "CHEMICAL", 148, 157], ["oxygen", "CHEMICAL", 225, 231], ["carbon dioxide", "CHEMICAL", 236, 250], ["heme", "CHEMICAL", 349, 353], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 19, 25], ["ORF10", "GENE_OR_GENE_PRODUCT", 27, 32], ["ORF3a", "GENE_OR_GENE_PRODUCT", 38, 43], ["hemoglobin 1", "GENE_OR_GENE_PRODUCT", 72, 84], ["iron", "SIMPLE_CHEMICAL", 135, 139], ["porphyrin", "SIMPLE_CHEMICAL", 148, 157], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 205, 215], ["oxygen", "SIMPLE_CHEMICAL", 225, 231], ["carbon dioxide", "SIMPLE_CHEMICAL", 236, 250], ["lung cells", "CELL", 307, 317], ["heme", "GENE_OR_GENE_PRODUCT", 349, 353], ["viral ORF1ab, ORF10, and ORF3a proteins", "PROTEIN", 13, 52], ["heme", "PROTEIN", 64, 68], ["hemoglobin 1-\u03b2 chain", "PROTEIN", 72, 92], ["hemoglobin", "PROTEIN", 205, 215], ["lung cells", "CELL_TYPE", 307, 317], ["the viral ORF1ab", "TEST", 9, 25], ["hemoglobin", "TEST", 72, 82], ["decomposing iron", "TREATMENT", 123, 139], ["porphyrin", "TREATMENT", 148, 157], ["hemoglobin carrying oxygen", "TREATMENT", 205, 231], ["carbon dioxide", "TEST", 236, 250], ["extremely strong poisoning", "PROBLEM", 260, 286], ["inflammation in lung cells", "PROBLEM", 291, 317], ["inflammation", "OBSERVATION", 291, 303], ["lung", "ANATOMY", 307, 311]]], ["Therefore, S protein and proteins derived from the ORF1ab as well as their cellular receptors, such as ACE2 (Zhou et al., 2020b) , AGTR2 (angiotensin II receptor type 2) , TMPRSS2 (Hoffmann et al., 2020) , and CD147 (Basigin or EMMPRIN) , are the most favorable cellular targets for the development of antiviral compounds.", [["cellular", "ANATOMY", 75, 83], ["cellular", "ANATOMY", 262, 270], ["angiotensin II", "CHEMICAL", 138, 152], ["S protein", "GENE_OR_GENE_PRODUCT", 11, 20], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 51, 57], ["cellular", "CELL", 75, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 103, 107], ["AGTR2", "GENE_OR_GENE_PRODUCT", 131, 136], ["angiotensin II receptor type 2", "GENE_OR_GENE_PRODUCT", 138, 168], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 172, 179], ["CD147", "GENE_OR_GENE_PRODUCT", 210, 215], ["Basigin", "GENE_OR_GENE_PRODUCT", 217, 224], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 228, 235], ["cellular", "CELL", 262, 270], ["S protein", "PROTEIN", 11, 20], ["ORF1ab", "PROTEIN", 51, 57], ["cellular receptors", "PROTEIN", 75, 93], ["ACE2", "PROTEIN", 103, 107], ["AGTR2", "PROTEIN", 131, 136], ["angiotensin II receptor type 2", "PROTEIN", 138, 168], ["TMPRSS2", "PROTEIN", 172, 179], ["CD147", "PROTEIN", 210, 215], ["Basigin", "PROTEIN", 217, 224], ["EMMPRIN", "PROTEIN", 228, 235], ["S protein", "TEST", 11, 20], ["proteins", "TEST", 25, 33], ["ACE2", "TEST", 103, 107], ["AGTR2 (angiotensin II receptor type", "TEST", 131, 166], ["TMPRSS2", "TEST", 172, 179], ["CD147", "TEST", 210, 215], ["antiviral compounds", "PROBLEM", 302, 321], ["most favorable", "OBSERVATION_MODIFIER", 247, 261], ["cellular targets", "OBSERVATION", 262, 278], ["antiviral compounds", "OBSERVATION", 302, 321]]]], "5d90fb7b571e9cfad48486c911796dbe9d917f33": [["The single nucleotide polymorphisms (rs12979860), near the IL28B gene, is correlated with a sustained virological response (SVR) in Hepatitis C Virus (HCV) infected patients treated with Pegylated Interferon-a combined with Ribavirin (1, 2) .", [["Hepatitis C Virus (HCV) infected", "DISEASE", 132, 164], ["Pegylated Interferon-a", "CHEMICAL", 187, 209], ["Ribavirin", "CHEMICAL", 224, 233], ["Ribavirin", "CHEMICAL", 224, 233], ["IL28B", "GENE_OR_GENE_PRODUCT", 59, 64], ["Hepatitis C Virus", "ORGANISM", 132, 149], ["HCV", "ORGANISM", 151, 154], ["patients", "ORGANISM", 165, 173], ["Ribavirin", "SIMPLE_CHEMICAL", 224, 233], ["rs12979860", "DNA", 37, 47], ["IL28B gene", "DNA", 59, 69], ["Hepatitis C Virus", "SPECIES", 132, 149], ["patients", "SPECIES", 165, 173], ["Hepatitis C Virus", "SPECIES", 132, 149], ["HCV", "SPECIES", 151, 154], ["The single nucleotide polymorphisms", "TEST", 0, 35], ["a sustained virological response", "PROBLEM", 90, 122], ["SVR", "TEST", 124, 127], ["Hepatitis C Virus (HCV)", "PROBLEM", 132, 155], ["Pegylated Interferon", "TREATMENT", 187, 207], ["Ribavirin", "TREATMENT", 224, 233]]], ["However, the association of rs12979860 polymorphism with immune function of the liver, the site of HCV production, and the mechanism of SVR remain still undefined.", [["liver", "ANATOMY", 80, 85], ["rs12979860", "GENE_OR_GENE_PRODUCT", 28, 38], ["liver", "ORGAN", 80, 85], ["HCV", "ORGANISM", 99, 102], ["HCV", "SPECIES", 99, 102], ["rs12979860 polymorphism", "PROBLEM", 28, 51], ["immune function of the liver", "PROBLEM", 57, 85], ["HCV production", "PROBLEM", 99, 113], ["SVR", "TEST", 136, 139], ["immune function", "OBSERVATION", 57, 72], ["liver", "ANATOMY", 80, 85], ["HCV", "OBSERVATION", 99, 102], ["SVR", "OBSERVATION", 136, 139]]]]}